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Abstract 
Fenretinide is a potent chemotherapeutic and chemopreventive against a 
range of cancer tumour cell lines, namely Ewing’s Sarcoma Family of 
Tumours (ESFT) which is an aggressive malignant tumour primarily affecting 
children and young adults. The mechanism of action of the drug is not 
known. The major disadvantage to fenretinide as a treatment for cancer is its 
poor in vivo efficacy due to poor oral bioavailability, requiring the patient to 
take many tablets per day regularly in order to achieve an adequate plasma 
concentration.  
By use of computational drug design and medicinal chemistry-led design, we 
have identified both novel retinoid and non-retinoid mimetics of fenretinide, 
which demonstrate comparable in vitro activity to fenretinide against ESFT 
cell types. This research has investigated the molecular features of 
fenretinide which contribute to its inhibition of cell growth in order to establish 
structure-activity relationships (SAR).  We have also investigated the 
mechanism of cell death for a number of compounds and have identified 
molecules which appear to induce cell death via a similar mechanism to 
fenretinide as well as those which function via an alternative mechanism. 
Additional studies aimed at understanding the mechanism of action of 
fenretinide through affinity chromatography studies, have implicated several 
proteins as potential binding partners for further investigation.   
The outcomes of the current project may aid the design of future retinoid or 
non-retinoid analogues of fenretinide with improved efficacy, whilst retaining 
the minimal toxicity profile of fenretinide as well as to better understand the 
mechanism of the chemotherapeutic induction of the cell death process in 
ESFT cells. 
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1. Introduction 
1.1 Cancer 
Cancer is a term which covers a broad class of diseases that arise leading to 
abnormal cells which divide uncontrollably and have aberrant cell survival 
pathways. Cancer cells emerge from normal tissue as a result of the 
accumulation of unchecked mutations in  genes within the cell.1 These could 
be mutations in genes that enhance proliferation (e.g. oncogenes such as 
Ras, receptor tyrosine kinases) or inhibit the tumour suppressor function 
(e.g. tumour suppressor genes such as p53, p16).2 The abnormal cells build 
up resistance to the regulatory pathways that maintain the tissue 
microenvironment, therefore allowing them to rapidly grow and resist 
apoptosis by programmed cell death. Six key biological features of cancer 
cells, described in the majority of cancer types,  are known as the ‘hallmarks 
of cancer’ and include the ability to invade adjacent tissues and metastasise 
by inducing angiogenesis (forming new blood vessels from pre-existing 
vessels, therefore creating its own independent microenvironment).3 Cancer 
cells  are self-sufficient in growth signals, with an ability to sustain unlimited 
proliferation, resist sensitivity to growth inhibitory signalling and evade 
apoptosis, leading to replicative immortality.4 
Although 90–95 % of cancers are attributed to environmental factors (for 
example, cigarette smoking, obesity, alcohol, sun exposure, environmental 
pollutants, infections), 5–10 % of all cancer cases are a result of somatic or 
germline genetic defects.1,5 Cancer is a major disease globally which is on 
the rise; as of 2012 there were 14 million new cases reported annually, 
predicted to increase to 22 million over the next two decades. In which time, 
deaths from the disease are predicted to escalate from ca.8 million to ca.13 
million annually.6 Furthermore, cancer is the most common disease 
responsible for mortality among children in developed countries.7 
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1.2 Ewing’s sarcoma family of tumours 
Although rare, Ewing’s sarcoma family of tumours (ESFT) and other small 
round cell tumours (e.g. neuroblastoma) account for approximately 15 % of 
known childhood cancers.8 Primarily affecting children and young adults, 
ESFT includes Ewing’s sarcoma, peripheral primitive neuroectodermal 
tumours and Askin’s tumour. This family of tumours is defined by non-
random gene rearrangements between the EWS gene and members of the 
ETS gene family. The majority of ESFT cell types contain a tumour-specific 
t(ll;22)(q24;ql2) chromosomal rearrangement, resulting in a EWS-Flil (type 1 
or type 2 ) or EWS-ERG fusion transcript.9 Ewing’s sarcoma is one of the 
most frequently encountered types of malignant bone tumour and was 
initially identified and characterised in 1921 by James Ewing as a small 
round blue cell tumour (Figure 1.1) emerging from endothelial cells.10 
However, it has since been identified as a neuroectodermal tumour arising 
from cells in the early stages of differentiation, most likely mesenchymal 
stem cells of the mesoderm or neural crest.11 The tumours arise in the 
majority of skeletal sites but predominate in long bones of the leg, the pelvis, 
arms and ribs and occasionally in soft tissues.12,13 Symptoms caused by the 
presence of the tumour can include pain and swelling in the region of the 
tumour, as well as weight loss and fever. The aetiology of ESFT is thought to 
 
Figure 1.1 Histology of Ewing’s sarcoma of the bone. The nuclei of tumour cells are 
stained blue with haematoxylin and the scant cytoplasm stained pink with eosin. 
The decalcified bone also takes up the eosin and so appears pink when examined 
by light microscopy. 
ESFT cells 
Decalcified bone  
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be a consequence of several contributing factors, both environmental and 
genetic.13 
Current treatment for ESFT typically includes local control of the tumour by 
radiotherapy and surgery, as well as essential systemic chemotherapy when 
there is disease at multiple sites. However, the disease is currently extremely 
difficult to cure, reflecting high local and systemic relapse rates even after an 
initial response to treatment.14 For those patients that present with localised 
disease, the disease free 5 year survival rate is ca. 45-60 %. In ca. 30 % of 
patients the disease will be metastatic at diagnosis, reducing  5 year survival 
rates to ca. 20-40 %; the 5 year disease free survival rate for patients with 
metastasis to the lungs is ca. 40 % and to the bone and/or bone marrow ca. 
20 %. Even when disease is localised at diagnosis ca. 50 % of patients 
experience recurrence of the tumour which is likely to be caused by minimal 
disease remaining at the treated site or that which has spread to multiple 
sites.15 These poor survival rates emphasise the need for new, more 
effective, therapeutic agents to treat patients with ESFT. 
1.3 Drug discovery process 
The discovery of drugs, validation and introduction into clinical practice is a 
long process with a high attrition rate. Development of anticancer drugs 
takes on average 10-15 years, with less than 7 % successfully progressing 
from phase 1 toxicity studies to approval.16,17,18 The drug discovery process 
starts by identifying molecules, called hits or leads, that demonstrate a 
phenotype appropriate for treatment of the disease in question. Hits or leads 
can be identified by a variety of methods including structure-based design 
(where the nature and structure of the biological target is known), ligand-
based design and high-throughput screening (HTS) of large libraries of 
compounds. Once a hit or lead is identified, extensive studies of its biological 
properties are performed in order to understand its pharmacology, 
pharmacokinetics and toxicology (preclinical testing, see Section 1.4). Over a 
long process iterative optimisation of these properties by structural 
modification of the hit or lead allows generation of a preclinical candidate 
suitable for progression into clinical trials. 
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1.4 Preclinical testing 
Preclinical testing is important to gain sound reassurance that potential drug-
like compounds are likely to have good efficacy and safety in clinical trials; 
indeed it is a prerequisite of law that a compound has been preclinically 
tested in an animal model before entering human clinical trials.19 
Unfortunately, many compounds fail during clinical trials, unduly costing lives 
of some patients.20 There is also a huge investment of time and money by 
pharmaceutical companies to enter a drug candidate into clinical trials which 
will often fail.20,21 
In vitro cell line screening is primarily used as an initial assay to identify 
compounds which have significant activity against a panel of cell lines.22 
However, this method has several drawbacks. Firstly, for many cancer types 
it can be difficult to establish a tumour cell line. Secondly, tumour cell lines 
will most likely consist of selected cells that survive under culture conditions 
and thirdly cell lines that have been in culture for many years are likely to 
have adapted. Consequently, most tumour cell lines lack particular tumour 
characteristics and do not truly represent the cancer type which they propose 
to model.22 Furthermore, where cell lines have been established they will 
lack supportive interactions from the host such as a stromal environment.20 
Factors which are not taken into account and tested in the in vitro model 
include tumour cell heterogeneity, pharmacokinetics and pro-drug bio-
activation; such in vitro assays are also unable to provide an indication of 
therapeutic index.23 Nevertheless, these high throughput and low-cost tests 
provide information on the activity of a compound in vitro and are frequently 
used as a first screen to identify compounds with the potential to be effective 
in vivo.  
A particularly high-throughput method for identifying hit compounds is to 
screen using the National Cancer Institute 60 (NCI60) anticancer drug 
screen. This consists of panels of cell lines that essentially represent a range 
of nine major tumour types: leukaemia, colon, lung, CNS, renal, melanoma, 
ovarian, breast and prostate.24 However, the panel primarily focuses on adult 
tumour types therefore ESFT and neuroblastoma cell lines are not included. 
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Compounds are screened over a 5-log concentration range over 48 h using 
the sulphorhodamine B assay. Although this colorimetric assay is less 
accurate at predicting cytotoxicity than measuring cell viability (i.e. using the 
trypan blue exclusion assay), it allows for high-throughput screening of large 
batches of compounds. The compound screening service is available free of 
charge and the results are publically available for 43,000 out of ca.85,000 
that have been screened.25 The database provides the largest source of cell-
based anticancer testing data to date which is accessible through 
PubChem.26 Using this database, it is also possible to identify compounds 
which may exhibit a similar mechanism of action by comparing patterns of 
activity across the cell line panel; this is achieved using a computerized 
pattern recognition programme known as the ‘COMPARE algorithm’. This 
method has proven successful in positively correlating the phenotype 
produced by compounds with known inhibitors to identify the target that the 
compound interacts with.27 The NCI60 drug evaluation programme remains 
an invaluable tool for identification of novel anticancer agents, with around 2 
% of the hit compounds proceeding from the in vitro screen to in vivo studies. 
Subcutaneous tumour growth in immune-compromised mice is used for initial 
toxicity and activity studies in vivo. Animal models provide vital information 
on how a potential drug compound may perform in living organisms and 
provide an invaluable bridge between in vitro studies to in vivo patient trials.28 
As well as potentially predicting the in vivo efficacy of the compound in 
humans, informative pharmacological and toxicological data can be 
obtained.21 As they possess genomes over 95 % identical to humans, mice 
are primarily used for in vivo studies of potential anti-cancer drugs.28 Human 
tumour xenografts can be easily formed in mice by injection of human tumour 
cells subcutaneously, which is the most widely employed method due to the 
reliability, reproducibility and predictions of efficacy in man are most 
accurate.21,28 Alternatively, an orthotopic model can be employed whereby a 
human tumour is implanted into the mouse at the site equivalent to where the 
tumour would arise in man. This method may possess benefit in that the 
tumour is in an environment that more closely represents the site in which 
the original tumour arose, and therefore may better represent the original 
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human tumour. However, insertion of the tumour into some anatomically 
relevant sites is often impractical and certainly more challenging that 
subcutaneous injection of tumour.28 Another possibility is to utilise genetically 
engineered mice that are susceptible to development of cancer that 
recapitulates the human disease. Such models are thought to have great 
potential in screening of target-based therapies which induce cytotoxicity 
through changes in the tumour or its microenvironment.21 However, this 
method is not routinely used in preclinical testing and may be the least 
reproducible across different laboratories as tumour location, metastasis and 
onset varies greatly between the mice used in any group.28  
Although in vivo studies benefit from providing a more realistic environment 
for the cells compared to in vitro studies, as the tumour is able to form 
interactions with surrounding microenvironment, this may differ considerably 
between the mouse model and humans. Therefore it cannot be assumed that 
this is an accurate prediction of how the drug candidate may perform in a 
human model. In man, the complexity of the human tumour can be much 
greater and many factors will differ to the mouse model, such as the size, 
position and stromal interactions with the tumour.  Therefore there is doubt 
over the predictive value of preclinical tests. Speculation over reliability arose 
when analysis of both xenograft data and Phase II clinical trial results by 
Johnson et al. found that data collected in in vitro studies did not correlate 
with activity in subcutaneously grown tumour models, which in turn was not 
reflected in clinical activity.29 However, there is strong evidence to support 
the reliability of the subcutaneous tumour model for prediction clinical 
activity. A study carried out by Fiebig et al., consisting of 80 comparisons 
between subcutaneous tumours in mice and clinical studies, found that 
clinical efficacy was correctly predicted in 90 % of tests for tumour sensitivity 
and 97 % for tumour resistance.30  Even with these limitations, preclinical 
testing is an important pathway to identify lead agents for evaluation in man; 
maybe most importantly identifying agents and agent combinations that are 
toxic and have poor bioavailability that should not be taken forward.      
An understanding of the pharmacokinetic properties of the drug candidate, 
can be assessed in vitro (e.g. permeability, solubility, metabolic stability) and 
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in in vivo animal models (e.g. clearance rate, half life and volume of 
distribution).31,32 These studies can support the pharmacological 
investigation by correlating predicted drug concentrations in plasma or tissue 
with predicted efficacy in man. 
1.5 Fenretinide background 
Vitamin A (retinol) was identified to have significant chemopreventive effects, 
due to observation of epithelial abnormalities that could progress to 
neoplastic lesions in retinol-deficient animals.33 However, the toxicity of 
vitamin A at the therapeutic dose has prevented it from being a successful 
treatment. Fenretinide (1) (Figure 1.2), an analogue of vitamin A, is a 
synthetic amide formed from all-trans-retanoic acid and 4-aminophenol and 
was first synthesised by Johnson & Johnson in the 1970s. It was initially 
patented as a potential sunscreen agent owing to its ultraviolet absorption 
properties34 and was later identified and patented as a potential 
chemotherapeutic agent for epithelial and breast cancer.35,36 However, the 
drug was not brought to market and is now out of patent.  
Fenretinide has since been found to have effective chemotherapeutic and 
chemopreventive activity in a wide range of human tumour cell lines by 
inducing apoptosis and growth inhibition.37 Clinical data suggests that it is 
one of a few retinoids which shows great potential as a chemotherapeutic 
agent due to its potent apoptosis-inducing properties, low off-target toxicity 
and favourable biological activity in a wide range of targets.38 It has been, 
and continues to be, evaluated in clinical trials where it has also been 
identified to be effective towards several cancer cell lines, including lung, 
breast, head and neck, prostate and skin cancer.39,40,41,42 Previous trials have 
evaluated fenretinide in children diagnosed with neuroblastoma as both a 
 
Figure 1.2 Molecular structure of fenretinide. 
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maintenance therapy as well as a primary anti-tumour agent in patients in 
early-stages of the disease (see Section 1.8). 
The major limitation which prevents fenretinide from being a successful 
chemotherapeutic agent is its poor oral bioavailability. The drug is not easily 
absorbed into the body due to the high lipophilicity of the compound, 
requiring administration of large quantities of the drug to achieve required 
plasma levels for effective activity.43,44 
1.6 Mechanism of action of fenretinide 
Although the intracellular pathways executing the effects of fenretinide have 
been well described in different cancer types, how fenretinide initiates cell 
death remains controversial.40,45,46 Potential mechanisms of action are cell-
type specific and can be retinoid-receptor mediated or non-receptor 
mediated.  
1.6.1 Retinoid-receptor mediated pathways 
A receptor-mediated pathway was identified by suppression of fenretinide-
induced apoptosis in the presence of a nuclear retinoic acid receptor-specific 
antagonist, indicating that retinoic acid receptors (RAR) may play an 
important role in apoptosis of a range of cancer cells (e.g. head and neck 
squamous cell carcinoma, non-small-lung cell carcinoma and human 
prostate cancer carcinoma cells).40,46 
In a study of the effect of fenretinide on a panel of F9 murine embryonal 
carcinoma cell lines, which includes wild-type (F9-WT) and mutant cells (F9-
KO) that have disrupted genes for both RXR-α and RAR-γ retinoid receptors, 
two distinct effects were identified. Firstly, inhibition of cell-growth is induced 
rapidly at higher concentrations in both F9-WT and F9-KO cells. Secondly, a 
slower induction of cell cycle arrest and accumulation in the G1 phase was 
observed at lower concentrations in F9-WT cells only.38 This indicates that 
fenretinide may function differently at varying concentrations (i.e. RAR/RXR-
dependent mechanism at lower concentrations and independent at higher 
concentrations).47 Transactivation assays have identified that fenretinide 
upregulates both RAR-β and RAR-γ gene expression at concentrations as 
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low as 1 µM, which is thought to be a contributor to its apoptotic effects.48,49 
However, the induction of apoptosis through this mechanism is not the 
predominant route to cell death in most cell lines due to the low affinity for 
binding of fenretinide to RARs. Fenretinide binds to RARs and activates 
these receptors much less strongly than the native ligand, all-trans-retinoic 
acid, and therefore exhibits significantly lower toxicity than the parent 
compound.43,50  
1.6.2 Retinoid receptor-independent mechanisms 
There are alternative mechanisms, independent of RAR activation, through 
which fenretinide initiates cell death in cancer but not in normal cells, 
although these are poorly understood.51,52  
A range of cell types have shown suppression of fenretinide-induced 
apoptosis upon pre-treatment with an oxidising agent, consistent with the 
hypothesis that the mechanism is dependent upon reactive oxygen species 
(ROS). The generation of ROS gives rise to an important retinoid receptor-
independent mediated pathway for fenretinide-induced cell death which has 
been described in several cell lines.40,45,46,49,53 
ROS are highly reactive activated species of oxygen in the reduced state. 
Examples of ROS measured within the cell include superoxide (O2•-), 
hydroxyl radicals (OH•), singlet oxygen (O2*) and hydrogen peroxide 
(H2O2).54 ROS are generated through multiple mechanisms which can be 
specific to cell type. A major source of ROS generation is NADPH complexes 
(primarily complexes I and III) and several additional sites located in cell 
mitochondria.55,56  
Although cellular functions of ROS remain largely unknown, they have been 
reported to drive cell signalling and cell death pathways.57,58,59 Elevated 
levels of production are known to play a role in tumour biology, with oxidative 
stress causing damage to DNA which can contribute to cancer initiation and 
progression.60 
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Despite their frequent involvement in the development of cancers, ROS are 
also known to have therapeutic effects by induction of necrosis and 
apoptosis. It is thought that the ROS can initiate several independent cell-
death cascades, for example, mitochondrial membrane permeability 
transition, caspase activation, protein degradation, DNA damage and 
extensive oxidation of cellular components, which leads to subsequent cell-
death.61,62,63  Oxidative stress resulting from accumulation of ROS in the cell 
is thought to activate sphingomyelinases and increase ceramide production, 
which in turn promotes apoptosis in response to secretion of inflammatory 
cytokines.64 Metabolism of ceramide to glycosphingolipid GD3 increases 
cellular levels of GD3, which is thought to increase the activity of 12-
lipoxygenase and has been shown to induce apoptosis through oxidative 
stress-dependent induction of the transcription factor GADD153 and pro-
apoptotic protein BAK.63,64,65 
Fenretinide is known to generate mitochondrial ROS, this being critical for 
induction of apoptosis in neuroblastoma cells.66 Previous research within our 
group has demonstrated that increased levels of ROS are observed in all 
substrate adherent ESFT cell lines compared to neuroblastoma cell lines, 
which correlated with the increased sensitivity of the ESFT cells towards 
fenretinide induced cell death.67 Furthermore, cell death of ESFT cells was 
rescued by co-treatment with antioxidant vitamin C which eliminates ROS, 
indicating that ROS play an important role in the initiation of cell death. 
Several possible co-factors for fenretinide-induced cell death by ROS-
dependent mechanisms have been identified within the group (Figure 1.3). 
p38MAPK is activated by release of apoptosis signal-regulating kinase 1 
(ASK1) from its complex with theoredoxin (TRX). TRX binds ASK1 in its 
reduced form but upon oxidation by ROS a disulphide bridge forms between 
two cysteine residues within the active site and releases ASK1.68 ASK1 
becomes activated by phosphorylation, which in turn leads to 
phosphorylation and activation of p38MAPK.69 Activated p38MAPK induces 
mitochondrial membrane depolarisation and subsequent release of 
cytochrome C into the cytoplasm; the release of cytochrome C can be 
regulated by pro- and anti-apoptotic mitochondrial membrane proteins such 
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as BAX and BCl-2.70,71 These are critical components of the cell death 
cascade which are downstream of elevated ROS levels. Activation of c-Jun 
N-terminal kinase (JNK) was also observed, although it is unclear as to 
whether this is dependent upon ROS production and if this is an essential 
component in the cell death cascade in all cell types. Finally, caspase-9 
followed by caspase-3 activation was observed, which was found to be 
dependent on ROS generation, p38MAPK activation and mitochondrial 
membrane depolarisation (∆ψm). Caspase activation is a critical step that 
marks the point of no return in the cell death cascade. Caspases are a family 
of cysteine proteases for which sequential activation leads to initiation of cell 
death via apoptosis. Full length caspases exist in the inactive form as 
proenzymes which undergo proteolytic cleavage at specific aspartate 
residues, to yield two sub-units (large and small), which upon dimerisation 
form the active enzyme.72,73 Caspase-3, for example, is cleaved from a 32 
kDa zymogen into 17 kDa and 12 kDa subunits upon activation by either 
intrinsic (pro-apoptotic intracellular mediated) or extrinsic (receptor–
mediated) pathways. 
ROS dependent cell death is consistent with findings made by other groups 
∆ψm = membrane depolarisation.
Figure 1.3 Intracellular signalling cascades of fenretinide-induced apoptosis.67,68,69,77  
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against a range of cancer types. For example, a stress response to an 
increase in cellular ROS has been observed to induce the elimination of 
ovarian cancer cells. This was also determined by the observation of 
inhibition of fenretinide-induced apoptosis upon pre-treatment of the cells 
with the antioxidant vitamin C, which quenches the ROS therefore blocking 
this mechanism of action.74 In this cell line, ROS were shown to activate the 
endoplasmic reticulum (ER) stress response, which subsequently induces 
JNK activation, consequently leading to apoptosis.30 Other cancer types for 
which fenretinide-induced ROS production is critical for cell death include 
selected cell lines of human prostate cancer,46 human leukemia,75 cervical 
carcinoma,76 head and neck, and lung cancer.46  
Another pathway of fenretinide-induced apoptosis, independent of 
mitochondrial membrane depolarisation but dependent on ROS generation, 
has been identified within the Burchill group. This is dependent on 
upregulation of cell surface death receptor (DR) proteins (DR5, Fas and 
p75NTR) in an ASK1- and p38MAPK-dependent manner.77 Our group 
investigated co-treatment of ESFT cells with fenretinide and TRAIL, a cell 
death ligand which induces caspase-dependent apoptosis. Activation of 
caspase-8 was observed upon co-treatment, but was not activated by the 
respective ligands independently. Fenretinide therefore appears to 
upregulate cellular DRs, enhancing the caspase-dependent apoptosis of 
TRAIL. 
Ulukaya et al. also recently investigated the application of fenretinide (due to 
its known ROS generation activity) in combination with caspase-activating 
TRAIL.78 Caspase-3 activation was not observed upon treatment of the 
MDA-MB-231 breast cancer cell line with fenretinide but was upon treatment 
with TRAIL. The IC50 values of fenretinide and TRAIL in this cell line were 2.7 
µM and 19.5 ng/ml respectively. It is therefore thought that fenretinide 
induces cell death via a caspase-3 independent mechanism in this cell line 
(e.g. ROS-dependent mechanism). Strikingly improved activity was observed 
at a combined dose of 2.5 µM fenretinide and 20 ng/ml TRAIL, where cell 
viability was reduced to ca. 25 %. At the same concentrations, cells treated 
with fenretinide or TRAIL separately demonstrated ca. 80 % and ca. 60 % 
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viability respectively. This suggests that fenretinide may act through different 
mechanisms in different cell lines and combining fenretinide treatment with a 
compound that activates a complementary cell death mechanism to itself 
may induce additive or synergistic cell death. 
1.7 Pharmacokinetics of fenretinide 
The pharmacokinetics (known as absorption, distribution, metabolism and 
excretion (ADME)), of fenretinide has been extensively studied. To be a 
useful clinical agent, a drug must not only elicit a potent and selective 
biological effect, but also demonstrate a good pharmacokinetic profile in 
order to have the potential for sufficient exposure at the target site. Ideally a 
drug will have a long half-life, low clearance and good oral bioavailability in 
order to limit the dosing requirements. 
1.7.1 Absorption 
The main disadvantage of fenretinide as a therapeutic agent is its poor 
bioavailability due to poor oral absorption of the drug. This could be due to 
several possible factors, including poor aqueous solubility (< 10 ng/ml), 
accumulation in lipophilic cell membranes, inadequate absorption in the 
gastrointestinal tract and poor metabolic stability.44,79,80,81,82 Reflecting the 
poor ability of fenretinide to pass through the gut wall, it is excreted primarily 
in faeces.44  
A study of transport of fenretinide across Caco-2 cell monolayers was carried 
out and the drug was found to permeate the membrane by passive diffusion, 
moving from a region of high concentration to a region of lower 
concentration, at a poor rate.44 After 3 h, there was a 16 % decrease in the 
initial fenretinide concentration in the donor well; however only 0.12 % of this 
diffused into the receiver well, indicating that the majority of the transported 
fenretinide was remaining within the cell bilayer. Accumulation of the drug in 
the lipid cell bilayer, commonly observed for highly hydrophobic molecules, is 
therefore a limitation to the rate of transport via the transcellular route. Tight 
junctions and a small surface area cause the paracellular route through the 
gut wall to be inefficient in comparison, and transport through the water-filled 
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pores is not considered to be a significant pathway for highly lipophilic 
species such as fenretinide. 
1.7.2 Distribution and intracellular delivery 
Using current oral formulations of fenretinide it is possible to achieve plasma 
concentrations of ca.10 µM, which may be effective for some cancer 
types.14,82 Unfortunately, the highly lipophilic nature of fenretinide results in 
accumulation of the drug in fatty tissue which is likely to hinder the 
distribution process and prevent high enough concentrations of the drug from 
reaching a specific target.45 In certain cases this property may also be a 
benefit, where the cancer is formed in an area with a high density of fatty 
tissue. For example, this may contribute to its effectiveness against breast 
cancer, for which a series of phase III trials proved that fenretinide 
significantly reduced the risk of recurrence of breast cancer in pre-
menopausal women.83 However, this property is a disadvantage for many 
other targets as the effective concentration at the required site can be 
significantly reduced. 
Fenretinide has been shown to bind to the retinol binding protein 4 (RBP4) in 
a similar manner to retinol, leading to suggestions that RBP4 is likely to be 
responsible for the transport of the drug in blood around the body and 
potentially a cofactor to its transport into the cell.84,85 It is thought that 
fenretinide is able to penetrate the cell membrane of ESFT cells through a 
cell surface receptor, STRA6, in a similar fashion to retinol; this hypothesis is 
currently being investigated by Dr Helen Payne and Professor Sue Burchill.86 
The STRA6 transmembrane protein is encoded by the gene STRA6 which is 
part of a collection of genes that are activated by retinoic acid. This extensive 
group of genes are known to encode many transmembrane proteins and 
other proteins for which their purpose is unknown.87 The STRA6 receptor is 
known to bind to the retinol-RBP4 complex at the cell surface with high 
affinity, aid removal of retinol from RBP4 and transport the molecule across 
the cell membrane.87  
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1.7.3 Metabolism 
As the liver metabolises foreign chemicals to more favourable compounds for 
excretion from the body, metabolism of fenretinide may be disadvantageous 
owing to a lowering of the plasma concentrations of the compound.47 Two 
metabolites of fenretinide have been described : 4’-methoxyphenylretinamide 
(4’-MPR) (2), containing a methoxy substituent in place of the hydroxy group 
of fenretinide and 4-oxo-fenretinide (3), which contains a carbonyl group at 
the 4-position of the cyclohexene ring of fenretinide (Figure 1.4.).37 4’-MPR is 
reported to be the most abundant metabolite in human plasma following 
fenretinide administration. However, this metabolite is biologically inactive.37 
This is thought to reflect the lack of an ionisable substituent on the 
phenylamine ring which may reduce binding affinity to a relevant receptor 
site(s) and also inhibit ROS formation, therefore preventing apoptosis via this 
mechanism.37,38,45 Breakdown of fenretinide to 4’-MPR may therefore be a 
disadvantage and it could be favourable to block the degradation of 
fenretinide via this route.  
4-Oxo-fenretinide (3) (Figure 1.4.) was later identified in the plasma and has 
been found to have significantly higher biological activity, including higher 
growth-inhibitory and apoptotic effects, than the parent drug.37 The IC50 
concentrations of 4-oxo-fenretinide are significantly (ca.2-4 times) lower than 
those for fenretinide in an in vitro cell proliferation assay against 
neuroblastoma cell lines,47 and are at least equivalent to the IC50 for 
fenretinide in ESFT cell lines.86 However induction of apoptosis by 4-oxo-
fenretinide induced cell cycle arrest in the G2-M phase, rather than the G1 
 
Figure 1.4 Molecular structures of metabolites methoxyphenylretinamide (2) and 4-oxo-
fenretinide (3). 
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phase as for fenretinide, resulting in lack of cross-resistance and synergy 
when combined with fenretinide.37 The formation of 4-oxo-fenretinide was 
identified to be due to induction of expression of a retinoic acid-metabolising 
enzyme, cytochrome P450 26A1, which catalyses the specific hydroxylation 
of fenretinide at the 4-position of the cyclohexene ring.80  
The observed Cmax observed for both metabolites was lower than that for 
fenretinide, indicating that they may be excreted from the blood more readily 
than the parent drug. Therefore, despite 4-oxo-fenretinide having higher 
biological activity, the lower achievable concentration in vivo could reduce 
the effective activity due to a significantly lower amount reaching the target. 
1.7.4 Limiting the rate of metabolism of fenretinide and analogues 
This section describes approaches to reduce the rate of metabolism of 
fenretinide and analogues in vivo. These methods include the inhibition of 
enzymes responsible for metabolism of fenretinide (using metabolism 
blocking agents), as well as the synthetic variation of fenretinide to generate 
analogues with an improved metabolically stability profile. 
1.7.4.1 Metabolism blocking agents 
Roberts et al. originally identified the cytochrome P450 enzymes (CYPs) to 
be primarily responsible for oxidative metabolism of retinoic acid (6). The 
group’s experiments concluded that the microsomal location of these 
enzymes, in addition to the requirement for NADPH and oxygen, suggested 
a CYP-dependent enzyme system.88 CYPs metabolise all-trans-retinoic acid 
via several routes leading to a mixture of polar metabolites. Initially, 4-
hydroxy-all-trans-retinoic acid (4) is formed; this is thought to be the 
physiologically most favourable pathway and rate-limiting step to alternative 
metabolites. Other metabolism products identified are 4-oxo-all-trans-retinoic 
acid 18-hydroxy-all-trans-retinoic acid (5), and 5,6- epoxy-all-trans-retinoic 
acid (8) by epoxidation and radical oxidation (Figure 1.5).89 
As discussed above, CYPs have also been reported to be responsible for 
oxidation of fenretinide to the polar metabolites 4-oxo-fenretinide and 4-OH-
fenretinide.90  
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There have been successful attempts at blocking undesired metabolism of 
retinoids in order to increase the effective concentration of the drug in the 
blood plasma. Extensive research into blocking of retinoic acid metabolism 
has been carried out by the Janssen Research Foundation (now Johnson 
and Johnson Pharmaceutical Research and Development). Initial 
compounds tested for a reduction in metabolism of retinoic acid include 
known CYP inhibitors; ketoconazole (9), liarozole (10) (Figure 1.6), 
aminoglutethimide, cimetidine, itraconazole, metyrapone and 
saperconazole.91 Pretreatment with ketoconazole or liarozole (40 mg/kg), 
when administered orally 1 h before intravenous retinoic acid treatment, 
reduced the elimination of retinoic acid from plasma and extended the half-
life in control-treated animals from 27 min to 43 min and 76 min, respectively. 
No significant effect was observed upon co-treatment with the remaining 
CYP inhibitors. Furthermore, ketoconazole (9) (Figure 1.6) has been 
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Figure 1.6 The chemical structure of fenretinide metabolism-blocking agent, 
ketoconazole. 
 
Figure 1.5 Known oxidative metabolites of retinoic acid. 
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demonstrated to successfully reduce fenretinide metabolism in vivo. One 
example is detailed in a patent application from the Children’s Hospital Los 
Angeles Research Institute, in which in vivo screening in mouse models 
looking at the effect of ketoconazole on plasma fenretinide levels found that 
the compound successfully increased fenretinide plasma levels.92  
Liarozole (10) (Figure 1.6) was subsequently approved in Europe and USA 
(2004) as an orphan drug for the treatment of congenital ichthyosis, providing 
therapeutic effects by slowing down metabolism of the body’s own retinoic 
acid.93 As an anti-cancer agent, it has been shown to demonstrate promising 
inhibition of metabolism of retinoic acid in MCF-7 human breast cancer cells 
and rat Dunning R3327G  prostate tumours.94,95 However, Liarozole was 
found to lack CYP specificity and inhibited the CYP-mediated bio-synthesis 
of steroid hormones.96,97 The Janssen Research Foundation subsequently 
identified two novel benzothiazolamine retinoic acid metabolism blocking 
agents (RAMBAs), R115866 (11) and R116010 (12) (Figure 1.7), as highly 
potent and selective second-generation RAMBAs. R115866 (11) is a 
nanomolar (IC50 4 nM) inhibitor of the CYP26-dependent retinoic acid 
conversion, making it 750 times more potent than liarozole (IC50 3 µM).98  In 
vivo studies found R116010 (12) potently inhibits retinoic acid metabolism in 
TA3-Ha murine mammary carcinoma cells (IC50 8.7 nM), making it  over 100-
fold more potent than liarozole (IC50 value 1.4 µM).99 In addition, R116010 is 
a selective inhibitor for several CYPs.  
Human liver microsomes, along with CYPs, are known to metabolise retinoic 
acid (6) by oxidation of the 4-position.90 Based on the retinoic acid scaffold, 
Patel et al. successfully synthesised a range of analogues which effectively 
inhibited hamster liver microsomal all-trans-retinoic acid metabolism 
 
Figure 1.7 RAMBAs identified by the Janssen Research Foundation. 
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enzymes.100 Compounds including (13) and (14) (Figure 1.8.), were designed 
to include a metabolically robust imidazole substituent at the 4-position of the 
cyclohexene ring. In addition to enhancing the activity of retinoic acid in an 
MCF-7 cellular assay, the compounds were found to also display potent 
antiproliferative effects and induction of apoptosis and differentiation was 
observed in several human cancer cell lines, giving these particular 
compounds an advantage of multiple mechanisms of action not observed in 
this model for fenretinide. 
1.7.4.2 Fenretinide analogues with improved metabolic stability 
Dawson et al. originally suggested that D-glucosiduronate analogues of 
fenretinide may be active in vivo due to metabolism of the phenol moiety by 
O-conjugation to D-glucuronic acid.101 The group detailed the synthesis of 
the proposed metabolism products, N-(4-hydroxyphenyl) retinamide-O-
glucuronide (4-HPROG) (15) and 2-retinamidoethyl-O-glucuronide (16) 
(Figure 1.9). Swanson et al. subsequently found that synergistic metabolism 
of fenretinide with dietary glucurate (D-glucuronic acid salt) provided an 
active compound which inhibited 7,12-dimethylbenz[a] anthracene (DMBA)-
 
Figure 1.8 Retinoic acid metabolism blocking agent and cyclohexyl analogues of retinoic 
acid. 
 
 
Figure 1.9 Structures of N-(4-hydroxyphenyl) retinamide-O-glucuronide (15) and 2-
retinamidoethyl-O-glucuronide (16). 
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induced mammary cancer in a rat model.102 Metabolism by β-glucuronidation 
improves solubility and detoxifies a compound by reducing its lipophilicity.103 
This finding was further investigated by Curley et al., whereby the stability of 
4-HPROG (15) was evaluated in MCF-7 cells.104 The group confirmed that 
the compound demonstrated good stability and interconversion to fenretinide 
was not observed over 24 h, concluding that this is an active species and not 
a pro-drug which yields fenretinide. The Curley group went on to develop 
additional analogues of 4-HPROG, whereby the hydrolysable O-glycosyl 
bond was replaced with a less hydrolysable CH2 group (compound 17) 
(Figure 1.10), and its biological activity was evaluated.105 Compound 17 was 
found to induce cell death in an in vivo rat mammary tumour model and 
displayed improved toxicity in vitro compared to fenretinide. Additionally, 
these non-hydrolysable analogues of 4-HPROG demonstrated good activity 
in the rat tumour model, confirming that the metabolite molecules induce 
activity and that conversion to fenretinide is not necessary for activity. 
However, activity of these metabolites was marginally reduced compared to 
the activity of fenretinide in MCF-7 breast cancer cells.  
Several modifications to the lipohilic trans-alkene portion of fenretinide have 
been made to increase the metabolic stability. This research will be 
discussed in Section 1.10.4.  
1.8 Clinical Efficacy of fenretinide 
In phase I clinical trials fenretinide has been well tolerated in both adults and 
children. A phase I trial in children with neuroblastoma was carried out in 
order to determine the maximum tolerated dose, toxicity and 
pharmacokinetics.106 Doses between 100 and 4,000 mg/m2/day were 
administered orally as an oil formulation in gelatine capsules. It was 
 
Figure 1.10 A non-hydrolysable analogue of N-(4-hydroxyphenyl) retinamide-O-
glucuronide, whereby the O-glycosyl bond was replaced with a CH2 group. 
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concluded that 4,000 mg/m2/day was well tolerated over 28-day courses 
when followed by a 7-day drug-free interval. Additional dose escalation was 
not possible due to large amounts of capsules (ca.40 per day) being 
unpalatable for the patient; therefore the maximum tolerated dose could not 
be established in this study. The same trial identified that the peak plasma 
concentration of fenretinide was achieved approximately 4-5 h after 
administration of the drug, and that peak levels and absolute bioavailability 
was increased 2-fold by day 28. Out of 53 patients treated for progressive 
disease, 88 % underwent further progression and died. However, prolonged 
disease stabilisation was observed in the majority of patients showing early 
progression, with some showing regression of neoplastic lesions. 
Subsequent phase II and III trials have confirmed that fenretinide does not 
demonstrate clinical efficacy at lower dose levels (600-900 mg/m2-
/day).107,108,109 It is stated that higher dose levels and prolonged treatment 
are required to obtain blood plasma concentrations to achieve a clinical 
benefit. Oral administration of a dose range between 300-4000 mg/m2/day 
maintains plasma concentration levels of fenretinide between 0.7-10 µM. The 
achieved plasma concentrations of the drug were found to be sufficient for 
required pharmacological activity and were successfully maintained for 24 h 
between dosing intervals, as supported by the calculation of an elimination 
half-life of 22 h.47 
Continuous administration of the drug over a longer period of time also 
improves growth inhibitory effects in solid tumours compared to shorter 
courses of treatment followed by a drug-free interval.47 This is likely to be a 
consequence of the significant reduction in half-life from ca.22 h to ca.12 h 
when a drug-free interval is incorporated into the scheduling, therefore 
reducing the exposure of the tumour to fenretinide and the active metabolite 
4-oxo-fenretinide. Unfortunately, continuous administration of fenretinide 
results in an unfavourable toxicity profile. Where side effects are minimal and 
reversible when a drug-free period is taken, they are likely to become 
unmanageable upon continuous administration where the maximal tolerated 
dose of 2,475 mg/m2/day can be exceeded.82 
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Co-treatment with Lym-X-Sorb (LXS), a novel lipid matrix drug delivery 
formulation, has been evaluated in an in vivo mouse model, where an 
increase in fenretinide plasma concentration of up to 4-fold and an increase 
in tissue concentrations of up to 7-fold compared with similar doses of 
fenretinide alone was observed.110 This therefore has potential for improving 
fenretinide plasma concentrations and increasing bioavailability and is 
currently being evaluated in two phase I clinical trials; ‘Intravenous 
Fenretinide in Treating Young Patients With Recurrent or Resistant 
Neuroblastoma’ and ‘Fenretinide LXS in Treating Patients With Recurrent, 
Refractory, or Persistent Neuroblastoma’.111 
Early trials on topical drug delivery of fenretinide have also been investigated 
in various cancer cell types including oral lichen planus, leukoplakias and 
facial actinic keratoses.112 Although topical administration is only possible for 
a narrow range of cancer types, this appears to be a highly effective 
treatment for the aforementioned cell types, with a high percentage of 
patients showing complete or partial regression. However, only a small 
number of patients were monitored in these trials therefore further 
investigation into this route is required to confirm findings.112  
1.9 Side effects of fenretinide 
Several toxicities have been observed upon administration of fenretinide in 
patients at the higher dose levels which exhibit a higher absolute 
bioavailability. There are several minor side effects associated with 
fenretinide, including skin xerosis, fatigue, nausea and diarrhoea. The most 
commonly encountered side effect associated with the drug is impairment to 
visual dark adaptation (night-blindness), which increases in severity with 
dose level. This is likely to be due in part to inhibition of binding of retinol to 
RBP4 caused by a similar mode of binding of fenretinide to the protein, 
therefore reducing the transport of retinol around the body and consequently 
the retinol plasma concentation.113 However, a phase I clinical trial showed 
that all of the adverse reactions were reversible upon discontinuation of the 
drug and that night-blindness significantly diminished upon reduction of dose 
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level. This effect can therefore be minimised by taking a 7-day drug-free 
interval after each 28-day treatment period.106  
Night-blindness may also be brought on by hydrolysis of fenretinide to 
retinoic acid, which has been found to inhibit ocular retinol dehydrogenases 
in vitro leading to a reduction in formation of 11-cis-retinal (a visual 
chromaphore).114,115 In an attempt to reduce night-blindness via this 
mechanism, Anding et al. investigated the possibility of reduction of the in 
vivo generation of retinoic acid from fenretinide by design of a hydrolytically 
stable version of fenretinide, 4-hydroxybenzylretinone (4-HBR) (18) (Figure 
1.11).114 As predicted, it was found that this compound was not hydrolysed in 
vivo to all-trans-retinoic acid, thus eliminating night-blindness induced by 
retinoic acid generation. Furthermore, 4-HBR was found to prevent a 
decrease in circulating retinol levels, also eliminating the risk of night-
blindness.  
Systemic side effects were eliminated upon topical administration as the drug 
was not absorbed into the circulation and no local side-effects were 
observed.112 Topical drug delivery or lower-dosage oral administration may 
therefore provide an alternative treatment with significantly lower toxicity. 
However, these may have limited application in the treatment of cancer due 
to the relatively high plasma concentration required to provide 
chemotherapeutic effects and sufficient activity to combat systemic 
metastasis, with the possible exception of those where you could apply 
fenretinide topically (e.g. melanoma, oral cancer, cervical cancer). 
1.10 Structure Activity Relationship (SAR) of fenretinide 
A structure activity relationship (SAR) is the relationship between the hit, lead 
or drug and its biological activity. The analysis of the SAR for a hit, lead or 
 
Figure 1.11 Molecular structure of 4-hydroxybenzylretinone. 
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drug enables the understanding of the chemical groups on the molecule 
which are responsible for evoking the biological activity. Hence, knowledge 
about the SAR allows for the predictive and rational modification of chemical 
structure in order to appropriately fine-tune the biological response. 
Very little is known about the SAR for fenretinide in cancer cell lines, 
including for the ESFT cell lines. Surprisingly few studies have been directed 
towards development of SAR, despite the fact that the cytotoxic properties of 
fenretinide have been known since the 1970s.36  This lack of investigation 
into the SAR for fenretinide is probably, at least in part, due to the fact that 
the biomolecular target of fenretinide is unknown, making structure-based 
design of new analogues impossible. The few analogues of fenretinide which 
have been generated to date have been screened using a range of cell lines, 
from a variety of different cancer types for induction of cell death. This has 
made it difficult to build up a coherent SAR for fenretinide as it is possible 
that different cell lines are affected differently and cell death could be initiated 
by different mechanisms of action. Equally, experimental methods within 
different laboratories vary, for example by treatment times, concentrations 
and assay types. 
This section describes the SAR for fenretinide and fenretinide analogues as 
chemotherapeutics. For organisation of this section, it has been divided into 
four parts based on substructures of fenretinide, to include the phenyl ring, 
the cyclohexene ring, the central scaffold, and the amide (Figure 1.12). 
Although this review is aimed primarily at discussion of the SAR of 
fenretinide, some of the discussion, particularly around the cyclohexene and 
central scaffold sub-sites, focuses on the SAR of alternative retinoids 
(retinoic acid and retinol) owing to their commonality of structure at this site 
and their common use as chemotherapeutics.  
 
Figure 1.12 A schematic outlining the 4 regions of variation of the fenretinide scaffold. 
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1.10.1 SAR of the phenyl ring 
Of the substructures highlighted in Figure 1.12, synthetic variation at the 
phenyl portion of fenretinide has been the most widely studied. This is 
presumably due to the relative simplicity of the chemistry involved in 
generation of analogues for variation at this site.  
A library of fenretinide-like compounds with variation on the phenyl ring was 
prepared by Sabichi et al.38 The group focussed on investigation of the effect 
of ortho-, meta- and para- ring substitution using a set of hydroxyl, carboxyl 
and methoxy substituents. Six compounds (19-24) (Table 1.1) were 
synthesised and tested in vitro for both cell growth inhibition and retinoid X 
receptor- (RXR) or RAR-dependence. To test RXR/RAR dependence, the 
group analysed the activity of the compounds on a panel of F9 murine 
embryonal carcinoma cell lines, which includes wild-type (F9-WT) and 
mutant cells (F9-KO) that have disrupted genes for both RXR-α and RAR-γ 
retinoid receptors. They found that all 6 compounds induced cell growth 
inhibition against both cell lines in an MTT assay, with 3 of the compounds 
(20, 21 and 24) inducing similar levels of activity to fenretinide at 10 µM (70-
80 % inhibition of cell viability vs > 80 % for fenretinide). The results 
suggested that, although relocation of the OH around the phenyl ring or its 
replacement with a carboxylic acid or methoxy group was tolerated, the para-
hydroxy substitution was still favoured. The activity of the compounds was 
 
Compound R2  R3 R4 R5 R6 Growth inhibition* 
1 (fenretinide) H H OH H H +++ 
19 OH H H H H + 
20 H OH H H H ++ 
21 CO2H H H H H ++ 
22 H CO2H H H H + 
23 H H CO2H H H + 
24 H H OCH3 H H ++ 
                                              * + ca.30-65% growth inhibition; ++ ca.70-80% growth inhibition; +++  
                                              ca.80% growth inhibition of F9-WT/F9-KO cells at 10 µM. 
Table 1.1 Analogues of fenretinide with varying phenylamine substituents synthesised by 
Sabichi et al and their effects on F9 murine embryonal carcinoma cell growth.38  
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similar in both the F9-WT and F9-KO cell lines, indicating a RXR/RAR-
independent mechanism. Retinoic acid displayed reduced activity in F9-KO 
compared to F9-WT, confirming its retinoid-receptor dependence which is 
associated with accumulation of cells in the G1 phase of the cell cycle. The 
group concluded that a polar substituent is necessary on the phenylamine 
ring to induce RAR-dependent G1 accumulation. This could be a hydroxyl 
(any position) or carboxyl substituent (ortho-/para-) to the alkyl chain. Unlike 
the compounds bearing a charged moiety, 4’-MPR (24) displayed an inability 
to induce RAR-dependent actions in cotransfection reporter assays, 
indicating that an alternative mechanism of action is responsible for activity 
of this compound. When tested against a panel of cell lines, 4’-MPR also 
failed to induce significant growth inhibition, suggesting that the high levels of 
inhibition observed upon treatment of F9-WT and F9-KO is cell-line 
specific.38 
Mershon et al. went on to prepare a library of 49 fenretinide analogues, 43 of 
which were substituted phenyl analogues representing a wider variation of 
substitution at the phenyl ring (21 and 24-65) (Table 1.2).116 Screening of this 
library using a cell viability assay against the MCF-7 human mammary 
tumour cell line identified 12 active analogues of fenretinide (with 25-100 % 
the activity of the fenretinide standard). The most active compound from the 
library, compound 42, displayed comparable levels of activity compared to 
fenretinide (activity ≥ 100 % the activity of the fenretinide standard), closely 
followed by compound 31 which displayed activity approaching that of 
fenretinide. Compound 42 contains a 2-hydroxy and 4-nitro substitution 
pattern on the phenyl ring, implying that a charged substituent on the ring is 
important for growth inhibition. However, relocation of the OH or NO2 groups 
to alternative positions around the ring (compounds 40, 41 and 43) 
significantly reduced activity, implying that the position of the polar moieties 
is important for activity for this compound series. It is noteworthy that the OH 
group was tolerated in a variety of positions around the phenyl ring. This was 
demonstrated for a series of compounds where the phenyl ring was 
substituted with both OH and CH3, Cl or NO2 group at the ortho-, meta- 
and/or para- positions; for instance, compounds 31 (3-OH, 4-CH3) and 42 (2-
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OH and 4-NO2) demonstrated comparable activity to fenretinide and 27 (2-
OH, 4-CH3), 35 (3-Cl, 4-OH) and 36 (2-OH, 5-Cl) over 50 % the activity of 
 
Compound R2  R3 R4 R5 R6 MCF-7 growth inhibition* 
1 (fenretinide) H H OH H H +++ 
25 CH3 H OH H H - 
26 CH3 H OH CH3 H - 
27 OH H CH3 H H ++ 
28 OH H H CH3 H - 
29 OH H H C(CH3)2 H - 
30 OH H H H CH3 - 
31 H OH CH3 H H +++ 
32 CH3 OH H H H - 
33 H OH OCH3 H H - 
34 Cl H OH H H - 
35 H Cl OH H H ++ 
36 OH H H Cl H ++ 
37 H Cl OH Cl H - 
38 H Br OH Br H - 
39 OH Cl CH3 Cl H - 
40 NO2 H OH H H - 
41 H NO2 OH H H - 
42 OH H NO2 H H +++ 
43 OH H H NO2 H + 
44 OH CO2CH3 H H H - 
45 OH CO2H H H H - 
46 OH H CO2CH3 H H + 
47 OH H CO2H H H - 
48 OH H H H CO2CH3 - 
49 OH H H H CO2H - 
50 H OH CO2CH3 H H - 
51 H OH CO2H H H - 
52 H CO2CH3 OH H H + 
53 H CO2H OH H H - 
54 OH H H CO2CH3 H - 
55 OH H SO2CH2CH3 H H - 
56 CH2OH H H H H ND 
57 H CH2OH H H H + 
58 H H NH2 H H ++ 
59 CO2CH3 H H H H ND 
21 CO2H H H H H + 
60 H H OCH2CH3 H H - 
61 H H H H H + 
62 H H Cl H H + 
24 H H OCH3 H H + 
63 H H CH3 H H - 
64 H Cl Cl H H + 
65 H H N(CH3)3 H H - 
                                                        *
 -, activity equivalent to the vehicle; +, ≥ 25% the activity of; ++, ≥ 50% the activity; +++, ≥ 100% the  
                                     activity of the fenretinide standard at 1 µM; ND, not determined. 
a 
at 0.59 µM; 
b
 at 0.39 µM; 
c
 at 0.66  
                                     µM; 
d
 at 0.74 µM. 
Table 1.2 Analogues of fenretinide with varying phenylamine substituents synthesised by 
Mershon et al.and the effects on MCF-7 human mammary tumour cell growth.116 
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fenretinide. Good activity (≥ 50 % fenretinide control) was also retained upon 
substitution of the para-OH with NH2 (compound 58), indicating that a 
hydroxy to amino substitution at this site can be tolerated.  
The inactive compounds from the set included a range of alkyl/OH, 
halogen/OH, nitro/OH, carboxyl/OH, di/tri-substituted analogues (e.g. 
compounds 25, 26, 34, 40 and 51). Addition of more steric bulk around the 
phenyl ring (e.g. C(CH3)2, CO2CH3, SO2CH2CH3, OCH2CH3 groups, 
compounds 29, 54, 55 and 60 respectively) significantly reduced or 
abolished activity, indicating the possibility of a sterically constrained binding 
pocket at this site on a hypothetical biological target. 
Although the authors were unable to identify a robust SAR for substitution at 
the phenyl ring, they were able to conclude that substitution both ortho- and 
meta- to the amide, as well as substitutions and/or a change in the position 
of the hydroxyl group, can be tolerated for activity against the breast cancer 
cell line, MCF-7. Highest activity was observed for compounds containing a 
charged substituent on the phenyl ring, which reaffirms the findings made by 
Sabichi et al.38                                                       
Das et al. synthesised a library of 14 substituted phenylamides (24, 35, 41, 
62 and 66-74) as agents to inhibit proliferation of rhabdoid tumour cells 
(Table 1.3).117 Of the para-hydroxy containing analogues, substitution meta- 
to the amide with a halogen (compound 70, F; compound 35, Cl; compound 
71, I) was well tolerated in an MTS cell proliferation assay against rhabdoid 
tumour cells. Specifically, the meta-fluoro and chloro analogues (70 and 35) 
displayed a similar level of activity (IC50 8.0 and 12.5 µM respectively) to 
fenretinide (19 µM), and the meta-iodo analogue (71) displayed significantly 
increased activity (IC50 3 µM). Substitution ortho- to the amide with a second 
OH group (compound 74) also resulted in an encouraging level of cytotoxicity 
(IC50 8 µM, compared to fenretinide 19 µM). Conversely, a meta-NO2 
substituent (compound 41) eliminated cytotoxic activity, suggesting that a 
weak electron donating group at this position (i.e. a halogen) is more 
favourable than a strong electron withdrawing group. An ortho-halogen 
substituent increases the hydrogen bond donor capabilities of the adjacent 
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Compound R2  R3 R4 R5 R6 IC50 (µM) 
1 (fenretinide) H H OH H H 9-19 
66 H H F H H 150 
62 H H Cl H H >200 
67 H H Br H H 150 
68 H H I H H N/A 
69 H H NO2 H H >200 
24 H H OCH3 H H N/A 
70 H F OH H H 8 
35 H Cl OH H H 12.5 
71 H I OH H H 3 
41 H NO2 OH H H >200 
72 H H CH2OH H H 25 
73 H H (CH2)2OH H H >50 
74 OH H OH H H 8 
Table 1.3 Structures and biological activity of fenretinide analogues with varying 
phenylamine substituents synthesised by Das et al.117 
 
OH moiety compared to the phenol, potentially aiding an important 
interaction with the target. The meta-nitro substituent will increase the pi-
orbital stacking capabilities of the phenyl group which could account for the 
insolubility of this compound that the group observed. 
It is noteworthy that all of the most active compounds from the library share a 
para-hydroxy group, which supports the findings of Sabichi et al., and in part, 
those of Mershon et al. which suggest that a para-hydroxy group may be an 
important moiety for biological activity, perhaps by forming hydrogen-bonding 
interactions with a biological target or enabling ROS production. 
Replacement of the OH with halogens (compounds 62 and 66-78), NO2 
(compound 69) and OMe (compound 24) was found to significantly reduce or 
eliminate cytotoxic activity. Supporting the hypothesis for requirement of 
hydrogen-bonding at this site, extension of the OH group to the benzyl 
alcohol at the para-position (compound 72) resulted in a similar IC50 (25 µM) 
compared to fenretinide (19 µM) although the IC50 was increased (> 50 µM) 
when substituted with a hydroxyethyl group at the same site (compound 73).  
Um et al. designed and synthesised a range of retinamide and retinoate 
derivatives containing butyryl derivatives of the aminophenol moiety 
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(compounds 75-79) (Figure 1.13), based on butyric acid having been 
previously identified as an anticancer agent.50 Two retinamide derivatives 
(compounds 75 and 76) with IC50 of 1.67 µM and 3.15 µM respectively and 
three of the retinoate derivatives (compounds 77, 78 and 79) with IC50 of 
0.65 µM, 3.01 µM and 4.08 µM respectively were found to have an increased 
cytotoxicity compared to fenretinide (IC50 8.21 µM) against HCT116 colon 
cancer cells. All of the active compounds contain an ester linkage either at 
the retinoate or the butyrate site. This may help to explain the improvement 
in activity of these compounds in comparison to fenretinide owing to cellular 
hydrolysis of the ester resulting in liberation of a cytotoxic agent, either 
retinoic acid or butyric acid. It is also noteworthy that each of the active 
compounds contains a hydrogen-bond donor at the para-position of the 
phenyl ring in accordance with the findings of Sabichi et al. previously.38  
Sadikoglou et al. reported a synthesis of a series of conjugates of amino 
acids with retinoic acid (Figure 1.14) by succinimidyl activated coupling 
reactions.118 It was shown that those analogues containing α-amino acids 
with a lipophilic (valine) side chain (80) or linear (β-alanine) amino acids (81) 
successfully induced cell death in a human prostate cancer cell line, whilst 
that bearing a highly polar carboxylic acid (aspartic acid) side chain (82) 
displayed no apoptotic effects, possibly due to a lack of cell penetration. 
 
Figure 1.13 Retinamide (75 and 76) and retinoate (77-79) butyryl derivatives of fenretinide 
synthesised by Um et al.50 
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Weiss et al. described the synthesis and biological evaluation of 4-HBR (18) 
(Figure 1.11, page 23), whereby the NH group was replaced with a 
methylene linkage.121 Weiss hypothesised that fenretinide may act as a pro-
drug, which liberates retinoic acid in vitro, and wished to investigate the 
possibility of this using the non-hydrolysable methylene variant (18). 4-HBR 
was found to induce comparable activity to fenretinide (77 % and 85 % 
decrease in tumour volume respectively, over 21 days treatment at 2 
mmol/kg) in DMBA-induced mammary tumours in rats. This suggested that 
the NH group was not important for the biological response in this assay, 
suggesting perhaps that the NH group does not interact with a target to elicit 
its biological effect. 4-HBR induced apoptosis was shown to be independent 
of the RAR signalling pathway. However, the presence of a ketone may 
result in additional toxicity compared to the amide variant due to its increased 
susceptibility towards nucleophilic attack and also an increased rate of 
metabolism owing to the newly exposed methylene group. 
Mershon et al. synthesised the N-methylated amide fenretinide (83) (Figure 
1.16).116 This compound demonstrated ≥ 25 % activity compared to the 
fenretinide control at 1 µM in a fluorescein diacetate cell viability assay 
against MCF-7 cells. The significant reduction in activity observed for this 
compound in comparison to the fenretinide control might suggest that the NH 
group is beneficial for activity in this cell type and/or that the N-Methyl group 
confers a negative steric or electronic effect impacting the pharmacology 
and/or pharmacokinetics of this compound.  
There is no evidence in the literature for modification of the carbonyl of the 
amide to understand its effects on SAR. 
1.10.3 SAR for cyclohexene derivatives 
A limited number of analogues of the cyclohexene ring of retinoids have 
been synthesised and investigated for their biological properties. Those that 
 
Figure 1.16 Molecular structure of N-methyl fenretinide analogue. 
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have been prepared to date have focussed exclusively on investigation of 
variation at the 4-position (Figure 1.17), presumably due the ease of 
synthetic accessibility. Substitution at the 4-position of the cyclohexene ring 
of retinoic acid has been investigated with molecules initially synthesised to 
function as retinoic acid metabolism blocking agents (as previously 
discussed in Section 1.7.4.1). These compounds were also found to induce 
significant levels of apoptosis and differentiation.100 Two compounds (13 and 
14) (Figure 1.8, page 19) with comparable activity to fenretinide were 
identified; both compounds are retinoic acid analogues containing an 
imidazole-substitution at the 4-position of the cyclohexene ring; compound 
13 as the carboxylic acid and compound 14 as the acyl imidazole variant.  
The structure and biology of 4-oxo-fenretinide (3) (Figure 1.4, page 15), an 
active metabolite of fenretinide bearing a carbonyl modification at the 4-
position of the cyclohexene ring, has also been previously discussed. When 
synthesised and tested in vitro by Villani et al., 4-oxo-fenretinide was found 
to be more potent than the parent drug in 13 out of 16 of the cell lines tested 
(a range of ovarian, breast and neuroblastoma lines) for growth inhibition 
using the sulforhodamine B assay.37,47 In these cell lines, the IC50 
concentrations of fenretinide were found to be significantly (ca.2-4 times) 
higher than that for 4-oxo-fenretinide.  
No other SAR for the cyclohexyl sub-site has been described, although an 
interesting acyclic variant of the cyclohexyl ring has been reported for the 
retinoic acid sub-structure. Suzui et al. originally identified that acyclic 
retinoic acid (ACR) (84) (Figure 1.18) inhibited growth in cell proliferation 
assays using human colon carcinoma cell lines.122 G1-phase cell cycle arrest 
and apoptosis was confirmed to be induced by ACR in these cell lines. 
 
Figure 1.17 A schematic highlighting the cyclohexyl subunit of fenretinide and the 
synthetically accessible 4-position for modification. 
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However, Wada et al. found that the rigid cyclohexane group is favourable 
for activity in HL-60 cells, as acyclic derivatives (85-90) (Figure 1.18) 
(cleaved 1–6 single bond and saturated adjacent double bonds) reduced 
activity by ca.3-fold compared to retinoic acid.123 This suggests that activity 
of acyclic analogues is cell line specific and, in this particular cell line, a rigid 
conjugated structure binds more efficiently to the target and therefore leads 
to an increase in potency. 
The cyclohexene ring may be important for in vivo biological activity as it has 
been proven to be a significantly important substituent in binding to the 
serum protein, RBP4, which may be a target for cell growth inhibition or 
transport of fenretinide.84 The crystal structure of the fenretinide-RBP4 
complex confirms this specific interaction (Figure 1.15, page 31); the 
cyclohexene ring of fenretinide is buried within a hydrophobic cavity in the 
protein, with the polar phenylamide group pointing towards the exterior of the 
protein.119,120 
1.10.4 SAR of the central scaffold  
This section describes the known SAR for the central hydrophobic linker 
(central scaffold) of the fenretinide sub-structure (Figure 1.19). The number 
 
Figure 1.18 Chemical structures of acyclic retinoic acid analogues. 
 
 
Figure 1.19 A schematic highlighting the central scaffold of fenretinide. 
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of synthetic variations of fenretinide at this site is rather limited, presumably 
due to the relative complexity of any chemistry involved in adapting this part 
of the molecule. 
Takahashi et al. synthesised a range of para-acylaminophenol (91 and 92) 
and para-alkylaminophenol (93-96) compounds, replacing the fenretinide 
isoprene ring and alkene scaffold with lipophilic alkyl chains of varying 
lengths (Figure 1.20).124,125 The chain length of the para-alkylaminophenols 
was proven to be proportional to growth suppression in a range of cancer cell 
lines including some human leukaemia cell lines, with an elongated chain 
length identified as a more potent chemopreventative and antiproliferative 
agent than a shorter chain length.124 Additionally, para-dodecylaminophenol 
(94) was found to show cell growth inhibition comparable/improved 
compared to fenretinide across several cell lines (HL60, HL60R, MCF7, 
HepG2, DU-145).125 The para-acylaminophenols were weakly active or 
inactive, therefore, the presence of the carbonyl moiety is detrimental to 
activity of these compounds against the cell lines tested.  
Das et al. designed and synthesised a range of rigidified analogues of 
fenretinide which involved substitution of the alkene backbone with a rigid 
phenyl ring (97-103) (Figure 1.21).83 It was found that incorporation of a 
phenyl ring into the alkene backbone did not reduce the activity compared to 
fenretinide in rhabdoid tumour cells at lower concentrations. However the 
compounds precipitated out in the cell culture medium at higher 
concentrations, preventing an IC50 from being determined. Analogues 
 
Figure 1.20 para-acylaminophenol (91 and 92) and para-alkylaminophenol (93-96) 
compounds synthesised by Takahashi et al.124 
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incorporating variation at the R2-R4 sites were synthesised. The most active 
compound amongst this set was compound 100 (R2 = H, R3
 
= I, R4 = OH) 
(Figure 1.21.) which was found to have increased cell death (IC50 3 µM) in 
vitro compared to fenretinide (IC50 15 µM). This preference for a para-
hydroxy, meta-iodo substitution pattern on the phenyl ring is consistent with 
previous studies carried out by Das of the retinoid substructure, as discussed 
previously (Section 1.10.1).117  
No further variations on the central scaffold of fenretinide have been 
described to date. However, several interesting variants of the central 
scaffold of retinoic acid have been reported which are worthy of comment.   
Simoni et al. synthesised a range of central scaffold variants of retinoic acid 
containing a 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronapthalene moiety and  
replacing a portion of the conjugated alkene with a phenyl (TTNBP, 
compound 104) or an isoxazole ring (105 and 106)  (Figure 1.22)126,127. They 
found that the trans-phenyl and trans-isoxazole variant, 104 and 105, to be 
largely inactive in cytotoxicity assays in the HL-60 promelocytic cell line using 
a trypan blue exclusion assay. However, the cis-isoxazole 106 was found to 
have 6.5 times increased apoptosis inducing activity compared to 13-cis-
retinoic acid. Although the trans-isoxazole analogue (105) displayed no 
 
Compound R2  R3 R4 IC50 (µM) 
1 (fenretinide) - - - 15 
97 H H OH N/A 
98 H Cl OH 10 
99 H F OH 13 
100 H I OH 3 
101 OH H OH 47 
102 H H -CH2OH 29 
103 H H -CH2CH2OH N/A 
Figure 1.21 Structure and biological activity of rigidified derivatives of fenretinide 
synthesised by Das et al.135 
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significant apoptotic activity some differentiating activity was observed, 
whereby differentiation of cancer cells into benign cells is induced by the 
compound. The group concluded that the cis- and trans- forms of retinoic 
acid and their isoxazole analogues are able to induce cell death through 
different mechanisms, apoptotic and differentiating mechanisms respectively.  
Baraldi et al. went on to design a range of heteroatom-containing retinol 
analogues (Figure 1.23) comprising of an isoxazole ring tethering the C10 
and C12 atoms of the central scaffold (compounds 107-112), OH and 
carbonyl functionalisation at C7 (compounds 107-110) and saturation of the 
C7/C8 double bond (compounds 109, 110 and 112).128 Compound 112 
differs from compounds 107-111 in that the double bonds are shifted from 
the 2- to 3-position of the cyclohexene ring and 7/8- to 6/7-position of the 
backbone. It was hypothesised that incorporation of the isoxazole ring in this 
compounds may increase potency by restricting the confirmation of the 
molecule and by also reducing the rate of metabolism in comparison to the 
parent alkene. The in vitro activity of the analogues was evaluated against a 
panel of cancer cell lines including erythromyeloid, erythroleukemic and B-
lymphoid cells. All of the compounds were seen to display comparable or 
improved toxicity compared to retinol across the panel of cell lines, with 
compound (111) displaying markedly improved inhibition of cell proliferation 
(IC50 of 2-15 µM compared to that of retinol, 18-55 µM). This indicates that 
quite drastic modification of the central scaffold is well tolerated and further 
 
Figure 1.22 The scaffold of retinoid analogues synthesised by Simoni et al.127 
Figure 1.23 Central scaffold derivatisation of retinol by Baraldi et al.128 
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restriction of the alkene chain by tethering with heteroatomic rings may 
improve selectivity and activity. 
Others have taken the approach of replacing the retinoid substructure with a 
more metabolically stable backbone. As well as oxidation at the 4-position of 
the cyclohexyl ring (as for fenretinide), retinoic acid is known to be 
metabolised to two additional products, 18-hydroxy-retinoic acid (5) and 5,6-
epoxy-retinoic acid (8) (Figure 1.5, page 17), by epoxidation and radical 
oxidation.89 Barnard et al. demonstrated that TTNBP (104) (Figure 1.22) 
(previously synthesised by Simoni et al.), incorporating replacement of the 
cyclohexyl ring/isoprene region with the non-oxidisable 1,1,4,4-tetramethyl-
1,2,3,4-tetrahydronapthalene moiety, was less liable to metabolism by 
epoxidation and radical oxidation in a hamster trachea organ culture (TOC) 
assay.89 Additionally, incorporation of diphenylacetylene or biaryl moieties 
into the central scaffold provided robust structures which retained significant 
activity, for example EC23 (113) and TTNN (114) respectively (Figure 1.24).  
Further modifications of the TTNPB structure were investigated by the group 
(Figure 1.25). However, they were unable to improve upon the activity 
observed for TTNBP in RXR/RAR binding studies. Selective removal of one 
(115 and 116) or both (117) of the methyl substituents required to block 
oxidation from the C4 position on the cyclohexene ring and substitution with 
a benzonorobornenyl analogue (118) resulted in loss of activity in varying 
magnitudes. 
Aromatistion of the cyclohexyl ring to the naphthalene ring (119) resulted in 
loss of activity by over two orders of magnitude, indicating that it is more 
favourable for the methyl groups to lie out of the plane of the ring. A C11-C14 
benzofused retinoic acid analogue (120) showed reduced activity to both 
 
Figure 1.24 Chemical structures of EC23 and TTNN synthesised by Barnard et al.89 
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retinoic acid (6) and TTNBP (104), as well as its de-methylated analogue 
(117), indicating that incorporation of the napthelene moiety in place of the 
isoprene ring, in addition to the C4 methyl groups, is favourable for activity. 
Incorporation of heteroatoms designed to prevent oxidation at the 4-position 
also lacked activity (compounds 121 and 122). This is likely to be due to 
removal of lipophilic bulk at this position, as well as the presence of polar 
heteroatoms which would reduce any hydrophobic interactions important for 
activity, since the more electronegative oxygen analogue displayed reduced 
activity compared to the sulphur analogue.  
Benbrook et al. have carried out extensive research to identify  
heteroarotinoid derivatives of TTNPB (104), in collaboration with Berlin et 
al.126,129,130 They reported that the arotionoid TTNBP (104) (Figure 1.22), 
previously reported to be inactive in the HL-60 promelocytic cell line by 
Simoni et al., displays significant anticancer activity a human cervical cell line 
(CC-1) but demonstrated a highly unfavourable toxicological profile in a 
mouse model. In an attempt to optimise the pharmacological and 
toxicological profile of TTNBP, Benbrook designed and synthesised a library 
 
Figure 1.25 Chemical structures of heteroarotinoids designed to block oxidative 
metabolism by Barnard, et al.89 
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of 21 heteroarotinoid variants. Screening of this library identified two 
compounds (123 and 124) (Figure 1.26) out of the library of 21 compounds 
which displayed much more acceptable toxicity levels (mean tolerated dose 
34 and 32 mg/kg/day respectively; and 3000-fold reduced toxicity compared 
to TTNBP (104) as well as 3-fold reduced toxicity compared to retinoic acid 
(6)).126 Although cell-based assays demonstrated growth inhibition was 
reduced by 27 % in cervical carcinoma cell line treated with compounds 
(123) and (124) compared to TTNBP (104), the significantly reduced toxicity 
profile is much more favourable therefore they have greater potential to 
become successful anticancer agents. The group subsequently synthesised 
a wide range of sulphur- and oxygen-containing heteroarotinoids primarily 
linked via an ester (e.g. Compounds 126 and 127) or (E)-2-methylenthenyl 
moiety (e.g. Compound 129) to a para-carboxylic acid (e.g. Compounds 125 
and 129) or para-ethyl ester (e.g. Compounds 126 and 128) phenyl moiety 
(Figure 1.27). Analogue 128, displaying an amide linker moiety, 
demonstrated the most activity (37 - 64 % growth inhibition), closely followed 
by the ester linked compound 127  (6-52 % growth inhibition), in mouse 
xenograft models of two head and neck cancer cell lines.129 
More recently, the group have synthesised a library of heteroarotinoid 
compounds containing urea and thiourea linker moieties, termed flexible 
heteroarotinoids (flex-hets) (Figure 1.28).131 All compounds demonstrated 
potent growth inhibition in ovarian cancer cell lines (EC50 0.2 ± 5 to 10.2 ± 
0.7 µM), many of which were comparable to fenretinide (3.7 ± 0.2 µM). In 
particular, compound 130 (Figure 1.28) demonstrated activity (37-84 % 
proliferation inhibition) which exceeded that of retinoic acid (7-52 % 
proliferation inhibition) and other analogues in the library across the majority 
 
Figure 1.26 Heteroarotinoids designed and synthesised by Benbrook et al. 126,129 
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of the cell lines tested. This compound was proceeded to further biological 
evaluation; it was found to be active against all cell lines in the NCI60 cell 
line panel as well as cervical and head and neck cancer cell lines at 10 µM, 
where it displayed improved activity compared to retinoic acid.132,133
 
Mechanistic studies identified that ‘flex-hets’ induce activity through a RAR-
independent mechanism by directly targeting the mitochondria.130 
Wada et al. identified the size of the group at position 3 of retinoic acid (6) to 
be of significant importance for biological activity, as substitution with 
hydrogen (Compound 138) resulted in a 10-fold decrease in activity 
 
Compound R1 X R2 Y 
130 H S H NO2 
131 H S H CO2Et 
132 H O H CO2Et 
133 H S CH3 NO2 
134 H S H SO2NH2 
135 CH3 O H CO2Et 
136 CH3 S H CO2Et 
137 CH3 S H SO2NH2 
Figure 1.28 Potent flexible heteroarotinoid synthesised by Benbrook et al.130 
 
        
 
Figure 1.27 Further heteroarotinoids designed and synthesised by Benbrook, et al.133 
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compared to the parent compound (6) (Figure 1.29).134 Substitution of the 
methyl with an ethyl moiety (compound 139) approximately halved the 
antiproliferative activity compared to retinoic acid (6). Addition of further 
steric bulk (e.g. Pr, Bu groups (compounds 140 and 141, respectively) led to 
a dramatic loss of activity rendering them inactive.
 
Das et. al. have synthesised a range of central scaffold variants of retinoic 
acid replacing a portion of the trans-alkene skeleton with a phenyl ring 
(compound 143 and 144) (Figure 1.30.).135 The biological evaluation of these 
compounds is as yet unpublished. 
1.11 Ligand-based design 
Ligand-based design is a powerful technique for computer-aided drug design 
of new chemical entities.136 Ligand-based design relies on the knowledge of 
the chemical structure of a molecule or molecules that bind to the biological 
target of interest or produce the desired phenotype. Such molecule(s) may 
then be used to derive a pharmacophore model that defines the minimum 
 
Figure 1.30 Constrained retinoic acid derivatives synthesised by Das et al.135 
 
Compound R 
Relative  
antiproliferative 
activity (%)a 
Apoptosis-inducing 
activityb 
6 (retinoic acid) Me 100 + 
138 H 11 - 
139 Et 43 - 
140 Pr† 1 - 
141 Bu† < 0.3 - 
142 PhCH2CH2 6 - 
                                                              a The potency of retinoic acid (6) at ED50 was normalized to 100%.  
                                        
b
 + positive; - negative. † Actual isomer not specified. 
Figure 1.29 Investigation of substitution of position 13 of retinoic acid by Wada et al.134  
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necessary structural characteristics a molecule must possess in order to bind 
to the target. In other words, a model of the biological target may be built 
based on the knowledge of what binds to it, and this model in turn may be 
used to design new molecular entities that interact with the target. The 
generation of the pharmacophore takes into account the molecular shape of 
the query molecule(s), as well as properties such as hydrogen-bond donors 
and acceptors, positive and negative charges, rings and hydrophobic groups. 
At a minimum, a single query molecule can be used to define a 
pharmacophore; although the more active compounds that can be used to 
build the model the more reliable it will typically be.  Ligand-based design 
can be used to identify new molecules which are either sub-structurally 
related or sub-structurally distinct to the query molecule(s). For those 
searches which generate molecules which are structurally distinct we term 
the technique ‘scaffold hopping’ as the substructure for a key unit in the 
molecule has been replaced with a pharmacophorically similar, but sub-
structurally different unit. Ligand-based design has been shown to be as 
powerful as structure-based design for the design of new bioactive 
molecules.137,138
 
A number of different software packages are available to 
perform ligand-based design, including ROCS (Rapid Overlay of Chemical 
Structures, OpenEye Scientific)139 and Phase (Schrodinger).140 
1.11.1 Rapid Overlay of Chemical Structures (ROCS) 
ROCS performs ligand-based virtual screening of large databases of 
compounds, requiring only the structure of a single known active compound 
(the query) as a starting point.139 ROCS works by measurement of the 3D 
‘similarity’ of chemical compounds measured by tanimoto comparison and 
chemical features (e.g. electrostatic/hydrogen bonding properties). A score 
(0-2) based on the similarity between each compound and the query 
molecule is calculated, allowing the compounds to be ranked in order of their 
‘likeness’ to the query. This score is called the ComboScore, which takes into 
account the shape-tanimoto (shape similarity) and scaled colour score 
(chemical similarity). The larger the number for the ComboScore score, the 
more similar the compound is to the query. On this scale if the molecules 
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being compared are the same then the ROCS ComboScore will give a score 
of 2. 
1.12 Target Validation 
Very little is known regarding the mechanism of action of fenretinide. 
Identification of a biological target responsible for the cell death process in 
ESFT cell lines and other cell lines is an attractive objective which may also 
aid in the design of future inhibitors. Although target identification is often 
challenging and time-consuming, knowledge of the actual biological target for 
a bioactive compound is fundamental objective for drug discovery. There are 
several methods available for the identification of the biological target of a 
bioactive molecule, including isolation of binding-proteins by use of affinity 
chromatography, drug affinity responsive target stability (DARTS), 
radioisotope-labelling, ion exchange chromatography and gel filtration.141,142 
1.12.1 Affinity chromatography  
Affinity chromatography is a well established method for protein purification, 
developed in the 1960s, and remains the most frequently utilised method for 
target validation due to a relatively short number of steps compared to other 
methods and comparable yields.143 The technique is unique in that it relies 
on the specificity of the binding interaction between a known inhibitor and the 
target protein. The inhibitor molecule is immobilised covalently on a solid 
resin. The amount of inhibitor that is successfully coupled to the Sepharose 
beads can be estimated by calculating the amount of the ligand (measured 
spectroscopically) recovered in the final washings. Alternatively, the loaded 
quantity can be measured by acid hydrolysis of the Sepharose and 
subsequent analysis of the recovered ligand.144 A schematic diagram 
depicting the affinity chromatography process is shown (Figure 1.31). Cell 
lysates of cells under investigation are passed over the resin, under low 
pressure in a suitable buffer at around physiological pH. Binding components 
are adsorbed onto the bead by interaction with the ligand. The column is 
washed to remove any non-binding components, and those fragments with a 
specific binding affinity to the ligand are subsequently dissociated and eluted, 
usually using a high salt buffer. The purified proteins can be analysed by 
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SDS-PAGE and protein bands identified by mass spectrometry. A 
simultaneous negative control, preferably utilising a ‘deactivated’ ligand (e.g. 
activity eliminated by removal of an essential binding region such as a 
hydrogen-bond donor, as confirmed by SAR studies), is essential to 
distinguish between potential targets and non-specific binders. Affinity 
chromatography has been used extensively in the past and has been 
optimised to successfully provide high selectivity, resolution and yields of 
target proteins in a relatively short amount of time.  
Several types of solid support for affinity chromatography studies are 
available, including cross-linked cellulose, Trisacryl, Fractogel and silica. 
However, the most widely used resin is an agarose, commonly known as 
Sepharose, due to its desirable qualities (i.e. good chemical stability, high 
surface:volume ratio, easy binding of ligand to linker moiety and good flow 
properties) and reliability over the years. Sepharose is a polysaccharide 
polymer extracted from seaweed which is bound in a cross-linked bead 
formation of approximately 50-400 µm diameter.143,144 
The importance of the length of the hydrocarbon chain linking the ligand to a 
Sepharose bead was highlighted by Cuatrecasas et al.145, who demonstrated 
that steric hindrance could be reduced, subsequently increasing the protein-
binding capacity of the gel, by placing the ligand a moderate distance from 
the gel (ca.7 atoms) compared to a ligand directly bound to the gel. However, 
Figure 1.31 A schematic diagram depicting the affinity chromatography process. 
(Adapted221) 
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the protein-binding capacity was not increased further by further extension of 
the hydrocarbon chain past this optimum length. Furthermore, O’Carrar et al. 
have subsequently demonstrated that the hydrophilicity of the linker moiety 
between the bead and ligand is significant, where highly hydrophobic chains 
result in an increase in non-specific binding to a wide range of enzymes.145 It 
is important that a more hydrophilic linker moiety is incorporated which, as 
observed by O’Carrar et al., results in elimination of the majority of the 
interfering adsorptions. 
Identification of an appropriate attachment point for a linker moiety onto the 
ligand is often the primary limitation of affinity chromatography, requiring 
extensive SAR studies which can be time consuming. Furthermore, many 
ligands may not allow for attachment of the linker moiety, as doing so 
impedes binding to the biological target and results in loss of activity.141 
1.12.2 Affinity chromatography for retinoid-based ligands 
Affinity chromatography has been a preferable method in the past for 
purification of RBP4 using retinoid ligands, due to its relative simplicity and 
similar yields in comparison to alternative methods (e.g. ion exchange, gel 
filtration).142,146 Sepharose was regularly used as the solid matrix to which 
the retinoid ligands were bound. First reported by Fex and Hansson in 1978, 
retinoic acid was linked to Sepharose via the carboxylic acid moiety.146 
Attempts to couple the preferred ligand, retinol, to Sepharose failed, 
therefore retinoic acid was used as an alternative due to the ease of coupling 
of a carboxyl group to the matrix and it is known to display similar binding 
properties to RBP4. Very strong binding was observed between RBP4 and 
retinoic acid-Sepharose and the protein was successfully purified from both 
serum and urine, with ca. 80 % apo-RBP4 recovered from the sample. 
Interestingly, predicted binding of cellular retinoic acid binding protein 
(CRABP) was not observed. This could possibly due to disruption of an 
important binding interaction between the protein and the carboxylic acid of 
retinoic acid, as this moiety is incorporated into the linker moiety and 
therefore unavailable.142 
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Chapman and Curley utilised an alternative approach, whereby two novel 
retinoids (145 and 146) based on β-ionone, bearing  amino and chloride 
warheads at the allylic 4-position for attachment to Sepharose (Figure 1.32) 
were designed and synthesised.142 The design of these ligands avoided the 
use of the relatively unstable retinol and retinol derivatives. Initial attempts to 
couple compound (146) to the terminal amino group of AH-Sepharose 4B 
were unsuccessful. The group subsequently found that a catalytic amount of 
sodium iodide aided coupling to Sepharose, by displacement of the chloride 
by the iodide, but only ca. 50 % of available binding sites were found to be 
occupied by the ligand. However, compound (146) was successfully coupled 
to the terminal carboxyl group of CH-Sepharose 4B, with virtually all possible 
binding sites occupied. The matrix proved to isolate apo-RBP4 selectively 
from rabbit serum with a yield of 11 % and 900-fold amplification. 
  
 
Figure 1.32 Two  novel retinoid affinity chromatography ligands based on β-ionone, 
synthesised by Chapman and Curley.142 
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1.13 Aims of this Thesis 
This research aims to apply classical medicinal chemistry and ligand-based 
approaches to identify and develop novel, potent and selective 
chemotherapeutics which may have improved efficacy compared to 
fenretinide. Screening of the compounds using biological assays will identify 
new potential anti-cancer leads with improved activity in Ewing’s Sarcoma 
Family of Tumours (ESFT). 
Through consideration of the molecular structure of both retinoid and non-
retinoids, a SAR for fenretinide in ESFT cells will be established. 
Understanding of the molecular features of fenretinide responsible for 
biological activity will guide the design of further analogues which should 
have improved potency compared to fenretinide, whilst retaining its minimal 
toxicity profile. The in vitro pharmacokinetic profile of new compounds will 
also be studied. 
Through mechanistic studies, the project will identify whether retinoid and 
non-retinoid fenretinide analogues induce cell death by induction of similar 
cell death pathways to fenretinide, or whether the compounds may activate 
novel pathways.  
Additionally, target validation studies using affinity chromatography methods 
will identify potential targets to which fenretinide may bind to initiate cell 
death which may inform the development of novel targeted therapeutics.     
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2. SAR for fenretinide in ESFT cells 
2.1 Introduction  
It was of interest to perform a molecule-wide systematic study of atom and 
functional group replacements on the structure of fenretinide to understand 
the molecular basis of its cytotoxic activity and identify the structural moieties 
critical for fenretinide-induced cell death in ESFT cells. This structure-activity 
relationship (SAR) study will help to determine whether it is possible to 
improve the biological effects of fenretinide in ESFT cell types by synthetic 
modification and to appropriately guide the design of new cytotoxic agents 
with improved pharmacological properties over fenretinide.  Through these 
studies, and by comparing observed results with those of the published 
literature, it will be possible to establish and understand the molecular 
features required for activity in different cell types/assays. 
The SAR study will also allow the design of target-capture probes for affinity 
chromatography to support identification of the biological target(s) 
responsible for initiation of the cell death process (Chapter 5) as well as 
guide the design of non-retinoid mimetics of fenretinide as novel cytotoxic 
agents (Chapter 3). 
2.2 SAR study 
Various structural analogues of fenretinide were designed and synthesised to 
probe the SAR for fenretinide in inducing cytotoxicity in ESFT TC32 cells. To 
ensure a systematic approach to structural modification, the structure of 
 
Figure 2.1 Fenretinide structure divided into four synthetically accessible regions. 
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fenretinide was subdivided into four discrete substructures for study; the 4-
hydroxyphenyl, amide, cyclohexyl and central scaffold (Figure 2.1).  
2.2.1 SAR for the 4-hydroxyphenyl group 
Since a polar para-substituent on the phenyl ring of fenretinide is reported to 
be important for cell death activity in F9 murine embryonal carcinoma and  
breast cancer cells38,116 and, more specifically, the para-hydroxy substitution 
is essential for cell death activity in rhabdoid tumour cell line117, it was of 
interest to investigate the hydroxy group to better understand its role in 
promoting cell death in ESFT cells. Additionally, since phenols are widely 
known to suffer high phase II metabolism by glucorinidation147, including that 
of fenretinide104, it would be desirable to identify a moiety that could replace 
the hydroxy group whilst retaining activity which might lead to an increase in 
bioavailability. 
For the SAR study, a number of variants of the para-hydroxyl group were 
designed; replacement of the OH with a OMe, NH2 or H, and movement of 
the polar group (OH or NH2) to the ortho- and meta- positions (Figure 2.2). 
2.2.2 Synthesis of 4-hydroxyphenyl variants 
The designed para-hydroxyl variants were all synthesised by amide coupling 
chemistry from the aniline containing the desired 4-hydroxyphenyl variant to 
retinoic acid (6). The preferred method involved the formation of a pivaleic 
mixed anhydride intermediate (148), derived from retinoic acid (6), followed 
by reaction with the substituted aniline to generate the desired amide 
(Scheme 2.1). Using this methodology, seven substituted amides were 
synthesised in variable yields (28-61 %) (entries 1-7, Scheme 2.1). The 
purity of the final compounds obtained via this method was significantly 
improved in comparison to a previously investigated method involving use of 
 
Figure 2.2 SAR study for the importance of the para-hydroxy group for induction of cell 
death in cancer cells. 
Relocation of OH (and NH2) to ortho- 
or meta-position 
Replacement with -OMe, -NH2 or -H 
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DCC/EDCI or HBTU mediated coupling reaction, which generated by-
products that were difficult to separate from the desired products. 
2.2.3 Biological evaluation of 4-hydroxyphenyl variants 
To determine the biological activity of the 4-hydroxyphenyl variants 
synthesised above, the compounds were screened against a single ESFT 
cell line (TC32) at 10 µM over 24 h (Table 2.1). Each compound was 
screened in triplicate and each independent experiment was repeated at 
least three times (n ≥ 9). Cell viability was measured on a ViCell machine 
which utilises the trypan blue exclusion assay148 to measure viable cell 
number; viable cell number was expressed as a percentage of that obtained 
 
Entry number H2NR Product Yield (%) 
1 
 
 
30 
2 
 
 
35 
4 
 
 
61 
3 
 
 
50 
5 
 
 
42 
6 
 
 
28 
7 
 
 
35 
Scheme 2.1 Synthesis of 4-hydroxyphenyl analogues of fenretinide via a mixed anhydride 
intermediate. 
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from cells treated with the vehicle control. Statistical analysis was evaluated 
by 1-way ANOVA with Dunnetts post hoc tests using GraphPad InStat 3.149 
Compounds were deemed to display statistically significant activity when p < 
0.05 compared to the vehicle control cell viability, and comparable activity to 
fenretinide when p > 0.05 compared to the fenretinide control cell viability. 
Any hit compounds were screened against a normal cell line, mesenchymal 
stem cells (MSCs), using the same assay, to identify compounds with in vitro 
activity in cancer cells but not in normal cells. Although this is a rudimentary 
measurement of potential toxicity and may not accurately reflect in vivo 
toxicity, which can be assessed more accurately using animal models (as 
described in Section 1.4), a significant decrease in the viable cell number of 
MSCs may identify compounds that are likely to have unfavourable toxicity 
and should not progress further. MSCs were treated with compounds at 10 
µM for 24 h and cell viability was analysed using the trypan blue exclusion 
assay, as described for the ESFT cells above.  
For each compound the ClogP and aqueous solubility was calculated using 
ChemBioDraw Ultra (PerkinElmer)150 and an estimation of solubility (logS), in 
a unit stripped logarithm (base 10) of the solubility measured in mol/litre, was 
calculated using OSIRIS property explorer.151 An estimated logS > −4 is 
favourable, which accounts for more than 80 % of the drugs on the market. 
The ClogP and solubility values can be used to support the understanding of 
the SAR. 
Initial screening confirmed that the hydroxy group at the para-position of 
fenretinide is important for activity in ESFT cells (Table 2.1). Removal of the 
hydroxy (i.e. replacement with H, compound 61) or its methylation 
(compound 24) resulted in loss of activity (90 ± 4 and 93 ± 2 % cell viability, 
respectively) compared to the fenretinide control (43 ± 2 % cell viability). 
Movement of the hydroxy group to the ortho- (19) and meta-positions (20) 
also resulted in loss or a significant decrease in activity (93 ± 3 and 83 ± 2 % 
cell viability respectively) compared to the para-hydroxy version (the 
fenretinide control) (43 ± 2 % cell viability). The results suggest the 
importance of a polar (hydroxy) group at the para-position. Consistent with 
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these findings, replacement of the para-hydroxy with H was found to be 
detrimental to cytotoxic activity in MCF-7 breast cancer cells reported by 
Mershon et al., where only weak activity (≤ 50 % activity of the fenretinide 
standard) was observed in a fluorescein diacetate cell viability assay.116 
In contrast, for the methoxy compound (24), Sabichi et al.38 reported 
cytotoxic activity approaching that of fenretinide when using F9 murine 
embryonal carcinoma cells in an MTT assay, suggesting that the biological 
activity of this compound may be cell line specific. Sabichi et al. also reported 
that the ortho- and meta-OH compounds (19 and 20) were weakly active in 
the same assay, although a similar trend in activity was observed to ours  
(para-OH > meta-OH > ortho-OH) suggesting that the para-position is 
favoured for biological activity, perhaps mediated by a H-bond interaction 
from the ligand to the protein at this site. 
Compound number R % TC32 
cell viability* 
% MSC 
cell viability* ClogP 
Predicted 
logS (mol/litre) 
1 ( fenretinide) 
 
43 ± 2 88 ± 5 7.1 -4.6 
61 
 
90 ± 4 - 7.8 −5.0 
24 
 
93 ± 2 - 7.9 −5.0 
19 
 
93 ± 3 - 7.4 −4.7 
20 
 
83 ± 2 - 7.1 −4.7 
58 
 
60 ± 3 101 ± 7 6.6 −5.1 
156 
 
83 ± 3 - 6.6 −5.1 
157 
 
80 ± 4 - 6.6 −5.1 
                *Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable  
                cell count as a % of the DMSO control ± SEM; −, not measured. 
Table 2.1 Chemical structures, biological activity and physiochemical properties of the 4-
hydroxyphenyl analogues of fenretinide.  
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The most active compound from the set was the para-amino-containing 
compound (58) which displayed good activity (60 ± 3 % cell viability) 
compared to the fenretinide control (43 ± 2 % cell viability). As this 
compound displayed an encouraging level of activity, it was screened against 
the MSC cell line. The compound was inactive against MSCs (101 ± 7 % cell 
viability), indicating that the observed activity is specific to the cancer cells. 
The activity observed for this compound supports the conclusions made for 
the hydroxy-containing compounds above, possibly suggesting that 
relocation of the amino group to the ortho- (156) and meta- (157) positions 
significantly reduced activity (83 ± 3 and 80 ± 4 % cell viability respectively), 
suggesting that para-substitution is preferred, consistent with the observation 
for the hydroxy group. The activity observed for the para-amino containing 
compound is consistent to that described by Mershon et al. for this  
compound  against the MCF-7 breast cancer cells (≥ 50 % activity compared 
to the fenretinide control).116 
A possible explanation for the reduced activity observed for the ortho-
hydroxy and amino substituted analogues (19 and 156) is the increased level 
of planarity associated with these compounds, owing to an intramolecular 
hydrogen bond extending from the H atom of the ortho-hydroxy or amino 
group to the oxygen atom of the carbonyl of the amide, forming a pseudo 7-
membered ring which cannot be present in the para/meta-substituted 
analogues.152 An increase in planarity might adversely affect 
physicochemical properties associated with the cell death response, 
including the aqueous solubility (planar compounds are typically less soluble 
than structurally related non-planar compounds153), as well as disrupt any 
hypothetical binding interactions to the target associated with a change in 
conformation of the molecule. It is noteworthy that the predicted aqueous 
solubility of the ortho- substituted molecules is roughly equivalent to that of 
the meta- and para- analogues (Table 2.1); however, aqueous solubility is a 
very difficult metric to predict accurately. 
2.2.4 para-hydroxy and para-amino isosteric replacement 
Since the para-hydroxy and para-amino moieties were found to be important 
for activity, a range of para-hydroxy or para-amino isosteres were 
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synthesised to investigate whether bioisosteric substitution at this position 
was tolerated. A range of classical isosteres of the phenol (or aniline)154, 
including phenyl sulfonamide/acetamide, indole and benzimidazolinone, and 
a range of substituted phenyls including hydroxymethyl, aminomethyl and a 
carboxylic acid were selected for investigation. 
2.2.5 Synthesis of para-hydroxy and para-amino  isosteres 
The para-hydroxy and para-amino isosteres planned for synthesis all relied 
on an amide coupling chemistry from the aniline containing the desired para-
hydroxy and para-amino isostere to the pivaleic mixed anhydride 
intermediate (148) (prepared from retinoic acid (6) as described previously, 
see page 50) (Scheme 2.3). Most of the anilines selected for use in this 
study were commercially available. However, one non-commercially 
available aniline was required for synthesis. The para-aminosulfonamide 
(160) was synthesised from para-nitroaniline (158) by addition of 
methanesulfonyl chloride in a 1:1 pyridine:DCM solution to generate the nitro 
sulfonamide (159) which was then reduced to the desired aniline (160) in 
excellent yield over two steps (Scheme 2.2).  
The amide coupling reactions to generate the desired amides progressed 
without incident for all but three of the library reactions (entries 8-10, Scheme 
2.3). The reaction of methylamine (170) generated the undesired N-
methylamide regioisomer (179) as the exclusive product rather than the 
desired NH-amide (178) (Scheme 2.4), as confirmed by 1H NMR based on 
the observed chemical shift of the N-methyl protons (δ 3.3) (predicted shift of 
the amide being higher (δ 3.4) than for the the amine variant (δ 2.7)).  
In an effort to generate the the desired regioisomer (178), the secondary 
amine was protected using a Boc-protection strategy. N-methyl-4-nitroaniline 
(180) was Boc-protected and the nitro group reduced to give the aniline (182) 
in excellent  yield over two steps (Scheme 2.5). The aniline (182) was then 
 
Scheme 2.2 Synthesis of the aniline precursor of the methylsulfonamido phenol isostere. 
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coupled to the mixed anhydride of retinoic acid (148) using the standard 
method to yield the Boc-protected amide (183) (Scheme 2.6). Unfortunately, 
upon attempted liberation of the desired N-methylamine (178) using TFA or 
2M HCl at varying concentrations and timescales, an uncharacterisable 
product was generated with only trace-quantities of the desired product 
visible as indicated by LCMS. 
 
Entry number H2NR Product Yield (%) 
1 
  
16 
2 
  
41 
3 
  
53 
4 
  
7 
5 
  
11 
6 
  
33 
7 
  
22 
8 
  
0 
9 
  
0 
10 
  
0 
Scheme 2.3 Synthesis of para-hydroxy and para-amino isosteres of fenretinide using the 
mixed anhydride method.   
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For the hydroxymethyl variant (72), a single regioisomer was obtained, which 
was confirmed as the amide (rather than the ester originating from coupling 
of the OH to the activated carboxylic acid) due to the observed chemical shift 
of the CH2 protons adjacent to the hydroxyl (observed: δ 4.44; predicted: δ 
4.16, compared to ester predicted: δ 5.16) in the 1H NMR specrum. The 
preference for reactivity of the NH2 over the OH for this class of substrate is 
 
Scheme 2.4 Coupling of N-methyl para-phenylenediamine (170) to the mixed anhydride 
(148) formed the methylamide (179) as the only regioisomer. 
 
 
Scheme 2.5 Synthesis of the Boc-protected N-methylbenzene-1,4-diamine precursor. 
 
 
Scheme 2.6 Synthesis of the Boc-protected N-methyl amine (183). Deprotection of the Boc 
group was unsuccessful. 
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consistent with that observed in the literature for amide bond formation using 
similar conditions.155 
The synthesis of the the sulfonamide (176) and benzimidazole (177) were 
also unsuccesful. In both cases the desired products were generated as 
observed by both NMR and LCMS but, upon standing, an impurity developed 
indicative of cleavage of the amide bond to retinoic acid. 
The desired final compound, aminomethyl derivative (184), was generated 
from the Boc-protected benzylamine (175) (entry 6, Table 2.2), by stirring in 
TFA/DCM for 1 h at room temperature (Scheme 2.7).  
2.2.6 Biological evaluation of the para-hydroxy and para-amine 
isosteres 
The nine compounds prepared above were screened in the TC32 cell 
viability assay, using the method as described previously (see page 51). The 
compounds demonstrated a range of activities from 62 ± 2 to 106 ± 6 % cell 
viability compared to the vehicle control, with three compounds (171, 172, 
and 174) demonstrating a statistically significant response (Table 2.2). 
The most potent compound from the set - the acetamide (172) – 
demonstrated good activity (62 ± 2 % cell viability) compared to the vehicle 
control, but reduced activity compared to fenretinide (43 ± 2 % cell viability). 
The next most active compound, the sulfonamide isostere (171), also 
displayed statistically significant activity (71 ± 2 % cell viability) compared to 
the vehicle control. As both the acetamide and sulphonamide are isosteres of 
phenol in which the NH can mimic the OH group, it may be that the OH (or 
NH) is acting as a hydrogen bond participator to a macromolecular target 
responsible for eliciting the biological effect. As the  NH-acetamide is a 
weaker H-bond donor than the OH of the phenol (increase in pKa from ca.10 
to ca.16 from OH of a phenol to NH-acetamide) this may correlate to a 
Scheme 2.7 deprotection of the Boc-protected benzylamine (175). 
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weaker polar interaction.156 Weak but statistically significant activity was also 
observed for the benzimadazolinone (174) (82 ± 3 % cell viability).  
Of the inactive compounds, a consistent feature is the presence of a 
methylene spacer between the phenyl ring and the functional group, i.e. the 
hydroxymethyl (72) and aminomethyl variants (175 and 184). The loss of 
activity for these compounds may be the result of a range of steric, electronic 
and/or hydrophobic factors associated with incorporation of the methylene 
spacer between the functional group and the aromatic ring. For instance, the 
incorporation of the methylene spacer will decrease the electron density of 
 
Compound number R TC32 
cell viability* ClogP 
Predicted 
logS (mol/litre) 
1 (fenretinide) 
 
43 ± 2 7.1 -4.7 
171 
 
71 ± 2 6.6 −6.1 
172 
 
62 ± 2 6.8 −5.3 
72 
 
88 ± 3 6.8 −4.9 
173 
 
87 ± 4 7.8 −5.5 
174 
 
82 ± 3 6.8 −5.9 
175 
 
106 ± 6 8.5 −6.2 
23 
 
100 ± 6 7.8 −5.0 
183 
 
88 ± 3 8.4 −8.4 
184 
 
99 ± 10 6.8 −4.9 
                     *Toxicity in TC32 cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell  
                     count as a % of the DMSO control ± SEM; –, not measured. 
Table 2.2 Chemical structures, biological activity and physiochemical properties of para-
hydroxy isosteres of fenretinide.  
 
- 60 - 
 
the phenyl ring compared to the phenol, possibly disrupting any pi-orbital 
interactions to a potential target. Also, the acidity and hydrogen bond 
donor/acceptor capability of the functional groups attached to a methylene or 
phenyl ring will vary owing to delocalisation. The loss of activity observed for 
compounds containing the methylene spacer is consistent with the earlier 
studies suggesting the importance of a hydroxy or amino group at the para-
position of the phenyl ring (Section 2.2.3). Interestingly, the loss of activity for 
the hydroxymethyl substitution (72) is consistent with that observed by Das 
et al. when this compound was screened against rhabdoid tumour cells using 
an MTS cell viability assay.117   
Completing this set of compounds, the Boc-protected N-methylamine (183), 
the NH-indole (173) and the carboxylic acid (23) were inactive. The lack of 
activity for the carboxylic acid is probably the result of the reduced ability of 
the compound to penetrate the cell memebrane. The inactivity of the indole 
may be attributed to the increase in hydrophobicity  in comparison to the 4-
aminophenyl variant (58) (ClogP 7.8 vs 6.6) or possibly the differing 
hydrogen-bonding capability of the NH.  
2.2.7 Substitution in the 4-hydroxyphenyl ring 
A range of molecules were designed to probe the relative importance of 
substitution of the 2- and 3-positions of the 4-hydroxyphenyl ring of 
fenretinide. The substituent groups were selected to encompass a range of 
substituents with varying hydrophobicity, size and electron 
withdrawing/donating parameters. 
2.2.8 Synthesis of substituted 4-hydroxyphenyl analogues 
A range of compounds was planned  based on the investigation of a range of 
substituted 4-hydroxyphenyl variants. Each of the proposed compounds was 
synthesised using amide coupling chemistry from the aniline containing the 
desired substituted 4-hydroxyphenyl variant to the pivaleic mixed anhydride 
intermediate (148) (prepared from retinoic acid (6) as described previously, 
see page 50). Most of the anilines were commercially available although two, 
the methoxyaniline (196) and the methyl aniline (197), were required in order 
to synthesise the desired 3-methoxy and 3-methyl fenretinide variants (192 
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and 193). These anilines were prepared from the parent nitro compounds 
194 and 195 using hydrogenation to give the anilines 196 and 197, 
respectively, in variable yields (Scheme 2.8). Using the pool of anilines 
assembled and the amide coupling chemistry described, six 4-
hydroxylphenyl variants were synthesised in modest yields (24-57 %) 
(entries 1-6, Scheme 2.9).  
An additional compound, the aniline (198), was synthesised by reduction of 
the nitro group of compound 41 to the primary amine using zinc powder in 
acetic acid in reasonable yield (Scheme 2.10). 
 
Entry number H2NR Product Yield % 
1 
 
 
40 
2 
 
 
27 
3 
 
 
57 
4 
 
 
24 
5 
 
 
29 
6 
 
 
33 
Scheme 2.9 Synthesis of substituted phenyl analogues of fenretinide from the mixed 
anhydride intermediate. 
 
 
Scheme 2.8 Hydrogenation of compounds 194 and 195 to form the anilines 196 and 197. 
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2.2.9 Biological evaluation of substituted 4-hydroxyphenyl 
analogues 
The seven compounds prepared above were screened in the TC32 cell 
viability assay, using the method as described previously (see page 51). 
Only one compound from the set demonstrated a significant induction of cell 
death in the TC32 assay (compound 198, 35 ± 3 % cell viability) which was 
statistically comparable to fenretinide (compound 1, 43 ± 2 % cell viability) 
(Table 2.3). This compound contains an amino group at the 2-position of the 
Compound number R % TC32 
cell viability* 
% MSC 
cell viability* ClogP 
Predicted  
logS (mol/litre) 
1 (fenretinide) 
 
43 ± 2 88 ± 5 7.1 -4.6 
70 
 
70 ± 7 - 7.5 -5.0 
191 
 
92 ± 3 - 8.1 -5.5 
41 
 
94 ± 4 - 7.2 -5.3 
198 
 
35 ± 3 93 ± 3 5.9 -4.8 
192 
 
87 ± 3 - 7.0 -4.7 
25 
 
90 ± 2 - 7.0 -5.0 
193 
 
84 ± 2 - 7.6 -5.0 
        *Toxicity in TC32 cells and MSC cells at 10 µM at 24 h. – not measured. Cell viability is expressed as the mean viable  
        cell count as a % of the DMSO control. 
Table 2.3 Chemical structures, biological activity and physiochemical properties of 
substituted 4-hydroxyphenyl analogues of fenretinide.  
 
 
Scheme 2.10 Zinc reduction to generate the anilino analogue (198) of the nitro compound  
(41). 
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phenyl ring of the fenretinide structure. The compound also failed to induce 
cytotoxicity when tested in the MSC cell assay (93 ± 3 % cell viability), 
therefore the activity for this compound is likely to be specific to the 
cancerous TC32 cells. Although the TC32 cell activity for this compound is 
not significantly better than for fenretininde, the compound is less 
hydrophobic (ClogP 5.9 vs 7.1 for fenretinide), suggesting the possibility that 
compound 198 may be more water soluble, although this is not truly reflected 
in the calculated aqueous solubility values (Table 2.3). 
Of the inactive compounds, the electron donating meta-OMe (192) and 
ortho- and meta-Me groups (25 and 193) were very weakly active or inactive 
(87 ± 3, 90 ± 2 and 84 ± 2 % cell viability respectively) compared to the 
vehicle control. The electron withdrawing substituents, Br at the 3-position 
(191), and nitro at the 2-position (41) resulted in complete loss of activity (92 
± 3 and 94 ± 4 % cell viability respectively), whilst 3-fluoro substitution (70) 
resulted in a significant reduction in activity (70 ± 7 % cell viability) compared 
to that of fenretinide (43 ± 2 % cell viability). The biological data for the range 
of inactive substituents suggests that the 4-hydroxyphenyl ring is highly 
sensitive to structural modification, although some of the data may be cell 
line specific. For instance, the same fluoro analogue (70) has been shown to 
demonstrate significant activity (IC50 8µM) which was similar to fenretinide 
(IC50 19 µM) when tested in a different cell line (rhabdoid tumour cells) as 
reported by Das et al.117 
The change from an electron withdrawing substituent (nitro 41) at the 2-
position to an electron donating (amino 198) at the same site was particularly 
interesting as the biological data demonstrated a steep SAR for this 
modification. The influence of the amino and nitro groups on the electronic 
and hydrophobic properties of the molecule will be different, which will 
influence the biological data obtained. The hydrophobicity of the nitro 
compound (41) is higher than the amino compound (198) (ClogP 5.9 vs 7.2) 
owing to the increased hydrophilicity of the amino substituent. The significant 
difference in the electronic properties of the substituents may influence the 
ability of the molecule to bind to a macromolecule either directly (hydrogen-
bonding site from or to the amino or nitro group), or indirectly (electronic 
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influence to interactions mediated through the amide, aromatic ring, or 
indeed the OH). Additionally, the nitro group is predicted to have a more 
significant influence on the pKa of the OH group than for the amino group 
(ca.8 vs ca.10). Additionally, the difference in biological activity observed for 
the nitro- and amino-substituted compounds could be a steric effect, either 
directly blocking binding to a macromolecule, or through a conformational 
change. For instance, the ortho-NO2 group may form an intramolecular 6-
membered ring hydrogen-bonding interaction between the δ+ nitrogen 
(which is not present in the amino variant) and the adjacent amide-carbonyl 
group157, therefore restricting flexibility and hindering a possible binding 
interaction. It is noteworthy that the same 2-nitro substituted fenretinide 
analogue (41) was found to be inactive against MCF-7 breast cancer cells by 
Mershon et al.116  
2.2.10 Additional phenyl analogues 
A range of additional analogues of the 4-hydroxyphenyl moiety were 
synthesised to further explore the SAR within this region. Designed 
analogues, all based on the aniline template, contained a range of functional 
groups; substituent heterocycles as well as saturated variants of the phenyl 
ring were investigated. In general the designed analogues were more diverse 
and less focused on specifc atom replacements than those analogues 
selected for the two previous rounds of synthesis and biological testing. 
2.2.11 Synthesis of additional phenyl analogues 
Each of the proposed compounds was synthesised using amide coupling 
chemistry from the aniline (or amine) containing the desired substituted 4-
hydroxyphenyl variant to the pivaleic mixed anhydride intermediate (148) 
(prepared from retinoic acid as described previously) (Scheme 2.11). Using 
this method, the  eight amides (199-207) were synthesised in varying yields 
(12-95 %) and without incident except for the nitro substitited compound 
(207) (Scheme 2.11). The reaction between para-nitroaniline and the mixed 
anhydride (148) failed to generate any evidence of the desired product, even 
when the temperature of the reaction was raised to reflux for 48 h. This is 
likely due to the deactivating nature of the para-NO2 substituent on the 
reactivity of amino group. No further efforts were made to synthesise this 
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compound. For the pyrazole (204), a mixture of inseparable regioisomers 
was obtained. The major product (> 70 % by 1H NMR) was tentatively 
assigned as the NH-amide due to the characteristic chemical shift of the 
carbon of the pyrazole bonded directly to the amide in the 13C NMR specrum 
(observed: δ 135.7; predicted: δ 135.4), compared to that for the carbon 
bonded directly to the primary amine of the acylpyrazole (predicted: δ 149.5). 
A preference for the same regiochemical outcome, i.e. reactivity from the 
NH2 rather than the NH of the imidazole to form the secondary amide instead 
of the acylpyrazole from carboxylic acids has been reported by others.158 
 
Entry number R1 R2 Product Yield % 
1 H 
 
 
37 
2 H 
 
 
48 
3 H 
 
 
12 
4 H 
 
 
44 
5 H 
 
 
31 
6† H 
 
 
26 
7 
 
 
95 
8 H 
 
 
36 
9 H 
 
 
0 
                    
†
 Exists as a mixture of inseparable regioisomers (major isomer reported). 
Scheme 2.11 Synthesis of selected phenyl analogues of fenretinide from the mixed 
anhydride. 
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An additional analogue (the meta-phenyl analogue, 208) was designed 
based on a Suzuki reaction of the meta-Br substituted compound (191) 
(prepared previously; Scheme 2.9, page 61) and phenylboronic acid.  
Unfortunately, the reaction failed to provide sufficient quantities of the 
desired product for purification (Scheme 2.12). As only small quantities of the 
bromide (191) were available an alternative approach was adopted, whereby 
the Suzuki coupling would be performed at an earlier stage for later coupling 
to retinoic acid, to generate the target compound. Following this strategy, the 
attempted Suzuki coupling of the bromoaniline (186) with phenyl boronic acid 
to form the aniline 209 was also unsuccessful (Scheme 2.13). 
2.2.12 Biological evaluation of additional phenyl analogues 
The compounds prepared above were screened in the TC32 cell viability 
assay as described previously (see page 51).  
Only one compound (the 4-pyridyl variant, 199) out of the eight compounds 
tested demonstarted a significant induction of cell death in the assay (50 ± 2 
% cell viability) which was comparable to that of fenretinide (43 ± 2 % cell 
viability) (Table 2.4). As this is contrary to our hypothesis that a hydrogen 
bond participator (possibly a donor) at the para-position is likely to be 
required for activity, it is possible that this analogue initiates cell death 
through an alternative mechanism to the parent compound. Alternatively, the 
nitrogen atom may form an interaction with a target through a water-
mediated hydrogen bond. The nitrogen may also form interactions directly 
 
Scheme 2.12 Failed synthesis of the biphenyl analogue (208). 
 
 
Scheme 2.13 Failed Suzuki coupling of bromophenol (186) to generate 5-aminobiphenyl-2-
ol (208). 
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with the target by acting as a hydrogen-bond acceptor, potentially forming a 
similar interaction to the oxygen atom of the para-hydroxy moiety in the 
parent compound. This compound also lacked activity in the MSCs (94 ± 7 % 
cell viability), therefore the observed activity in TC32 cells is likely to be 
specific to the cancerous cells. 
Interestingly, the pyridinone (200) displayed only weak activity (82 ± 2 % cell 
viability). Of the inactive compounds, the saturated ring variants of 
fenretinide, the hydroxycyclohexyl (205) and hydroxypiperidine (206) 
displayed no activity (90 ± 5 % and 98 ± 6 % cell viability, respectively), 
indicating that the aromatic or planar nature of the phenyl ring could be 
 
Compound number R % TC32 
cell viability* 
% MSC 
cell viability* ClogP 
Predicted 
logs (mol/litre) 
1 (fenretinide) 
 
43 ± 2 88 ± 5 7.1 -4.6 
199 
 
50 ± 2 94 ± 7 7.1 −4.2 
200 
 
82 ± 2 - 5.6 −4.4 
201 
 
82 ± 2 - 6.9 −4.5 
202 
 
105 ± 3 - 7.8 −5.5 
203 
 
88 ± 4 - 7.9 −5.1 
204† 
 
97 ± 6 - 6.7 −4.1 
205 
 
90 ± 5 - 5.8 −4.6 
206 
 
98 ± 6 - 5.3 −3.7 
                *Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable  
                cell count as a % of the DMSO control ± SEM; –, not measured.  † Compound exists as mixture of inseparable 
                regioisomers (major isomer reported). 
Table 2.4 Chemical structures, biological activity and physiochemical properties of the 
additional phenyl analogues of fenretinide.  
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important for biological activity, or that the donor/acceptor capability of the 
hydroxyl group is playing a role. Furthermore, the amide of the 
hydroxypiperidine (206) is tertiary. The indole and indazole analogues (202 
and 203) displayed no significant activity (105 ± 3 and 88 ± 4 % cell viability, 
respectively) consistent with  attempts to incorporate other heterocyclic 
variants (indole (173), and benzimidazolinone (174), Table 2.2) in the 
previous round of testing, although the position of the NH on the phenyl ring 
is altered between these structures. The pyrazole analogue (204) was also 
inactive (97 ± 6 % cell viability). The hydroxybenzylamide (201) was weakly 
active (82 ± 2 % cell viability). 
2.3 Amide isosteres 
This section describes the synthesis and biological evaluation of isosteres of 
the amide of fenretinide. The aim was to synthesise variants by strategic 
replacement of the N-H and carbonyl moieties, with for instance an N-methyl 
(as replacements for the N-H) and a methylene group (as replacement for 
the carbonyl) to better understand the importance of the N-H and carbonyl 
groups for the activity of fenretinide (Figure 2.3). 
2.3.1 Variation at the N-H position of the amide group 
The keto isostere of fenretinide (the N-H of fenretinide replaced with a 
methylene spacer, compound 18) was proposed for synthesis. The 
methylene group was proposed for introduction to fenretinide by benzylation 
of retinal (210) at the 1-position, mediated by a transient nitrile group 
(Scheme 2.14). 
The nitrile group was incorporated into retinal (210) using a method 
described by Kobayashi et al.,159 involving substitution of retinal (210) with 
TMSCN in DCM in the presence of triethylamine in poor yield  (14 %) 
(Method A, Scheme 2.14). Owing to the low yield obtained for this reaction, 
 
Figure 2.3 The amide group of fenretinide selected for isosteric replacement. 
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an alternative method involving a solvent-free protocol catalysed by 
triethylamine (as described by Baesa et al.160) was attempted, providing 
compound 211 in excellent yield (98 %) with no need for purification (Method 
B, Scheme 2.14). The next step involved alkylation of the site of the acidic 
proton with a silyl protected benzyl bromide (212). The silyl protected benzyl 
bromide (212) was prepared from 4-hydroxybenzaldehyde using the protocol 
described by Olszewski et al.161 (Scheme 2.15). The hydroxyl group of the 
aldehyde (214) was protected with TBDMSCl in dry THF and sodium 
hydride, to generate the silyl protected compound (215) in low yield (10 %) 
(Method A, Scheme 2.15). Owing to the poor yield obtained, an alternative 
method for synthesis of this compound was attempted employing the same 
phenolic aldehyde (214) and silyl chloride but this time in dry DCM in the 
presence of triethylamine (Method B, Scheme 2.15). This efficiently 
generated the desired product (215) in 72 % yield. The incorporation of the 
organic base may aid formation of a very reactive pentavalent silica 
intermediate with TBDMSCl.159 Reduction of the aldehyde (215) to the 
benzylalcohol (216) using NaBH4 was achieved in 75 % yield, followed by 
activation of the hydroxyl group with TFAA and displacement of the 
      
Scheme 2.14 Protocol for synthesis of the keto isostere of fenretinide.161 
 
Scheme 2.15 Synthesis of benzylbromide (212) from 4-hydroxybenzaldehyde (214). 
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Scheme 2.16 Synthesis of ester (218) and N-methyl amide (220) from the mixed anhydride 
of retinoic acid. (Physicochemical property profile for compound 218: ClogP 7.9, 
predicted logS −4.6; 220: ClogP 8.0, predicted logS −4.7.) 
trifluoroacetate with lithium bromide to form the benzylbromide (212) in 57 % 
yield. Returning to the synthesis of the ketone (18), deprotonation of the 
cyanohydrin (211) with NaHMDS at −78 °C and alkylation with the silyl-
protected benzyl bromide (212) was unsuccessful, yielding retinoic acid as 
the major product (Scheme 2.14). Repeating the reaction using LDA as base 
was also unsuccessful. Although the synthesis of ketone (18) from retinal 
(210) has previously been reported (by Weiss et al.121), the specific 
experimental conditions were not detailed and no further efforts were made 
to synthesise the compound. 
Instead, two further isosteres of the amide were investigated for synthesis, 
the analogue containing an oxygen atom in place of the N-H group (218) (i.e. 
the ester variant of fenretinide) and the N-methyl variant (220) (Scheme 
2.16). The compounds were synthesised in each case by reaction of the 4-
hydroxyphenol (217) or 4-methylamino phenol (219), as appropriate, with the 
mixed anhydride (148) (prepared from retinoic acid as described previously, 
see page 50) to generate the desired ester (218) and amide (220) in 
acceptable yields (Scheme 2.16). For the N-methyl variant, evidence for 
formation of the preferred regioisomer (N-linked amide rather than O-linked 
ester) was confirmed by the characteristic chemical shift of the N-methyl 
amide protons (δ 3.4 predicted vs 3.3 observed, compared to the predicted 
amine δ 2.7), indicative of a N-methyl amide rather than a N-methyl aniline. 
Additionally, the preferred reactivity for the NH2 over the OH is consistent 
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with that reported in the literature for formation of amides using this 
reagent.162 
2.3.2 Variation at the carbonyl group 
The amino variant of the amide of fenretinide (i.e. where the carbonyl of the 
amide has been reduced to a methylene group) was proposed for synthesis. 
Various attempts at synthesis of this compound were attempted. The first 
method involved preparation of an activated retinol for displacement with 4-
aminophenol. Synthesis of the tosyl- (222) (Method A), mesyl- (223) (Method 
B) or chloro-retinol (224) (Method C) was attempted, but in each case the 
activated retinol was not observed (Scheme 2.17).  
The next method involved reductive amination of 4-aminophenol (225) and 
retinal (210) using sodium borohydride as a reducing agent (Scheme 2.18). 
This provided trace quantities of the desired product (226) (6.5 % by LCMS) 
and the unreduced imine (227) as the major product. Attempts to force the 
reaction to completion by addition of additional quantities of sodium 
 
Scheme 2.17 Unsuccessful activation of the retinol hydroxyl group. 
 
 
Scheme 2.18 Failed reductive amination reaction to form the amino variant of the amide of 
fenretinide. Formation of the imine was observed. 
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borohydride were unsuccessful. Use of sodium triacetoxyborohydride, 
borane (1M in THF) under reflux and Red-Al in toluene at room temperature 
was also unsuccessful. 
Owing to the failure of the above reductive amination reactions, a model 
reaction was carried out in which the 4-aminophenol was replaced with 
aniline to test whether the hydroxy group was interfering with the reaction. 
Aniline (149) and retinal (210) were mixed and then reduced using sodium 
borohydride to deliver the desired amine (228) in modest yield (44 %) 
(Scheme 2.19). Evidently the OH of 4-aminophenol in the previous synthesis 
was interfering with reaction. 
The required hydroxyaniline (226) was eventually synthesised via protection 
of the hydroxyl group with a silyl ether. Reaction of 4-nitrophenol (229) with 
TBDMSCl yielded the protected phenol (230) in moderate yield (Scheme 
2.20). The nitro group was then reduced by palladium catalysed 
hydrogenation to generate the primary amine (231) in modest yield. The 
amine was then exposed to retinal (210) in the presence of sodium 
borohydride to generate the desired secondary aniline (232)
 
in good yield 
(Scheme 2.21), consistent with the hypothesis that the hydroxy group was 
inhibiting the previous reaction. Upon deprotection with TBAF, the aniline 
(226) was obtained in excellent yield, together with a small amount of the 
imine (227) as an inseparable contaminant (< 5 %).  
 
Scheme 2.20 Synthesis of the TBDMS-oxyaniline precursor to the aniline analogue of 
fenretinide. 
 
Scheme 2.19 Synthesis of the reduced amide variant of fenretinide. (Physicochemical 
property profile for compound 228: ClogP 8.8, predicted logS −5.0.) 
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It was also of interest to synthesise a a cyclic isostere of the amide – firstly 
the benzimidazole 233. This was attempted by a T3P®/DIPEA promoted 
aromatisation of the amino variant (198) of fenretinde prepared previously 
(Section 2.2.8) upon microwave radiation (100 °C, 200 bar) but the reaction 
led to an uncharacterisable single product and no further efforts were made 
to synthesise this compound (Scheme 2.22).  
Synthesis of another amide isostere - an oxadiazole - was also attempted. 
For this, the amidoxime (235) required for synthesis of the planned 
oxadiazole was synthesised by reaction of benzonitrile (234) with 
hydroxylamine hydrochloride (Scheme 2.23). This amidoxime was then 
reacted with the mixed anhydride of retinoic acid (148) to generate the 
acylamidoxime (236). However, attempted cyclisation of this using both 
TBAF to catalytically aid cyclisation and by heating to reflux in DMF failed to 
 
Scheme 2.21 Synthesis of the aniline analogue of fenretinide. (Physicochemical property 
profile for compound 226: ClogP 8.1, predicted logS −4.7.) 
 
 
Scheme 2.22 Failed T3P®-catalysed synthesis of a benzimidazole isostere of the amide. 
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yield the expected oxadiazole containing compound (237), instead 
generating a mixture of uncharacterisable reaction products (Scheme 2.24). 
2.3.3 In vitro activity of amide isosteres 
The six amide isosteres prepared above were screened in the TC32 cell 
viability assay, as described previously (see page 51). 
The ester isostere (218) was statistically inactive (89 ± 2 % cell viability), 
suggesting that the hydrogen-bond donor capability of the NH of fenretinide 
could be important for activity. The loss of activity for the ester may also be 
explained by the potential for hydrolysis of the ester in the cell to the 
carboxylic acid (hence retinoic acid (6)). Previous studies have shown that 
retinoic acid does not induce cell death or decrease viable cell number in 
TC32 cells.86 
The N-methylamide (220) was weakly active (81 ± 5 % cell viability). 
Similarily the N-methylated amide (para-amino version) (179) (synthesised 
as a by-product of the reaction in Scheme 2.6, Section 2.2.5), lacked any 
significant activity (96 ± 5 % cell viability) suggesting that a H-bond donor at 
 
Scheme 2.24 Failed synthesis of the oxadiazole (237) from the amidoxime intermediate 
(235). (Physicochemical property profile for compound 236: ClogP 7.5, logS −5.0.) 
 
Scheme 2.23 Synthesis of N,4-dihydroxybenzimidamide from 4-hydroxybenzonitrile. 
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this position may be important for activity. Alternatively, the additional 
hydrophobicity or a steric effect associated with the N-methyl group may 
hinder any interaction with a target. These findings are consistent with 
Mershon et al. for the N-methylamide (220) where only weak activity was 
observed for induction of cell death in MCF-7 breast cancer cells in 
comparison to fenretinide.116 
The 4-hydroxyphenyl amine (226) showed some activity in vitro (74 ± 3 % 
cell viability) but this was not comparable to fenretinide (43 ± 2 % cell 
viability). The data may suggest that the oxygen of the carbonyl may act as a 
hydrogen bond acceptor.  
Both the amidoxime (236) (Scheme 2.24) and the phenylamine (228) 
(Scheme 2.19) showed little or no activity (92 ± 6 % vs 102 ± 6 % cell 
viability). The lack of activity for the phenylamine (228) was perhaps not 
unexpected as the molecule does not possess a polar substituent (e.g. a 
para-hydroxy group) on the phenyl ring. 
2.4 Central scaffold analogues 
Two isosteres of the central repeating isoprenoid scaffold of fenretidine were 
proposed for synthesis in order to identify whether the shape and rigidity at 
this region of the molecule was important for activity. The two isosteres 
planned for synthesis were a simple unsaturated variant of the isoprenoid 
scaffold (91) and the geometric isomer (238) (Figure 2.4). 
 
Figure 2.4 Proposed adaptations to the central scaffold of fenretinide. 
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2.4.1 Synthesis of central scaffold analogues 
13-Cis-fenretinide (238) was synthesised from 13-cis-retinoic acid (239) via a 
mixed anhydride intermediate from trimethyl acetyl chloride (147) and 4-
amino phenol (225) in moderate yield (58 %) (Scheme 2.25).  
The propsed alkyl variant (91) was synthesised by coupling of 4-
aminophenol (225) to lauroyl chloride (241) (Scheme 2.26).  
2.4.2 Biological evaluation of central scaffold analogues 
The central scaffold analogues were screened in the TC32 cell viability assay 
(as described previously, see page 51). 
The 13-cis-fenretinide (238) largely showed weak activity in vitro. However 
the standard error of the mean of the viable cell count for this particular 
compound was relatively large (76 ± 10 % cell viability). This could be a 
consequence of slow isomerisation to all-trans-fenretinide (1), initiated by 
warming in the incubator to 37.5 °C and exposure to light. Armstrong et al. 
reported that isomerisation of cis-retinoic acid to the trans- isomer to be heat 
 
Scheme 2.26 Reaction of lauroyl chloride (241) with 4-aminophenol (225) to form the alkyl 
chain derivatives (91). (Physicochemical property profile for compound 95: ClogP 
5.8, predicted logS -4.4.) 
 
Scheme 2.25 Synthesis of 13-cis-fenretinide from 13-cis-retinoic acid via a mixed 
anhydride intermediate. (Physicochemical property profile for compound 238: 
ClogP 7.1, predicted logS −4.7.) 
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and light activated, leading to the hypothesis that 13-cis retinoic acid is likely 
to act as a prodrug for trans-retinoic acid.163 Previously, cis-fenretinide has 
been found to be significantly less active as a cytotoxic than trans-fenretinide 
in squamous metaplasia in hamster trachea organ cultures164 but showed 
comparable activity to fenretinide in urinary bladder carcinogenesis in 
mice.165 
In screening of the alkyl chain analogue (91), cell death was also somewhat 
variable across the nine experiments carried out in triplicate (ranging from 
35-117 % cell viability compared to the vehicle control, n=27), with an 
average cell viability of 76 ± 5 %. This could be due to the ability of the 
compound to form aggregates in media, with the flexible alkyl chain and 
polar phenylamine groups ideal structures for forming micellic assemblies. 
This may remove some of the compound from solution and therefore reduce 
the effective concentration. The compound was screened against MSC cells 
where no significant activity was observed (95 ± 7 % cell viability), therefore 
the activity observed in TC32 cells is likely to be specific to the cancer cells. 
Takahashi et al. also found this compound to demonstrate activity against 
breast cancer, leukaemia and prostate cancer cell lines.124 To identify the 
importance of the OH group for activity of this compound, a methylated 
analogue (242) was synthesised as a negative control (based on the 
hypothesis that methylation of the hydroxy group should reduce activity 
consistent with the result for 4-methoxyfenretinide (24), Table 2.1).  The 
compound was prepared using the same method as for the hydroxyl-
containing compound above, substituting 4-aminophenol for 4-
methoxyaniline (150) (Scheme 2.27). Screening of this compound resulted in 
loss of activity (95 ± 2 % cell viability) in comparison to the para-hydroxy 
compound (91) (76 ± 5 % cell viability), consistent with the result for the 
 
Scheme 2.27 Reaction of lauroyl chloride (241) with 4-methoxyaniline (150) to form the 
alkylamide (242). (Physicochemical property profile for compound  242: ClogP 6.5, 
predicted logS -4.7.) 
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methylated version of fenretinide and hence suggesting that the para-
hydroxy analogue may be initiating activity in TC32 cells by interaction with 
the same target as fenretinide.  
2.5 Substituted cyclohexyl analogues 
Variants of the cyclohexyl group were designed based on compounds 
previously investigated within the Foster group. Unpublished research has 
identified a cyclohexyl-analogue of fenretinide (243) (Figure 2.5), containing 
a methyloxime group at the 4-position of the cyclohexyl ring, which has been 
found to induce cell death at a similar rate to fenretinide in six ESFT cell lines 
at 5 µM over 48 h (screening performed by Dr Helen Payne). A good 
therapeutic ratio was observed in TC32 and mesenchymal stem cells (38 ± 2 
% vs 77 ± 10 % cell viability, respectively). The compound has since 
progressed to in vivo studies to evaluate efficacy in a tumour regression 
model (data for this study is confidential). Based on the encouraging 
biological data obtained for this compound, further oxime (plus hydrazone) 
variants were designed for synthesis. 
2.5.1 Synthesis of substituted cyclohexyl analogues 
The proposed oxime and hydrazone variants were planned for synthesis by a 
condensation chemistry from the parent ketone, 4-oxo-fenretinide (3), which 
itself was synthesised in 4-steps from retinoic acid (6) (Scheme 2.28). 
Retinoic acid (6) was methylated using trimethylsilyl diazomethane, providing 
the methyl ester (244) in quantitative yield (Method A, Scheme 2.28). An 
excess of trimethylsilyl diazomethane (2.5 eq) was required to achieve 
completion of this reaction. This was undesirable as the reagent is both 
expensive and potentially hazardous for use on a larger scale (explosion 
risk). Fortunately, methylation of the carboxylic acid (6) with methyl iodide as 
replacement for trimethylsilyl diazomethane provided a safer alternative, 
 
Figure 2.5 The chemical structure of an active cyclohexyl analogue of fenretinide. 
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generating the desired ester (244) in quantitative yield (Method B, Scheme 
2.28). Oxidation at the desired position of the cyclohexyl ring was achieved 
by stirring the methyl ester with a large excess of activated manganese 
dioxide for 72 h. Hydrolysis of the resulting ketone (245) with 10 % NaOH 
solution in MeOH/THF yielded 4-oxo-retinoic acid (7) in good yield (89 %). 
For formation of the desired amide (3), the acid-free synthesis of acyl 
chlorides described by Villeneuve et.al.4 was adapted (Method C, Scheme 
2.28). Here, 4-oxo-retinoic acid (7) was mixed with 
hexachloroacetone/triphenylphosphine to form an acid chloride which was 
reacted in situ with para-aminophenol to give 4-oxo-fenretinide (3) in poor 
yield (9 %), owing to difficulties in purification due to co-elution of 
contaminants originating from the triphenylphosphine complex upon column 
chromatography. As multi-gram quantities of 4-oxo-fenretinide were required 
in order to synthetically elaborate the ketone functionality, an alternative 
method for synthesis of the compound was sought. As the mixed anhydride 
method had proved useful for synthesis of many of the amides prepared 
throughout this chapter, these conditions were adopted to the current 
scheme. Hence, 4-amino phenol was reacted with the pivaleic mixed 
anhydride generated from 4-oxo-retinoic acid (7) to generate the desired 
product (3) in 41 % yield (Method D, Scheme 2.28).  
 
Scheme 2.28 Synthesis of 4-oxo-fenretinide (3).  
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The synthesis of the planned oxime and hydrazone variants was then 
achieved by acid catalysed condensation of the respective hydroxylamine or 
hydrazine with 4-oxo-fenretinide (3) in variable yields (16-79 %) (Scheme 
2.29). Three oximes (methyl 243, ethyl 246 and benzyl 247) and two 
hydrazones (methyl 248 and phenyl 249) were synthesised. In each case a 
single regiosomer was obtained but attempts to characterise the 
stereochemistry for one of these products (the benzyl oxime, 247) by nOe 
enhancement experiments was inconclusive.  
2.5.2 Biological evaluation of substituted cyclohexyl analogues 
The oxime and hydrazone analogues plus 4-oxo-fenretinde (3) were 
screened in the TC32 cell viability assay, using the method as described 
previously (see page 51). Of the six compounds tested, three showed a 
statistically significant response when compared to vehicle control; two from 
the oxime series and 4-oxo-fenretinde (compounds 243, 246 and 3, 
respectively) (Table 2.5). 
An interesting trend was observed for the oxime series, in which an increase 
in size of the R substituent (methyl (243) > ethyl (246) > benzyl (247)) 
corresponded to a decrease in activity (68 ± 2.7, 79 ± 2, 89 ± 2 % cell 
viability, respectively), suggesting that increase in hydrophobicity, either 
locally at the site of the oxime, or whole molecule (logP), was disfavoured for 
activity.  
Conversely, the less hydrophobic methyl hydrazone (248) was found to be 
less active (94 ± 7 % cell viability) than for the more hydrophobic 
 
Compound X R Yield (%) 
243 O CH3 50 
246 O Et 79 
247 O Bn 76 
248 N CH3 46 
249 N Ph 16 
Scheme 2.29 Synthesis of substituted cyclohexyl analogues. 
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phenylhydrazine (249) (79 ± 4 % cell viability). Taken together, the biological 
data for the oximes and hydrazones would appear to indicate that the nature 
of the R group has a significant influence on activity in the TC32 cells, 
although any detailed analysis of trends between the oxime and hydrazone 
series is complicated by the number of analogues prepared and screened 
from which to base a SAR. 
The lack of activity in the MSC cell line observed for the methyloxime (243) 
(77 ± 10 % cell viability) would imply that incorporation of an oxime 
functionality might offer some potential for the generation of compounds with 
a fold-differential toxicity between normal and cancerous cell death, 
assuming a similar trend for related analogues can be established. Owing to 
time constraints and lack of availability of MSC cells at the time of testing, no 
further oximes were investigated in the MSC assay, although further 
investigation of the normal and cancerous cell toxicity for oximes (and 
hydrazones) will be returned to in Chapter 5 (Target identification by affinity 
chromatography).  
The 4-oxo-fenretinide (3) was the most active of the series of compounds 
tested, displaying impressive activity (41 ± 1 % cell viability), comparable to 
fenretinide (43 ± 2 % cell viability).  However, unlike the methyloxime (243), 
 
Compound number X R % TC32  
cell viability* 
% MSC  
cell viability ClogP 
Predicted logs  
(mol/litre) 
1 (fenretinide) H - 43 ± 2 88 ± 5 7.1 -4.6 
3 (4-oxo-fenretinide) O - 41 ± 1 58 ± 11 4.8 -4.3 
243 N OMe 68 ± 3 77 ± 10 5.8 -5.0 
246 N OEt 79 ± 2 - 6.3 -5.3 
247 N OBn 88 ± 2 - 7.5 -6.4 
248 N NMe 94 ± 7 - 6.3 -5.0 
249 N NPh 79 ± 4 - 7.1 -5.9 
                        *Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the  
                        mean viable cell count as a % of the DMSO control ± SEM; –, not measured.  Fenretinide control:  
                        43 ± 2 % cell viability; ClogP 7.1; predicted logS -4.7. 
Table 2.5 Chemical structures, biological activity and physiochemical properties of 
substituted cyclohexyl compounds.  
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4-oxo-fenretinide also displayed significant activity in the MSCs (58 ± 11 % 
cell viability) indicating unfavourable toxicity which suggests that the ability of 
this compound to induce cell death may not be specific to the cancer cells.  
2.6 Summary of SAR for fenretinide in ESFT cells 
This chapter has investigated the SAR for modifications to the structure of 
fenretinide having evaluated the activity in ESFT cells. A systematic 
approach to structural variation was adopted in which synthetic variations 
were targeted at four sub-sites of the fenretinide structure. Although the 4-
hydroxyphenyl site of fenretinide has proved quite resistant to structural 
modification, several interesting analogues have been identified which 
demonstrate fenretinide-like activity in TC32 cells and MSCs. Of these, the 4-
aminophenyl (58, Table 2.1), the 4-pyridyl (199, Table 2.3) and 2-
aminophenyl-4-hydroxyphenyl variants (198, Table 2.4) demonstrate the 
most interesting results in terms of activity in TC32 vs MSCs as well as 
structural variety. In terms of rationalisation of the SAR, it would appear that 
replacment of the 4-hydroxy group with a methoxy (24, Table 2.1) is not 
tolerated, consistent with the finding of others for this compound in related 
cell types. Conversely, replacement of the OH for the amino group is well 
tolerated, suggesting perhaps that the OH (and NH2) act as hydrogen-
bonding donors in a polar interaction to a protein. The activity observed for 
the acetamide (172, Table 2.2) also supports this hypothesis. In general, 
efforts to incorporate heterocycles and substituents other than a 2-amino 
group (compound 198, Tabe 2.4) to the phenyl ring are not well tolerated. 
Attempts to improve the activity by modification of the amide portion of the 
molecule were met with little success, although weak activity of the 4-
hydroxyphenyl amine (226, Scheme 2.21) showed some activity in vitro, 
suggests perhaps that some modification may be possible. Establishment of 
an SAR at the central scaffold is complicated by the fact that few compounds 
were synthesised and tested based on modification at this site. However, it 
would seem that an extended alkyl variation (compound 91, Scheme 2.26) is 
tolerated, although structurally this molecule is quite distinct to the fenretinide 
structure. At the cyclohexyl ring, a number of variations were tolerated at the 
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4-postion with an interesting SAR apparent for hydrophobicity of the oxime 
substituent (hydrophobicity of alkyl substituent correlates positively with 
activity). In general, an increase in hydrophobicity for the molecules 
investigated throughout this chapter appears to favour improved activity in 
TC32 cells, although it is difficult to correlate this trend to activity at a specific 
site of the molecule.  
Although this work appears to show the development of a preliminary SAR 
for fenretininde activity in TC32 cells, it is important to state that the 
compounds investigated herein may be interacting at one or more targets 
and/or pathways to elicit the same phenotype which will naturally complicate 
any rationalisation of the SAR. 
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3. Non-retinoid mimetics of fenretinide 
This chapter describes the design, synthesis, biological evaluation and 
optimisation of non-retinoid mimetics of fenretinide.  
Non-retinoid mimetics of fenretinide can be described as molecules which 
share a similar 3-dimensional structure and pharmacophore to fenretinide, 
but pertain to a structurally distinct substructural class. This class of molecule 
may offer advantages over fenretinide as the basis of design of 
chemotherapeutics as they have potential for improved pharmaceutical 
properties, including improved solubility, permeability and metabolic stability, 
as well as the potential for novel composition of matter intellectual property. 
Additionally, non-retinoids may offer advantage as tools to support the 
understanding of the mechanism of action of fenretinide and analogues. 
The highly hydrophobic nature of the retinoid subsubstructure of fenretinide 
confers a number of inherent liabilities to the molecule, limiting the clinical 
development of drugs based on this scaffold. For instance, the poor solubility 
and high metabolic liability for fenretinide, has been ascribed, at least in part, 
to the molecule’s high lipophilicity.44,79 Hence, we and others have 
hypothesised that replacement of the hydrophobic cyclohexyl/isoprenoid 
regions of the molecule with polar isosteres, by incorporating heteroatoms, 
may confer improved physicochemical and pharmaceutical properties for 
potential use as more effective pharmaceutical agents.126,127,128 
It is also of interest to use non-retinoid mimetics of fenretinide as tools to 
reaffirm findings from the earlier SAR study which may help to elucidate the 
molecular requirements and mechanism for fenretinide induced cell death. It 
may be possible to achieve this by development of chemical tools based on 
comparison to the retinoid SAR, by synthesis of non-retinoids containing 
elements of the retinoid SAR, so called ‘hybrid’ compounds.  
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3.1 General strategy 
The identification and optimisation of non-retinoid mimetics of fenretinide was 
achieved by iterative compound purchase and biological screening 
employing ligand-based design and directed by the SAR identified for 
fenretinide as described in Chapter 2. 
3.2 Identification of non-retinoid mimetics of fenretinide by 
ligand-based design. 
This section describes the identification of non-retinoid mimetics of 
fenretinide via iterative virtual screening and biological evaluation. 
3.2.1 Hit identification by ligand-based searches using ROCS 
A flow diagram illustrating the process of identification of non-retinoid 
mimetics of fenretinide using a ROCS-based screening approach is 
described in Figure 3.1. The ligand-based search tool, ROCS (described in 
Chapter 1, Section 1.11.1), was used to search a library of compounds (the 
 
 
                             
Figure 3.1 A flow diagram illustrating the process of hit identification of non retinoid 
analogues of fenretinide using ligand-based design (ROCS) and screening. 
Search using ROCS (50K 
compound DIVERSet™-EXP 
library)
Identify potential hits
Select and screen 
compounds
Identify active 
compounds
Hits progress 
to optimisation
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50,000 compound DIVERSet™-EXP library from the commercial vendor, 
ChemBridge150) for those which exhibit a high similarity (assessed by ROCS 
Comboscore) to fenretinide.139 The ROCS Comboscore takes into account 
the shape-tanimoto (shape similarity) and scaled color score (chemical 
similarity) between the query molecule (fenretinide) and the members of the 
library. The outcome of the search provided a ‘hit list’ of compounds ranked 
according to the ROCS Comboscore in order of their ‘similarity’ to 
fenretinide. The top 500 hits based on the ComboScore were filtered for 
visualisation using the molecular modelling software, VIDA (Visualization and 
Communication of Modeling,  OpenEye Scientific).166 
Nine compounds were then chosen by eye for purchase and screening 
based on a requirement for the molecule to share a similar size or ‘length’ to 
fenretinide and to contain the 4-hydroxyphenyl moiety which was identified 
as an important feature of biological activity for fenretinide in the SAR study 
(Chapter 2) (Table 3.1). Additionally, the compounds were selected to ensure 
they had an improved predicted physicochemical property profile (ClogP, 
solubility) in comparison to fenretinide.  
3.2.2 Biological evaluation  
To determine the biological activity of the compounds selected from the 
above ROCS-based search, the compounds were screened against a single 
ESFT cell line at 10 µM over 24 h. Cell viability was analysed via the trypan 
blue exclusion assay, as previously described (see page 51), except that the 
compounds were screened against A673 cells rather than TC32 cells (TC32s 
were used for screening of all compounds described in Chapter 2) due to the 
unavailability of TC32 cells at the time of testing. A673 cells are a suitable 
alternative to TC32 cells as they demonstrate a similar response to 
fenretinide (mid-range cell-death compared to alternative ESFT cell lines) as 
well as similar genetic features associated with the ESFT phenotype (p16 
expression, EWS-FL1 type 1 fusion type).86 A673 cells differ from TC32 cells 
in that they do not express p53; however, fenretinide is known to initiate cell 
death independent of p53.167 
 Of the nine compounds purchased, 
statistically significant activity (
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there may be a specific (i.e. non-promiscuous) effect associated with this 
compound.  
For the two most active compounds from the screen (rhodanine 250 and bis-
amide 251), testing was continued using the normal cell line (MSCs) to 
ensure that any activity observed in vitro is cancer cell specific and the 
compound does not significantly decrease viable cell number in normal cells. 
The MSCs were treated with the two compounds at 10 µM for 24 h and cell 
viability was analysed using the trypan blue exclusion assay, as described 
Compound 
number Structure ROCS ComboScore 
% A673 
cell viability* 
% MSC 
cell viability* MW ClogP 
1 (fenretinide) 
 
n/a 6 ± 2 88 ± 5 391 7.1 
250 
 
0.928 41 ± 4 82 ± 4 422 4.4 
251 
 
1.138 47 ± 12 98 ± 10 346 3.3 
252 
 
0.791 59 ± 3 - 361 2.0 
253 
 
0.815 61 ± 8 - 352 2.5 
254 
 
0.738 71 ± 10 - 428 2.7 
255 
 
0.804 81 ± 8 - 332 2.8 
256 
 
0.782 85 ± 6 - 376 2.6 
257 
 
0.823 89 ± 4 - 416 4.3 
258 
 
0.937 89 ± 6 - 408 4.0 
 
*Toxicity in A673 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. 
Table 3.1 Chemical structures, biological and physiochemical properties of compounds 
identified by a ROCS search using fenretinide as the query. 
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previously (see page 51). Encouragingly, the compounds 250 and 251 did 
not display statistically significant activity (82 ± 4 and 98 ± 10 % cell viability, 
respectively) compared to the DMSO control. This indicates that the 
cytotoxicity maybe specific to the A673 cancer cells, and hence these 
compounds may demonstrate low toxicity in vivo.  
The activity of the two most active compounds was subsequently confirmed 
in TC32 cells (as cells available again), to ensure consistency with the 
historical data. Gratifyingly, both compounds demonstrated statistically 
significant cytotoxicity in TC32 cells (64 ± 2 % and 63 ± 2 % cell viability for 
compounds 250 and 251 respectively), consistent with the result generated 
with the A673 cells. The activity of compounds 250, 251 and fenretinide was 
reduced in TC32 cells, indicating that the compounds have increased 
specificity towards the A673 cell line. 
As both of the compounds demonstrated an acceptable preliminary in vitro 
profile, they were progressed for chemical optimisation with the aim of 
improving the therapeutic ratio for TC32 vs MSC toxicity, as well as to 
develop a preliminary SAR for their respective compound class. 
3.2.3 Optimisation of the rhodanine (250) and bis-amide (251) 
This section describes the process of optimisation of the hits 250 and 251 
from above using a combination of ROCS-based and ‘SAR-by-catalogue’ 
substructural searches using eMolecules169, as illustrated by the process in 
Figure 3.3.  
3.2.3.1 Optimisation using ROCS  
The 50,000 compound DIVERSet™-EXP library from the commercial vendor, 
ChemBridge, was searched for compounds which exhibit a high ROCS 
Comboscore to either the rhodanine (250) or bis-amide (251). The outcome 
of the search provided a pooled ‘hit list’ of 500 compounds ranked according 
to the ROCS Comboscore in order of the similarity to their respective query 
compound. The results were visualised using VIDA, and prioritised by eye to 
give six compounds for purchase; three based on the structure of 250 and 
three based on 251. 
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3.2.3.2 Optimisation using substructural searches  
In parallel to the ROCS-based method above, substructure searches of the 
rhodanine (250) and bis-amide (251) were carried out using the website 
eMolecules to identify additional structural analogues for testing. eMolecules 
allows the user to perform a substructure search of a query molecule against 
a commercially available small molecule library comprising of 6 million 
compounds from multiple commercial vendors.169 A substructure of each of 
the molecules, 250 and 251 (Figure 3.4), was queried in eMolecules to 
identify commercially available compounds containing the specified 
substructure. The substructure for each compound was selected to contain 
the para-hydroxyphenylamido moiety (identified as a key pharmacophore for 
fenretinide-like activity) and a ‘further portion’ of the active compound.  This 
 
Figure 3.4 Chemical structures of compounds 250 and 251, with substructures for  the 
eMolecules search highlighted in blue. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 A schematic illustrating the process of identification of analogues of compounds 
250 and 251 using ROCS overlay and substructure searches. 
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‘further portion’ of each molecule was prescribed to maintain some potential 
for identification of substructurally similar molecules and to help support the 
development of a SAR for each new compound class. The searches 
provided ca.50-100 analogues of each compound, which were filtered by eye 
and any duplicates previously identified in the ROCS searches removed. Six 
compounds based on the substructural query of the bis-amide (251) were 
selected. These compounds were added to the pool of compounds 
previously selected from the above ROCS-based search for biological 
testing. No compounds based on the rhodanine (250) were selected owing to 
a significant overlap with the ROCS-based output for this query. 
3.2.3.3 Biological evaluation of analogues of rhodanine 250 
The three analogues of rhodanine 250 (all selected from the ROCS based 
searches, as described above) were screened in the TC32 cell viability assay 
at 10 µM compound concentration over 24 h, as described previously (see 
page 51).  
Of the three analogues, one compound (259) demonstrated  statistically 
significant activity compared to the DMSO control (65 ± 6 % cell viability) 
which was comparable to the parent hit compound (250) (64 ± 2 % cell 
viability) (Table 3.2). Both compound 259 and its parent 250 share a 
common N-propyl linked thiazolidinedione ring with variation at the 
conjugated lipophilic moiety extending from the 5-position of the heterocycle. 
It is interesting to note that the two inactive compounds (compound 260 and 
261) have groups other than a para-hydroxy at the phenyl ring (para-carboxyl 
and meta-hydroxyl for 260 and 261, respectively), supporting our observation 
that a para-hydroxyphenyl is an important moiety for maintaining fenretinide-
like activity.  
The active compound 259 was screened against MSCs (assay as described 
previously) and no significant toxicity was observed (77 ± 10 % cell viability) 
(Table 3.2). This indicates that the activity of this compound may be specific 
to the cancer cells, although the therapeutic ratio observed is quite narrow 
(65 ± 6 % for TC32 and 77 ± 10 % for MSC cell viability respectively). 
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3.2.3.4 Biological evaluation of analogues of bis-amide 251 
The nine analogues of bis-amide (251) (three selected based on ROCS and 
six based on the substructural searches, as described above) were screened 
in the TC32 cell viability assay at 10 µM compound concentration over 24 h, 
using the method as described previously (see page 51). All nine compounds 
displayed statistically significant activity compared to the DMSO control, 
demonstrating < 86 ± 3 % cell viability (Table 3.3). The most potent 
compound (262) displayed very good activity (38 ± 4 % cell viability) that was 
statistically comparable to the fenretinide control (44 ± 2 % cell viability) and 
more active than the parent hit compound 251 (63 ± 2 % cell viability). The 
compounds 251 and 262-264 all share the common bis-benzamide scaffold, 
differing by a minor variation at the lipophilic tail, distal to the OH group. 
Compound 265 is a mono-sulfonamide variant of the bis-amide, suggesting 
that a sulfonamide may be a suitable isostere for the amide at this site in this 
class of molecule. The weak activity observed for compounds 268-270 may 
be attributed to the replacement of the amide para- to the hydroxy group with 
a dioxo-iso-indolinyl group, reaffirming findings from the SAR study (Chapter 
Compound 
number Structure 
Identified by 
ROCS 
(ComboScore)/ 
eMolecules 
% TC32 
cell 
viability* 
% MSC 
cell 
viability* 
MW ClogP 
251 (hit 
compound) 
 
n/a 
 
64 ± 2 82 ± 4 422 4.4 
259 
 
ROCS (1.375) 65 ± 6 77 ± 10 412 3.3 
260 
 
ROCS (1.764) 90 ± 6 - 450 5.1 
261 
 
ROCS (1.740) 95 ± 8 - 422 4.4 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.2 Chemical structure, biological activity and physicochemical properties of 
compounds identified by ROCS and substructural searches based on the non-retinoid 
rhodanine  250.  
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2) which suggest that a NH-amide at this site may be important for biological 
activity.  
The top five compounds 262-266 were then progressed for screening against 
MSCs at 10 µM compound concentration over 24 h (assay as described 
previously). Encouragingly, no significant toxicity was observed for any of the 
Compound 
number Structure 
Identified by 
ROCS 
(ComboScore) 
/ eMolecules 
TC32 cell 
viability* 
MSC cell 
viability* MW ClogP 
251 (hit 
compound) 
 
n/a 
 
63 ± 2 98 ± 10 346 3.2 
262 
 
ROCS (1.547) 38 ± 4 88 ± 7 404 4.3 
263 
 
ROCS (1.729) 64 ± 2 89 ± 8 312 2.8 
264 
 
eMolecules 65 ± 5 87 ± 12 326 1.5 
265 
 
ROCS (1.297) 66 ± 4 89 ± 7 322 1.6 
266 
 
eMolecules 69 ± 7 94 ± 5 440 3.9 
267 
 
eMolecules 80 ± 2 - 372 2.8 
268 
 
eMolecules 86 ± 2 - 430 4.1 
269 
 
eMolecules 86 ± 3 - 456 4.9 
270 
 
eMolecules 86 ±3 - 440 3.5 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.3 Chemical structure, biological activity and physiochemical properties of 
compounds identified by ROCS and eMolecules substructure searches based on the 
non-retinoid bis-amide (251).  
- 94 - 
 
compounds (Table 3.3), indicating that the activity of these compounds is 
specific to the cancer cells. 
3.2.4 Summary of results 
Two compounds (250 and 251) were identified from ROCS-based searches 
of fenretinide which demonstrated an acceptable preliminary in vitro profile of 
induction of cytoxicity of TC32 cells with absence of significant toxicity in 
MSCs. These compounds were progressed for chemical optimisation with 
the aim of improving the therapeutic ratio for TC32 vs MSC toxicity, as well 
as to develop a preliminary SAR for their respective compound class.  
Several analogues were identified which displayed significant activity, with 
one compound from the bis-amide series (262) displaying comparable 
activity to that of fenretinide.  
As the bis-amide series demonstrated an encouraging level of activity and 
some evidence for selectivity towards the TC32 cells, this series was 
selected for further optimisation (discussed later in Section 3.6). Despite the 
encouraging therapeutic ratio observed for the rhodanine-containing 
compounds (maximum therapeutic ratio observed for compound 250, TC32 
62 ± 2 % vs MSC 82 ± 4 % cell viability), this series was not progressed for 
optimisation owing to the well known potential for promiscuous modulation of 
proteins associated with this compound class.   
3.3 Identification of non-retinoid mimetics of fenretinide by 
substructural search. 
To investigate the potential to identify a range of other structurally distinct 
non-retinoid scaffolds, we returned to the fenretinide structure as a starting 
point to identify new analogues, this time employing a substructural search of 
the para-hydroxyphenyl fragment as an alternative to the ROCS-based 
search performed previously, see Section 3.2).   
3.3.1 Substructural search 
The polar head-unit (para-hydroxyphenyl group) of fenretinide was used as a 
substructural search query to identify structurally distinct analogues of 
fenretinide for screening (Figure 3.5).  The eMolecules search returned a 
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large number of potential hits which was filtered down to 15 compounds for 
testing based on a qualitative assessment of diversity of the structures 
returned. 
3.3.2 Biological evaluation 
The 15 compounds containing the 4-hydroxyphenyl substructure (271-285) 
were screened in the TC32 cell viability assay at 10 µM compound 
concentration over 24 h, as described previously (see page 51). The 
biological activity of the 15 compounds is detailed in Table 3.4. Of these, 12 
displayed statistically significant activity with cell viability ranging from 59 ± 2 
to 83 ± 4 % cell viability compared to the DMSO control.  However, even the 
most potent compound (271), demonstrated a significant decrease in activity 
(59 ± 2 % cell viability) compared to the fenretinide control (44 ± 2 % cell 
viability).  
Most of the active compounds from this set are highly structurally related, 
bearing a short aliphatic linker from the amide nitrogen to an aromatic ring. 
Many of the compounds contain minor variations in structure, for instance 
compounds 274, 275, 278 and 279 are related by the differing substitution 
pattern of the alkyl groups on the terminal aromatic ring. Gratifyingly, the 
TC32 cell viability observed for these compounds was similar (66 ± 2, 69 ± 2, 
70 ± 4 and 79 ± 2 % cell viability for compounds 274, 275, 278 and 279, 
respectively) indicative of some commonality of activity for this structural 
class, although it is not possible to identify a clear SAR for preference for 
substitution at the phenyl ring. The less active compounds from the set are 
typically based on structures with a significant structural or physicochemical 
property variation in comparison to the most active compounds. For instance, 
compound 285 contains no amide group, compounds 281, 283 and 284 
contain no aromatic region at the lipophilic side of the molecule, and the 
 
Figure 3.5 The chemical structure of fenretinide with the selected substructural search 
query highlighted in blue. 
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hydrophobicity of compounds 281, 282 and 285 (ClogP < 1) is significantly 
less than for the average of the set. A shift in hydrophobicity may be an 
important factor in modulating the activity of compounds in ESFT cells. 
Indeed, it is noteworthy that a reduction in hydrophobicity for a series of 
related alkylaminophenol analogues was also found to be detrimental to 
biological activity, where a decrease in activity was observed for shorter 
hydrophobic chain lengths when tested in human leukemia cell lines using 
the trypan blue exclusion assay.124,125 Compound 285, bearing an oxadiazole 
ring at the site of the amide of fenretinide, was completely inactive which 
supports our understanding of the requirement for an amide for activity in 
TC32 cells (Chapter 2). 
Four of the five most active compounds from the above studies (271-273 and 
275) were progressed for toxicity screening against MSC cells (assay details 
described previously). Encouragingly, compounds 272, 273 and 275 did not 
show statistically significant activity compared to the DMSO control (74 ± 7, 
75 ± 4 and 78 ± 5 % cell viability, respectively), indicating that the cytotoxicity 
of these compounds is statistically specific to the cancer cell line. The ester 
272 showed marginally the greatest fold-differential over normail cell toxicity.  
In contrast, compound 273 demonstrated markedly significant activity (61 ± 4 
% cell viability) indicating that cytotoxicity of this compound may be non-
specific to the cancer cell line. The toxicity of compounds 272, 273 and 275 
was statistically comparable to fenretinide (88 ± 5 % cell viability) which has 
a favourable in vivo toxicity profile, therefore it is possible that the toxicity of 
these compounds may be tolerated in vivo and hence it might be of interest 
to investigate the potential for further development of these compounds. 
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*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. 
Table 3.4 Chemical structures, biological activity and physicochemical properties of 
compounds identified by substructural search of the para-hydroxyphenyl unit of 
fenretinide. 
Compound number Structure % TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
1 (fenretinide, query 
compound) 
 
44 ± 2 88 ± 5 391 7.1 
271 
 
59 ± 2 61 ± 4 297 4.3 
272 
 
59 ± 3 74 ± 7 406 2.9 
273 
 
63 ± 3 75 ± 4 294 3.3 
274 
 
66 ± 2 - 271 3.0 
275 
 
69 ± 2 78 ± 5 271 3.0 
276 
 
68 ± 4 - 241 2.6 
277 
 
68 ± 2 - 247 3.7 
278 
 
70 ± 4 - 299 3.8 
279 
 
79 ± 2 - 243 2.0 
280 
 
82 ± 3 - 313 4.4 
281 
 
82 ± 4 - 326 0.81 
282 
 
83 ± 4 - 309 0.38 
283 
 
86 ± 2 - 193 2.1 
284 
 
88 ± 4 - 290 2.8 
285 
 
95 ± 2 - 176 0.58 
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3.4 Identification of non-retinoid mimetics of fenretinide with 
novel polar head-units 
This section describes an approach to identify non-retinoid-based molecules 
incorporating polar phenyl variants other than the para-hydroxyl group. The 
SAR studies in Chapter 2 identified three isosteres of the ‘head-unit’ (the 
para-phenol moiety) of fenretinide which were tolerated for induction of 
cytotoxicity in TC32 cells; the 4-aminophenyl-, the 2-amino-4-hydroxy- and 
the 4-pyridyl-groups (substructures of compounds 58, 198 and 199, 
respectively) (Figure 3.6). It was of interest to consider whether these 
isosteres could also be accommodated into non-retinoid-based molecules.   
3.4.1 Substructural searches 
Substructural searches were performed to identify new compounds for 
testing based on the need to maintain both the ‘active’ head unit plus a 
novel, non-retinoid scaffold. The searches were performed in eMolecules 
using the substructures highlighted in Figure 3.6.  
The outputs from the substructural searches were combined to generate a 
pool of virtual hits for selection of compounds for screening. A large number 
of potential hits was obtained containing the 4-aminophenyl- and 4-pyridyl-
groups (substructures of compounds 58 and 199, respectively) (Figure 3.6). 
However, the 2-amino-4-hydroxy fragment (substructure of compound 198) 
returned no hits. The pool of virtual hits was filtered to a list of 500 
compounds and then compounds were selected by eye for screening to 
represent both a diverse range of scaffolds as well as to incorporate 
examples based on each of the queried head units of compounds 58 and 
 
Figure 3.6 Active retinoids bearing novel head units identified in Chapter 2. (Substructure 
query for eMolecules search highlighted in blue). 
 
- 99 - 
 
199. In total, 21 compounds were selected for screening; 12 based on the 4-
aminophenyl substructure of compound 58 (286-297, Table 3.5) and nine 
based on the 4-pyridyl substructure of compound 199 (298-306, Table 3.6).  
3.4.2 Biological evaluation of compounds containing the 4-
aminophenyl substructure 
The 12 compounds containing the 4-aminophenyl substructure (286-297) 
were screened in the TC32 cell viability assay at 10 µM compound 
concentration over 24 h, as described previously (see page 51); the 
biological activity is detailed in Table 3.5. Out of the 12 analogues selected 
for screening, seven displayed statistically significant activity (compounds 
286-292), with cell viability ranging from 76 ± 3 to 86 ± 3 % compared to the 
DMSO control.  However, there was a significant decrease in activity for 
these compounds compared to the fenretinide control (44 ± 2 % cell viability) 
as well as the parent compound (58) (60 ± 3 % cell viability). Although the 
activity observed for these analogues is quite weak in general, compounds 
containing the 4-aminophenyl moiety appeared to have the potential to show 
a desirable cytotoxic effect in TC32 cells and there is evidence that 
substitution of the para-hydroxy with an amino group may be tolerated, 
reaffirming findings from the SAR study (Chapter 2). The general decrease in 
activity observed for these compounds in comparison to fenretinide and 
compound 58 may be attributed to a general reduction in lipophilicity within 
the compound set, owing to the limited availability of suitable compounds for 
testing containing the appropriate 4-aminophenyl head-unit. Those 
compounds containing a 2-hydroxy-4-amino substituted phenyl group (293 
and 294) were statistically inactive. Although the threshold for activity 
assessment for these compounds is narrow, it would appear that the addition 
of the additional hydroxy group at the 2-position is not well tolerated, 
although care needs to be observed when drawing conclusions from this 
result as the dataset is small and the compounds demonstrate some 
variation at the lipophilic side in comparison to compounds tested containing 
just the amino group, which may also be responsible for the drop in activity 
observed. Compound 291 is the most structurally distinct compound within 
the set, bearing a benzoxazole isostere for the amide group. The lack of 
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activity observed for this compound may support our hypothesis that an 
amide at this site is important for induction of cytotoxicity, as was suggested 
based on the studies from the retinoid SAR (Chapter 2).  
Due to the relatively poor level of activity observed for the compounds from 
this set, none were taken forward for further screening in MSCs to determine 
comparable toxicity in normal cells. 
Compound 
number Structure 
% TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
58 (query 
compound)  
 
60 ± 3 101 ± 7 391 6.5 
286 
 
76 ± 3 - 216 1.5 
287 
 
76 ± 4 - 164 0.48 
288 
 
79 ± 5 - 226 1.9 
289 
 
80 ± 5 - 192 1.4 
290 
 
81 ± 4 - 240 2.4 
291 
 
82 ± 2 - 224 3.0 
292 
 
86 ± 3 - 224 1.9 
293 
 
88 ± 2 - 272 1.5 
294 
 
89 ± 5 - 234 1.5 
295 
 
91 ± 2 - 192 1.5 
296 
 
92 ± 5 - 213 0.76 
297 
 
95 ± 3 - 204 1.4 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % 
of the DMSO control ± SEM; –, not measured, Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 
391; ClogP 7.1. 
Table 3.5 Chemical structures, biological activity and physiochemical properties of 
compounds identified by substructural search containing  the 4-aminophenyl 
substructure of compound 58. 
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3.4.3 Biological evaluation of compounds containing the 4-pyridyl 
substructure 
The nine compounds containing the containing the 4-pyridyl substructure 
(298-306) were screened in the TC32 cell viability assay at 10 µM compound 
concentration over 24 h, as described previously (see page 51); the 
biological activity is detailed in Table 3.6. Of the nine compounds screened, 
seven compounds (compounds 298-304) displayed statistically significant 
activity with cell viability ranging from 60 ± 2 to 84 ± 4 % compared to the 
DMSO control.  However, there was a statistically significant decrease in 
activity for these compounds compared to both the fenretinide control (44 ± 2 
% cell viability) and the parent 4-pyridyl retinoid (199) (50 ± 2 % cell viability). 
The most active compound from the set (298) contains a lipophilic 
Compound 
number Structure 
% TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
199 (query 
compound) 
 
50 ± 2 94 ± 7 377 7.1 
298 
 
60 ± 2 67 ± 3 280 4.8 
299 
 
70 ± 2 - 310 2.9 
300 
 
71 ± 3 - 232 3.7 
301 
 
74 ± 2 - 256 3.0 
302 
 
75 ± 4 - 270 3.4 
303 
 
80 ± 2 - 226 2.6 
304 
 
84 ± 4 - 206 3.1 
305 
 
88 ± 3 - 218 3.1 
306 
 
89 ± 5 - 224 3.0 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.6 Chemical structures, biological activity and physiochemical properties of 
compounds identified by substructural search based on the 4-pyridyl substructure of 
compound 199.  
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conjugated amide in place of the repeating isprenoid unit of feneretinide and 
is structurally the most reminiscent of fenretinide of the analogues tested. 
Interestingly, the least active compound from this set (306) is a close variant 
of this compound containing the same conjugated amide and phenyl 
substituents, but no tert-butyl group in the para-position of the phenyl ring, 
implying that hydrophobicity in this region of the molecule might be important 
for activity. The rest of the compounds within the screening set contain 
various linear hydrophobic variants at the repeating isoprenoid region of 
fenretinide, except for compound 299 which contains two basic nitrogens. 
This compound is particularly interesting as it contains a significant 
hydrophilic character at the repeating isoprenoid region, suggesting that 
incorporation of polar groups at this site offers potential for development of 
retinoid mimetics with improved pharmacokinetic properties, assuming a 
general trend for tolerance of hydrophilic variation at this site can be 
established.  
The most potent compound from this set (298) was selected for screening in 
MSCs to determine toxicity against normal cells (using the methods as 
described previously). Although this compound contains a Michael acceptor 
functionality - a moiety usually avoided in drug discovery for reasons of 
potential indiscriminate toxicity - it was deemed of sufficient interest to 
evaluate further due to its acceptable level of activity in TC32 cells. Despite 
our interest in the tertiary amine (299), restrictions to availability of cells at 
the time of screening meant that only one compound was selected for further 
screening. Using the standard MSC viability assay, compound 298 
demonstrated significant activity (67 ± 3 % cell viability) compared to the 
DMSO control (Table 3.6); a relatively poor therapeutic ratio. 
3.4.4 Summary of results 
This section has investigated the potential to identify active compounds 
bearing a novel polar ‘head-unit’ identified from the retinoid SAR, and 
combining this with a non-retinoid scaffold. Significant activity was observed 
for a number of compounds bearing both of the selected polar head groups, 
indicating that a 4-aminophenyl or 4-pyridyl moiety may be a suitable 
alternative to the 4-hydroxyphenyl moiety as a general warhead for use as a 
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chemotherapeutic. A general theme throughout the results is that reduction 
in lipophilicity of the molecules often results in loss of activity, consistent with 
chain-length dependant activity of the para-alkylaminophenols observed by 
Takahashi et al.,124 although there are clear exceptions to this, for instance 
for the tertiary amine 299 (Table 3.6) which has a significantly lower ClogP 
than for the majority of compounds tested.  Additionally, those compounds 
containing anything other than a secondary amide at the central portion of 
the molecule were inactive. 
3.5 Optimisation of compounds 271-273, 275 and 298 
A subset of compounds from the most recent rounds of testing 
(encompassing the non-retinoid 4-hydroxyphenyl and polar head-unit 
variants, Sections 3.3 and 3.4, respectively) were prioritised for optimisation. 
The five compounds which showed the highest level of activity (59 ± 2 to 69 
± 2 % cell viability) and with some evidence for lack of induction of 
cytotoxicity in the MSC assay were selected to take forward for further 
optimisation (Table 3.7). The compound set comprised four compounds 
containing the 4-hydroxyphenyl group (from Section 3.3) (compounds 271, 
272, 273 and 275) and one containing the 4-pyridyl motif (from Section 3.4) 
(compound 298). Although non-specific toxicity was a determinant in 
Compound number Structure % TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
271 
 
59 ± 2 61 ± 4 297 4.3 
272 
 
59 ± 3 74 ± 7 406 2.9 
298 
 
60 ± 2 67 ± 3 280 4.8 
273 
 
63 ± 3 75 ± 4 294 3.3 
275 
 
69 ± 2 78 ± 5 271 3.0 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.7 Biological data of the 5 hit compounds selected for further optimisation. 
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selection of these compounds for optimisation, the level of non specific 
activity observed for these compounds (61 ± 4 to 78 ± 5 % cell viability in 
MSC) was less than ideal. In an effort to improve the specificity against 
MSCs as well as the activity to comparable or improved cytotoxicity 
compared to fenretinide, the five hits were taken forward for structural 
searches to identify close analogues for further biological investigation. 
3.5.1 Substructural searches of compounds compounds 271-273, 
275 and 298 
For each of the hit compounds (271, 272, 273, 275 and 298), a substructure 
search was performed based on the apportioned substructure highlighted in 
blue in Figure 3.7. The substructure for each hit was selected based on the 
need for both availability of a certain number of substructural analogues, with 
the requirement for development of a SAR (i.e. not too broad a search to 
allow for positive development of SAR and not too narrow a search to return 
a minimum number of compounds to select for testing). For each of the 
selected substructures, a number of analogues were identified and pooled to 
generate a list of 500 compounds for selection. From this list, 29 compounds 
(11 analogues of 273, 10 of 275, 5 of 298, two of 272, one of 271) were 
selected by eye to represent a range of structurally diverse analogues of 
each of the hits.  
 
Figure 3.7 Substructures (highlighted in blue) of the active compounds selected for 
optimisation.  
 
- 105 - 
 
3.5.2 Biological evaluation of compounds bearing the 
substructure of compound 273 
The 11 compounds bearing the 273 substructure (Figure 3.7) were screened 
in the TC32 cell viability assay at 10 µM compound concentration over 24 h, 
as described previously (see page 51). Out of these, seven compounds 
(307-313) demonstrated significant activity compared to the DMSO control, 
ranging from 70 ± 2 to 81 ± 9 % cell viability (Table 3.8), although none 
achieved activity comparable to that of the fenretinide control (44 ± 2 % cell 
viability), or that of the parent compound (273) (63 ± 3 % cell viability). As a 
result, none of these compounds were taken forward for screening in MSCs 
or for further optimisation. 
Compound 
number Structure 
% TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
273 (hit 
compound) 
 
63 ± 3 75 ± 4 294 3.3 
307 
 
70 ± 2 - 324 3.3 
308 
 
70 ± 3 - 341 1.7 
309 
 
76 ± 5 - 343 1.4 
310  
 
75 ± 7 - 292 -0.4 
311 
 
80 ± 5 - 298 1.6 
312 
 
87 ± 2 - 325 1.8 
313 
 
81 ± 9 - 351 3.2 
314 
 
92 ± 3 - 353 1.8 
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315 
 
97  ± 2 - 327 1.7 
316 
 
95 ± 8 - 305 0.8 
317 
 
92 ± 8 - 329 1.4 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.8 Chemical structures, biological activity and physicochemical properties of 
compounds identified by substructural search based on the substructure of compound  
273.  
 
3.5.3 Biological evaluation of compounds bearing the 275 
substructure 
Ten compounds bearing the apportioned substructure of compound 275 
(Figure 3.7) were screened at 10 µM compound concentration over 24 h 
using the TC32 cell viability assay, as described previously (see page 51). Of 
these, all except compound 327 demonstrated statistically significant activity 
compared to the DMSO control, ranging from 54 ± 3 to 84 ± 2 % cell viability 
(Table 3.9). The phenylether 318 was the most active compound, achieving 
activity statistically comparable (54 ± 3 % cell viability) to fenretinide (44 ± 2 
% cell viability) and was marginally more active than the parent compound 
275 (69 ± 2 % cell viability). Interestingly, this compound is the most 
structurally similar of all of the compounds of the set to the parent compound 
with only a variation in position of a methyl group on the phenyl ring. This 
and the next most active compound - the dichloro analogue (compound 319) 
- were screened against MSCs to determine a therapeutic ratio. 
Unfortunately, both of these compounds displayed significant activity in this 
assay (70 ± 5 and 67 ± 3 % cell viability respectively) compared to the 
DMSO control, indicating that the compounds may be demonstrating 
unfavourable toxicity which is not specific to the TC32 cells. The compounds 
are also more toxic than the parent compound 275 (78 ± 5 % cell viability). 
However, in vivo assessment may provide a more accurate prediction as to 
the true toxicity for these compounds as the toxicity of the compounds was 
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statistically comparable to fenretinide (88 ± 5 % cell viability). Owing to the 
relatively poor activity and therapeutic ratio no compounds from this set were 
selected for further biological evaluation. 
 3.5.4 Biological evaluation of compounds bearing the 4-pyridyl 
substructure of compound 298 
Five compounds bearing the apportioned substructure of compound 298 
(Figure 3.7) were screened at 10 µM compound concentration over 24 h 
using the TC32 cell viability assay, as described previously (see page 51). Of 
these, four compounds (328-331) demonstrated significant activity compared 
Compound 
number Structure 
% TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
275 (hit 
compound) 
 
69 ± 2 78 ± 5 271 3.0 
318 
 
54 ± 3 70 ± 5 271 3.0 
319 
 
60 ± 3 67 ± 3 326 3.7 
320 
 
65 ± 3 - 257 2.5 
321  
 
65 ± 6 - 293 3.2 
322 
 
66 ± 3 - 306 3.9 
323 
 
66 ± 3 - 312 3.4 
324 
 
73 ± 4 - 293 3.2 
325 
 
83 ± 2 - 271 3.0 
326 
 
84 ± 2 - 273 2.1 
327 
 
100 ± 2 - 207 0.7 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.9 Chemical structures, biological activity and physicochemical properties of 
compounds identified by substructural search based on substructure 275. 
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to the DMSO control, ranging from 57 ± 2 to 84 ± 2 % cell viability (Table 
3.10). The most active compound, the dichloro amide (328), displayed good 
activity (57 ± 2 % cell viability) which was approaching that of fenretinide (44 
± 2 % cell viability) and comparable to that of the parent compound (298) (60 
± 2 % cell viability). Interestingly, the mono-Cl analogue of this compound 
(331) is significantly less active (84 ± 2 vs 57 ± 2 % cell viability). This may 
be the result of loss of a specific halogen-mediated interaction to a target 
responsible for induction of cell death or more likely a general reduction of 
hydrophobicity of the molecule, a trend which is observed to generally 
correlate with reduction of activity within this set of compounds.  
The dichloro amide (328) was taken forward for screening in MSCs, where 
significant activity was observed compared to the vehicle control (67 ± 3 % 
cell viability). However, this toxicity was statistically comparable to that of 
fenretinide, therefore further evaluation for toxicity (e.g. in vivo study) may 
provide a more accurate assessment of true toxicity. 
 
Compound 
number Structure 
% TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
298 (hit 
compound) 
 
60 ± 2 67 ± 3 280 4.8 
328 
 
57 ± 2 67 ± 3 293 4.4 
329 
 
71 ± 2 - 303 3.9 
330 
 
77 ± 2 - 314 2.3 
331 
 
84 ± 2 - 259 3.7 
332 
 
91 ± 1 - 268 3.0 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.10 Chemical structures, biological activity and physicochemical properties of 
compounds identified by substructural search of the 4-pyridyl unit of compound 298.  
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3.5.5 Biological evaluation of compounds bearing the 271 and 272 
substructures  
A discussion of the screening results for the analogues selected from the 
substructural search of the 4-hydroxyphenyl amidoalkyl moiety of 
compounds 271 and 272, has been grouped together as they are structurally 
related and only three analogues in total were identified for screening. The 
three compounds (333-335) were screened in the TC32 cell viability assay 
but none of the compounds displayed significant activity compared to the 
DMSO control (Table 3.11). This is perhaps not surprising given the 
significant variation of structure of these compounds to the parent 
compounds as a result of the rather limited availability of close structural 
analogues for selection. Additionally, compound 333 contains a carboxylic 
acid group which will be highly ionised at the pH of the assay (7.4), limiting 
uptake of the compound into the cell. 
Compound number Structure % TC32 cell 
viability* 
% MSC cell 
viability* MW ClogP 
271 
(hit compound) 
 
59 ± 2 61 ± 4 297 4.3 
272 
(hit compound) 
 
59 ± 3 74 ± 7 406 2.9 
333 
 
95 ± 2 - 223 0.7 
334 
 
99 ± 6 - 352 2.6 
335 
 
102 ± 5 - 305 3.4 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.11 Chemical structures, biological activity and physicochemical properties of 
compounds identified by substructural search based on compounds 271 and 272.  
 
3.5.6 Summary of results 
Chemical optimisation of the five hits identified from the the most recent 
rounds of testing (encompassing the non-retinoid 4-hydroxyphenyl and polar 
head-unit variants) by use of ‘SAR-by-catalogue’ purchase and testing 
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identified a number of structurally diverse non-retinoids with an ability to 
induce cytotoxicity in TC32 cells and which demonstrate a lack of toxicity 
towards the normal cell type, MSCs. The activity in TC32 cells and 
therapeutic ratio in all cases was less than for fenretinide; as a result none of 
the compounds from this round of optimisation were progressed for further 
study. 
Instead, the hit compounds originating from the original ROCS-based search 
and optimisation (Section 3.2) (compounds 251, 262, 263) and substructural 
search of the 4-hydroxyphenyl (275) and 4-pyridyl (298) groups (Table 3.12) 
were selected for further biological evaluation, to include SAR studies, dose 
response studies across multiple cell lines and mechanistic studies. The 
compounds were selected for optimisation because in each case the hit 
compounds demonstrated good activity against TC32 cells and acceptable 
toxicity in the MSCs.  
Compound 
number Structure 
TC32 cell 
viability* 
MSC cell 
viability* MW ClogP 
262 
 
38 ± 4 
 
88 ± 7 404 4.3 
251 
 
47 ± 12 89 ± 9 346 3.3 
263 
 
64 ± 2 98 ± 5 312 2.8 
298 
 
60 ± 2 67 ± 3 280 4.8 
275 
 
69 ± 2 78 ± 5 271 3.0 
*Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count as a % of 
the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell viability; MW 391; 
ClogP 7.1. 
Table 3.12 Biological data of the five non-retinoid compounds selected for further biological 
evaluation. 
3.6 Validation of the hit compounds 
In this section, selected hit compounds were resynthesised in order to 
confirm the structure of the compounds and to provide sufficient quantity of 
each for thorough biological evaluation and re-screening. 
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3.6.1 Resynthesis of selected hits 
Compounds 251 and 263 (Table 3.12) are based on a common bis-
benzamide scaffold with variation at the hydrophobic portion at the site distal 
to the OH group. The compounds were synthesised from a common 
intermediate (338), which itself was synthesised in a two-step process by 
amide coupling of TBDMS-protected para-aminophenol (231) with para-
nitrobenzoyl chloride (336), followed by hydrogenation of the nitro group to 
afford the primary amine (338) (Scheme 3.1). Subsequent coupling of the 
amine with meta-toluoyl chloride or isovaleryl chloride, as appropriate, 
followed by silyl-deprotection using TBAF, yielded compounds 251 and 263, 
respectively, in moderate to good yields over two steps.  
Compound 275 (Table 3.12) was synthesised by HOBt/EDC mediated 
coupling of 2,5-dimethylphenoxyacetic acid (341) to 4-aminophenol (225) 
(Scheme 3.2). Although the yield for the reaction was poor, the product was 
easily obtained by recrystallisation in excellent purity and in sufficient 
quantity for screening. 
 
Compound R Yield 
251 
 
89% 
263 
 
100% 
Scheme 3.1 Synthesis of non-retinoid compounds (251) and (263). 
Compound R Yield 
339 
 
25% 
340 
 
91% 
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An attempt to synthesise the most active compound, amide 262 (Table 3.12) 
was unsuccessful. The aniline 338, previously prepared as a precursor to 
compounds 251 and 263 (Scheme 3.1), was successfully coupled to 
chloroacetyl chloride to afford the activated chloride 342 in modest yield. 
However, attempts to alkylate the chloride with 2,4,5-trimethyl phenol 
generated a highly insoluble product which could not be characterised 
(Scheme 3.3).  
3.6.2 Biological evaluation of resynthesised hits 
The three resynthesised compounds (251, 263, 275) were screened in the 
TC32 cell viability assay at 10 µM compound concentration over 24 h, using 
the method as described previously (see page 51). 
Screening of the resynthesised bis-amides 251 and 263 confirmed activity 
against TC32 cells. However, the activity was marginally reduced in both 
cases (73 ± 4 % and 76 ± 3 % cell viability, respectively) compared to the 
previously investigated (purchased) compounds (63 ± 2 % and 64 ± 2 % cell 
Scheme 3.3 Proposed synthesis of compound 262. 
  
 
Scheme 3.2 Synthesis of compound 275 via a HOBt/EDC amide coupling reaction. 
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viability compared to the DMSO control) (Table 3.13). This reduction in 
activity was statistically significant in the case of 263, but not 251. Further 
repeats of the experiment were carried out (total n = 18), in which the result 
was confirmed. When screened alongside each other in the same 
experiment there was a difference in activity of 30 % and 23 % between 
purchased and resynthesised compounds, 251 and 263 respectively (Table 
3.13).  
The resynthesised phenylether 275 displayed considerably increased activity 
(54 ± 4 % cell viability) compared to the purchased compound (69 ± 2 % 
decrease in cell viability), which is statistically significant. Furthermore, the 
activity of the resynthesised compound demonstrated activity statistically 
comparable to fenretinide (44 ± 2 % cell viability). 
The variation observed between purchased and resynthesised samples 
could possibly be due to discrepancies in aliquoting/weighing of the 
compounds or the presence of minor impurities in the purchased sample 
which were not detected upon analysis by LCMS or NMR. Although the 
resynthesised bis-amides 251 and 263 still demonstrate a significant 
response in comparison to the DMSO control, the variation in assay result 
between the purchased and resynthesised compound was somewhat 
concerning and hence these compounds were not progressed for further 
biological evaluation. Conversely, phenylether 275 demonstrated only a 
minor variation. The compound also consistently demonstrated very good 
activity in TC32 cells, as well as a good fold-differential of activity for the 
resynthesised compound in TC32 cells (54 ± 4 % cell viability vs MSC cells 
78 ± 5 % cell viability). Therefore, this compound was taken forward for 
 
Overall average of TC32 cell viability  
(%, n ≥ 9) 
TC32 cell viability within the same 
experiment (%, n = 9)  
Compound Purchased 
compound 
Resynthesised 
compound 
Purchased 
compound 
Resynthesised 
compound  
251 63 ± 2 73 ± 4 44 ± 1 74 ± 2  
263 64 ± 2 76 ± 3 48 ± 2 71 ± 2  
275 69 ± 2 54 ± 4 - -  
            *Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell  
            count as a % of the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability;  
            88 ± 5 % MSC cell viability; MW 391; ClogP 7.1. 
Table 3.13 A table comparing the biological data of purchased and resynthesised non-
retinoid. -, not screened within the same experiment. 
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further study (to dose response and mechanism of action studies, see 
Chapter 4).  
3.7 Hybrid analogues 
In this section, analogues of the 4-hydroxyphenyl-containing hit compounds 
263 and 275 were designed whereby the polar head group was substituted 
with alternative head groups previously investigated in the retinoid SAR 
study (Chapter 2) with the intention of either reducing activity (by selection of 
‘inactive’ head groups from the SAR study), or retaining or improving activity 
(by selection of ‘active’ head groups). ‘Inactive’ head groups can be defined 
as the head groups which reduced or abolished activity when substituted into 
the fenretinide structure in place of the 4-hydroxyphenyl group, whereas 
‘active’ head groups retained or promoted activity (4-pyridyl, 4-aminophenyl 
and 4-amino-2-hydroxyphenyl). Biological evaluation of these ‘hybrid’ 
analogues may help to elucidate the molecular requirements for retinoid/non-
retinoid induced cell death, as well as to investigate whether these 
structurally disparate compounds (in comparison to fenretinide) may be 
acting via a similar mechanism to fenretinide.   
3.7.1.Design and synthesis of hybrid analogues 
We hypothesised that introduction of a methoxy group at the OH site of the 
non-retinoid hits 263 and 275 should decrease or abolish activity based on 
our understanding of the SAR from the retinoid studies (OMe abolishes 
activity, Chapter 2). The para-methoxy analogue (348) of bis-amide 263 was 
synthesised over 3 steps in a similar manner as for the parent hydroxyl 
variant, by replacing TBDMS protected para-aminophenol for para-
methoxyaniline. Using this method, para-methoxyaniline (150) was coupled 
to para-nitrobenzoyl chloride (336) and the resulting amide (345) reduced to 
the amine (346), followed by amide coupling to isovaleryl chloride (347) to 
generate the methoxy compound (348) (Scheme 3.4). 
The para-methoxy analogue of the other hit, phenylether 275, was also 
synthesised to further qualify the importance of the OH/OMe exchange for a 
structurally distinct non-retinoid scaffold. In addition, the influence of 
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replacement of the 4-hydroxyphenyl group for 4-pyridyl and 4-aminophenyl 
was studied within this molecule to investigate whether modification for these 
variants was also tolerated (para-amino and 4-pyridyl retain activity, Chapter 
2). These compounds were all synthesised using the same general method 
employing a HOBt/EDC mediated coupling of 2,5-dimethylphenoxyacetic 
acid (341) to the required aniline - 4-aminopyridine, para-phenylenediamine 
or para-methoxyaniline - to give the required amides 349, 350 and 351, 
respectively (Scheme 3.5). Although the yields of the reactions were quite 
poor in each case, the products were easily obtained by recrystallisation in 
excellent purity and in a sufficient quantity for screening.  
3.7.2 Biological evaluation of the ‘hybrid’ compounds  
The four ‘hybrid’ compounds were screened in the TC32 cell viability assay 
at 10 µM compound concentration over 24 h, as described previously (see 
page 51).  
 
Scheme 3.4 Synthesis of the para-methoxy analogue (348) of the bis-amide (263). 
 
 
Compound R Yield (%) 
349 
 
21 
350 
 
26 
351 
 
14 
Scheme 3.5 Synthesis of three ‘hybrid’ analogues of compound (275) via a HOBt/EDC 
amide coupling reaction. 
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The methoxy analogue (348) of the bis-amide 263 showed no significant 
activity (98 ± 3 % cell viability) compared to the DMSO control. The lack of 
activity observed for this compound in comparison to the parent hydroxy 
compound (263) (70-76 % cell viability), suggests that the methoxy group is 
not tolerated and that compound 263 may be having a specific cytotoxic 
effect on TC32 cells. This lack of activity for the methoxy analogue is 
consistent with the SAR identified with the retinoids which might suggest that 
bis-amide (263) may be binding to the same target and/or acting via a similar 
mechanism to fenretinide. 
Similarly, the methoxy analogue (349) of the phenylether 275 demonstrated 
no significant activity (95 ± 6 % cell viability) compared to the DMSO control, 
reaffirming our observation about the importance of the methoxy substitution 
to biological activity. Interestingly, the other ‘hybrid’ compounds based on 
compound 275 (4-aminophenyl analogue (350), and 4-pyridyl (351)) also 
demonstrated no significant activity (97 ± 7 % and 93 ± 5 % cell viability, 
respectively). This is contradictory to the SAR identified for the retinoids, 
whereby the 4-aminophenyl and 4-pyridyl isosteres demonstrated significant 
activity. This could imply that compound 275 is affecting a different target 
and/or acting via an alternative mechanism to fenretinide. It was therefore of 
interest to take this compound forward for further mechanistic studies 
(Chapter 4) in attempt to identify whether this compound initiates 
programmed cell death by the same pathways that are known to contribute 
to fenretinide induced cell death. 
3.8 Conclusions 
Through iterative ROCS shape- and electrostatic-based similarity and 
substructural searching methods, a range of novel and highly structurally 
diverse non-retinoid mimetics have been identified which demonstrate a 
significant cell death capability in TC32 cells, as well as evidence for an 
encouraging therapeutic ratio to normal MSCs. As these compounds have 
been designed to incorporate a more favourable predicted physicochemical 
profile, by reduction in the lipophilic capacity of the molecule, these 
compounds may also demonstrate more favourable pharmacokinetic 
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properties including improved metabolic stability and solubility, resulting in an 
improved bioavailability than that which is achieved by fenretinide. The actual 
physicochemical (and pharmacokinetic) properties of the non-retiniods will be 
returned to for discussion in Chapter 4. 
All active non-retinoids identified within this Chapter contained substructures 
of compounds found to display activity in the retinoid SAR study, namely a 
para-hydroxyphenyl, para-aminophenyl or 4-pyridyl susbtructure. Synthesis 
and screening of the methylated ‘hybrid’ analogues for two of the most 
interesting hits resulted in loss of activity. This indicates that these 
compounds may be binding to the same target and acting via a similar 
mechanism to the parent compound. Additionally, those compounds with 
reduced hydrophobicity in comparison to fenretinide generally exhibited 
reduced activity, indicating that hydrophobicity may be an important factor for 
binding or for delivery to the target. 
Of the specific hits identified in this chapter, the hydroxyphenyl phenyl ether 
(275) and 4-pyridyl-containing compound (298) were of most interest based 
on a good, consistent activity against TC32 cells and represent a diverse set 
of structures for optimisation (Table 3.14).  Compound 275 also did not 
demonstrate statistically significant activity in MSCs, hence the observed 
activity has the potential to be specific to the cancer cells. In contrast, 
compound 298 bearing the 4-pyridyl polar head group did demonstrate 
significant activity in MSCs. However toxicity in this cell line was statistically 
comparable to that of fenretinide and therefore a more substansive 
assessment of the toxicity is required. It was of particular interest to 
understand the biological activity of this compound due to its structural 
diversity in comparison to the other hit compounds which typically bear the 
fenretinide-like 4-hydroxyphenol moiety. 
The ‘hybrid’ analogues of hydroxyphenyl phenyl ether 275, whereby the 
para-hydroxyphenyl component was replaced with 4-pyridyl and 4-
aminophenyl, were only weakly active or inactive, which is contradictory to 
the SAR identified for the retinoids, whereby the 4-aminophenyl and 4-pyridyl 
isosteres demonstrated significant activity. This could imply that 
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hydroxyphenyl phenyl ether 275 is affecting a different target and/or acting 
via an alternative mechanism to fenretinide.  
Both of these compounds (275 and 298) were prioritised for optimisation and 
taken forward for further biological evaluation, including dose response 
studies across multiple cell lines and mechanism of action studies (Chapter 
4). 
Compound 
number Structure TC32 cell viability* MSC cell viability* MW ClogP 
275 
 
54 ± 4 a 
69 ± 2b 78 ± 5 271 3.0 
298 
 
60 ± 2 67 ± 3 280 4.8 
         *Toxicity in TC32 cells and MSC cells treated at 10 µM for 24 h; Cell viability is expressed as the mean viable cell count  
          as a % of the DMSO control ± SEM; –, not measured. Fenretinide control: 44 ± 2 % TC32 cell viability; 88 ± 5 % MSC cell  
          viability; MW 391; ClogP 7.1. aresynthesised compound, bpurchased compound.
 
Table 3.14 Biological data of the two non-retinoid hits selected for further biological 
evaluation (Chapter 4). 
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4. Preclinical evaluation of hit compounds 
The goal in this Chapter was to examine and compare the concentration-
dependent activity of the fenretinide analogues and non-retinoid compounds 
of most interest and through mechanistic studies establish if these 
compounds might be effecting cell death through the intrinsic mitochondrial 
death pathway that is activated by fenretinide.  
In addition to establishing the range of activity of the hit compounds across 
the heterogeneous tumour types, these studies may also highlight any 
genetic factors which might influence the activity of some compounds. p53 
and p16 are tumour suppressor proteins which are responsible for the arrest 
of cell growth in DNA damaged cells. p53/p16 are capable of holding the 
damaged cell at the G1 regulation point, where DNA repair proteins fix any 
damage before the cell is allowed to proceed to the S phase, or by induction 
of apoptosis through programmed cell death in irreparable cells. Most 
chemotherapeutic drugs cause DNA damage, which is sensed by p53 or p16 
checkpoint proteins. Therefore mutations leading to loss of tumour 
suppressor protein expression can influence the response of cells to some 
therapeutics. Since cells which do not express p53/p16 are more resistant to 
apoptosis, it may be favourable to identify cytotoxic agents that induce cell 
death independently of these. Fenretinide is known to induce cell death 
independently of p53 and p16 in a wide range of cancer types, including 
ESFT.67,167 
ROS are species of reduced oxygen that are in a more reactive state than 
molecular oxygen. It was of interest to examine the effect of the most active 
compounds on ROS levels, as one of the earliest effects of fenretinide in 
cancer cells is a time and concentration dependent induction of ROS.40,67 
Inhibition of ROS rescues cells from fenretinide-induced cell death in many 
cell lines, including ESFT cells, which is consistent with the hypothesis that 
elevated levels of ROS activate cell death in cancer cells.67,74,170,171 The 
intracellular levels and activity of ROS will be dependent on both the 
production and inhibition of ROS. Variation in both ROS production and 
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elimination most likely regulate the selective initiation of cell death in cancer 
cells by fenretinide. Consistent with this hypothesis, fenretinide fails to 
increase ROS in normal cells, which are resistant to fenretinide induced cell 
death.51,52 The lack of fenretinide toxicity in normal cells, substantiated in 
phase 1 clinical trials, is one of the reasons why fenretinide is  such an 
attractive therapeutic candidate.106 ROS modulate the activity of many 
cellular signalling molecules, and appears to mediate fenretinide induced 
cancer cell death through different cancer-type dependent pathways.67,74 
However, the morphological cellular changes induced by fenretinide cell 
death are known to be a consequence of the activation of intracellular 
cysteine-aspartic proteases known as caspases.62,65,67 Therefore it was also 
of interest to examine the effect of the most active compounds on caspase 3 
cleavage.  
By screening against multiple cell lines and investigating cell-death 
pathways, these studies may help to further establish the SAR required for 
activity within individual cell lines. Identification of an important pathway in 
the cell death process may aid the design of future potentially active 
compounds. This chapter describes an investigation into the mechanism of 
initiation of cell death in ESFT cells for 5 active compounds (three retinoids 
identified by the SAR studies (58, 198 and 199) and two non-retinoids (275 
and 298) identified by in silico searches (Figure 4.1) following concentration 
 
Figure 4.1 Three retinoids (58, 198 and 199) and two non-retinoids (275 and 298) 
selected for further biological evaluation. 
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response studies across multiple cell lines. The 5 compounds were assessed 
for their ability to generate ROS and cleave caspase-3. 
4.1 Concentration response studies 
Prior to embarking on mechanistic studies, concentration response studies 
were carried out using the five compounds selected for further biological 
evaluation in order to determine whether activity reflects that of fenretinide 
across a wide concentration range and multiple cell lines. 
Activity of the compounds was tested at 3, 6, 10, 20 and 40 µM against three 
ESFT cell lines (TC32, A673, SK-N-MC) and two neuroblastoma cell lines 
(SHEP-1 and SK-N-SH). ESFT cell lines were selected to represent the 
range of genetic features associated with the ESFT phenotype (Table 4.1). 
Cell viability was analysed using the trypan blue exclusion assay (as 
previously described, see page 51). Biological experiments consisted of 
three technical repeats per experiment and three independent experiments 
were carried out (n = 9). Statistical analysis was carried out as described 
previously. Compounds were deemed to display statistically significant 
activity or ROS production when p < 0.05 compared to that of the vehicle 
control viability, and comparable to fenretinide when p > 0.05 compared to 
the fenretinide control. Here, data is illustrated in charts displaying the 
activity of each respective compound against all five cell lines tested. Charts 
displaying all compounds against each respective cell line can be found in 
Appendix B. 
4.1.1 Concentration response of fenretinide 
As expected, fenretinide (1) demonstrated statistically significant activity 
across all cell lines tested (Chart 4.1). Activity was significant compared to the 
vehicle control across the concentration range (3-40 µM) in TC32 and SK-N-
 Cell line p53 expression p16 expression Fusion type 
TC32 + - EWS-FL1 type 1 
SK-N-MC - + EWS-FL1 type 1 
TTC466 + + EWS-ERG 
Table 4.1 Characteristics of the three ESFT cell lines prioritised for the concentration 
response studies. 
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SH cell lines, at concentrations ≥ 6 µM in TTC466 and SHEP-1 cells and ≥ 10 
µM in SK-N-MC cells. 
Chart 4.1 Effect of fenretinide (1) (3-40 µM) on ESFT (TC32, TTC466, SK-N-MC) and 
neuroblastoma (SHEP-1, SK-NS-H) viable cell number. Viable cell number was 
counted after treatment of cells for 24 hours. Results are shown as mean ± SEM, n = 
9. 
 
4.1.2 Concentration response of compound 199 
The 4-pyridyl analogue (199) demonstrated dose-dependent activity across all 
cell lines tested (Chart 4.2). Activity was significant compared to the DMSO 
control and comparable or approaching activity of fenretinide across the 
concentration range in SK-N-SH cells. Significant activity was observed at 
higher concentrations (20 and 40 µM) in SK-N-MC cell lines and activity was 
comparable to fenretinide at 20 µM. Activity in TC32 cells was significant at ≥ 6 
µM concentrations compared to the DMSO control which was comparable to 
fenretinide at 6 µM; however, activity was slightly reduced compared to 
fenretinide at ≥ 10 µM concentrations. TTC466 cell death was significant at 20-
40 µM, but was also reduced compared to fenretinide, particularly at the lower 
concentrations.  A considerable reduction in activity was observed in the 
SHEP-1 cell line; activity of compound 199 was only significant at 40 µM (63 ± 
16 % cell viability) and this was markedly reduced compared to fenretinide (13 
± 2 % cell viability). 
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4.1.3 Concentration response of compound 198 
The ortho-amino substituted analogue (198) demonstrated activity comparable 
to fenretinide across the concentration range in the three EFST cell lines 
tested, and improved activity at 3 µM in TC32 and TTC466 cells (55 ± 3 and 
68 ± 5 % cell viability) compared to fenretinide (80 ± 4 and 90 ± 5 % cell 
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Chart 4.3 Effect of the ortho-amino substituted analogue (198) (3-40 µM) on ESFT (TC32, 
TTC466, SK-N-MC) and neuroblastoma (SHEP-1, SK-N-SH) viable cell number. 
Viable cell number was counted after treatment of cells for 24 hours. Results are 
shown as mean ± SEM. n = 9.  
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Chart 4.2 Effect of the 4-pyridyl analogue (199) (3-40 µM) on ESFT (TC32, TTC466, SK-N-
MC) and neuroblastoma (SHEP-1, SK-N-SH) viable cell number. Viable cell number was 
counted after treatment of cells for 24 hours. Results are shown as mean ± SEM, n = 9.  
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viability respectively) (Chart 4.3). In SHEP-1, activity was comparable to 
fenretinide at 10 µM but was improved compared to fenretinide at 3-6 µM. 
Although activity was reduced compared to fenretinide at 20 and 40 µM 
concentrations, good cytotoxicity was still observed (55 ± 5 and 59 ± 4 % cell 
viability respectively). Similarly, in SK-N-SH cells, reduced activity was 
observed at the higher concentrations (≥ 10 µM) but was comparable to 
fenretinide at 3 and 6 µM, although significant cytotoxicity was observed 
across the concentration range (48 ± 4 to 80 ± 6 % cell viability). Interestingly, 
this compound demonstrated a marked increase in activity compared to 
fenretinide in 3/5 of the cell lines tested (TC32, TTC466, SHEP-1) at 3 µM. 
Highest levels of activity induced by compound 199 were observed in the SK-
N-MC cell line, closely followed by TC32, TTC466 and SHEP-1. The SK-N-SH 
cell line demonstrated the most resistance to this compound; however, 
significant activity was still observed across the concentration range.  
4.1.4 Concentration response of compound 58 
The para-amino analogue (58) demonstrated significant activity in all three 
ESFT cell lines at concentrations ≥ 10 µM and both neuroblastoma cell lines at 
≥ 20 µM (Chart 4.4). In the ESFT cell lines, activity is approaching that of 
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Chart 4.4 Effect of the para-amino analogue (58) (3-40 µM) on ESFT (TC32, TTC466, SK-N-
MC) and neuroblastoma (SHEP-1, SK-N-SH) viable cell number. Viable cell number was 
counted after treatment of cells for 24 hours. Results are shown as mean ± SEM, n = 9.  
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fenretinide at lower concentrations and comparable at higher concentrations. 
Although this compound consistently showed reduced activity to fenretinide 
across the concentration range in SHEP-1 cells, very good activity was still 
observed at 40 and 20 µM (32 ± 2 and 48 ± 3 % cell viability respectively) 
compared to fenretinide (11 ± 1 and 23 ± 2 % cell viability respectively). 
Similarly, good activity was observed in SK-N-SH cells at 20 and 40 µM (30 ± 
1 and 40 ± 2 % cell viability respectively), which was comparable to fenretinide 
at 40 µM. 
4.1.5 Concentration response of compound 298 
The 4-pyridyl-containing non-retinoid compound (298) demonstrated 
significant activity in the TC32 and SK-N-SH cell lines across the concentration 
range, and in the TTC466, SK-N-MC and SHEP-1 cell lines at concentrations 
≥ 10 µM (Chart 4.5). In all three ESFT cell lines and SK-N-H neuroblastoma 
cells, activity is comparable or approaching that of fenretinide across the 
concentration range. A reduction in activity compared to fenretinide was 
observed in the SHEP-1 cell line, particularly at higher concentrations (20 and 
40 µM). 
Chart 4.5 Effect of the 4-pyridyl-containing non-retinoid compound (298) (3-40 µM) on ESFT 
(TC32, TTC466, SK-N-MC) and neuroblastoma (SHEP-1, SK-N-SH) viable cell 
number. Viable cell number was counted after treatment of cells for 24 hours. Results 
are shown as mean ± SEM, n = 9.  
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4.1.6 Concentration response of compound 275 
The 4-hydroxyphenyl non-retinoid compound (275) demonstrated activity 
comparable to or approaching that of fenretinide in TC32 and SK-N-SH cell 
lines across the concentration range, which was significant at concentrations 
≥ 6 µM (Chart 4.6). However, the compound was dramatically less active in 
the other four cell lines tested. At 10 µM in SHEP-1 cells, activity was 
comparable to fenretinide but a reduction in activity was observed at higher 
concentrations (possibly due to precipitation of the compound). Activity was 
significant at ≥ 20 µM in TTC466 cells; however, observed activity was 
markedly reduced compared to fenretinide. Interestingly, this compound did 
not induce cytotoxicity across the concentration range in SK-N-MC cells.  
 
Chart 4.6 Effect of the 4-hydroxy-containing non-retinoid  compound (275) (3-40 µM) on 
ESFT (TC32, TTC466, SK-N-MC) and neuroblastoma (SHEP-1, SK-N-SH) viable cell 
number. Viable cell number was counted after treatment of cells for 24 hours. Results 
are shown as mean ± SEM, n = 9.  
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4.2 Caspase-3 activation 
Caspase-3 is known to be activated by fenretinide, as well as other 
retionids,172,173 and is an important effector of fenretinide-induced cell death in 
many cancer types including ESFT cells.67 In order to determine whether the 
hit compounds identified in this study induce caspase-3 cleavage, TC32 cells 
were treated for 24 h with the five hit compounds (58, 198, 199, 275 and 298). 
SDS-PAGE and western blot analysis were used to assess cleavage 
(activation) of caspase-3 from full length (35 kDa) to cleaved products (17 and 
19 kDa) following treatment with the selected compounds. As expected, 
cleavage of caspase-3 by fenretinide was observed, with an increasing 
amount of cleaved product and decreasing amount of full length caspase-3 
observed with increasing concentration of fenretinide (Figure 4.2). The same 
pattern of caspase-3 cleavage was observed for the para-amino isostere (58) 
and the ortho-amino substituted analogue (198) of fenretinide. This suggests 
that these compounds are effecting cell death through caspase-3 cleavage, 
which may be induced through the same programmed cell death signalling 
pathway as fenretinide. Interestingly, both of the non-retinoid-based 
compounds (275 and 298) and the 4-pyridyl fenretinide analogue (199) did not 
activate caspase-3. This was rather surprising as caspase-3 cleavage is a 
common effector of programmed cell death through apoptosis or autophagy; 
this suggests that these compounds may be killing cells through alternative 
non physiological mechanisms and requires further investigation. Two of the 
compounds that are unable to activate the caspase-3 cleavage mechanism 
(compounds 199 and 298), bear a 4-pyridyl moiety in place of the para-
hydroxyphenyl group. This might suggest that the para-hydroxy/amino group is 
important for initiating programmed cell death by interacting with a protein 
target facilitated through an OH/NH2-mediated hydrogen bond interaction or by 
generation of reactive oxygen species mediated by the presence of the 
OH/NH2 group. Proteins were not detected in cells treated with 40 µM of 
compounds 58 or 198, which may reflect the low yield and poor quality of 
protein extracted due to high levels of toxicity at these concentrations. 
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Figure 4.2 Western blot analysis of caspase-3 activation in TC32 cells after 24 h treatment 
with A. Fenretinide, B. Compound 298, C. Compound 275, D. Compound 199, E.  
Compound 58 and F. Compound 198 over a concentration range (3-40 µM). Tubulin 
was probed as a loading control. Compounds were labelled with Alexa flurophore 
680 and visualised using a LI-CORE Odyssey CLx Infrared Imaging System. These 
data are representative of two independent experiments. 
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4.3 Generation of ROS  
Fenretinide is known to produce ROS in a dose-dependent manner in ESFT 
cells; this is thought to be a major factor in induction of cell death in the TC32 
cell line.67 In order to determine whether ROS are produced by the five 
selected compounds (58, 198, 199, 275 and 298), TC32 cells were treated 
with each compound  and fenretinide (the control) at a concentration of 3-40 
µM for 30 minutes. ROS accumulation in cells, fluorescently labelled with a 
molecular probe, was detected by flow cytometry (see Chapter 8). ROS 
accumulation was measured at 30 minutes, as a prior time course study 
(between 15 to 60 minutes) had identified optimum levels of ROS 
accumulation after 30 minutes of exposure to fenretinide (Chart 4.7). 
Consistent with previous data, fenretinide induced a concentration-dependent 
increase in ROS (Chart 4.8). However, there was a drop in ROS levels when 
cells were exposed to 40 µM of fenretinide; this may reflect the increased 
amount of cell death that was observed after 30 minutes exposure to 
fenretinide at this concentration. At this high concentration, fenretinide 
appeared to be toxic to the cells and consequently the dye (DCFDA) might be 
leaking from cells that were not intact, therefore leading to a false decrease in 
ROS levels.  
 
Chart 4.7 ROS levels upon treatment of TC32 cells with fenretinide (3-40 µM) at 15, 30 
and 60 minute timepoints (n = 3). 
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None of the test compounds produced ROS across the concentration range of 
3-40 µM (Chart 4.8).  
4.4 ADME properties 
To investigate whether any of the compounds have physiochemical and 
pharmacokinetic properties consistent with a good hit compound, three hits 
(58, 198 and 275) plus fenretinde (1) and 4-oxo-fenretinide (3) as controls 
were selected for ADME testing, carried out by Cyprotex.174 The potential for 
improved aqueous solubility, metabolic stability and intestinal permeability 
was quantified (Table 4.2). All of the retinoid-based structures (1, 3, 58 and 
198) demonstrate quite poor aqueous solubility under the conditions tested 
(≤ 6 µM), as would be predicted based on the high hydrophobicity for these 
compounds. In contrast, the aqueous solubility for the non-retinoid 
compound was high (80 µM), presumably owing to the reduced 
hydrophobicity of this compound. The metabolic stability for both retinoids 
and non-retinoids in mouse and human liver microsomes is relatively high, 
indicating that the compounds are quite stable to phase 1 metabolism. 
Passive diffusion of the compounds was tested using the Caco-2 cell 
monolayer simulated intestinal permeability assay. The apparent 
 
Chart 4.8 A graph to show ROS accumulation in TC32 cells after 30 min treatment with 
fenretinide, three retinoids (58, 198 and 199) and two non-retinoids (275 and 298) (n 
= 9). 
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permeability coefficient (Papp) for the retinoids was 0 (i.e. none of the 
compound diffused across the cell monolayer from the donor well to receiver 
well). For fenretinide and the 4-amiophenyl (58), 69 % and 42 % of the 
compound was recovered from the donor well, respectively, indicating that 
these lipophilic compounds accumulate in the lipid bilayer of the Caco-2 
cells. This correlates with the poor permeability of fenretinide in Caco-2 cells 
observed by others44 and supports our hypothesis that entry of fenretinide 
into the cancer cells is facilitated by a cell surface receptor (e.g. STRA6, 
currently under investigation within our group). In contrast, the non-retinoid 
compound (275) is more permeable (Papp 0.81 × 10-6 cms-1). In all, the data 
suggests that the generation of non-retinoid mimetics might offer a more 
attractive scaffold for the generation of drug candidates, owing to a 
significantly improved solubility and permeability, whilst maintaining the 
robust metabolic stability of the compounds.  
Compound Estimated precipitation (µM) 
t1/2 (min) 
(mouse/human) 
Mean Papp  
(10-6 cms-1) ± SD 
Mean  Recovery 
from donor well (%) 
1 (fenretinide) 3.75 62/49 0 69 
3 (4-oxo-fenretinide) <5 ND/5 ND ND 
58 2 78/68 0 42 
198 6 69/ND 0 ND 
275 80 120/ND 0.81 ± 0.20 ND 
Table 4.2 ADME data quantified for 3 selected hit compounds (58, 198 and 275), alongside 
fenretinide (1) and 4-oxo-fenretinide (3) controls. (ND = not determined.) 
4.5 Conclusion 
The ortho-amino substituted analogue (198) demonstrated very interesting 
activity in the concentration response studies. Not only did this compound 
induce similar levels of activity to fenretinide in all of the ESFT and 
neuroblastoma cell lines, activity was significantly increased compared to 
fenretinide at the lowest concentration (3 µM) in three out of the five cell lines 
(TC32, TTC466 and SHEP-1). 
The 4-pyridyl analogue (199) demonstrated dose-dependent activity across all 
cell lines tested. However, this was often reduced compared to fenretinide, 
particularly in the SHEP-1 and TTC466 cell lines. Activity of this compound 
was comparable or approaching that of fenetinide in TC32, SK-N-MC and SK-
N-SH cell lines, particularly at the lower concentrations.  
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The para-amino analogue (58) demonstrated significant dose-dependent 
activity in all cell lines tested. Activity in ESFT cells was comparable to 
fenretinide at higher concentrations and approaching that of fenretinide at 
lower concentrations. Likewise, good activity was observed against 
neuroblastoma cell lines at higher concentrations and activity was comparable 
to fenretinide in SK-N-SH cells. Although this compound consistently showed 
reduced activity to fenretinide across the concentration range in SHEP-1 cells, 
very good activity was still observed at the higher concentrations. 
Of the non-retinoid compounds tested, the 4-pydridyl compound (298) 
demonstrated activity comparable to or approaching that of fenretinide in the 
TC32 and SK-N-SH cell lines across the concentration range, and in the 
TTC466, SK-N-MC and SHEP-1 cell lines at concentrations ≥ 10 µM. The 4-
hydroxyphenyl non-retinoid compound (275) also demonstrated activity 
comparable to or approaching that of fenretinide in TC32 and SK-N-SH cell 
lines across the concentration range. However, the compound was 
dramatically less active in the other four cell lines tested. At 10 µM in SHEP-1 
cells, activity was comparable to fenretinide but a reduction in activity was 
observed at higher concentrations (possibly due to precipitation of the 
compound). Activity in TTC466 cells was markedly reduced compared to 
fenretinide and the compound did not induce cytotoxicity across the 
concentration range in SK-N-MC cells. Since SK-N-MC and TTC466 cell lines 
differ from the others by deletion and missense mutation of p53 respectively, 
this could indicate that this compound acts via a p53-dependent mechanism.  
Consistent with published studies, fenretinide increased ROS and induced 
cleavage of caspase-3 in ESFT cells that correlated with a decrease in viable 
cell number.         
Due to lack of ROS production (for all synthetic compounds) and caspase-3 
activation (for the 4-pyridyl retinoid (199) and non-retinoid analogues (275 
and 298), it is possible that these compounds induce cell death via an 
alternative mechanism to fenretinide (Table 4.3). Alternatively, this could 
indicate that ROS production and/or caspase-3 activation is not essential for 
activation of the cell death pathway. However, caspase-3 cleavage would be 
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expected if the compound induces programmed cell death. It could be that 
the time course of caspase-3 cleavage varies between the different 
compounds. Alternatively, compounds could be acting through 
nonphysiological pathways to kill the cell. e.g. necrosis. Similarly, ROS may 
be elevated at different time courses; however, this is less likely to be the 
case as there are many opportunities to initiate programmed cell death 
through ROS independent pathways. The cell death pathway could be 
activated via multiple mechanisms, for example, mitochondrial membrane 
depolarisation,175 increase in intracellular calcium concentration176 or via the 
caspase-independent apoptosis inducing factor which is a flavoprotein that 
initiates apoptosis by inducing DNA fragmentation and chromatin 
condensation.177 
 
Compound ROS elevation Caspase-3 cleavage 
1 (fenretinide) + + 
58 - + 
198 - + 
199 - - 
275 - - 
298 - - 
Table 4.3 A summary table of observed ROS elevation and caspase-3 cleavage. 
The physicochemical and in vitro pharmacokinetic properties of the non-
retinoid analogue (275) demonstrated a markedly improved simulated 
intestinal permeability and solubility as well as low phase 1 metabolism 
liability. This suggests that the generation of non-retinoid mimetics might 
offer a more attractive scaffold for new chemotherapeutic agents, with 
improved pharmaceutical properties compared to retinoids. 
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5. Target identification by affinity chromatography 
Isolation of binding-proteins using affinity chromatography is an attractive 
method for discerning the protein binding partners of ligands (as discussed in 
Chapter 1, Section 1.1). The technique relies on specific binding interactions 
between a known inhibitor, which is covalently immobilised on a solid resin 
(e.g. Sepharose), and the target protein within cell lysates. 
This chapter describes the design and synthesis of suitable ligands and 
negative controls, their immobilisation onto a solid supported medium, and 
their application in a pull-down assay to identify binding partners to 
fenretinide. 
5.1 Design of Sepharose-supported ligands for affinity 
chromatography 
For affinity chromatography, the biologically active ligand is covalently 
immobolised on a solid resin through a linker. The siting of the linker on the 
active ligand is a crucial concern such that the biological activity of the ligand 
is maintained, i.e. so that incorporation of the linker does not adversely affect 
the biological activity of the ligand. Identification of an appropriate attachment 
point for a linker moiety on to the ligand is often the primary limitation of 
affinity chromatography, requiring extensive SAR studies. Synthetically, there 
are two amenable sites of attachment of a linker on the fenretinide structure, 
one at each of the two termini of the ligand; the phenyl and cyclohexyl rings 
(Figure 5.1). The SAR studies in Chapter 2 showed that substitution of the 
phenyl ring invariably results in loss or reduction of activity of the ligand. 
 
Figure 5.1 Synthetically accessible sites for attachment of a linker on the fenretinide 
structure for affinity chromatography studies. 
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Hence, this would suggest that this region of the molecule may interact 
directly with a macromolecular target responsible for the observed biological 
activity and therefore may not be a suitable site for incorporation of a linker 
for affinity chromatography studies. In contrast, substitution at the 4-position, 
of the cyclohexene ring is tolerated, at least for certain oximes (See Chapter 
2). Therefore it is possible that the 4-position of the cyclohexyl ring could be 
a suitable site for incorporation of a linker, as substitution at this site may not 
adversely compromise the binding activity of the ligand. As such, the affinity 
chromatography ligands proposed for synthesis were planned with linkers 
extending from the 4-position of the cyclohexyl ring. Two ligands which were 
expected to be inactive in vitro were also synthesised as negative controls 
which, in addition to uncoupled Sepharose beads, were used to eliminate 
any proteins which bound non specifically to the column or a column plus 
linker that had no activity. 
5.2 Synthesis and biological affirmation of solid supported 
ligands for affinity chromatography 
This section describes the design and synthesis of two solid supported 
ligands for affinity chromatography. The section also describes the biological 
affirmation of the ligands prior to incorporation of the affinity support (to act 
as a control validating the biological activity of the affinity supported ligand).  
5.2.1 Design of solid supported ligands  
Two solid-supported ligands predicted to have in vitro activity based on SAR 
studies were designed, utilising two different linker groups, one based on an 
amino oxime (352), the other on an amino acylhydrazone (353) (Figure 5.2). 
These ligands were chosen for synthesis to satisfy that, a) they should be 
readily synthesisable from a common intermediate, 4-oxo-fenretinide (3), 
based on a simple condensation chemistry, and b) the location of the linker 
or affinity support accommodated at this position should not interfere with 
binding to the biological target based on historical SAR for substitution at this 
site (Chapter 2). Two structurally distinct linkers were chosen for synthesis in 
an attempt to negate any non-specific binding due to the presence of groups 
within the linker moiety.  
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5.2.2 Synthesis of the oxime linkered solid supported ligand (352) 
The key intermediate, hydroxylamine (356), was synthesised in a two step 
process from N-Boc-ethanolamine (354) (Scheme 5.1). The pthalimide (355) 
was generated from the alcohol (354) using a Mitsunobu reaction from N-
hydroxypthalimide, PPh3 and DIAD in moderate yield. Deprotection of the 
pthalimide (355) with hydrazine then generated the amine (356) in excellent 
yield following purification by silica column chromatography and 
recrystallisation (Scheme 5.1).  
Coupling of the hydroxylamine (356) to 4-oxo-fenretinide (3) (previously 
synthesised in Chapter 2, Scheme 2.28) was firstly attempted by adaptation 
 
Figure 5.2 Two solid-supported ligands for affinity chromatography proposed for 
synthesis from 4-oxo-fenretinide. 
 
 
Scheme 5.1 Synthesis of the hydroxylamine linker as a precursor for the affinity 
chromatography ligand (352). 
- 137 - 
 
of a method for the synthesis of oximes under non acidic conditions reported 
by Dirksen et al.
 
(Scheme 5.2, Method A).178 The synthesis of oximes by 
condensation of a hydroxylamine and a carbonyl group under non-acidic 
conditions is known to be quite slow.179 However, Dirksen et al. showed that 
aniline can act as an effective nucleophilic transamination catalyst which 
forces the equilibrium towards oxime formation.178 Upon application of these 
conditions to our reaction, this generated only trace quantities of the desired 
oxime (357) together with a large quantity of unreacted starting material 
observed by LCMS after 48 h at room temperature.  
No attempt was made to force this reaction to completion. Instead, an 
alternative method for formation of the desired oxime was attempted by use 
of weak acid catalysis (Scheme 5.2, Method B).180 Here, an acetate buffer 
solution of pH 4.6 was prepared and added to a mixture of compounds 3 and 
356 at room temperature. This generated a 2:1 mixture of the desired 
product (357) plus remaining starting material (3) after 72 h. Addition of a 
further quantity of acetic acid and stirring for a further 24 h forced the 
reaction to completion giving the oxime (357), with no evidence of 
deprotection of the Boc group, in reasonable yield (50 %) after purification. 
The product exists as a single isomer; however, nOe experiments to identify 
this were inconclusive. 
Compound 357 was then deprotected using TFA and the resulting free 
amine (358) obtained in good yield (76 %) after trituration with Et2O. Notably, 
it appeared that deprotection of protected amine (357) had resulted in 
isomerisation of the hydrazone to yield an approximately 1:1 E:Z ratio by 1H 
NMR. E,Z isomerisation of oximes by acid catalysis has previously been 
described by others.181 
Compound 358 was then coupled to epoxy-activated Sepharose beads (359) 
under weakly basic conditions. Epoxy-activated Sepharose is a pre-activated 
medium for immobilization of a range of ligand types bearing hydroxyl, amino 
or thiol groups which can be readily coupled to the epoxide. This medium 
has a long hydrophilic spacer arm, making it particularly suitable for 
immobilization of small molecules.182 Following incubation overnight, any 
remaining active epoxy groups were blocked using ethanolamine and the 
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resin was washed with alternating pH cycles (pH 4 and 8) to remove any 
unbound molecules. In order to confirm that the ligand had been successfully 
immobolised on to the support, LCMS was used to compare the relative 
 
Scheme 5.2 Synthesis of an oxime-linkered solid supported affinity chromatography ligand. 
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extinction coefficient for the non-immobolised ligand (358) on the loading and 
eluted solution, respectively, with reference to an internal standard (an 
uncharacterisable minor impurity of mass 476.3, RT ca.2.30 min remaining in 
the sample following deprotection, which was not detected by 1H NMR) 
(Figure 5.3). It was noted that the absorbance for the ligand (358) (RT 
ca.1.65 min) was reduced by 1 order of magnitude relative to the internal 
standard (RT ca.2.30 min). Thus, it was reasoned that a considerable 
amount of the ligand was successfully immobilised on the resin. Analysis of 
the condensed elution fraction by 1H NMR also confirmed the presence of 
little or no recovered ligand, supporting the conclusion that a significant 
quantity of the ligand had been bound to the solid support. 
5.2.3 Affirming biological activity of the oxime linkered ligand 
To confirm the biological activity of the oxime-linkered ligand (358), the 
compound was screened at 10 µM over 24 h in the TC32 cell viability assay, 
as described previously (see page 51). Encouragingly, compound 358 
displayed statistically significant activity (72 ± 2 % cell viability), although the 
activity was reduced in comparison to the fenretinide control (38 ± 2 % cell 
viability) in this experiment. The observed reduction in activity may be due to 
the presence of the polar NH2 moiety which will reduce the concentration of 
a)  
 
b)  
 
Figure 5.3 LCMS analysis of affinity chromatography ligand present in a) loading solution 
and b) eluted solution. 
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compound available to permeate the cell membrane. To support the 
affirmation of the biological activity of the oxime ligand, the Boc-protected 
precursor (357) was also screened. This compound displayed a similar level 
of activity (78 ± 2 % cell viability) as for the deprotected compound. Although 
the activity for both the protected and non-protected compounds was 
reduced in comparison to fenretinide, the demonstration of a statistically 
significant cell death response for the compounds suggests that 
incorporation of a narrow, extended polar linker at the 4-position of the 
cyclohexyl ring is tolerated and does not appreciably eliminate binding. 
5.2.4 Synthesis of the acyl-hydrazone linkered solid supported 
ligand 
The acyl-hydrazone linked solid supported ligand (353) was synthesised in 
four steps from 4-oxo-fenretinide (3) and the methyl ester, 361. The 
acylhydrazine (361) was synthesised in quantitative yield by substitution of 
the methyl ester (360) with hydrazine at room temperature (Scheme 5.3). 
Condensation of acylhydrazine (361) with 4-oxo-fenretinide (3) under 
microwave conditions (100 °C at 200 bar) (Method 1) yielded the 
acylhydrazone (362) in moderate yield as a single isomer. This reaction was 
very slow, requiring 72 h heating in order for the reaction to go to completion. 
No nOe studies were carried out to confirm the stereochemistry of the single 
isomer. 
In an attempt to improve the efficiency of the reaction, the hydrazone (362) 
was also synthesised using the acid catalysed method deployed for the 
oxime formation (Method 2, Scheme 5.4). Using this method the hydrazone 
(362) was generated in a lower yield than for the microwave approach (45 % 
vs 58 %) but the reaction was complete in a much shorter period of time (24 
h vs 72 h). 
 
Scheme 5.3 Synthesis of the acylhydrazine linker moiety. 
 
- 141 - 
 
The Boc-group of compound 362 was then removed using TFA and the 
resulting free amine (363) was obtained in modest yield (37 %) after 
 
 
Scheme 5.4 Synthesis of an acyl-hydrazone linkered solid supported ligand. 
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purification by HPLC. Interestingly, unlike compound 4 which was obtained 
as a single isomer, compound 363 was generated as an inseparable mixture 
of two isomers (assumed to be the E/Z isomers) as observed by 1H NMR. 
Owing to the complexity of the NMR (also evidence for amide 
rotation/rotamers) no attempt was made to confirm the ratio of E- and Z-
isomer present in the sample. 
Compound 363 was then coupled to epoxy activated Sepharose beads (359) 
using the method described previously (see page 137) (Scheme 5.4).  
 5.2.5 Affirming biological activity of the acyl-hydrazone linkered 
solid supported ligand 353 
Both the Boc-protected amine (362) and the amine (363) were assessed for 
their ability to induce cell death in the TC32 cell viability assay using the 
method as  previously described, see page 51). Encouragingly, the Boc-
protected amine (362) showed a similar level of activity (40 ± 2 % cell 
viability) to fenretinide (38 ± 2 % cell viability) in vitro. However, the 
deprotected amine (363) was inactive (109 ± 6 % cell viability). The apparent 
inactivity of compound 363 may be attributed to the presence of the polar 
primary amine group, which might limit the amount of compound able to 
permeate through the cell membrane and reach the intracellular target. 
5.3 Negative controls 
A negative control is required for the affinity chromatography experiment to 
eliminate non-specific binding to the column. Two Sepharose supported 
ligands were designed for this purpose. The SAR work in Chapter 1 
suggested that the biological activity of variants at the phenyl ring-side of 
fenretinide is quite sensitive to synthetic modification. Hence, it seemed 
sensible to base the negative control ligands from within the pool of ‘inactive’ 
ligands identified during the SAR section of the project, which principally 
focussed on modifications to this portion of the molecule. Of the inactive 
ligands identified, the methoxy (24) and benzylamine (184) analogues were 
selected as ligands from which to base the negative controls as they showed 
no statistically significant activity in the cell viability assay (93 ± 2 % and 99 ± 
10 % cell viability, respectively). Furthermore, the methoxy analogue (24) 
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has previously been found to be incapable of inducing RAR-dependent 
activity in F9 murine embryonal carcinoma cells (discussed in Section 
1.10.1). Equally, these ligands would allow for synthetic accessibility to the 
proposed affinity supported ligand. Using the methoxy (24) and benzylamine 
(184) analogues as starting points, affinity chromatography supported 
ligands were designed such that the linker to the solid support extended from 
the fenretinide structure from one of two termini of the molecule, i.e. to 
generate one solid supported ligand from the phenyl, and one supported 
ligand from cyclohexyl ring side of the molecule (Figure 5.4). Specifically, the 
benzylamine affinity ligand (364) was designed with the linker extending from 
the amine (so from the phenyl ring side of the molecule). In contrast, the 
methoxy variant (366) was planned to extend with a linker from the 
cyclohexyl ring. The methoxy variant (366) should behave as a direct 
negative control of the oxime-linkered ligand (352) as the substitution of the 
para-hydroxy group with para-methoxy has previously been confirmed to be 
detrimental to activity for fenretinide (Chapter 2, Section 2.2.3). If the lack of 
 
Figure 5.4 Structures of proposed negative control ligands for affinity chromatography. 
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activity for methoxy substitution is a result of disruption of binding to the 
target protein(s) through which cell death is initiated, the proposed OMe 
affinity supported ligand should not identify these proteins. However, the 
possibility that the reduction of activity for this compound reflects disruption 
of a downstream pathway involved in the execution of fenretinide-induced 
cell death rather than its initiation cannot be excluded.     
5.3.1 Synthesis of the benzylamine linkered solid supported 
ligand (364) 
The pre-solid supported ligand for affinity ligand 364 – amine 184 – was 
synthesised by coupling of the Boc-protected aniline (166) to the mixed 
anhydride (148) in modest yield after purification (Scheme 5.5). The Boc-
group of compound 175 was removed using TFA and the resulting free 
amine (184) was obtained in excellent yield without need for further 
purification.  
Amine 184 was then coupled to epoxy-activated Sepharose beads (359) to 
generate the benzylamine supported ligand (364) using the method as 
described previously (see page 137).  
5.3.2 Affirmation of absence of biological activity of the 
benzylamine solid supported ligand 
The biological inactivity of the pre-supported ligand, amine 184, has been 
previously described (99 ± 10 % cell viability vs fenretinide 43 ± 2 % for 
fenretinide, see Section 2.2.6). As confirmation to validate the biological 
relevance of extending from the amine, in vitro screening of the Boc-
protected compound (175) also showed absence of any activity (106 ± 6 % 
cell viability vs 43 ± 2 % for fenretinde). Hence, the SAR shows that the 
incorporation of the aminomethyl group as well as a lipophilic extension to 
the aminomethyl group at the para-position of the phenyl ring were both 
detrimental to activity; thus validating the approach for use of the 
benzylamine-derived solid supported ligand (364) as a negative control to 
distinguish between potential targets and non-specific binders. 
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5.3.3 Synthesis of the para-methoxy oxime solid supported ligand 
The pre-Sepharose supported ligand (369) was synthesised via an acid-
catalysed condensation of the hydroxylamine linker (356) (synthesised 
previously, see page 136) to the methylated 4-oxo-fenretinide (368) (itself 
synthesised by coupling of para-methoxyaniline (150) to the mixed anhydride 
of 4-oxo-retinoic acid (367) which was synthesised previously in Chapter 2) 
at room temperature in reasonable yield (Scheme 5.6). A single isomer was 
observed; however, nOe studies to identify this were inconclusive. 
 
Scheme 5.5 Synthesis of a benzyl amide ‘negative control’ affinity chromatography ligand. 
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5.3.4 Affirmation of absence of biological activity of the para-
methoxy oxime solid supported ligand 
In order to confirm that the pre-Sepharose loaded para-methoxy oxime 
ligand showed no biological activity, the Boc-protected compound (369) was 
tested in the same cell viability assay. Unexpectedly, compound 369 
decreased viable cell number (59 ± 4 % cell viability) in the assay, 
demonstrating activity which was approaching that of fenretinide (43 ± 2 % 
cell viability). This result was contradictory to the historical SAR developed 
for fenretinide activity (Chapter 2) in which the importance of the OH group 
on the phenyl ring was established. Hence, this ligand cannot be used as 
negative control in the affinity chromatography experiment. Interestingly, the 
para-methoxy-4-oxo-fenretinide precursor (368) also demonstrated 
significant activity (66 ± 4 % cell viability). The ability of this compound to 
induce cell death has never before been described, despite the fact that 
fenretinide is known to metabolise to both the 4-oxo- and methoxy-variants 
(see Chapter 1). It is possible that the positive biological data observed for 
compounds 369 and 368 may be the result of the compounds acting via an 
alternative mechanism to fenretinide, yet producing the same phenotype in 
this assay. The deprotected precursor (365) was not screened owing to the 
likelihood of poor cell permeability for this compound (as has been proposed 
 
Scheme 5.6 Synthesis of the methylated negative control affinity chromatography ligand. 
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for other ligands with protonatable primary amines). This ligand was 
therefore not taken forward for binding to the epoxy activated Sepharose. 
No further negative controls were proposed for synthesis, although 
Sepharose itself was also used as a negative control in the experiment.    
5.4 Affinity chromatography 
This section describes the processes used in order to carry out the affinity 
chromatography pull down assay using the selected ligands discussed 
above. Fragments bound to the linker with activity (but not the negative 
control or Sepharose column alone) were subsequently identified and 
isolated using SDS-PAGE and identified using mass spectrometry. A 
literature review was carried out on any fragments which were found to bind 
specifically to those ligands which demonstrated activity in vitro, without non-
specific binding to the negative controls.  
5.4.1 Isolation of membrane proteins binding to fenretinide 
The affinity chromatograpy studies were carried out by Dr Paul O’Regan 
(LICAP, University of Leeds).  
Precleared membrane enriched biotinylated cell lysate from SKES1 ESFT 
cells was incubated with the each of the covalently immobilised molecules 
(352, 353 and 364) bound to the Sepharose resin or Sepharose resin alone 
overnight at 4 °C. The resin was then poured into a column under gravity and 
the flow through (fraction containing unbound proteins) was collected. The 
column was then washed in wash buffer (10 mM, HEPES (pH 7.1), 100 mM 
KCl, 2 mM MgCl2, 1 mM EDTA) to remove any unbound proteins. Bound 
proteins were subsequently eluted in 50 mM glycine pH 2.3, 10 % sucrose 
buffer.   
The purified proteins were analysed by 1D gradient SDS-PAGE (4-20 % 
acrylamide) and silver staining (Proteosilver Plus, Sigma). In total 12 bands 
were identified that were eluted from the specific affinity columns but were 
absent in the non-specific negative control column (Figure 5.6).  
Each protein band was analysed by mass spectrometry for identification. 
using an Agilent 1100 Series nano-LC System (Agilent Technologies) 
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coupled online with a QSTAR XL quadrupole TOF hybrid mass spectrometer 
(Applied Biosystems) as previously described.183 Data was analysed using a 
local Mascot database search engine (Matrix Science) and the UniProt 
protein sequence database (restricted to human; 88214 sequences). 
Peptides with scores over the identity threshold (p < 0.05) were considered 
as identified, proteins required at least one significant bold red peptide (that 
is, the highest scoring match to a particular query listed under the highest 
scoring protein containing that match). 
The expression of proteins that appeared to be specifically binding to the 
fenretinide molecule was confirmed by western and immunoprecipitation blot 
of ESFT cellular extracts (results not shown). No hits were identified for two 
bands, one at ca.100 kDa and one at ca.30 kDa. In the remaining bands 
many ribosomal proteins were identified, along with tubulin and nucleolin (an 
exhaustive list of which can be found in the Appendix C). Five proteins were 
identified to bind to one or both of affinity chromatography ligands 352 or 
353, with weak or no non-specific binding to the negative control ligand (364) 
or Sepharose (discussed below). 
 
    
Figure 5.6 SDS-PAGE of silver-stained proteins from SKES1 cells in the flow-through and 
isolated by binding to the ligands 364 (negative control), 352, 353 and Sepharose 
(negative control). The size of isolated proteins was identified by comparing to the 
molecular weight markers (MW). 
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5.4.2 Literature review of binding fragments 
Q00839 - Heterogeneous nuclear riboprotein U (HNRPU) 
Strong binding of HNRPU to both ligands 352 and 353 was observed. 
However, the protein was also seen to bind to the Sepharose and the 
negative control ligand (364), albeit much more weakly, meaning binding 
may not be specific to the ligand under investigation. HNRPU is 
predominantly localised in the nucleus, cytoplasm and cell surface. The 
protein has multiple functions; firstly, binding to RNA has been observed and 
the protein is a component of HNRNP complexes, important in RNA 
processing (splicing, polyA addition, cytoplasmic shuttling).184 HNRPU 
inhibits transcript elongation by RNA polymerase II.185 Additionally, scaffold 
attachment regions of HNRPU bind DNA to tether chromatin loops to nuclear 
matrix.186 More relevantly, the protein is cleaved in the DNA-binding domain 
during apoptosis and released from the nuclear matrix, which may contribute 
to apoptotic nuclear breakdown.187 Interactions with the Wilms tumour 
suppressor gene 1 (WT1) have been reported188 and binding to EWS protein 
was observed by Pahlich et al.189 However, in the pull-down assay of Pahlich 
et al., it was noted that the interaction could be a non-specific interaction with 
the Agarose pull-down resin. HNRPU is a substrate for and is 
phosphorylated by DNA-PK in response to DNA double strand breaks.190 
Together with IGF2BP1, also identified as a bound fragment in the pull-down 
assay, HNRPU forms part of a complex that protects c-Myc mRNA (a 
template for the Myc protein, which is associated with rapid proliferation of 
cancer cells and is upregulated in ESFT cells) from degradation.191 
Q9NZ18 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)  
IGF2BP1 was identified as a binding protein for both affinity chromatography 
ligands (352 and 353), although stronger binding to ligand 353 was observed. 
No apparent binding to Sepharose was observed and very weak binding to 
the negative control ligand (364). IGF2BP1 is localised in cytoplasmic mRNP 
particles containing untranslated mRNAs. It functions as a binding partner to 
mRNAs of certain genes (e.g. IGF2, beta actin) and regulates their 
translation and is a component of the coding region instability determinant 
(CRD)-mediated complex that promotes Myc mRNA stabilisation. IGF2BP1 is 
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a target of the Wnt signalling pathway and knockdown of the CRD-binding 
protein induces apoptosis.192 Wnt signalling is reported to be upregulated in 
metastatic compared to localised Ewing sarcoma and several lines of 
evidence suggest that another component of the IGF pathway, IGF1R 
signalling, is critical to the biology of ESFT.193 Additionally, increased 
expression of IGF2BP1 is associated with advanced clinical stage and poor 
prognosis in ovarian cancer.194 
P68104 Elongation factor 1-alpha 1 (EF1a1) 
EF1a1 was found to bind to both ligands (352 and 353), binding to 352 with 
greater affinity. No apparent binding to the Sepharose and the negative control 
ligand (364) was observed. However, the protein was abundant in all flow-
through fractions. This could be due to very high levels of the protein present 
in the sample, therefore the column becomes saturated. The protein is an 
isoform of the α-subunit of the elongation factor-1 complex and is highly 
abundant in cytoplasm. The protein is responsible for enzymatic transfer of 
aminoacyl tRNAs to the ribosome. It is known to have GTP-binding and 
hydrolysis activity,195 which implies that the enzyme may be druggable via 
small molecule inhibition. EF1a1 binds to and activates Sphingosine Kinase 1, 
a cell proliferation regulator which converts the proapoptotic lipid sphingosine 
into the antiapoptotic lipid sphingosine-1-phosphate.196 Increased expression 
of EF1a1 correlates with poor prognosis in prostate cancer.197 
P08865 40S ribosomal protein SA (RPSA)  
RPSA was identified bound to the hydrazone ligand (353). No apparent 
binding to the oxime ligand (352) was observed, nor the Sepharose or 
negative control ligand (364); however, the protein was abundant in all flow-
through fractions. RPSA is found in the cell membrane (as 67kDa dimer), 
cytoplasm and nucleus and is involved in the maturation of ribosomal subunit 
proteins. It also functions as a cell surface receptor for laminin, implicated in 
cell adhesion to the basement membrane, differentiation, migration, signalling 
transduction pathways, neurite outgrowth and metastasis. Expression of 
RPSA is induced by hypoxia and it is over expressed in many types of cancer, 
as well as being an important factor in tumour cell migration, invasion and 
angiogenesis.198 The target is potentially druggable and there are currently 14 
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known active peptide mimetics identified.199 Virtual screening has also 
identified a small molecule inhibitor, NSC47924 (370) (Figure 5.7).200 In future 
experiments it would be interesting to investigate the effect of this small 
molecule inhibitor in ESFT cells. 
Q01105 Phosphatase 2A inhibitor I2PP2A (aka SET) 
Strong binding of I2PP2A to the hydrazone ligand (353) was observed. There 
was no apparent binding to the oxime ligand (352) nor the negative controls, 
ligand 364 and Sepharose. I2PP2A is a multifunctional protein expressed in 
proliferating cells. It is predominantly nuclear but relocalises to cytoplasm 
under genotoxic stress, which in turn induces cytotoxicity.201 SET was found to 
relocate to the plasma membrane as part of Rac1-mediated cell migration, 
responsible for cell adhesion and motility.202 It has histone chaperone activity 
and along with ANP32A, is a subunit of the inhibitor of acetyltransferases 
complex. SET is a negative regulator of neuronal development203 and is 
associated with a neuronal apoptotic pathway in Alzheimer's disease.204 PP2A 
activity is inhibited by SET (as well as ANP32A), which targets proteins of 
oncogenic signalling cascades.205 SET is a target of chromosomal 
translocation in leukaemia205 and is overexpressed in primary chronic 
lymphocytic leukemia cells, where increased expression levels correlate with 
severity and progression of disease.206 A peptide antagonist COG449 was 
developed against SET by Christensen et al. and successfully inhibited growth 
of NHL tumour xenografts in mice.206 SET binds ceramides, which decreases 
association with PP2A, leading to c-Myc degradation.207 With ANP32A, SET 
has function in Granzyme-A induced apoptosis.208 Overexpression of SET is 
known to activate MAPK and prevent Fas-mediated apoptosis.209 
 
Figure 5.7 A small molecule inhibitor of RPSA identified by virtual screening. 
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Non-specific binders 
Many ribosomal proteins were identified, along with tubulin and nucleolin. 
These proteins frequently bind to Sepharose, and therefore may not be 
specifically associated with binding to the fenretinide molecule.210 Three 
proteins bound to both the solid-supported ligand 353 and the Sepharose and 
ligand 364 negative controls; P19338 nucleolin and both Q6PKH8 Acidic 
nuclear phosphoprotein 32 members A and B (ANP32A and ANP32B). There 
was no apparent binding of these proteins to solid supported ligand 352.  
5.5 Conclusion 
Very little is known about the mechanism through which fenretinide initiates 
cell death. The identification of a biological target or targets responsible for 
activation of the cell death cascade following exposure of ESFT cells to 
fenretinide may aid in the design of future therapeutic agents. The target may 
also be useful as a biomarker to identify which cancers are likely to respond 
to fenretinide, allowing for selection of patients for so called personalised 
medicine. 
Several proteins were identified that bound to affinity chromatography ligands  
352 and 353, where binding to the 364 negative control was not observed 
(Table 5.1). However, non-specific binding to Sepharose was observed for 4/8 
of the proteins isolated. Previous studies have identified non-specific binding 
of hnRNP and nucleolin proteins to Sepharose resin, with nucleolin proteins 
extracted in 73 % of all pull-down experiments using Sepharose beads.210 
RPSA and SET were found to bind specifically to ligand 353, both of which 
have significant associations to a range of cancer types and are potentially 
druggable, with peptide inhibitors of both and a small molecule inhibitor of 
Protein  Binding to Localisation*  Druggable?  
hnRNP U  353, 354, Sepharose  nuc / cyt   
Nucleolin  353, Sepharose nuc / cyt / memb  + (peptide)  
IGF2BP1  353, 354 cyt   
EF1a1  352, 353 cyt  ++ (GTP binding)  
RSSA  353 nuc / cyt / memb  ++ (peptide, small molecule)  
ANP32A  353, Sepharose  nuc / cyt   
ANP32B  353, Sepharose  nuc / cyt   
I2PP2A (SET)  353  nuc / cyt / memb  + (peptide) 
                                      *nuc = nucleus; cyt = cytoplasm; memb = membrane. 
Table 5.1 Summary of affinity chromatography binding proteins. 
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RPSA already identified. IGF2BP1 bound strongly to ligand 353 and weakly to 
352 and the negative control ligand (364). Binding of this protein is perhaps 
most relevant, as reports by Elcheva et al. suggest this is a target of the Wnt 
signalling pathway, upregulated in metastatic ESFT.192 Additionally, Ho et al. 
have suggested that that IGF1R signalling is critical to the biology of ESFT.193 
Although current literature suggests that EF1a1 is likely to be the least 
relevant potential target isolated, this protein is known to have GTP-binding 
and hydrolysis activity implying that it may be druggable via small molecule 
inhibition. 
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6. Discussion and future work 
Through extensive design and synthesis for biological evaluation studies, a 
series of compounds which demonstrate fenretinide-like activity in ESFT 
cells have been identified. Compounds containing both retinoid and non-
retinoid structural features have been investigated. The studies have allowed 
the development of a preliminary SAR for retinoid and non-retinoid molecules 
for fenretinide-like activity in ESFT cells. Much of the SAR developed within 
the project to-date can be summarised as described in Figure 6.1.  
 
 
Figure 6.1 SAR for retinoids and non-retinoids demonstrating fenretinide-like activity in 
TC32 cells. 
 
Perhaps the most significant observation is the requirement for the presence 
of a NH or OH group at the 4-position of the phenyl ring which would appear 
to be important for induction of cell death in ESFT TC32 cells. Additionally, 
incorporation of a NH2 group at the ortho-position of the fenretinide structure 
was well tolerated, as was replacement of the 4-hydroxyphenyl group with a 
4-pyridyl structure. Although the 4-pyridyl structure does not contain a 
hydroxy group at the position corresponding to that of fenretinide, it does 
contain a polar atom at this site which may, in part, be responsible for the 
activity observed. Many of the other variants investigated at the phenyl ring 
of fenretinide, including replacement of the phenyl group for a range of 
heterocycles, as well as incorporation of variable substituents, and 
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substituent patterns, were either less active or not tolerated in TC32 cells. As 
for substitution at the phenyl ring, variation at the amide group suggested 
that this site was relatively sensitive to synthetic modification, with only the 
ester variant showing positive biological activity. The SAR at the central 
repeating isoprenoid scaffold and the cyclohexyl ring regions of fenretinide is 
complicated by the lack compound numbers synthesised and tested based 
on variation at these sites, however there does seem to be some tolerance to 
substitution (with an oxime or hydrazone, at least) at the 4-position of the 
cyclohexyl ring. Future work could look at incorporation of alternative 
cyclohexyl moieties, including heterocycles, which may reduce the 
lipophilicity at this site. Few variations of the isoprenoid scaffold were 
investigated. However, principally through investigative SAR work carried out 
for the non-retinoid compounds, it would appear that a number of different 
structural variations at this site are tolerated and as such further synthetic 
variation at the central scaffold would appear warranted by, for instance, 
incorporation of heterocycles or polar atoms to improve both the 
physicochemical profile of the compounds as well as the activity.  
Mechanistic studies on hit compounds from the retinoid and non-retinoid 
series demonstrated interesting mechanisms of action, possibly distinct from 
fenretinide. For the retinoids, the phenyl-containing retinoid mimetics - the 
para-amino (58) and the direct ortho-amino
 
substituted analogue of 
fenretinide (198) - induced caspase-3 cleavage, indicating that these 
compounds initiate programmed cell death through a mechanism that may 
be similar to fenretinide. However, the 4-pyridyl containing retinoid (199) did 
not induce caspase-3 cleavage, suggesting a novel mechanism of 
decreasing viable cell number. None of the three retinoids were found to 
induce ROS in TC32 cells, which is reported to be important for fenretinide-
induced activity in a range of cancer types.40,46,49,53,66,67 This observation 
suggests that elevated ROS levels are not essential for the activity of these 
compounds and programmed cell death (and caspase-3 activation in the 
case of 58 and 198) is initiated via an alternative mechanism. It is currently 
unclear as to whether ROS generation is an important factor in fenretinide-
induced apoptosis or whether it is generated as a consequence of cell 
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death.71 There are conflicting reports that fenretinide can act through 
different mechanisms in different cell types; ROS-independent mechanisms 
such as endoplasmic reticulum stress70, and ceramide production71 as well 
as via ROS-dependent mechanisms such as modulation of p38MAPK activity 
and mitochondrial membrane depolarisation.67 Future work may look at more 
detailed studies on the mechanism through which the compounds are killing 
the cancer cells, including possible alternative mechanisms such as 
mitochondrial membrane depolarisation175, intracellular calcium 
concentration176 or apoptosis inducing factor studies.177 Alternatively, 
compounds could be acting through nonphysiological pathways to kill the cell 
(e.g. necrosis) therefore it is important to carry out further toxicity studies (i.e. 
in vivo). 
In dose response studies across multiple cell lines, the three retinoids, in 
particular the ortho-amino substituted analogue (198), demonstrated very 
interesting activity in the concentration response studies. Not only did this 
compound induce similar levels of activity to fenretinide in all of the ESFT 
and neuroblastoma cell lines, activity was significantly increased compared 
to fenretinide at the lowest concentration (3 µM) in three out of the five cell 
lines (TC32, TTC466 and SHEP-1). The 4-pyridyl and para-amino analogues 
(199 and 58) also demonstrated dose-dependent activity across all cell lines 
which was comparable to or approaching that of fenretinide. 
Through ligand-based studies directed towards generation of non-retinoid 
mimetics of fenretinide, we have discovered that it is relatively straightforward 
to identify fenretinide-like activity using a variety of mainly hydrophobic 
scaffolds as retinoid mimetics. The activity and therapeutic ratio of the hit non-
retinoid compounds identified through these studies, suggest they are not as 
active or safe (i.e. potential therapeutic ratio) as the retinoids, although there is 
considerable scope for optimisation of these compounds given the 
encouraging data achieved to-date and the relative ease with which it should 
be possible to synthesise libraries of variants for future testing.  
The mechanism-based studies for the non-retinoids suggest that the 
compounds may induce activity via alternative processes to fenretinide. The 
two non-retinoids selected for investigation (compounds 275 and 298) did not 
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induce elevation of ROS levels or activation of caspase-3 (which would be 
expected if programmed cell death was induced). It is therefore possible that 
these compounds are inducing cytotoxicity by necrosis or an alternative 
mechanism. Concentration-response studies against multiple cell lines 
highlighted that the phenyl ether (275) may induce activity via a p53-
dependent mechanism due to inactivity/reduced activity in those cell lines 
which do not express p53. This is in contrast to fenretinide which is known to 
induce activity via a p53-independent mechanism.167 Future work should 
further investigate the possible alternative mechanisms (described above) to 
identify whether these compounds are suitable lead compounds for further 
optimisation. It would also be of interest to further rationalise the mechanism 
of action of these compounds and to determine whether there was any 
mechanistic commonality between different (non-retinoid) scaffold types. 
Future work should aim to identify additional non-retinoids with a good activity 
and increased fold-differential toxicity over normal cells to demonstrate a more 
complete SAR for one or more of the non-retinoid scaffold types. The data 
generated to-date for the non-retinoids has been rather sporadic based on the 
acquisition of biological data for a number of different scaffold types. It would 
be beneficial to focus the collection of biological data on one (or possibly two) 
scaffold types for optimisation. Non-retinoids are particularly interesting as 
they offer the potential to instil favourable pharmaceutical properties, including 
improved metabolic stability, solubility and reduced lipophilicity, which 
consequently may improve the bioavailability (and possibly efficacy) achieved 
in comparison to fenretinide. A focus of future work may be to generate 
additional hybrid molecules containing features of the positive pharmacokinetic 
profile of the non-retinoids with the more favourable activity, therapeutic ratio 
and mechanism of action of the retinoids. 
The best of the compounds characterised to date from both the retinoid and 
non-retinoid optimisation studies have the potential to progress for additional 
biological evaluation in a range of cancer cell line types (e.g. the NCI60 
panel), in vivo preclinical studies with pharmacokinetic assessment and 
combination therapy studies (for compounds which may indicate that their 
activity is induced by opposing mechanisms, therefore may act 
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synergistically). Although the compounds demonstrate a robust metabolic 
stability profile, additional metabolism studies (hepatocyte stability, for 
instance) would be useful to identify whether the compounds are less liable 
to oxidative metabolism than fenretinide. It would also be of value to 
understand whether the metabolites of the compound were themselves 
cytotoxic. The metabolites of fenretinide behave in this way; 4-oxo-
fenretinide and the glucuronidation product of the phenol are known to be 
active in cancer cells and positively reinforce the cytotoxic effect in 
vivo.47,80,102 All of the hit compounds generated within this project contain a 
polar head group which could potentially undergo glucuronidation, therefore 
future work may include synthesis of the glucuronate product to test for their 
activity. In the case of the retinoid-containing lead compound(s), this could 
also include oxidation at the 4-position of the cyclohexyl ring.  
By screening against MSCs it has been helpful to identify compounds with 
minimal toxicity in normal cells. However, it was unclear as to what level of 
toxicity should be considered acceptable (there is currently no literature 
precedence for this). An acceptable therapeutic index is important to ensure 
safe concentrations of the drug can be administered to achieve the desired 
therapeutic effect. Unfortunately, due to the slow-growing nature of MSCs, it 
was not possible to obtain enough cells to carry out concentration response 
studies to identify optimum concentrations whereby toxicity in the cancer 
cells is significantly higher than the normal cells. The majority of compounds 
tested demonstrated activity statistically comparable to or less than that of 
fenretinide. The accuracy of the predictive value of this screening could be 
tested by comparing the outcome from MSC screen with a classical toxicity 
study in mice. It would certainly provide a cheaper, more convenient method 
for initial toxicity predictions than the classic in vivo preclinical screens if this 
proved to be the case.  
In an effort to support the understanding of the mechanism of action of 
fenretinide, a protein-capture technique (affinity chromatography) was utilised 
in an attempt to identify the macromolecule(s) within the cancer cell through 
which fenretinide might interact with to initiate cell death. To optimise the 
likelihood of binding of ligands to proteins that are involved in initiation of cell 
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death, affinity chromatography was carried out on membrane enriched protein 
extracts. Fenretinide is known to efficiently bind RBP4, however, this was not 
pulled out by affinity chromatography as this is not a membrane protein. This 
implies that the strategy to enrich membrane proteins was somewhat 
successful. However, proteins predominantly located in the nucleus and 
cytoplasm as well as the cell surface were isolated, therefore further 
optimisation of this technique may allow for identification of less abundant 
proteins in the cell membrane which have greater significance. Several 
proteins were identified to bind to a fenretinide-like ligand in affinity 
chromatography studies.  Four proteins were identified to have selectivity to 
the ligand compared to the negative controls. 3 of these (IGF2BP1, RPSA and 
SET) have significant associations to a range of cancer types, with IGF2BP1 
reported to have implications in the biology of ESFT.189,192,193,195,198 
Furthermore, RPSA and SET are potentially druggable with peptide inhibitors 
and a small molecule inhibitor for RPSA already identified.199 Crystal 
structures of both IGF2BP1 (PDB ID: 3KRM) and SET (PDB ID: 2E50) are 
available, therefore it would be interesting to identify, by structure-based 
design, potential small molecule inhibitors of these proteins which could be 
synthesised/purchased and screened against ESFT cells. Activity of these 
inhibitors or elimination of fenretinide activity upon co-treatment with the 
inhibitors may help to confirm or eliminate the potential role of this protein as a 
target for fenretinide-induced cell death.  Also isolated in the pull-down assay 
was EF1a1. Although literature suggests that this protein is perhaps least 
relevant potential target isolated, this protein is known to have GTP-binding 
and hydrolysis activity, implying that it may be druggable via small molecule 
inhibition.195 There are some limitations to the affinity chromatography 
approach, for example, fenretinide might bind to proteins through which it does 
not induce cell death. Furthermore, this approach will preferentially identify 
abundant proteins to which fenretinide binds, although these may not be the 
most important factors through which fenretinide initiates cell death. For 
example, STRA6 was not identified, but this has been shown to regulate 
fenretinide induced cell death.86 
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7. Experimental 
7.1 Materials 
All chemicals and solvents that were purchased were used without further 
purification. Anhydrous solvents were passed through activated alumina in a 
solid state still (SPS PureSolve MD6). 
7.2 Methods 
1H Nuclear Magnetic Resonance spectra were recorded at 500 MHz using a 
Bruker DRX 500 instrument or at 300 MHz using a Bruker DPX 300. 1H 
spectra are referenced based on the residual proton in the solvent (e.g. the 
CHCl3, 0.01 % in 99.99 % CDCl3). Coupling constants (J) are reported to the 
nearest 0.1 Hz.  13C NMR spectra were recorded at 75 MHz on 300 MHz 
spectrometers or at 125 MHz on 500 MHz spectrometers. Infrared spectra 
were recorded on a Perkin-Elmer Spectrum 1 or Bruker Alpha Platinum ATR 
FTIR spectrometer and samples analysed in the solid phase. LCMS was 
performed on a Bruker Daltonics instrument running a gradient of increasing 
acetonitrile (5 to 95 %) in water both containing 0.1 % formic acid at 1 
ml/min, on a short path C18 reverse phase column (Luna 5µ C18(2) 100A, 
50 × 2.00 mm), detecting compounds with both a diode array detector and a 
Bruker HCT Ultra analyser. High resolution mass spectra were recorded on a 
Waters Micromass GCT Premier for electron impact (EI) spectra.  
Electrospray (ESI) spectra were recorded on a Bruker Daltonics micrOTOF 
or Bruker MaXis Impact spectrometer.  Melting points were measured on a 
Stuart SMP30. Biotage silica column chromatography was carried out using 
an Isolera Four EXP with Spektra. HPLC was performed on an Agilent 1290 
Infinity Series instruments equipped with a UV detector and Hyperprep C18 
reverse phase column, running a gradient of increasing acetonitrile (5 to 95 
%) in water containing 0.1 % formic acid at 0.5 ml/min over an eight minute 
period. 
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7.3 Synthesis 
7.3.1 Phenyl analogues 
(2E,4E,6E,8E)-N-(2-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (19) 
 
The mixed anhydride (148) (49.9 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and 2-aminophenol (151) (18.5mg, 1.3 
eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (31 mg, 61 %). LCMS (M+H)+ found 392.2, requires 392.2, 
RT 2.68 min; HRMS ESI (M+H)+ found 392.2588, C26H34NO2 requires 
392.2584; δH (500 MHz, CDCl3) 1.02 (6H, s, C11(CH3)2), 1.38 (2H, m, 
C12H2), 1.56 (2H, m, C13H2), 1.65 (3H, s, C3CH3), 1.96 (2H, m, C14H2), 
1.94 (3H, s, C7CH3), 2.36 (3H, s, C15CH3), 5.81 (1H, s, C2H), 6.26 (5H, m, 
C5-, C4-, C6-, C8-, C9-H), 6.96 (4H, m, C3’-, C4’-, C5’-,C6’-H), 9.26 (1H, br 
s, OH); δC (125 MHz; CDCl3) 12.89 (C3CH3), 13.95 (C7CH3), 20.33 (C13), 
21.96 (C15CH3), 29.43 (C11(CH3)2), 34.00 (C14), 35.27 (C11), 40.79 (C12), 
117.70 (C3’), 120.77 (C2), 122.24 (C6’), 123.35 (C5’), 126.63 (C4’), 127.67 
(C1’), 129.31 (C5), 130.63 (C15), 131.08 (C9), 131.51 (C6), 136.98 (C4), 
139.02 (C8), 139.10 (C7), 140.05 (C10), 149.60 (C3), 149.60 (C2’), 151.77 
(C1); IR (cm-1) 3288, 2922, 2854, 1605, 1520, 1469, 1453, 1313, 1173, 966, 
749, 634; MP 138-140 °C. 
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(2E,4E,6E,8E)-N-(3-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (20) 
 
The mixed anhydride (148) (50.1 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and 3-aminophenol (152) (18 mg, 1.3 
eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (25 mg, 50 %). LCMS (M+H)+ found 392.2 requires 392.2, 
RT 2.53 min; HRMS ESI (M+H)+ found 392.2595, C26H34NO2 requires 
392.2584; δH (500 MHz, CDCl3) 1.07 (6H, s, C11(CH3)2), 1.50 (2H, m, 
C12H2), 1.67 (2H, m, C13H2), 1.75 (3H, s, C3CH3), 2.10 (3H, s, C7CH3), 
2.10 (2H, m, C14H2), 2.40 (3H, s, C15CH3), 5.84 (1H, s, C2H), 6.20 (1H, s, 
C2’H), 6.26 (4H, m, C4-, C6-, C8-, C9-H), 6.54 (1H, d, J = 8.1 Hz, C6’H), 
6.76 (1H, d, J = 8.1 Hz, C4’H), 7.00 (1H, m, C5H), 7.05 (1H, t, J = 8.1 Hz, 
C5’H), 7.49 (1H, br s, OH); δC (125 MHz, CDCl3) 12.99 (C3CH3), 14.02 
(C7CH3), 20.37 (C13), 22.06 (C15CH3), 29.51 (C11(CH3)2), 34.04 (C14), 
35.29 (C11), 40.80 (C12), 108.25 (C2’), 112.04 (C6’), 112.35 (C4’), 123.18 
(C2), 129.23  (C5’), 130.50 (C5), 131,12 (C9), 131.19 (C6), 131.78 (C15), 
137.07 (C4), 139.01 (C7), 139.08 (C8), 139.84 (C1’), 141.31 (C10), 150.98 
(C3), 158.87 (C3’), 167.77 (C1); IR (cm-1) 3311, 2924, 1598, 1415, 964, 773, 
686; MP 101-104 °C. 
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4-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraenamido)benzoic acid (23) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (5 ml) and 
pyridine (200 µL) at room temperature and 4-aminobenzoic acid (167) (90 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (49 mg, 22 %). LCMS (M+H)+ found 420.2, requires 420.3, 
RT 2.53 min; HRMS ESI (M+H)+  found 420.2542, C27H34NO3 requires 
420.2533; δH (300 MHz, CDCl3) 1.05 (6H, s, C11(CH3)2), 1.60 (2H, m, 
C12H2), 1.65 (2H, m, C13H2), 1.73 (3H, s, C3CH3), 2.03 (3H, s, C7CH3), 
2.04 (2H, t, J = 6 Hz, C14H2), 2.42 (3H, s, C15CH3), 6.04 (1H, s, C2H), 6.19 
(4H, m, C4-, C6-, C8-, C9-H), 7.11 (1H, m, C5-H), 7.73 (2H, d, J = 8.7 Hz, 
C3’-, C5’-H), 7.87 (2H, d, J = 8.7 Hz, C2’-, C6’-H), 10.00 (1H, s, NH); δC (125 
MHz; CDCl3) 12.93 (C3), 14.05 (C7), 20.38 (C13), 21.98 (C15CH3), 29.47 
(C11(CH3)2), 34.06 (C14), 35.32 (C11), 40.85 (C12), 119.98 (C2’, C6’), 
122.58 (C2), 126.64 (C4’), 129.49 (C5), 131.07 (C9), 131.78 (C6), 131.85 
(C3’, C5’), 136.91 (C4), 139.05 (C8), 140.30 (C10), 144.93 (C1’), 152.28 
(C3), 167.96 (C1), 169.66 (C4’CO); IR (cm-1) 3333, 2919, 2861, 1682, 1308, 
854, 768; MP 174-178 °C. 
 
 
 
 
- 164 - 
 
(2E,4E,6E,8E)-N-(4-methoxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (24) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and para-methoxyaniline (150) (39 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (37 mg, 35 %). The product was not ionised by LCMS. 
HRMS ESI (M+H)+ found 406.2724, C27H36NO2 requires 406.2741; δH (300 
MHz, CDCl3) 0.98 (6H, s, C11(CH3)2), 1.46 (2H, m, C12H2), 1.53 (2H, m, 
C13H2), 1.83 (3H, s, C3CH3), 1.95 (2H, m, C14H2), 2.34 (3H, s, C7CH3), 
3.71 (3H, s, OCH3), 5.74 (1H, s, C2H), 6.10 (4H, m, C4-, C6-, C8-, C9-H), 
6.78 (2H, d, J = 9 Hz, C3’-, C5’-H), 6.90 (1H, m, C5-H), 7.42 (1H, s, NH). ), 
7.53 (2H, d, J = 9 Hz, C2’-, C6’-H); δC (125 MHz; CDCl3) 12.91 (C3CH3), 
13.65 (C7CH3), 19.23 (C13), 21.78 (C15CH3), 28.97(C11(CH3)2), 33.11 
(C14), 34.27 (C11), 39.58 (C12), 55.47 (OCH3), 114.09 (C3’, C5’), 114.93 
(C2), 121.52 (C2’, C6’), 128.41 (C5), 129.59 (C9), 129.91 (C1’), 130.17 (C6), 
131.47 (C15), 135.47 (C4), 137.32 (C8), 137.73 (C7), 139.10 (C10), 150.11 
(C3), 156.19 (C4’), 165.11 (C1); IR (cm-1) 3301, 2933, 1653, 1506, 1241, 
1172, 1035, 828; MP 124-127 °C. 
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(2E,4E,6E,8E)-N-(4-hydroxy-2-methylphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (25) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 2-methyl-4-aminophenol (189) 
(39 mg, 1.2 eq) was added. The solution was allowed to stir overnight at 
room temperature. Once complete by TLC, the reaction was diluted with 
EtOAc (50 ml) and washed with saturated sodium bicarbonate solution (2 × 
50 ml) and brine (2 × 50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo. The residue was purified using Biotage 
silica column chromatography eluted, eluted with 0-100 % EtOAc in hexane, 
to yield the product as a yellow solid (31 mg, 29 %). LCMS (2M+Na)+ found 
833.4, requires 833.5, RT 2.54 min; HRMS ESI (M+H)+ found 406.2746, 
C27H36NO2 requires 406.2741; δH (300 MHz, CDCl3) 0.96 (6H, s, C11(CH3)2), 
1.39 (2H, m, C12H2), 1.55 (2H, m, C13H2), 1.59 (3H, s, C15CH3), 1.94 (3H, 
s, C3H3), 1.96 (2H, m, C14H2), 2.11 (3H, s, C2’CH3), 2.35 (3H, s, C7CH3), 
5.78 (1H, s, C2H), 6.18 (4H, m, C4-, C6-, C8-, C9-H), 6.62 (1H, d, J = 8 Hz, 
C5’H), 6.78 (1H, s, C3’H), 6.89 (1H, m, C5H), 7.28 (1H, d, J = 8 Hz, C6’H); 
δC (125 MHz; CDCl3) 12.88 (C3CH3), 13.92 (C7CH3), 18.36 (C2’CH3), 20.34 
(C13), 21.98 (C15), 29.44 (C11(CH3)2), 34.00 (C14), 35.27 (C11), 40.76 
(C12), 113.94 (C6’), 116.11 (C5’), 117.87 (C3’), 122.71 (C2), 128.57 (C5), 
128.71 (C1’), 129.12 (C9), 130.55 (C15), 131.06 (C6), 131.13 (C4), 136.29 
(C2’), 137.08 (C7), 139.09 (C8), 139.70 (C15), 150.54 (C3), 156.92 (C4’), 
168.66 (C1); IR (cm-1) 3298, 2927, 2417, 1637, 1608,1586, 1501, 1437, 
1381, 965; MP 170-173 °C. 
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(2E,4E,6E,8E)-N-(4-hydroxy-2-nitrophenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (41) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (4 ml) and 
pyridine (200 µL) at room temperature and 4-amino-3-nitrophenol (187) (96 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (130 mg, 57 %). LCMS (M+H)+ found 437.3, requires 437.2; 
HRMS ESI (M+H)+ 437.2436 C26H33N2O4 requires 437.2435;  δH (500 MHz, 
CDCl3) 1.07 (6H, s, C11(CH3)2), 1.51 (2H, m, C12H2), 1.65 (2H, m, C13H2), 
1.77 (3H, s, C3CH3), 2.06 (3H, s, C7CH3), 2.07 (2H, m, C14H2), 2.43 (3H, s, 
C15CH3), 5.99 (1H, s, C2H), 6.102 (1H, s, OH), 6.21 (2H, m, C4-, C6-H), 
6.38 (2H, m, C8-, C9-H), 6.83 (1H, d, J = 9 Hz, C5’-H), 7.13 (1H, m, C5-H), 
7.21 (1H, d, J = 9 Hz, C6’-H), 7.91 (1H, s, C3’-H); δC (75 MHz; CDCl3) 12.98 
(12.98), 14.17 (14.17), 19.22 (19.22), 21.75 (15CH3), 28.97 (C11(CH3)2), 
33.15 (C14), 34.45 (C11), 39.64 (C12), 116.37 (C3’), 118.46 (C2), 119.16 
(C5’), 129.31 (C6’), 129.35 (C5), 130.65 (C9), 131.56 (C15), 132.39 (C6), 
134.54 (C4), 137.14 (8), 137.68 (C1’), 137.71 (C7), 140.75 (C10), 142.42 
(C2’), 142.46 (C3), 156.36 (C4’), 165.48 (C1); IR (cm-1) 3478, 3354, 1704, 
1572, 1513, 1125, 974; MP 150-153 °C. 
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(2E,4E,6E,8E)-N-(4-aminophenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (58) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (250 µL) at room temperature and para-phenylenediamine (153) (34 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a red gum (43 mg, 42 %). LCMS (M+H)+ found 391.2, requires 391.3, RT 
2.19 min; HRMS EI (M)+ found 390.2680, C26H34N2O requires 390.2671; δH 
(300 MHz, CDCl3) 1.05 (6H, s, C11(CH3)2), 1.50 (2H, m, C12H2), 1.63 (2H, 
m, C13H2), 1.74 (3H, s, C3CH3), 2.02 (3H, s, C7CH3), 2.04 (2H, t, J = 6 Hz, 
C14H2), 2.43 (3H, s, C15CH3), 3.65 (2H, br s, NH2), 5.79 (1H, s, C2H), 6.18 
(4H, m, C4-, C6-, C8-, C9-H), 6.67 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 6.98 (1H, 
m, C5-H), 7.03 (1H, s, NH), 7.35 (2H, d, J = 8.7 Hz, C2’-, C6’-H); δC (125 
MHz; CDCl3) 12.92 (C3CH3), 13.64 (C7CH3), 19.25 (C13), 21.81 (C15CH3), 
28.99 (C11(CH3)2), 33.12 (C14), 34.28 (C11), 39.60 (C12), 115.44 (C3’, C5’), 
121.84 (C2), 121.91 (C2’, C6’), 128.27 (C5), 129.69 (C9), 129.77 (C1’), 
129.86 (C15), 129.88 (C6), 135.69 (C4), 137.36 (C8), 137.75 (C7), 138.87 
(C10), 143.09 (C4’), 149.54 (C3), 165.17 (C1); IR (cm-1) 3429, 3320, 2939, 
1626, 1510, 969, 839, 515. 
 
 
 
 
- 168 - 
 
(2E,4E,6E,8E)-3,7-dimethyl-N-phenyl-9-(2,6,6-trimethylcyclohex-1-
enyl)nona-2,4,6,8-tetraenamide (61) 
 
The mixed anhydride (148) (17.8 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and aniline (149) (1 ml, 4.2 eq) was 
added. The solution was allowed to stir overnight at room temperature. Once 
complete by TLC, the reaction was diluted with EtOAc (50 ml) and washed 
with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml).  
The organic layer was dried over sodium sulphate and concentrated in 
vacuo. The residue was purified using silica column chromatography, eluted 
with 0-100 % EtOAc in hexane, to yield the product as a yellow solid (5.2 mg, 
30 %). LCMS (2M+Na)+ found 774.0 requires 773.5, RT 2.45 min; HRMS ESI 
(M+H)+ found 376.2648, C26H34NO requires 376.2635; δH (500 MHz, CDCl3) 
1.04 (6H, C11(CH3)2), 1.46 (2H, m, C12H2), 1.57 (2H, m, C13H2), 1.65 (3H, 
s, C15CH3), 1.85 (3H, s, C3CH3), 2.95 (2H, m, C14H2), 2.34 (3H, s, C7CH3),  
5.74 (1H, s, C2H), 6.23 (4H, m, C4-, C6-, C8-, C9-H), 6.90 (1H, m, C5H), 
7.00 (1H, t, J = 7.5 Hz, C4’H), 7.23 (2H,  t, J = 7.5 Hz, C3’-, C5’-H), 7.48 (2H, 
d, J = 7.5 Hz, C2’-, C6’-H).  δC (125 MHz, CDCl3) 12.91 (C3CH3), 13.73 
(C7CH3), 19.24 (C13), 21.76 (C15CH3), 28.97 (C11(CH3)2), 33.12 (C14), 
34.28 (C11), 39.63 (C12), 119.79 (C2), 121.35 (C5), 124.07 (C9), 128.51 
(C4’), 128.96(C2’, C6’), 129.55 (C3’, C5’), 129.93 (C15), 130.40 (C6), 135.34 
(C4), 137.30 (C8), 137.75 (C7), 138.32 (C10), 139.25 (C1’), 150.58 (C3), 
165.35 (C1); IR (cm-1) 3306, 2822, 1649, 1596, 1511, 1436, 1154, 965, 749, 
690; MP 120-122 °C. 
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(2E,4E,6E,8E)-N-(2-fluoro-4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (70) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (2 ml) and 
pyridine (200 µL) at room temperature and 4-amino-2-flurophenol (185) (40 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (3 × 50 ml) 
and brine (3 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (43 mg, 40 %). LCMS (2M+Na)+ found 841.6, requires 
841.5, RT 2.63 min; HRMS ESI (M+H)+  found 410.2494, C26H33FNO2 
requires 410.2490; δH (500 MHz, CDCl3) 0.96 (6H, s, C11(CH3)2), 1.39 (2H, 
m, C12H2), 1.55 (2H, m, C13H2), 1.64 (3H, s, C3CH3), 1.92 (3H, s, C7CH3), 
1.95 (2H, m, C14H2), 2.32 (3H, s, C15CH3), 5.69 (1H, s, C2H), 5.91 (1H, s, 
OH), 6.14 (5H, m, C4-, C5-, C6-, C8-, C9-H), 6.85 (3H, m, C2’-, C5’, C6’-H), 
7.47 (1H, s, NH); δC (75 MHz; CDCl3) 12.94 (C3CH3), 13.77 (C7CH3), 19.23 
(C13), 21.80 (C15CH3), 28.98 (C11(CH3)2), 33.13 (C14), 34.27 (C11), 39.59 
(C12), 108.94 (C2’), 109.24 (C5’), 116.67 (C6’), 117.34 (C2), 120.88 (C1’), 
128.59 (C5), 129.54 (C9), 130.00 (C15), 130.64 (C6), 137.22 (C4), 137.29 
(C8), 137.71 (C7), 139.45 (C10), 149.13 (C4’), 150.97 (C3), 152.28 (C3’), 
165.58 (C1); IR (cm-1) 3313, 2924, 1608, 1511, 1187, 963; MP 118-120 °C. 
(2E,4E,6E,8E)-N-(4-(hydroxymethyl)phenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (72) 
 
The mixed anhydride (148) (50.2 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and 4-aminobenzylalcohol (163) (20.3 
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mg, 1.3 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (28 mg, 53 %). LCMS (2M+Na)+ found 833.5, requires 
833.5, RT 2.52 min; HRMS ESI (M+H)+ found 406.2741, C27H36NO2 requires 
406.2741; δH (500 MHz, CDCl3) 1.02 (6H, s, C11(CH3)2), 1.45 (2H, m, 
C12H2), 1.56 (2H, m, C13H2), 1.69 (3H, s, C15CH3), 1.98 (3H, m, C3CH3), 
2.05 (2H, m, C14H2), 2.36 (3H, m, C7CH3), 4.44 (2H, d, J = 5.4 Hz, C4’CH2), 
5.08 (1H, t, J = 5.4 Hz, OH),  6.04 (1H, s, C2H), 6.29 (4H, m, C4-, C6-, C8-, 
C9-H), 6.99 (1H, m, C5-H), 7.24 (2H, d, J = 8.4 Hz, C3’-, C6’-H), 7.61 (2H, d, 
J = 8.4 Hz, C2’-, C7’-H), 9.95 (1H, s, NH); δC (125 MHz, CDCl3) 12.54 (C3), 
13.22 (C7), 18.71 (C13), 21.46 (C15CH3), 28.75(C11(CH3)2), 32.57 (C14), 
33.81 (C11), 39.21 (C12), 62.65 (C4’CH2), 118.61 (C2), 122.71 (C5), 126.86 
(C2’, C6’), 127.43 (C9), 129.29 (C15), 129.67 (C3’, C5’), 130.06 (C6), 135.97 
(C4), 136.96 (C8), 137.09 (C1’), 137.15 (C4’), 137.23 (C7), 138.13 (C10), 
148.17 (C3), 164.62 (C1); IR (cm-1) 3300, 2920, 2854, 1649, 1598, 1522, 
1159, 965, 824; MP 163-166 °C. 
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraenoic pivalic anhydride (148) 
 
This compound was synthesised as previously described by Cabaj et al.211 
Retinoic acid (6) (500 mg, 1 eq) and triethylamine (280 µl, 2.3 eq) were 
dissolved in ethyl acetate (10 ml) at −5 ˚C. Trimethyl acetyl chloride (147) 
(250 µl, 1.2 eq) was slowly added and the mixture was allowed to warm to 
room temperature and stirred for 1 hour. The reaction was monitored by 
LCMS and when complete, diluted with EtOAc (50 ml), washed with 20 % 
HCl (2 × 50 ml) and saturated sodium bicarbonate solution (2 × 50 ml). The 
organic layer was dried over sodium sulphate and concentrated in vacuo. 
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The mixture was purified using a silica flash column chromatography plug 
with 20 % ethyl acetate and hexane. The pure compound was obtained as a 
yellow oil (640 mg, 100 %). The compound was not ionised by LCMS; δH 
(500 MHz, CDCl3) 1.05 (6H, s, C11(CH3)2), 1.28 (9H, s, C(CH3)3), 1.49 (2H, 
m, C12H2), 1.64 (2H, m, C13H2), 1.73 (3H, s, C15CH3), 2.04 (3H, s, C3CH3), 
2.05 (2H, m, C14H2), 2.42 (3H, s, C7CH3), 5.75 (1H, s, C2H), 6.15 (2H, m, 
C8-, C9-H), 6.34 (2H, m, C4-, C6-H), 7.14 (1H, m, C5H); δC (125 MHz, 
CDCl3) 13.01 (C3CH3), 14.43 (C7CH3), 19.21 (C13), 21.76 (C15CH3), 26.64 
(C(CH3)3), 28.97 (C11(CH3)2), 33.15 (C14), 34.28 (C11), 39.62 (C(CH3)3), 
39.72 (C12), 116.32 (C2), 129.26 (C5), 129.70 (C9), 130.43 (C6), 133.31 
(C15), 134.24 (C4), 137.09 (C7), 137.66 (C8), 141.39 (C10), 158.51 (C3), 
162.37 (C1), 174.75 (OCO). 
(2E,4E,6E,8E)-N-(2-aminophenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (156) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (2 ml) and 
pyridine (200 µL) at room temperature and ortho-phenylenediamine (154) (34 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (30 mg, 28 %). LCMS (2M+Na)+ found 803.6, requires 
803.5, RT 2.57 min; HRMS ESI (M+H)+  found 391.2750, C26H35N2O requires 
391.2744; δH (500 MHz, CDCl3) 1.96 (6H, s, C11(CH3)2), 1.40 (2H, m, 
C12H2), 1.49 (2H, m, C13H2), 1.65 (3H, s, C3CH3), 1.93(3H, s, C7CH3),  
1.95 (2H, m, C14H2), 2.33 (3H, s, C15CH3), 3.66 (2H, br s, NH2), 5.78 (1H, s, 
C2H), 6.17 (4H, m, C4-, C6-, C8-, C9-H), 6.72 (2H, m, C3’-, C5’-H), 6.90 (1H, 
m, C5-H), 6.97 (1H, m, C6’-H), 7.13 (1H, m, C4’-H), 7.35 (1H, s, NH); δC (75 
MHz; CDCl3) 12.92 (C3CH3), 13.73 (C7CH3), 19.23 (C13), 21.79 (C15CH3), 
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28.98 (C11(CH3)2), 33.12 (C14), 34.28 (C11), 39.59 (C12), 119.10 (C2’), 
120.54 (C4’), 121.04 (C6’), 125.28 (C2), 125.71 (C15), 126.92 (C5), 128.52 
(C9), 129.59 (C5’), 129.96 (C1’), 130.54 (C6), 135.41 (C4), 137.33 (C8), 
137.72 (C7), 138.15 (C10), 139.30 (C3’), 150.96 (C3), 165.90 (C1); IR (cm-1) 
2915, 1655, 1580, 1509, 1449, 1157, 966, 746; MP 131-133 °C. 
(2E,4E,6E,8E)-N-(3-aminophenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (157) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (2 ml) and 
pyridine (200 µL) at room temperature and meta-phenylenediamine (155) (34 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (36 mg, 35 %). LCMS (M+H)+ found 391.3, requires 391.3, 
RT 2.49 min;  HRMS ESI (M+H)+ found 391.2753, C26H34N2O requires 
391.2744; δH (500 MHz, CDCl3) 0.96 (6H, s, C11(CH3)2), 1.41 (2H, m, 
C12H2), 1.55 (2H, m, C13H2), 1.64 (3H, s, C3CH3), 1.92(3H, s, C7CH3),  
1.95 (2H, m, C14H2), 2.33 (3H, s, C15CH3), 5.71 (1H, s, C2H), 6.17 (4H, m, 
C4-, C6-, C8-, C9-H), 6.33 (1H, d, J = 7.8 Hz, C6’-H), 6.62 (1H, d, J = 7.8 Hz, 
C4’-H), 6.88 (1H, m, C5-H), 6.98 (1H, t, J = 7.8 Hz, C5’-H), 7.16 (1H, br s, 
NH), 7.25 (1H, s, C2’-H); δC (75 MHz; CDCl3) 12.93 (C3CH3), 13.70 
(C7CH3), 19.24 (C13), 21.80 (C15CH3), 28.99 (C11(CH3)2), 33.12 (C14), 
34.28 (C11), 39.60 (C12), 106.45 (C2’), 109.70 (C4’), 110.89 (C6’), 121.57 
(C2), 128.47 (C5), 129.59 (C9), 129.66 (C5’), 129.94 (C15), 130.34 (C6), 
135.40 (C4), 137.32 (C8), 137.73 (C7), 139.21 (C1’), 139.36 (C10), 147.21 
(C3’), 150.42 (C3), 165.28 (C1); IR (cm-1) 3313, 2923, 1604, 1538, 1437, 
1155, 964, 686; MP 106-108 °C.  
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N-(4-nitrophenyl)methanesulfonamide (159) 
 
This compound was synthesised as previously described by Lee et al.212 
MsCl (1.6 g, 1 eq) was dissolved in 1:1 pyridine:DCM (15 ml) and the 
solution was cooled to 0 °C. para-nitroaniline (158) (1.6 g, 1.2 eq) was added 
and the reaction was allowed to warm to room temperature and stirred for 3 
hours. Solvents were removed under reduced pressure. The reside was re-
dissolved in EtOAc (50 ml) and washed with deionised water (3 × 50 ml), 
saturated sodium bicarbonate solution (3 × 50 ml), CuSO4 solution (3 × 50 
ml) and brine (2 × 50 ml). The organic layer was dried over sodium sulphate 
and concentrated in vacuo to yield the product as a white powder (1.8 g, 72 
%). The product was not ionised by LCMS. δH (500 MHz, CDCl3) 3.17 (3H, s, 
CH3), 7.32 (2H, d, J = 9 Hz, C2-, C6-H), 8.27 (2H, d, J = 9 Hz, C3-, C5-H). 
N-(4-aminophenyl)methanesulfonamide (160) 
 
This compound was synthesised as previously described by Lee et al.212 
Compound (159) (1.8 g) was dissolved in MeOH (50 ml) to which Pd/C (500 
mg) was added. The reaction was allowed to stir under H2 overnight. The 
Pd/C was filtered through Celite and the filtrate was concentrated in vacuo to 
yield the product as a white solid (1.6 g, 100 %). LCMS (M-CH2)+ found 
173.0, requires 173.0, RT 0.27 min; δH (500 MHz, CDCl3) 2.89 (1H, s, CH3), 
4.88 (2H, br s, NH2), 6.77 (2H, d, J = 8.4 Hz, C2-, C6-H), 7.08 (2H, d, J = 8.4 
Hz, C3-, C5-H). 
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(2E,4E,6E,8E)-3,7-dimethyl-N-(4-(methylsulfonamido)phenyl)-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (171) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (2 ml) and 
pyridine (200 µL) at room temperature and compound 160 (59 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography  eluted with 0-100 % EtOAc in hexane and recrystalised in 
MeOH to yield the product as a yellow solid (19 mg, 16 %). LCMS (2M+Na)+ 
found 959.5, requires 959.5, RT 2.58 min; HRMS ESI (M+H)+ found 
469.2522, C27H37N2O3S requires 469.2519; δH (500 MHz, CDCl3) 0.95 (6H, 
s, C11(CH3)2), 1.52 (2H, m, C12H2), 1.67 (2H, m, C13H2), 1.73 (3H, s, 
C3CH3), 2.03 (3H, s, C7CH3), 2.03 (2H, m, C14H2), 2.40 (3H, s, C15CH3), 
2.94 (3H, s, SO2C-H), 6.01 (1H, s, C2H), 6.23 (4H, m, C4-, C6-, C8-, C9-H), 
7.08 (1H, m, C5-H), 7.23 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 7.59 (2H, d, J = 8.7 
Hz, C4’-, C6’-H); δC (125 MHz; MeOD) 12.58 (C3CH3), 13.27 (C7CH3), 18.71 
(C13), 21.49 (C15CH3), 33.85 (C11(CH3)2), 33.85 (C11), 38.90 (C12), 39.61 
(SO2CH3), 119.85 (C3’, C5’), 121.34 (C2’, C6’), 122.54 (C2), 127.49 (C5), 
129.37 (C1’), 129.81 (C9), 130.07 (C6), 133.15 (C15), 135.94 (C4), 136.17 
(C4’), 136.95 (C8), 137.26 (C7), 138.25 (C10), 148.32 (C3), 164.59 (C1); IR 
(cm-1) 3213, 2922, 1571, 1511, 1269, 1123, 961, 729; MP 154-156 °C. 
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(2E,4E,6E,8E)-N-(4-acetamidophenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (172) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 4-aminoacetanilide (162) (94 mg, 
1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (93 mg, 41 %). LCMS (2M+Na)+ found 887.8, requires 
887.5,  RT 2.53 min; HRMS ESI (M+H)+ found 433.2858, C28H37N2O2 
requires 433.2850; δH (500 MHz, CDCl3) 1.02 (6H, s, C11(CH3)2), 1.45 (2H, 
m, C12H2), 1.57 (2H, m, C13H2), 1.69 (3H, s, C3CH3), 1.98 (3H, s, C7-H), 
2.00 (2H, m, C14H2), 2.01 (3H, s, COCH3), 1.34 (3H, s, C7CH3), 6.01 (3H, s, 
C15CH3), 6.29 (4H, m, C4-, C6-, C8-, C9-H), 6.98 (1H, m, C5-H), 7.48 (2H, 
d, J = 8.7 Hz, C3’-, C5’-H), 7.55 (2H, d, J = 8.7 Hz, C2’-, C6’-H), 9.85 (1H, s, 
C4’-NH), 9.93 (1H, s, C1-NH); δC (75 MHz; DMSO-d6) 12.55 (C3CH3), 13.21 
(C7CH3), 18.69 (C13), 21.48 (C15CH3), 23.83 (COCH3), 28.77 (C11(CH3)2), 
32.58 (C14), 33.82 (C11), 40.31 (C12), 119.30 (C2’, C3’, C5’, C6’), 122.69 
(C2), 127.42 (C5), 129.33 (C15), 129.66 (C9), 130.08 (C6), 134.63 (C1’), 
134.75 (C4’), 145.99 (C4), 136.95 (C8), 137.24 (C7), 138.14 (C10), 148.03 
(C3), 164.44(C1), 167.68 (CO); IR (cm-1) 3299, 2919, 2859, 1661, 1518, 
963; MP 235-238 °C. 
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(2E,4E,6E,8E)-N-(1H-indol-5-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-
1-enyl)nona-2,4,6,8-tetraenamide (173) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 5-aminoindole (164) (41 mg, 1.2 
eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (8 mg, 7 %) LCMS (2M+Na)+ found 851.4, requires 851.5, 
RT 2.66 min; HRMS ESI (M+H)+ found 415.2752, C28H35N2O requires 
415.2744; δH (500 MHz, CDCl3) 1.09 (6H, s, C11(CH3)2), 1.51 (2H, m, 
C12H2), 1.58 (2H, m, C13H2), 1.81 (3H, s, C3CH3), 2.02 (3H, s, C7CH3), 
2.06 (2H, m, C14H2), 2.46 (3H, s, C15CH3), 5.87 (1H, s, C2H), 6.17 (4H, m, 
C4-, C6-, C8-, C9-H), 6.32 (1H, s, C2’-H), 6.98 (1H, m, C5-H), 7.16 (1H, s, 
C4’-H), 7.44 (1H, s, C5’-H), 7.91 (1H, s, C7’-H), 8.41 (1H, s, C8’-H); δC (125 
MHz; CDCl3) 12.86 (C3CH3), 13.65 (C7CH3), 19.22 (C13), 21.72 (C15CH3), 
28.94 (C11(CH3)2), 33.09 (C14), 34.25 (C11), 39.60 (C12), 102.48 (C4’), 
102.55 (C2’), 111.14 (C8’), 112.31 (C7’), 116.12 (C5’), 121.94 (C2), 125.18 
(C1’), 127.98 (C5), 128.26 (C9), 129.54 (C3’), 129.63 (C9), 129.82 (C6’), 
129.89 (C6), 130.57 (C15), 135.62 (C4), 137.34 (C8), 137.75 (C7), 138.86 
(C10), 149.51 (C3), 165.48 (C31); IR (cm-1) 3401, 3268, 2925, 1645, 1539, 
1471, 968; MP 155-157 °C. 
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(2E,4E,6E,8E)-3,7-dimethyl-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-
yl)-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (174) 
 
The mixed anhydride (148) (53 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 5-aminobenzimidazolinone (165) 
(25 mg, 1.2 eq) was added. The solution was allowed to stir overnight at 
room temperature. Once complete by TLC, the reaction was diluted with 
EtOAc (50 ml) and washed with saturated sodium bicarbonate solution (2 × 
50 ml) and brine (2 × 50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo. The residue was purified using silica 
column chromatography, eluted with 0-40 % EtOAc in hexane, to yield the 
product as a yellow solid (7 mg, 11 %). LCMS (M+H)+ found 432.2, requires 
432.3, RT 2.39 min; HRMS ESI (M-H)+  found 430.2491, C27H32N3O2 requires 
430.2489; δH (500 MHz, CDCl3) 0.98 (6H, s, C11(CH3)2), 1.41 (2H, m, 
C12H2), 1.52 (2H, m, C13H2), 1.62 (3H, s, C3CH3), 1.91 (3H, s, C7CH3), 
1.95 (2H, m, C14H2), 2.29 (3H, s, C15CH3), 5.90 (1H, s, C2H), 6.22 (4H, m, 
C4-, C6-, C8-, C9-H), 6.87 (1H, d, J = 8.4 Hz, C6’-H), 9.96 (1H, m, C5-H), 
6.98 (1H, d, J = 8.4 Hz, C7’-H), 7.49 (1H, s, C2’-H). ); δC (125 MHz; CDCl3) 
12.93 (C3CH3),13.99 (C7CH3), 20.39 (C13), 22.00 (C15CH3), 29.49 
(C11(CH3)2), 34.06 (C14), 35.32 (C11), 40.85 (C12), 103.52 (C6’), 110.25 
(C2’), 115.10 (C7’), 123.13 (C2), 127.44 (C15), 129.27 (C5), 130.65 (C3’), 
131.02 (C1’), 131.13 (C9), 131.18 (C6), 134.66 (C5’), 137.11 (C4), 139.09 
(C8), 139.17 (C7), 139.88 (C10), 150.85 (C3), 158.38 (C4’), 167.77 (C1);  IR 
(cm-1) 2934, 1736, 1505, 1363, 1193, 966, 714; MP 223-226 °C. 
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tert-butyl 4-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-
enyl)nona-2,4,6,8-tetraenamido)benzylcarbamate (175) 
 
The mixed anhydride (148) (50.2 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and 4-[(N-Boc)aminomethyl]aniline 
(166) (35 mg, 1.2 eq) was added. The solution was allowed to stir overnight 
at room temperature. Once complete, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (22 mg, 33 %). LCMS (M+H)+ found 505.5, requires 505.3, 
RT 2.51 min; HRMS ESI (M+H)+ found 505.3426, C32H45N2O3 requires 
505.3430; δH (500 MHz, CDCl3): 1.04 (6H, s, C11CH3), 1.39 (9H, s, (CH3)3), 
1.42 (2H, m, C12H2), 1.55 (2H, m, C13H2), 1.68 (3H, s, C15CH3), 1.89 (3H, 
s, C3CH3), 1.93 (2H, m, C14H2), 2.35 (3H, s, C7CH3), 4.19 (2H, d, J = 5.4 
Hz, C4’H2), 4.76 (1H, s, OH), 5.73 (1H, s, C2H), 6.09 (4H, m, C4-, C5-, C8-, 
C9-H), 6.92 (1H, m, C6-H), 7.12 (2H, d, J = 7.5 Hz, C3’-, C6’-H), 7.43 (2H, d, 
J = 7.5 Hz, C2’-, 7’-H); IR (cm-1) 3320, 3124, 2927, 1696, 1652, 1601, 1391, 
1361, 1254, 1167, 1027, 966, 827, 729, 509; MP 69-71 °C. 
tert-butyl methyl(4-nitrophenyl)carbamate (181) 
 
N-methyl-4-nitroaniline (180) (500 mg, 1 eq) was dissolved in anhydrous 
THF (20 ml) and Boc anhydride (860 mg, 1.2 eq) was added slowly, followed 
by DMAP (482 mg, 1.2 eq). The mixture was stirred for 4 h at room 
temperature until the reaction was seen to be complete by TLC. The volatiles 
were removed in vacuo and the residue was washed with 20 % HCl (2 × 50 
ml) and saturated sodium bicarbonate solution (2 × 50 ml) in EtOAc (50 ml). 
The organic layer was dried over sodium sulphate and concentrated in vacuo 
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to yield the product as a light brown solid (667 mg, 80 %). The product was 
not ionised by LCMS. δH (500 MHz, CDCl3) 1.48 (9H, s, C(CH3)3), 3.32 (3H, 
s, CH3), 7.44 (2H, d, J = 9.2 Hz, C3-, 5-H), 6.15 (2H, d, J = 9.2 Hz, C2-, 6-H). 
tert-butyl 4-aminophenyl(methyl)carbamate (182) 
 
This compound was synthesised as previously described by Martini et. al.213 
Compound (181) (755 mg) and Pd/C (100 mg) were dissolved in MeOH (10 
ml). The reaction was allowed to stir under H2 overnight. The Pd/C was 
filtered through Celite and the filtrate was concentrated in vacuo to yield the 
product as a light brown solid (667 mg, 100 %) LCMS (2M+Na)+ found 467.2, 
requires 467.3, RT 1.57 min; δH (500 MHz, CDCl3) 1.36 (9H, s, C(CH3)3), 
3.09 (3H, s, CH3), 4.52 (2H, br s, NH2), 6.58 (2H, d, J = 5.4 Hz, C2-, 6-H), 
6.88 (2H, d, J = 5.4 Hz, C3-, 5-H). 
tert-butyl 4-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-
enyl)nona-2,4,6,8-tetraenamido)phenyl(methyl)carbamate (183) 
 
The mixed anhydride (148 (200 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and compound 182 (139 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (136 mg, 52 %). The compound was not ionised by LCMS. 
δH (300 MHz, CDCl3) 0.96 (9H, s, C(CH3)3), 1.38 (6H, s, C11(CH3)2), 1.41 
(2H, m, C12H2), 1.54 (2H, m, C13H2), 1.64 (3H, s, C3CH3), 1.92 (3H, s, 
C7CH3), 1.95 (2H, t, J = 6 Hz, C14H2), 2.33 (3H, s, C15CH3), 3.13 (3H, s, 
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NCH3), 5.75 (1H, s, C2H), 6.11 (4H, m, C4-, C6-, C8-, C9-H), 6.89 (1H, m, 
C5-H), 7.04 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 7.40 (2H, d, J = 8.7 Hz, C2’-, 
C6’-H), 7.80 (1H, s, NH). 
(2E,4E,6E,8E)-N-(4-(aminomethyl)phenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (184) 
 
TFA (1 ml) was added to a stirred solution of Boc-protected retinoic 4-
aminobenzylamide (175) (56.6 mg, 1.1 mmol) in DCM (5 ml) for 1 h. The 
progress of the reaction was monitored by LCMS and once complete the 
DCM was removed in vacuo to afford the pure product as a yellow oil (44.8 
mg, 98.9 %). LCMS (M+H)+ found 405.3, requires 405.3; δH (500 MHz, 
CDCl3) 1.17 (6H, s, C11CH3), 1.50 (2H, m, C12H2), 1.61 (2H, m, C13H2), 
1.72 (2H, m, C14H2), 2.52 (3H, s, C15CH3), 3.35 (3H, s, C3CH3), 4.30 (2H, 
m, C4’H2), 5.77 (1H, s, C2H), 6.05 (5H, m, C4-, C5-, C6-,C8-, C9-H), 7.29 
(4H, m, C2’-, C3’-,C6’,C7’-H), 8.14 (2H, s, NH2), 10.21 (1H, s, NH); IR (cm-1)  
3392, 2928, 1650, 1439, 1289, 1140, 1019, 952, 707, 616. 
(2E,4E,6E,8E)-N-(3-bromo-4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (191) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 4-amino 2-bromophenol (186) (59 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (33 mg, 27 %). The compound was not ionised by LCMS. 
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HRMS ESI (M+H)+ found 470.1699, C26H33BrNO2 requires 470.1689; δH (500 
MHz, CDCl3) 1.07 (6H, s, C11(CH3)2), 1.50 (2H, m, C12H2), 1.58 (2H, m, 
C13H2), 1.70 (3H, s, C15CH3), 2.01 (3H, s, C3H3), 2.04 (2H, m, C14H2), 2.46 
(3H, s, C7CH3), 5.78 (1H, s, C2H), 6.17 (2H, m, C4-, C6-H), 6.31 (2H, m, C8-
, C9-H), 6.99 (1H, d, J = 9 Hz, C5’H), 7.04 (1H, m, C5H), 7.08 (1H, s, C2’H), 
7.25 (1H, d, J = 9 Hz, C6’H), 7.97 (1H, s, NH); δC (75 MHz; CDCl3) 12.94 
(C3CH3), 13.95 (C7CH3), 20.34 (C13), 22.02 (C15CH3), 29.47 (C11(CH3)2), 
34.01 (C14), 35.28 (C11), 40.76 (C12), 110.44 (C3’), 116.99 (C5’), 121.74 
(C2), 122.78 (C6’), 125.96 (C2’), 129.24 (C5), 130.61 (C15), 131.09 (C9), 
131,27 (C6), 133.19 (C1’), 137.00 (C4), 139.06 (C8), 139.10 (C7), 139.91 
(C10), 151.07 (C3), 151.95 (C4’), 167.57 (C1); IR (cm-1) 2924, 2498, 2346, 
1625, 1492, 1380, 1282, 958, 814; MP 193-196 °C. 
(2E,4E,6E,8E)-N-(4-hydroxy-3-methoxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (192) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (4 ml) and 
pyridine (200 µL) at room temperature and compound (188) (78 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (52 mg, 24 %). LCMS (2M+Na)+ found 865.6, requires 
865.5, RT 2.60 min; HRMS ESI (M)+ found 422.2692, C27H36NO3 requires 
422.2689; δH (500 MHz, CDCl3) 0.96 (6H, s, C11(CH3)2), 1.39 (2H, m, 
C12H2), 1.54 (2H, m, C13H2), 1.64 (3H, s, C3CH3), 1.92 (3H, s, C7CH3), 
1.95 (2H, m, C14H2), 2.34 (3H, s, C15CH3), 3.78 (3H, s, OCH3), 5.51 (1H, br 
s, OH), 5.72 (1H, s, C2H), 6.14 (4H, m, C4-, C6-, C8-, C9-H), 6.62 (1H, d, J = 
8.4 Hz, C5’-H), 6.72 (1H, d, J = 8.4 Hz, C6’-H), 6.89 (1H, m, C5-H), 7.39 (1H, 
s, C2’-H), 7.51 (1H, s, NH); δC (75 MHz; CDCl3) 12.89 (C3CH3), 13.68 
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(C7CH3), 19.23 (C13), 21.74 (C15CH3), 29.05 (C11(CH3)2), 33.11 (C14), 
34.27 (C11), 39.61 (C12), 104.61 (OCH3), 112.42 (C2’), 121.47 (C6’), 128.46 
(C5’), 129.54 (C2), 129.90 (C5), 130.25 (C9), 131.33 (C15), 135.38 (C4), 
137.29 (C8), 137.73 (1’), 139.16 (C10), 142.26 (C4’), 146.43 (C3), 150.18 
(C3’), 165.16 (C1); IR (cm-1) 3303, 2923, 1510, 1150, 963; MP 119-121 °C. 
(2E,4E,6E,8E)-N-(4-hydroxy-3-methylphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (193) 
 
The mixed anhydride (148) (195 mg, 1 eq) was dissolved in DCM (5 ml) and 
pyridine (200 µL) at room temperature and 2-methyl 4-aminophenol (190) 
(77, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography eluted with 0-100 % EtOAc in hexane and recrystalised in 
MeOH to yield the product as a yellow solid (68 mg, 33 %). LCMS (2M+Na)+ 
found 833.9, requires 833.5, RT 2.62 min; HRMS ESI (M+Na)+ found 
428.2557, C27H35NNaO2 requires 428.2560; δH (500 MHz, CDCl3) 0.96 (6H, 
s, C11(CH3)2), 1.41 (2H, m, C12H2), 1.55 (2H, m, C13H2), 1.65 (3H, s, 
C15CH3), 1.87 (3H, s, C3H3), 1.96 (2H, m, C14H2), 2.09 (3H, s, C3’CH3), 
2.34 (3H, s, C7CH3), 5.71 (1H, s, C2H), 6.14 (4H, m, C4-, C6-, C8-, C9-H), 
6.62 (1H, d, J = 7.5 Hz, C5’H), 6.90 (1H, app t, J = 13 Hz, C5H), 7.06 (1H, s, 
C2’H), 7.20 (1H, d, J = 7.5 Hz, C6’H); δC (125 MHz; CDCl3) 12.93 (C3CH3), 
13.74 (C7CH3), 15.95 (C3’CH3), 19.23 (C13), 21.79 (C15CH3), 28.97 
(C11(CH3)2), 33.12 (C14), 34.27 (C11), 39.59 (C12), 115.24 (C5’), 119.67 
(C6’), 121.22 (C2), 123.69 (C2’), 124.58 (C3’), 128.51 (C5), 129.54 (C9), 
129.96 (C15), 130.38 (C6), 130.56 (C1’), 135.31 (C4), 137.30 (C8), 137.73 
(C7), 139.29 (10), 150.40 (C3), 151.06 (C4’), 165.46 (C1); IR (cm-1) 3347, 
2921, 1645, 1549, 1416, 1199, 958, 807; MP 165-167 °C. 
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4-amino-2-methoxyphenol (196) 
 
This compound was synthesised as described by Mérnard et. al.214 4-
nitroguaiacol (194) (505 mg) and Pd/C (100 mg) were dissolved in MeOH (10 
ml). The reaction was allowed to stir under H2 overnight. The Pd/C was 
filtered through Celite and the filtrate was concentrated in vacuo to yield the 
product as a black/brown solid (233 mg, 57 %) LCMS (M+H)+ found 140.0, 
requires 140.1, RT 0.15 min; δH (500 MHz, CDCl3) 3.51 (2H, br s, NH2), 3.62 
(3H, s, CH3), 5.10 (1H, br s, OH), 6.24 (1H, d, J = 8.1 Hz, C6-H), 6.32 (1H, s, 
C2-H), 6.75 (1H, d, J = 8.1 Hz, C6-H); δC (75 MHz; CDCl3) 55.22 (OMe), 
100.15 (C3), 105.95 (C5), 116.01 (C6), 137.13 (C1), 141.31 (C4), 147.96 
(C2). 
4-amino-2-methylphenol (197) 
 
This compound was synthesised as previously described by Ménard, et. 
al.214 2-Methyl 4-nitrophenol (195) (1g) was dissolved in MeOH (10 ml) and 
Pd/C (50mg) was added as a solution in MeOH. The reaction was stirred 
under H2 overnight at room temperature. The Pd/C was filtered and the 
residue was concentrated in vacuo to yield the product as a black/brown 
solid (837mg, 100 %) LCMS (M+H)+ found 124.0, requires 124.0, RT 0.16 
min; δH (500 MHz, CDCl3) 2.34 (3H, s, CH3), 6.56 (1H, brs, ArOH), 6.85 (2H, 
d, J = 9 Hz, C2-, C6-H), 8.02 (1H, d, J = 9 Hz, C5-H), 8.09 (1H, s, C3-H); δC 
(125 MHz; CDCl3) 16.38 (CH3), 115.39 (C5), 120.43 (C6), 126.30 (C3), 
127.10 (C2), 139.93 (C4), 149.57 (C1); IR (cm-1) 3355, 3287, 1585, 1468, 
1211; MP 99-102 °C. 
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(2E,4E,6E,8E)-N-(2-amino-4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (198) 
 
Compound (148) (45 mg) was dissolved in acetic acid (3 ml) and zinc 
powder (68 mg, 10 eq) was added. The reaction was allowed to stir for 1 h at 
room temperature and monitored by LCMS. Once complete, zinc was 
removed by filtration through Celite. The filtrate was diluted with EtOAc (50 
ml) and washed with 10 % NaOH solution (3 × 50 ml), saturated sodium 
bicarbonate solution (3 × 50 ml) and brine (3 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified using Biotage silica column chromatography, eluted with 0-100 % 
EtOAc in hexane, to yield the product as a yellow solid (17 mg, 41 %). LCMS 
(M+H)+ found 407.2, requires 407.3, RT 2.43 min; HRMS EI (M)+  found 
407.2693, C26H35N2O2 requires 407.2693; δH (500 MHz, CDCl3) 1.06 (6H, s, 
C11(CH3)2), 1.49 (2H, m, C12H2), 1.66 (2H, m, C13H2), 1.74 (3H, s, C3CH3), 
2.04 (3H, s, C7CH3), 2.04 (2H, m, C14H2), 2.13 (3H, s, C15CH3), 3.41 (2H, 
br s, NH2), 5.98 (1H, s, C2H), 6.18 (2H, m, C4-, C6-H), 6.48 (3H, m, C8-, C9-
, C5’-H), 6.69 (1H, d, J = 8.1 Hz, C6’-H), 7.08 (1H, m, C5-H); δC (125 MHz; 
CDCl3) 12.95 (C3), 14.03 (C7), 19.23 (C13), 21.75 (C15CH3), 28.97 
(C11(CH3)2), 33.14 (C14), 34.28 (C11), 39.64 (C12), 109.98 (C3’), 112.61 
(C5’), 117.10 (C2), 117.62 (C6’), 128.98 (C9), 129.44 (C6), 130.15 (C1’), 
131.65 (C5), 131.93 (C15), 134.94 (C4), 135.84 (7), 137.23 (C8), 137.71 
(C10), 140.14 (C2’), 144.44 (C3), 154.86 (C4’), 166.06 (C1); IR (cm-1) 3396, 
3369, 3207, 2925, 1699, 1515, 1354, 1205, 1025, 878; MP 169-173 °C. 
(2E,4E,6E,8E)-3,7-dimethyl-N-(pyridin-4-yl)-9-(2,6,6-trimethylcyclohex-1-
enyl)nona-2,4,6,8-tetraenamide (199) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (4 ml) and 
pyridine (400 µL) at room temperature and 4-aminopyridine (61 mg, 1.2 eq) 
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was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (72 mg, 37 %). LCMS (M+H)+ found 377.2, requires 377.3, 
RT 2.35 min;  HRMS ESI (M+H)+  found 377.2596, C25H33N2O requires 
377.2587; δH (500 MHz, CDCl3) 1.05 (6H, s, C11(CH3)2), 1.50 (2H, m, 
C12H2), 1.64 (2H, m, C13H2), 1.73 (3H, s, C3CH3), 2.02 (3H, s, C7CH3), 
2.06 (2H, m, C14H2), 2.45 (3H, s, C15CH3), 5.86 (1H, s, C2H), 6.24 (4H, m, 
C4-, C6-, C8-, C9-H), 7.05 (1H, m, C5-H), 7.57 (2H, d, J = 6 Hz, C2’-, C6’-H), 
8.37 (1H, s, NH), 8.48 (2H, d, J = 6 Hz, C3’-, C5’-H); δC (75 MHz; CDCl3) 
13.09 (C3), 14.18 (C7), 20.38 (C13), 22.15 (C15CH3), 29.57 (C11(CH3)2), 
34.08 (C14), 35.29 (C11), 40.81 (C12), 114.84 (C2’, C6’), 122.40 (C2), 
129.62 (C5), 130.80 (C15), 131.02 (C9), 132.20 (C6), 136.70 (C4), 138.89 
(C8), 139.03 (C7), 140.57 (C10), 148.59 (C3), 150.60 (C3’, C5’), 153.31 
(C1’), 168.01 (C1); IR (cm-1) 2929, 1588, 1560, 1140, 828; MP 111-115 °C. 
(2E,4E,6E,8E)-N-(6-hydroxypyridin-3-yl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (200) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (4 ml) and 
pyridine (400 µL) at room temperature and 5-amino 2-hydroxypyridine (70 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (97 mg, 48 %). LCMS (M+H)+ found 393.2, requires 393.3, 
RT 2.37 min; HRMS ESI (M+H)+ found 393.2541, C25H33N2O2 requires 
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393.2537; δH (500 MHz, CDCl3) 0.95 (6H, s, C11(CH3)2), 1.40 (2H, m, 
C12H2), 1.48 (2H, m, C13H2), 1.63 (3H, s, C15CH3), 1.94 (3H, s, C3H3), 1.88 
(2H, m, C14H2), 2.28 (3H, s, C7CH3), 5.79 (1H, s, C2H), 6.14 (4H, m, C4-, 
C6-, C8-, C9-H), 6.31 (1H, d, J = 7.5 Hz, C5’H), 6.83 (1H, m, C5H), 7.48 (1H, 
d, J = 7.5 Hz, C6’H), 7.65 (1H, s, C2’H), 8.89 (1H, s, NH); δC (75 MHz; 
CDCl3) 12.93 (C3CH3), 13.94 (C7CH3), 20.34 (C13), 22.00 (C15CH3), 29.46 
(C11(CH3)2), 34.01 (C14), 35.27 (C11), 40.79 (C12), 120.73 (C5’), 121.90 
(C6’), 123.24 (C15), 126.60 (C2), 129.38 (C2’), 130.67 (C7), 131.02 (C5), 
131.59 (C9), 136.81 (C6), 138.93 (C4), 138.97 (C8), 139.08 (C10), 140.14 
(C1’), 151.64 (C3), 163.73 (C4’), 167.57 (C1); IR (cm-1) 3271, 2926, 1664, 
1607, 1564, 967, 833; MP 95-98 °C.  
(2E,4E,6E,8E)-N-(4-hydroxybenzyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (201) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 4-hydroxybenzylamine 
monohydrate (45 mg, 1.2 eq) was added. The solution was allowed to stir 
overnight at room temperature. Once complete by TLC, the reaction was 
diluted with EtOAc (50 ml) and washed with saturated sodium bicarbonate 
solution (2 × 50 ml) and brine (2 × 50 ml). The organic layer was dried over 
sodium sulphate and concentrated in vacuo. The residue was purified using 
Biotage silica column chromatography, eluted with 0-35 % EtOAc in hexane, 
to yield the product as a yellow solid (13 mg, 12 %) LCMS (2M+Na)+ found 
833.4, requires 833.5, RT 2.50 min; HRMS EI (M)+  found 405.2688, 
C27H35NO2 requires 405.2668; δH (300 MHz, CDCl3) 0.98 (6H, s, C11(CH3)2), 
1.41 (2H, m, C12H2), 1.57 (2H, m, C13H2), 1.67 (3H, s, C3CH3), 1.90 (3H, s, 
C7CH3), 1.95 (2H, m, C14H2), 2.33 (2H, d, J = 5.7 Hz, C1’H), (3H, s, 
C15CH3), 5.62 (1H, s, C2H), 5.70 (1H, t, J = 5.4 Hz, NH), 6.06 (4H, m, C4-, 
C6-, C8-, C9-H), 6.73 (2H, d, J = 8.4 Hz, C4’-, C6’-H), 6.86 (1H, m, C5-H), 
7.13 (2H, d, J = 8.4 Hz, C3’-, C7’-H); δC (125 MHz; CDCl3) 12.88 (C3CH3), 
13.78 (C7CH3), 19.24 (C13), 21.74 (C15CH3), 28.97 (C11(CH3)2), 33.11 
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(C14), 34.27 (C11), 39.63 (C12), 43.18 (C1’), 115.72 (C4’, C6’), 121.01 (C2), 
128.35 (C5), 129.21 (C3’, C7’), 129.50 (C15), 129.56 (C9), 129.86 (C2’), 
130.06 (C6), 135.40 (C4), 137.31 (C8), 137.74 (C7), 138.95 (C10), 149.24 
(C3), 155.88 (C5’), 167.38 (C1); IR (cm-1) 3332, 2925, 1645, 1515, 1446, 
1361, 1229; MP 78-80 °C. 
 (2E,4E,6E,8E)-N-(1H-indol-6-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-
1-enyl)nona-2,4,6,8-tetraenamide (202) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 6-aminoindole (42 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (47 mg, 44 %). LCMS (M+H)+ found 415.2, requires 415.3, 
RT 2.65 min;  HRMS ESI (M+H)+ found 415.2763, C28H35N2O requires 
415.2744; δH (500 MHz, CDCl3) 1.08 (6H, s, C11(CH3)2), 1.52 (2H, m, 
C12H2), 1.66 (2H, m, C13H2), 1.76 (3H, s, C3CH3), 2.04 (3H, s, C7CH3), 
2.07 (2H, m, C14H2), 2.48 (3H, s, C15CH3), 5.87 (1H, s, C2H), 6.30 (4H, m, 
C4-, C6-, C8-, C9-H), 6.52 (1H, s, C2’-H), 7.00 (1H, m, C5-H), 7.19 (1H, s, 
C4’-H), 7.39 (1H, s, C5’-H), 7.94 (1H, s, C7’-H), 8.36 (1H, s, C8’-H); δC (125 
MHz; CDCl3) 12.93 (C3CH3), 13.97 (C7CH3), 20.36 (C13), 22.02 (C15CH3), 
29.48 (C11(CH3)2), 34.02 (C14), 35.28 (C11), 40.79 (C12), 102.56 (C5’), 
112.11 (C2’), 113.47 (C8’), 117.03 (C7’), 123.59 (C2), 126.49 (C5), 129.07 
(C4’), 129.43 (C6’), 130.56 (C1’), 130.80 (C9), 131.17 (C6), 131.75 (C15), 
135.08 (C3’), 137.25 (C4), 139.06 (C8), 139.10 (C7), 139.57 (C10), 150.07 
(C3), 167.82 (C1); IR (cm-1) 3306, 2923, 1538, 1474, 1360, 1186, 966, 727; 
MP 157-160 °C. 
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(2E,4E,6E,8E)-N-(1H-indazol-6-yl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (203) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 6-aminoindazole (83 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight at room temperature. 
Once complete by TLC, the reaction was diluted with EtOAc (50 ml) and 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (65 mg, 31 %). LCMS (M+H)+ found 416.3, requires 416.3, 
RT 2.52 min; HRMS ESI (M+H)+ found 416.2704, C27H34N3O requires 
416.2696; δH (500 MHz, CDCl3) 1.07 (6H, s, C11(CH3)2), 1.52 (2H, m, 
C12H2), 1.66 (2H, m, C13H2), 1.73 (3H, s, C3CH3), 2.02 (3H, s, C7CH3), 
2.05 (2H, m, C14H2), 2.42 (3H, s, C15CH3), 6.05 (1H, s, C2H), 6.33 (4H, m, 
C4-, C6-, C8-, C9-H), 6.52 (1H, s, C2’-H), 7.08 (1H, m, C5-H), 7.09 (1H, d, J 
= 8.7 Hz, C7’-H), 7.68 (1H, d, J = 8.7 Hz, C6’-H), 7.95 (1H, s, C2’-H), 8.23 
(1H, s, C4’-H); δC (75 MHz; CDCl3) 12.94 (C3), 14.02 (C7), 20.34 (C13), 
22.00 (C15CH3), 29.46 (C11(CH3)2), 34.02 (C14), 35.28 (C11), 40.79 (C12), 
100.96 (C2’), 116.27 (C7’), 120.93 (C5’), 121.97 (C6’), 122.94 (C2), 129.31 
(C5), 130.63 (C15), 131.06 (C9), 131.38 (C6), 134.66 (C4), 136.99 (C4’), 
139.01 (C8), 139.10 (C1’), 139.25 (C7), 139.99 (C10), 142.19 (C3’), 151.38 
(C3), 168.03 (C1); IR (cm-1) 3179, 2923, 1567, 1356, 1152, 943, 839; MP 
227-229 °C. 
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(2E,4E,6E,8E)-3,7-dimethyl-N-(1H-pyrazol-3-yl)-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (204) 
 
The mixed anhydride (148) (150 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µL) at room temperature and 3-amino-1H-pyrazole (39 mg, 1.2 
eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete by TLC, the reaction was diluted with EtOAc 
(50 ml) and washed with saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using silica column 
chromatography eluted with a hexane / EtOAc gradient (1:0 to 0:1) to yield 
the product as a yellow solid (37mg, 26 %). The product was obtained as a 
mixture of isomers (major isomer (> 70 % by 1H NMR) reported). LCMS 
(2M+Na)+ found 753.8, requires 753.5, RT 2.59 min; HRMS ESI (M+Na)+  
found 388.2363, C23H32N3O requires 388.2359;  δH (300 MHz, CDCl3) (major 
isomer) 0.96 (6H, s, C(CH3)2), 1.39 (2H, m, C12H2), 1.55 (2H, m, C13H2), 
1.64 (3H, s, C3CH3), 1.94 (3H, s, C7CH3), 1.95 (2H, m, C14H2), 2.29 (3H, s, 
C15CH3), 5.73 (1H, s, C2H), 5.81 (1H, d, J = 3 Hz, C2’-H), 6.16 (4H, m, C4-, 
C6-, C8-, C9-H), 6.93 (1H, s, NH), 6.97 (1H, m, C5-H), 8.03 (1H, d, J = 3 Hz, 
C3’H);  δC (125 MHz; CDCl3) (major isomer) 12.93 (C3), 14.05 (C7), 19.22 
(C13), 21.74 (C15CH3), 28.96 (C11(CH3)2), 33.12 (C14), 34.27 (C11), 39.61 
(C12), 100.17 (C2’), 117.75 (C2), 128.99 (C5), 129.41 (C9), 130.14 (C15), 
131.77 (C6), 132.17 (C3’), 134.93 (C4), 135.72 (C1’), 137.21 (C8), 137.67 
(C7), 140.19 (C10), 155.11 (C3), 172.14 (C1); IR (cm-1) 3350, 2926, 1683, 
1572, 1159, 963; MP 127-130 °C. 
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(2E,4E,6E,8E)-1-(4-hydroxypiperidin-1-yl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-one (205) 
 
The mixed anhydride (148) (100 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (100 µl) at room temperature and 4-hydroxypiperidine (32 mg, 1.2 
eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow oil (95 mg, 95 %). LCMS (M+H)+ found 384.4, requires 384.3, RT 
2.39 min; HRMS ESI (M+H)+  found 384.2912, C25H38NO2 requires 384.2897; 
δH (500 MHz, CDCl3) 0.93 (6H, s, C11CH3), 1.37 (2H, m, C3’a-, C5’a-H), 
1.40 (2H, m, C12-H), 1.52 (2H, m, C3’b-, C5’b-H), 1.60 (3H, s, C15CH3), 
1.74 (2H, m, C13H2), 1.88 (3H, s, C3CH3), 1.92 (3H, s, C7CH3), 1.92 (2H, m, 
C14-H), 3.20 (2H, m, C2’-a, C6’-a-H), 3.74 (2H, m, C2’b-, C6’b-H), 3.99 (1H, 
m, C4’H), 6.12 (5H, m, C2-, C4-, C6-, C8, C9-H), 6.77 (1H, m, C5H); δC (125 
MHz, CDCl3) 15.47 (C3(CH3), 17.26 (C7(CH3), 22.91 (C13), 24.59 (C15CH3), 
32.05 (C11(CH3)2), 36.55 (C14), 37.38 (C11), 37.82 (C3’, C5’), 38.17 (C3’, 
C5’), 42.65 (C12), 43.33 (C2’, C6’), 47.67 (C2’, C6’), 70.27 (C4’),  125.33 
(C2), 131.30 (C5), 132.34 (C9), 132.96 (C15), 133.64 (C6), 138.63 (C4), 
141.52 (C7), 141.60 (C8), 141.64 (C10), 148.14 (C3), 171.69 (C1); IR (cm-1) 
3386, 2925, 1602, 1447, 1266, 1199, 1077, 966. 
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(2E,4E,6E,8E)-N-((1r,4r)-4-hydroxycyclohexyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (206) 
 
The mixed anhydride (148) (50.0 mg, 1 eq) was dissolved in DCM (3 ml) and 
pyridine (200 µl) at room temperature and trans-4-aminocyclohexanol (18.2 
mg, 1.2 eq) was added. The solution was allowed to stir overnight at room 
temperature. Once complete, the reaction was diluted with EtOAc (50 ml) 
and washed with saturated sodium bicarbonate solution (2 × 50 ml) and 
brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified using Biotage silica column 
chromatography, eluted with 0-100 % EtOAc in hexane, to yield the product 
as a yellow solid (18.1 mg, 36 %). LCMS (2M+Na)+ found 817.6, requires 
817.6, RT 2.38 min; HRMS EI (M)+ found 397.2986, C26H39NO2 requires 
397.2981; δH (500 MHz, CDCl3) 1.00 (6H, s, C11CH3), 1.25 (2H, m C3’a-, 
C5’a-H), 1.39 (2H, m, C3’b-, C5’b-H), 1.47 (2H, m, C12H2), 1.63 (2H, m , 
C13H2), 1.72 (3H, s, C15CH3), 2.00 (3H, s, C3CH3), 2.03 (6H, m , C2’-, C6’, 
C14-H2), 2.36 (3H, s, C7CH3), 3.60 (1H, m, C4’H), 3.81 (1H, m, C1’H), 5.32 
(1H, d, J = 8.1 Hz, OH), 5.63 (1H, S, C2H), 6.20 (4H, m, C4-, C6-, C8, C9-H), 
6.93 (1H, m, C5H), 7.3 (1H, s, NH); δC (125 MHz, CDCl3) 12.86 (C3CH3), 
13.55 (C7CH3), 19.24 (C13), 21.72 (C15CH3), 28.95 (C11(CH3)2), 31.00 
(C2’, C6’), 33.10 (C14), 34.05 (C3’, C5’), 34.27 (C11), 39.63 (C12), 47.43 
(C1’), 69.91 (C4’), 121.51 (C2), 128.23 (C5), 129.56 (C9), 129.70 (C6), 
129.79 (C15), 135.49 (C4), 137.32 (C8), 137.76 (C7), 138.71 (C10), 148.48 
(C3), 166.43 (C1); IR (cm-1) 3400, 2936, 1655, 1542, 1437, 1364, 1293, 
1140, 1019, 952, 901, 707; MP 88-91 °C. 
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7.3.2 Central scaffold analogues 
N-(4-hydroxyphenyl)dodecanamide (91) 
 
Lauroyl chloride (241) (0.4 ml, 1 eq), 4-aminophenol (225) (208.0 mg, 1.1 eq) 
and pyridine (0.2 ml, 1.5 eq) were dissolved in THF and stirred overnight. 
The solution was washed with saturated sodium bicarbonate solution (2 × 50 
ml) in ethyl acetate (50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo. The residue was purified by silica 
column chromatography eluted with a 0-100 % EtOAc in hexane. The pure 
compound was obtained as a white solid (50 mg, 90 %). LCMS (2M+Na)+ 
found 605.5 requires 605.4, RT 2.20 min; HRMS ESI (M+H)+ found 
292.2279, C18H30NO2 requires 292.2271; δH (500 MHz, CDCl3) 0.93 (3H, t, J 
= 6.4 Hz, C12H3), 1.32 (16H, m, C4-C11H2), 1.61 (2H, m, C3H2), 2.33 (2H, 
m, CH2), 4.88 (1H, s, OH), 6.75 (2H, d, J = 8.8 Hz, C3’-, C5’-H), 6.95 (1H, s, 
NH), 7.33 (2H, d, J = 8.8 Hz, C2’-, C6’-H); δC (125 MHz, CDCl3) 14.51 (C12), 
23.78 (C11), 27.15 (C3), 30.40 (C5), 30.52 (C9, C8), 30.68 (C4), 30.77 (C7, 
C6), 33.12 (C10), 37.89 (C2), 116.25 (C3’, C5’), 123.48 (C2’, C6’), 131.79 
(C1’), 155.41 (C4’), 174.52 (C1) ; IR (cm-1) 3311, 2916, 2850, 1651, 1545, 
1515, 1245, 831, 534; MP 128-130 °C. 
(2Z,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (238) 
 
 
 
4-aminophenol (225) (22.5 mg, 1.3 eq) was added to a stirred solution of 
mixed anhydride (240) (60 mg, 1 eq) in DCM (3 ml) and pyridine (200 µl). 
The solution was stirred overnight at room temperature. Once complete, as 
observed by LCMS, ethyl acetate (5 ml) was added and the solution was 
washed with saturated sodium bicarbonate solution (2 × 50 ml) and brine (2 
× 50 ml). The organic layer was dried over sodium sulphate and 
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concentrated in vacuo. The mixture was purified by Biotage column 
chromatography, eluted with 0-100 % EtOAc in hexane, to afford the pure 
compound was as a yellow oil (36 mg, 58 %). LCMS (2M+Na)+ found 805.6 
requires 805.5, RT 2.50 min; HRMS ESI (M+H)+ found 392.2596, C26H34NO2 
requires 392.2584; δH (500 MHz, CDCl3) 1.06 (6H, C11CH3), 1.40 (2H, m, 
C12H2), 1.58 (2H, m, C13H2), 1.64 (2H, C15CH3), 1.81 (3H, m, C3CH3), 1.99 
(2H, m, C14H2), 2.23 (3H, m, C7CH3),  5.70 (1H, s, C2H), 6.10 (4H, m, C4-, 
C6-, C8-, C9-H), 6.60 (2H,  d, J = 8.7 Hz, C3’-, C5’-H), 6.90 (1H, dd, J1 = 
15.3, J2 = 11.4, C5H), 7.27 (2H, d, J = 8.7 Hz, C2’-, C6’-H), 7.78 (1H, d, J = 
15.3 Hz, C4H); δC (125 MHz; CDCl3) 12.89 (C7CH3), 20.39 (C13), 21.17 
(C3CH3), 21.98 (C15CH3), 29.47 (C11(CH3)2), 34.05 (C14), 35.32 (C11), 
40.85 (C12), 116.30 (C3’, C5’), 121,16 (C2), 123.25 (C1’, C6’), 129.18 (C5), 
130.66 (C15), 131.26 (C9), 131.81 (C6), 132.06 (C7), 132.10 (C4), 139.15 
(C8), 140.03(C10), 148.97 (C3), 155.35 (C4’), 167.17 (C1); IR (cm-1) 3302, 
2924, 1608, 1509, 1442, 1316, 1237, 968, 837, 519; MP 85-87 °C. 
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraenoic pivalic anhydride (240) 
 
 
13-cis-Retinoic acid (239) (49.5 mg, 1 eq) and trimethyl acetyl chloride (147) 
(30 µl, 1.5 eq) were dissolved in ethyl acetate (5 ml) at −5˚C. Triethylamine 
(10 µl, 0.5 eq) was added and the mixture was stirred for 2 hours. The 
reaction was monitored by LCMS and when complete, washed with 20 % 
HCl (2 × 50 ml) and saturated sodium bicarbonate solution (2 × 50 ml). The 
organic layer was dried over sodium sulphate and concentrated in vacuo. 
The mixture was purified using a silica flash column chromatography plug 
with 20 % ethyl acetate and hexane. The pure compound was obtained as a 
yellow oil (60 mg, 95 %). The compound was not ionised by LCMS. δH (500 
MHz, CDCl3) 0.95 (6H, s, C11(CH3)2), 1.19 (9H, s, pivaloyl(CH3)3), 1.38 (2H, 
m, C12H2), 1.52 (2H, m, C13H2), 1.64 (3H, s, C15CH3), 1.94 (3H, s, C3CH3), 
1.96 (2H, m, C14H2), 2.02 (3H, s, C7CH3), 5.62 (1H, s, C2CH), 6.09 (1H, d, J 
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= 16 Hz, C9H), 6.18 (1H, d, J = 11.5 Hz, C4H), 6.25 (1H, d, J = 16 Hz, C9H), 
7.04 (1H, dd, J1 = 11.5, J2 = 15.5, C5H), 7.67 (1H, d, J = 15.5 Hz, C6H); δC 
(125 MHz, CDCl3) 13.0, 14.3, 14.4, 19.2, 21.8, 26.5, 26.6, 29.0, 33.2, 34.3, 
39.6, 39.7, 116.3, 129.3, 129.7, 130.4, 133.3, 134.2, 137.1, 137.7, 141.4, 
158.5, 162.4, 174.8. 
N-(4-methoxyphenyl)dodecanamide (242) 
 
Lauroyl chloride (241) (200 µl, 1 eq), para-methoxyaniline (150) (128 mg, 1.1 
eq) and pyridine (130 µl, 1 eq) were dissolved in DCM (3 ml) and stirred 
overnight. The solution was washed with saturated sodium bicarbonate 
solution (2 × 50 ml) and brine (2 × 50 ml) in ethyl acetate (50 ml), dried over 
sodium sulphate, and concentrated in vacuo. The residue was recrystallised 
from MeOH to yield the pure compound as a white solid (25 mg, 9 %). LCMS 
(2M+Na)+ found 633.4 requires 633.5, RT 2.52 min; HRMS ESI (M+H)+ found 
306.2439, C19H33NO2 requires 306.2428; δH (500 MHz, CDCl3) 0.81 (3H, t, J 
= 6.3 Hz, C12H3), 1.12 (16H, m, C4-C11H2), 1.64 (2H, m, C3H2), 2.24 (2H, 
m, C2H2), 3.71 (3H, s, CH3), 6.77 (2H, d, J = 9 Hz, C3’-, C5’-H), 7.19 (1H, s, 
NH), 7.33 (2H, d, J = 9 Hz, C2’-, C6’-H); δC (125 MHz, CDCl3) 14.15 (C12), 
22.71 (C11), 25.76 (C3), 29.33 (C4), 29.36 (C5), 29.43 (C9), 29.52 (C8), 
29.63 (C7), 31.93 (C6), 37.65 (C2), 55.47 (OMe), 114.07 (C3’, C5’), 121.77 
(C2’, C6’), 131.11 (C1’), 156.28 (C4’), 171.43 (C1); IR (cm-1) 3302, 2916, 
2848, 1651, 1513, 1247, 1030, 826; MP 102-104 °C. 
7.3.3 Amide isosteres 
(2E,4E,6E,8E)-N-(4-aminophenyl)-N,3,7-trimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (179) 
 
The mixed anhydride (148) (200 mg, 1 eq) was dissolved in DCM (1 ml) and 
pyridine (200 µL) at room temperature and N-methyl-1,4-phenylenediamine 
- 195 - 
 
dihydrochloride (170) (79 mg, 1.2 eq) was added. The solution was allowed 
to stir overnight at room temperature. Once complete by TLC, the reaction 
was diluted with EtOAc (50 ml) and washed with saturated sodium 
bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified using silica column chromatography, eluted with a 0-100 % EtOAc in 
hexane, to yield the product as a yellow solid (43 mg, 20 %). LCMS (M+H)+ 
found 405.3, requires 405.3, RT 2.52 min; HRMS ESI (M+H)+ found 
405.2912, C27H37N2O requires 405.2900; δH (300 MHz, CDCl3) 0.93 (6H, s, 
C11(CH3)2), 1.38 (2H, m, C12H2), 1.53 (2H, m, C13H2), 1.61 (3H, s, C3CH3), 
1.87 (3H, s, C7CH3), 1.93 (2H, m, C14H2), 2.23 (3H, s, C15CH3), 3.19 (3H, 
s, NCH3), 5.55 (1H, s, C2H), 6.01 (4H, m, C4-, C6-, C8-, C9-H), 6.57 (2H, d, 
J = 8.4 Hz, C3’-, C5’H), 6.73 (1H, m, C5-H), 6.84 (2H, d, J = 8.4 Hz, C2’-, 
C3’-H); δC (125 MHz; CDCl3) 12.79 (C3CH3), 13.79 (C7CH3), 19.22 (C13), 
21.69 (C15CH3), 28.93 (C11(CH3)2), 33.06 (C14), 34.23 (C11), 39.58 (C12), 
115.47 (C3’, C5’), 121.61 (C2), 127.78 (C5), 127.99 (C9), 128.71 (C6), 
129.61 (C15), 129.71 (C2’, C6’), 134.94 (C1’), 136.24 (C4), 137.44 (C8), 
137.77 (C7), 138.08 (C10), 145.60 (C4’), 147.02 (C3), 167.72 (C1); IR (cm-1) 
3347, 2923, 1621, 1514, 1360, 1278, 1120, 964, 829, 555; MP 93-96 °C. 
(3E,5E,7E,9E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-enyl)-2-
(trimethylsilyloxy)deca-3,5,7,9-tetraenenitrile (211) 
 
This compound was synthesised as previously described by Weiss et al.121 
TMSCN (250 µl, 2 eq) was added to retinal (210) (52 mg, 1 eq) at room 
temperature. Triethylamine (1 drop) was added and the solution was allowed 
to stir for 2 h. The excess TMSCN and triethylamine were removed under 
reduced pressure to yield the product as a yellow solid (69 mg, 98 %). The 
product was not ionised by LCMS. δH (500 MHz, CDCl3) 0.25 (9H, s, 
Si(CH3)3), 1.08 (6H, s, C11(CH3)2), 1.50 (2H, m, C12H2), 1.66 (2H, m, 
C13H2), 1.75 (3H, s, C3CH3), 1.95 (3H, s, C7CH3), 2.02 (3H, s, C15CH3), 
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2.08 (2H, m, C14H2), 5.28 (1H, d, J = 8.5 Hz, C1H), 5.59 (1H, d, J = 8.5 Hz, 
C2H), 6.20 (4H, m, C4-, C6-, C8-, C9-H), 6.76 (1H, m, C5H). 
(4-(bromomethyl)phenoxy)(tert-butyl)dimethylsilane (212) 
 
This compound was synthesised as previously described by Weiss et al.121 
Compound (216) (228 mg, 1 eq) was dissolved in dry THF (4 ml). TFAA (3 
ml, 2.2 eq) was added at room temperature and allowed to stir for 1 h, then 
LiBr (88 mg, 0.8 eq) was added. The mixture was allowed to stir for 1 h and 
once complete by TLC the residue was purified by filtration through a bed of 
silica eluting with DCM (100 ml) to yield the product as a colourless oil (164 
mg, 57 %). LCMS (M−Br)+ found 221.1 requires 221.1, RT 2.47 min; δH (500 
MHz, CDCl3) 0.19 (6H, s, SiCH3), 1.01 (9H, s, SiC(CH3)3), 4.45 (2H, s, 
CH2Br), 6.79 (2H, d, J = 6.5 Hz, C2-,C6-H), 7.15 (2H, d, J = 6.5 Hz, C3-,C5-
H); δC (125 MHz, CDCl3) 18.21 (C(CH3)3), 25.70 (C(CH3)3), 64.96 (CH2Br), 
120.13 (C2, C6), 128.55 (C3, C5), 133.76 (C4), 155.25 (C1). 
4-(tert-butyldimethylsilyloxy)benzaldehyde (215) 
  
The synthesis of this compound was adapted from that previously detailed by 
Weiss et al.121 4-hydroxybenzaldehyde (214) (200.1 mg, 1 eq) was dissolved 
in dry DCM (5 ml) at room temperature. Triethylamine (370 µl, 1.5 eq) was 
added, followed by TBDMSCl (321 mg, 1.2 eq). The reaction mixture was 
stirred for 2 h and monitored by TLC. The solution was diluted with DCM (50 
ml) and washed with saturated sodium bicarbonate solution (3 × 50 ml). The 
organic layer was dried over sodium sulphate and concentrated in vacuo. 
The residue was purified by silica plug, eluting with DCM, to yield the product 
as a viscous yellow oil (304 mg, 72 %). LCMS (M+H)+ found 237.1 requires 
237.1, RT 2.33 min; δH (500 MHz, CDCl3) 0.00 (6H, s, SiCH3), 0.744 (9H, s, 
SiC(CH3)3), 6.70 (2H, d, J = 3.5 Hz, C2-,C6-H), 7.55 (2H, d, J = 3.5 Hz, C3-
,C5-H), 9.60 (1H, s, CHO). 
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 (4-(tert-butyldimethylsilyloxy)phenyl)methanol (216) 
 
This compound was synthesised as previously described by Weiss et al.121 
Compound (215) (304 mg, 1 eq) was dissolved in EtOH (3 ml) at room 
temperature and NaBH4 (244 mg, 5 eq) was added. The solution was 
allowed to stir for 1 h and monitored by TLC. Once complete, the reaction 
was quenched with water (20 ml), washed with saturated sodium bicarbonate 
solution (3 × 50 ml) in DCM (50 ml) and dried over sodium sulphate. The 
solvents were removed under reduced pressure to yield the pure residue as 
a colourless oil (228 mg, 75 %). LCMS (M−OH)+ found 221.1 requires 221.1, 
RT 2.14 min; δH (500 MHz, CDCl3) 0.00 (6H, s, SiCH3), 0.80 (9H, s, 
SiC(CH3)3), 4.40 (1H, s, CH2OH), 6.63 (2H, d, J = 3.5 Hz, C2-,C6-H), 7.46 
(2H, d, J = 3.5 Hz, C3-,C5-H). 
(2E,4E,6E,8E)-4-hydroxyphenyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-
1-enyl)nona-2,4,6,8-tetraenoate (218) 
 
The mixed anhydride (148) (50.3 mg, 1 eq) was dissolved in pyridine (3 ml) 
at room temperature and the hydroquinone (217) (18.2 mg, 1.3 eq) was 
added. The solution was allowed to stir overnight. Once complete, the 
reaction was diluted with EtOAc (50 ml) and washed with saturated sodium 
bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified using silica column chromatography, eluted with 0-100 % EtOAc in 
hexane, to yield the product as a yellow solid (31 mg, 61 %). LCMS (M+H)+ 
found 393.2 requires 393.2, RT 2.78 min; HRMS ESI (M+H)+ found 
393.2426, requires 393.2424; δH (500 MHz, CDCl3) 1.08 (6H, s, C11(CH3)2), 
1.50 (2H, m, C12H2), 1.71 (2H, m, C13H2), 1.74 (3H, s, C3CH3), 2.10 (2H, m, 
C14H2), 2.20 (3H, s, C7CH3), 2.45 (3H, s, C15CH3), 5.54 (1H, br s, C4’OH), 
6.02 (1H, s, C2H), 6.79 (4H, m, C4-, C6-, C8-, C9-H), 6.78 (2H, d, J = 8.5 Hz, 
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C3’-, C5’-H), 6.95 (2H, d, J = 8.5 Hz, C2’-, C6’-H), 7.13 (1H, m, C5H); δC 
(125 MHz, CDCl3) 12.64 (C3CH3), 13.72 (C7CH3), 18.70 (C13), 21.49 
(C15CH), 28.77 (C11(CH3)2), 32.61 (C14), 33.84 (C11), 40.02 (C12), 115.47 
(C3’, C5’), 117.10 (C2), 122.47 (C2’, C6’), 128.31 (C5), 129.65 (C15), 129.75 
(C9), 132.18 (C6), 134.83 (C4), 136.86 (C8), 137.22 (C7), 139.94 (C10), 
142.52 (C1’), 154.82 (C3), 165.11 (C1); IR (cm-1) 3447, 2923, 2853, 1704, 
1602, 1579, 1580, 1448, 1376, 1348, 1238, 1185, 1143, 966, 873, 841, 777, 
721, 595, 524, 461; MP 180-182 °C. 
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-N,3,7-trimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide (220) 
 
The mixed anhydride (148) (115 mg, 1 eq) was dissolved in DMF (1 ml) and 
pyridine (200 µL) at room temperature and 4-methylaminophenol sulphate 
(219) (126 mg, 1.2 eq) was added. The solution was allowed to stir overnight 
at room temperature. Once complete by TLC, the reaction was diluted with 
EtOAc (50 ml) and washed with saturated sodium bicarbonate solution (2 × 
50 ml) and brine (2 × 50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo. The residue was purified using silica 
column chromatography, eluted with a 0-100 % EtOAc in hexane, to yield the 
product as a brown oil (22 mg, 18 %) LCMS (2M+Na)+ found 833.9, requires 
833.5, RT 2.53 min; HRMS ESI (M+Na)+ found 428.2565, C27H35NNaO2 
requires 428.2560; δH (300 MHz, CDCl3) 0.95 (6H, s, C11(CH3)2), 1.40 (2H, 
m, C12H2), 1.50 (2H, m, C13H2), 1.63 (3H, s, C3CH3), 1.88 (3H, s, C7CH3), 
1.93 (2H, t, J = 6 Hz, C14H2), 2.24 (3H, s, C15CH3), 3.24 (3H, s, NCH3) 5.54 
(1H, s, C2H), 6.02 (4H, m, C4-, C6-, C8-, C9-H), 6.71 (1H, m, C5-H), 6.76 
(2H, d, J = 8.7 Hz, C3’-, C5’H), 6.95 (2H, d, J = 8.7 Hz, C2’-, C3’-H); δC (125 
MHz; CDCl3) 12.83 (C3CH3), 14.27 (C7(CH3), 20.38 (C13), 21.96 (C15CH3), 
29.45 (C11(CH3)2), 34.62 (C14), 35.29 (C11), 37.71 (NCH3), 40.84 (C12), 
117.21 (C3’, C5’), 122.64 (C2), 124.59 (C15), 128.96 (C2’, C6’), 129.33 (C5), 
130.53 (C9), 131.13 (C6), 136.77 (C7), 136.88 (C4), 139.10 (C8), 139.16 
- 199 - 
 
(C1’), 139.41 (C10), 148.44 (C3), 158.36 (C4’), 170.01 (C1); IR (cm-1) 2951, 
1558, 1516, 1373, 1275, 1126, 974, 841. 
4-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraenylamino)phenol (226) 
 
Compound (232) (348 mg, 1 eq) was dissolved in THF and TBAF (200 µl, 1.1 
eq) was added. The reaction was allowed to stir at room temperature for 40 
minutes. Once seen to be complete by TLC, the reaction was diluted with 
EtOAc (50ml) and washed with saturated sodium bicarbonate solution (3 × 
50 ml) and brine (3 × 50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo. The residue was purified using Biotage 
silica column chromatography, eluted with 0-35 % EtOAc in hexane, to yield 
the product as a brown oil (67.2 mg, 25 %); LCMS (M-H)+ found 376.2, 
requires 376.3, RT 2.15 min; HRMS ESI (M-H)+ found 376.2661, C26H34NO 
requires 376.2635;* δH (500 MHz, CDCl3) 1.04 (6H, s, C11(CH3)2) 1.48 (2H, 
m, C12H2), 1.62 (2H, m, C13H2), 1.72 (3H, s, C15CH3), 1.90 (3H, s, C3H3), , 
1.97 (3H, s, C7CH3), 2.03 (2H, m, C14H2), 3.84 (2H, d, J = 7 Hz, C1H2), 5.64 
(1H, t, J = 7 Hz, C2H), 6.16 (4H, m, C4-, C6-, C8-, C9-H), 6.56 (2H, d, J = 
8.5 Hz, C3’, C5’-H), 6.62 (1H, m, C5-H), 6.62 (2H, d, J = 8.5 Hz, C2’, C6’-H); 
δC (125 MHz; CDCl3) 12.76 (C3CH3), 12.83 (C7CH3), 19.28 (C13), 21.79 
(C15CH3), 28.98 (C11(CH3)2), 33.07 (C14), 34.27 (C11), 39.60 (C12), 43.55 
(C1), 115.02 (C2’, C6’), 116.28 (C3’, C5’), 124.51 (C2), 126.60 (C5), 129.12 
(C9), 129.28 (C15), 130.17 (C6), 135.95 (C3), 136.40 (C4), 136.71 (C7), 
137.71 (C8), 137.84 (C10), 141.86 (C1’), 148.42 (C4’); IR (cm-1) 3003, 1708, 
1588, 1505, 1372, 1233, 964, 828, 728; MP 68-70 °C. 
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N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraenyl)aniline (228) 
 
Retinal (210) (49.1 mg, 1 eq) and aniline (149) (20 µl, 1.3 eq) were dissolved 
in methanol (3 ml) and the reaction mixture was allowed to stir at room 
temperature overnight. Sodium borohydride (74.2 mg, 1.96 eq) was added 
and allowed to stir for a further 6 h. Once complete, as observed by LCMS, 
ethyl acetate (50 ml) was added and the solution was washed with saturated 
sodium bicarbonate solution (2 × 50 ml). The organic layer was dried over 
sodium sulphate and concentrated in vacuo. The mixture was purified by 
Biotage column chromatography eluted with 0-100 % EtOAc in hexane. The 
pure compound was obtained as a brown oil (28 mg, 44 %). The compound 
was not ionised by LCMS; HRMS ESI (M-H)+ found 360.2701, C26H34N 
requires 360.2686; δH (500 MHz, CDCl3) 1.37 (6H, C11CH3), 1.48 (2H, m, 
C12H2), 1.50 (2H, m, C13H2), 1.54 (2H, C15CH3), 1.61 (3H, m, C7CH3),  
1.88 (3H, m, C3CH3), 1.89 (2H, m, C14H2), 3.59 (1H, br s, NH), 3.81 (2H, d, 
J = 6.6 Hz, C1H2), 5.43 (2H, t, J = 6.6 Hz, C2H2), 6.05 (4H, m, C4-, C6-, C8-, 
C9-H), 6.58 (2H,  m, C2’-, C6’-H), 6.64 (1H, t, J
 
= 7.5 Hz, C4’H), 7.11 (2H, 
app t, J = 7.5 Hz, C5H);  IR (cm-1) 3404, 2927, 2864, 1601, 1504, 967, 748, 
692, 510. 
tert-butyldimethyl(4-nitrophenoxy)silane (230) 
 
This compound was synthesised as previously described by Bridgeman et 
al.215 para-nitrophenol (229) (601 mg, 1 eq) and TBDMSCl  (724 mg, 1.1 eq) 
were dissolved in DCM and NEt3 (500 µl) and allowed to stir for 2 h at room 
temperature. Once seen to be complete by TLC, the reaction was diluted 
with EtOAc (50ml) and washed with saturated sodium bicarbonate solution (3 
× 50 ml) and brine (3 × 50 ml). The organic layer was dried over sodium 
sulphate and concentrated in vacuo to yield the product as a colourless 
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viscose oil (994 mg, 90 %). The product was not ionised by LCMS. δH (500 
MHz, CDCl3) 0.23 (6H, s, Si(CH3)2), 0.96 (9H, s, C(CH3)3), 6.86 (2H, d, J = 9 
Hz, C2-, C6-H), 8.10 (2H, d, J = 9 Hz, C3-, C5-H). 
4-(tert-butyldimethylsilyloxy)aniline (231) 
 
This compound was synthesised as previously described by Bridgeman et 
al.215 Tert-butyldimethyl(4-nitrophenoxy)silane (230) (994 mg, 1 eq) was 
dissolved in MeOH (10 ml) and Pd/C (50mg) was added as a solution in 
MeOH. The reaction was stirred under H2 overnight at room temperature. 
The Pd/C was filtered and the residue was concentrated in vacuo to yield the 
product as a dark brown viscose oil (790 mg, 90 %). LCMS (M+H)+ found 
224.1, requires 224.1, RT 1.62 min; δH (300 MHz, CDCl3) 0.00 (6H, s, 
Si(CH3)2), 0.82 (9H, s, C(CH3)3), 6.38 (2H, d, J = 8.7 Hz, C2-, C6-H), 6.49 
(2H, d, J = 8.7 Hz, C3-, C5-H). 
4-(tert-butyldimethylsilyloxy)-N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl)aniline (232) 
 
Retinal (210) (203 mg, 1 eq) and 4-(tert-butyldimethylsilyloxy)aniline (231) 
(183 mg, 1.1 eq) were dissolved in MeOH (5 ml) and NaBH4 (275 mg, 10 eq) 
was added. The reaction was allowed to stir at room temperature for 2 h. The 
reaction was monitored by TLC and once complete, diluted with EtOAc 
(50ml) and washed with saturated sodium bicarbonate solution (3 × 50 ml) 
and brine (3 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo to yield the product as a yellow oil (348 mg, 98 %). 
The product was not ionised by LCMS. δH (500 MHz, CDCl3) 0.61 (6H, s, 
Si(CH3)2), 0.82 (9H, s, C(CH3)2), 0.88 (6H, s, C11(CH3)2) 1.33 (2H, m, 
C12H2), 1.46 (2H, m, C13H2), 1.56 (3H, s, C15CH3), 1.76 (3H, s, C3H3), 1.85 
(2H, m, C14H2), 1.95 (3H, s, C7CH3), 3.53 (1H, br s, NH), 3.6 (2H, d, J = 6 
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Hz, C1H2), 5.45 (1H, t, J = 6 Hz, C2H), 6.01 (4H, m, C4-, C6-, C8-, C9-H), 
6.50 (5H, m, C5, C2’-, C3’, C5’, C6’-H). 
 (Z)-N',4-dihydroxybenzimidamide (235) 
 
This compound was synthesised as previously described by Porwal et al.216 
Hydroxylamine hydrochloride (3.51 g, 42.1 mmol) was added to a solution of 
hydroxybenzonitrile (234) (5.02 g, 51.7 mmol) and sodium biocarbonate 
(7.06 g, 84.0 mmol) in methanol (4 ml/mmol of nitrile) at room temperature. 
The solution was heated to reflux at 80 °C overnight. The mixture was 
analysed by LCMS and, upon completion, the methanol was removed and 
the residue triturated with deionised water, filtered and concentrated in vacuo 
to afford the pure amidoxime as a white solid (1.48 g, 23 %). LCMS (M+H)+ 
found 153.0, requires 153.1, RT 0.50 min; δH (300 MHz, DMSO) 3.32 (1H, s, 
NOH), 5.61 (1H, s, ArOH), 6.74 (2H, d, J = 8.6 Hz, C2-, C6-H), 7.49 (2H, d, J 
= 8.6 Hz, C3-, C5-H), 9.32 (1H, s, NH), 9.57 (1H, s, NH); δC (300 MHz, 
MeOH) 116.15 (C3, C5), 125.16 (C1), 128.75 (C2, C6), 155.90 (C4), 160.29 
(CN); IR (cm-1) 3440, 3315, 2431, 1645, 1505, 1392, 1285, 1185, 1119, 
1005, 835, 731, 667, 637, 609, 520; mp 149 °C. 
(2E,4E,6E,8E)-N-((E)-(hydroxyimino)(4-hydroxyphenyl)methyl)-3,7-
dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide 
(236) 
 
The mixed anhydride (148) (50.1 mg, 1 eq) was dissolved in pyridine (3 ml) 
at room temperature and 4-hydroxyphenylimidoxime (235) (24 mg, 1.2 eq) 
was added. The solution was allowed to stir overnight. Once complete, the 
reaction was diluted with EtOAc (50 ml) and washed with saturated sodium 
bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
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purified using silica column chromatography, eluted with a 0-100 % EtOAc in 
hexane, to yield the product as a yellow solid (31 mg, 55 %). LCMS (M+H)+ 
found 435.4 requires 435.2, RT 2.48 min; HRMS ESI (M+H)+ found 
435.2647, C27H35N2O3 requires 435.2642;  δH (500 MHz, CDCl3) 1.07 (6H, s, 
C11(CH3)2), 1.51 (2H, m, C12H2), 1.65 (2H, m, C13H2), 1.75 (3H, s, C3CH3), 
2.02 (3H, s, C7CH3), 2.09 (2H, m, C14H2), 2.44 (3H, s, C15CH3), 2.90 (1H, 
m, NH), 5.86 (1H, s, C2H), 6.32 (4H, m, C4-, C6-, C8-, C9-H), 6.86 (2H, d, J 
= 8.2 Hz, C3’-, C5’-H), 7.12 (1H, m, C5H), 7.48 (2H, d, J = 8.2 Hz, C2’-, C6’-
H), 7.96 (1H, d, J = 8.7 Hz, oxime-NH), 8.67 (1H, br s, OH); δC (125 MHz, 
CDCl3) 12.91 (C3CH3), 13.98 (C7CH3), 20.38 (C13), 21.96 (C15CH3), 29.46 
(C11(CH3)2), 34.05 (C14), 35.31 (C11), 40.84 (C12), 117.44 (C2), 119.92 
(C3’, C5’), 120.62 (C5), , 130.75 (C1’), 131.00 (C9), 132.25 (C6), 132.62 
(C15), 135.30 (C2’, C6’), 136.59 (C4), 139.02 (C8), 139.08 (C7), 139.14 
(C10), 140.50 (C3), 154.30 (C4’), 164.02 (CN), 170.63 (C1); IR (cm-1) 3351, 
2922, 1710, 1608, 1133, 839; MP 101-104 °C. 
7.3.4 Cyclohexyl analogues 
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-3-
oxocyclohex-1-enyl)nona-2,4,6,8-tetraenamide (3) 
 
Compound (376) (196 mg, 1 eq) and 4-aminophenol (225) (65 mg, 1.2 eq) 
were dissolved in DCM (5 ml) and pyridine (400 µl) was added. The reaction 
was allowed to stir overnight at room temperature. Once complete, the 
reaction was diluted with EtOAc (50 ml) and washed with saturated sodium 
bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified using silica column chromatography, eluted with a 0-100 % EtOAc in 
hexane, and recrystalised in MeOH to yield the product as a yellow solid (81 
mg, 41 %). LCMS (M+H)+ found 406.2, requires 406.2, RT 2.09 min; HRMS 
ESI (M+H)+  found 406.2392, C26H32NO3 requires 406.2377; δH (300 MHz, 
CDCl3) 1.12 (6H, s, C11(CH3)2), 1.79 (3H, s, C3CH3), 1.79 (2H, m, C12H2), 
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1.96 (3H, s, C7CH3), 2.35 (3H, s, C15CH3), 2.45 (2H, m, C13H2), 5.23 (1H, 
br s, OH), 5.77 (1H, s, C2H), 6.25 (4H, m, C4-, C6-, C8-, C9-H), 6.71 (2H, d, 
J = 4.8 Hz, C3’-, C5’-H), 6.90 (1H, m, C5-H), 7.31 (2H, d, J = 4.8 Hz, C2’-, 
C6’-H); δC (125 MHz; DMSO) 12.43 (C3), 13.16 (C7), 13.47 (C15CH3), 27.32 
(C11(CH3)2), 33.80 (C13), 36.89 (C12), 39.03 (C11), 115.02 (C3’, C5’), 
122.70 (C2’, C6’), 123.91(C2), 125.48 (C9), 125.79 (C15), 129.05 (C5), 
131.14 (C1’), 133.24 (C6), 137.19 (C7), 137.84 (C4), 140.36 (C8), 147.14 
(C7), 153.22 (C3), 160.48 (C4’), 164.04 (C10), 164.04 (C1), 197.80 (C14); IR 
(cm-1) 3330, 2916, 1644, 1510, 1250, 1175, 968, 826; MP 233-235 °C. 
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohex-1-
enyl)nona-2,4,6,8-tetraenoic acid (7) 
 
Compound (245) was dissolved in 1:1 MeOH:THF solution (5 ml) and 10 % 
NaOH solution was added. The reaction was allowed to stir at room 
temperature overnight. 20 % HCl (2 ml) solution was added and the product 
formed a yellow precipitate. The product was purified using Biotage silica 
column chromatography, eluted with a 0-100 % EtOAc in hexane, to yield the 
product as a yellow solid (15 mg, 17 %) LCMS (M+H)+ found 315.2, requires 
315.2, RT 2.06 min; δH (300 MHz, CDCl3) 1.21 (6H, s, C11(CH3)2), 1.78 (3H, 
s, C3CH3), 1.78 (2H, m, C13H2), 1.97 (3H, s, C7CH3), 2.30 (3H, s, C15CH3), 
2.45 (2H, m, C14H2), 5.77 (1H, s, C2H), 6.27 (4H, m, C4-, C6-, C8-, C9-H), 
6.94 (1H, m, C5-H). 
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-9-((E)-3-(methoxyimino)-2,6,6-
trimethylcyclohex-1-enyl)-3,7-dimethylnona-2,4,6,8-tetraenamide (243) 
 
4-Oxo-fenretinide (3) (50 mg, 1 eq) and methoxylamine hydrochloride (12 
mg, 1.1 eq) were dissolved in EtOH (3 ml) and the reaction was stirred at 
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room temperature. After 72 h the reaction was seen to be complete by 
LCMS. The residue was concentrated in vacuo to yield the product as a 
yellow solid (27 mg, 50 %). LCMS (M+H)+ found 435.4, requires 435.3, RT 
2.41 min; HRMS ESI (M+H)+  found 435.2652, C27H35N2O3 requires 
435.2642; δH (300 MHz, CDCl3) 1.10 (6H, s, C11(CH3)2), 1.59 (2H, t, J = 6.6 
Hz, C12H2), 1.92 (3H, s, C3CH3), 2.04 (3H, s, C7CH3), 2.39 (3H, s, 
C15CH3), 2.60 (2H, t, J = 6.6 Hz, C13H2), 5.86 (1H, s, OH), 6.00 (1H, s, 
C2H), 6.30 (4H, m, C4-, C6-, C8-, C9-H), 6.75 (2H, d, J = 8.7 Hz, C2’-, C6’-
H), 7.04 (1H, m, C5-H), 7.39 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 7.94 (1H, br d, 
J = 15.3 Hz, NH); δC (125 MHz; CDCl3) 12.82 (C15), 13.91 (C3), 15.29 (C7), 
23.03 (C13), 28.12 (C11(CH3)2), 35.80 (C11), 37.40 (O12), 62.03 (OCH3), 
116.26 (C3’, C5’), 123.17 (C2’, C6’), 123.72 (C2), 126.39 (C15), 127.74 (C9), 
130.69 (C5), 132.05 (C1’), 132.75 (C6), 138.08 (C4), 139.06 (C7), 140.48 
(C8), 150.09 (C3), 150.23 (C4’), 155.27 (C4), 157.74 (C10), 167.48 (C1); IR 
(cm-1) 3291, 2929, 1607, 1511, 1050, 832; MP 108-111 °C. 
(2E,4E,6E,8E)-methyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-
enyl)nona-2,4,6,8-tetraenoate (244) 
 
Synthesis of this compound was adapted from that previously described by 
Patel, et. al.100 Retinoic acid (6) (500 mg, 1 eq) was dissolved in MeOH (10 
ml) and TMSCH2N2 (2 M in hexanes) (1 ml) was added. The reaction was 
allowed to stir at room temperature overnight. The reaction was seen to have 
not proceeded to completion by TLC, therefore additional TMSCH2N2 (2 M in 
hexanes) (2 ml) was added and the reaction was allowed to stir for a further 
2 h. The reaction was seen to be complete by TLC and the volatiles were 
removed under reduced pressure to yield the product as a yellow oil (523 
mg, 100 %). 
OR 
Retinoic acid (6) (2 g, 1 eq) and  K2CO3 (2 g, 2 eq) were dissolved in DMF 
(20 ml) and iodomethane
 
(11 ml, 11.6 eq) was added under N2. The reaction 
was allowed to stir overnight at room temperature. The reaction was seen to 
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be complete by TLC and was diluted with EtOAc (50 ml), washed with 
deionised water (2 × 50 ml) and brine (2 × 50 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo to yield the product as 
a yellow oil (2.1 g, 100 %).Product did not ionise by LCMS. δH (300 MHz, 
CDCl3) 1.04 (6H, s, C11(CH3)2), 1.48 (2H, m, C12H2), 1.63 (2H, m, C13H2), 
1.72 (3H, s, C3CH3), 2.01 (3H, s, C7CH3), 2.03 (2H, m, C14H2), 2.37 (3H, s, 
C15CH3), 3.72 (3H, s, OCH3), 5.79 (1H, s, C2H), 6.17 (4H, m, C4-, C6-, C8-, 
C9-H), 7.01 (1H, m, C5-H). 
(2E,4E,6E,8E)-methyl 3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohex-1-
enyl)nona-2,4,6,8-tetraenoate (245) 
 
This compound was synthesised as previously described by Patel, et. al.100 
Compound (244) (2.1 g, 1 eq) was dissolved in DCM (200 ml) and MnO2 (30 
g, 50 eq) was added. The reaction was allowed to stir at room temperature 
for 72 h. The reaction was seen to be complete by TLC and the MnO2 was 
removed by filtration through Celite. The filtrate was concentrated in vacuo to 
yield the product as a yellow oil (1.4 g, 64 %). The product was not ionised 
by LCMS. δH (300 MHz, CDCl3) 1.12 (6H, s, C11(CH3)2), 1.78 (3H, s, 
C3CH3), 1.78 (2H, m, C13H2), 1.96 (3H, s, C7CH3), 2.29 (3H, s, C15CH3), 
2.44 (2H, m, C14H2), 3.65 (3H, s, OCH3), 5.75 (1H, s, C2H), 6.32 (4H, m, 
C4-, C6-, C8-, C9-H), 6.92 (1H, m, C5-H). 
(2E,4E,6E,8E)-9-((E)-3-(ethoxyimino)-2,6,6-trimethylcyclohex-1-enyl)-N-
(4-hydroxyphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide (246) 
 
4-Oxo-fenretinide (3) (40 mg, 1 eq) and O-ethylhydroxylamine (11 mg, 1.1 
eq) were dissolved in EtOH (3 ml) and the reaction was allowed to stir 
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overnight at room temperature. The reaction was seen to be complete by 
LCMS. The residue was concentrated in vacuo and purified by Biotage silica 
column chromatography, eluted with a 0-100 % EtOAc in hexane, to yield the 
product as a brown oil (35 mg, 79 %). LCMS (M+H)+ found 449.3, requires 
449.3, RT 2.51 min; HRMS ESI (M+H)+ found 449.2811,  C28H37N2O3 
requires 449.2799; δH (500 MHz, CDCl3) 1.07 (6H, s, C11(CH3)2), 1.22 (3H, 
t, J = 6.9 Hz, C17-H), 1.51 (2H, t, J = 6.9 Hz, C12H2), 1.86 (3H, s, C3CH3), 
1.94 (3H, s, C7CH3), 2.33 (3H, s, C15CH3), 2.55 (2H, t, J = 6.9 Hz, C14H2), 
4.09 (2H, q, J = 6.9 Hz, C16-H), 5.08 (2H, s, C16-H), 5.75 (1H, s, C2H), 6.18 
(4H, m, C4-, C6-, C8-, C9-H), 6.67 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 6.17 (1H, 
m, C5-H), 7.23 (2H, d, J = 6.9 Hz, C2’-, C6’-H); δC (75 MHz; CDCl3) 12.81 
(C15CH3), 13.76 (C3CH3), 14.74 (CH2CH3), 14.95 (C7CH3), 20.12 (C13), 
27.69 (C11(CH3)2), 34.78 (C11), 36.29 (C12), 69.41 (OCH2), 115.85 (C3’, 
C5’), 121.93(C2’), 122.75 (C2’, C6’), 125.63 (C15), 127.01 (C9), 129.93 (C5), 
130.22 (C1’), 131.25 (C6), 136.44 (C4), 138.32 (C7), 138.87 (C8), 148.34 
(C3), 150.02 (C4’), 153.39 (C14), 156.61 (C10), 165.76 (C1); IR (cm-1) 3280, 
2923, 1510, 1161, 1050, 961, 831. 
(2E,4E,6E,8E)-9-((E)-3-(benzyloxyimino)-2,6,6-trimethylcyclohex-1-enyl)-
N-(4-hydroxyphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide (247) 
 
4-Oxo-fenretinide (3) (49 mg, 1 eq) and O-benzylhydroxylamine 
hydrochloride (21 mg, 1.1 eq) were dissolved in EtOH (3 ml) and the reaction 
was allowed to stir overnight at room temperature. The reaction was seen to 
be complete by LCMS. The residue was concentrated in vacuo and purified 
by Biotage silica column chromatography eluted, with a 0-100 % EtOAc in 
hexane, to yield the product as a yellow solid (47 mg, 76 %). LCMS (M+H)+ 
found 511.3, requires 511.3, RT 2.57 min; HRMS ESI (M+H)+ found 
511.2968, C33H39N2O3 requires 511.2955; δH (500 MHz, CDCl3) 0.99 (6H, s, 
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C11(CH3)2), 1.49 (2H, t, J = 6.6 Hz, C12H2), 1.83 (3H, s, C3CH3), 1.89 (3H, 
s, C7CH3), 2.30 (3H, s, C15CH3), 2.58 (2H, t, J = 6.6 Hz, C13H2), 5.08 (2H, 
s, C16H), 5.75 (1H, s, C2H), 6.14 (4H, m, C4-, C6-, C8-, C9-H), 6.65 (2H, d, 
J = 8.4 Hz, C3’-, C5’-H), 6.85 (1H, m, C5-H), 7.26 (7H, m, C18-22-, C2’-, C6’-
H), 7.52 (1H, s, OH); δC (75 MHz; CDCl3) 12.83, 13.77, 14.98, 20.29, 27.69, 
34.81, 36.20, 76.05, 115.86, 121.91, 122.76, 125.51, 126.94, 127.68, 
128.20, 128.29, 129.95, 130.24, 131.32, 136.47, 138.22, 138.31, 138.96, 
148.79, 150.06, 153.38, 157.25, 165,74;  IR (cm-1) 3479, 3357, 2924479, 
3357, 2924, 1707, 1573, 1514, 1246, 1195, 1116, 964; MP 101-103 °C. 
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-((Z)-2,6,6-trimethyl-3-
(2-methylhydrazono)cyclohex-1-enyl)nona-2,4,6,8-tetraenamide (248) 
 
4-Oxo-fenretinide (3) (50 mg, 1 eq) and methylhydrazine (7.5 µl, 1.1 eq) were 
dissolved in EtOH (3 ml). Acetic acid (3 drops) was added and the reaction 
was stirred at room temperature for a 72 h when it was seen to be complete 
by LCMS. The residue was concentrated in vacuo to yield the product as a 
yellow solid (23 mg, 46 %). LCMS (M+H)+ found 434.4, requires 434.3, RT 
1.86 min; HRMS ESI (M+H)+  found 434.2797, C32H38N3O2 requires 
434.2802; δH (300 MHz, CDCl3) 0.99 (6H, s, C11(CH3)2), 1.76 (2H, m, 
C12H2), 1.82 (3H, s, C3CH3), 1.92 (3H, s, C7CH3), 2.27 (3H, s, C15CH3), 
2.80 (2H, m, C14H2), 2.80 (3H, s, NHCH3), 6.00 (1H, s, C2H), 3.21 (1H, m, 
NH), 5.88 (1H, s, C2-H), 6.21 (4H, m, C4-, C6-, C8-, C9-H), 6.64 (2H, d, J = 
8.7 Hz, C17-H), 6.93 (1H, m, C5-H), 7.28 (2H, d, J = 8.7 Hz, C3’-, C5’-H); δC 
(125 MHz; CDCl3) 12.71 (C15CH3), 13.90 (C3CH3), 14.00 (C7CH3), 24.47 
(C13), 27.95 (C11(CH3)2), 35.18 (C11), 36.93 (NHCH3), 38.41 (C12), 116.31 
(C3’, C5’), 123.16 (C2’, C6’), 123.65 (C2), 124.31 (C9), 126.58 (C5), 130.48 
(C6), 130.76 (C15), 132.07 (C1’), 134.60 (C4), 138.63 (C7), 139.18 (C8), 
142.43 (C14), 150.06 (C3), 155.38 (C10), 164.17 (C4’), 167.47 (C1); IR (cm-
1) 3287, 2920, 2851, 1640, 1440, 1225, 1165, 966, 831; MP 79-82 °C. 
- 209 - 
 
(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-((Z)-2,6,6-trimethyl-3-
(2-phenylhydrazono)cyclohex-1-enyl)nona-2,4,6,8-tetraenamide (249) 
 
4-Oxo-fenretinide (3) (20 mg, 1 eq) and phenylhydrazine (9 mg, 1.1 eq) were 
dissolved in EtOH (3 ml) and the reaction was stirred at room temperature. 
The reaction was seen to be partially complete by LCMS after 48h. Acetic 
acid (3 drops) was added and the reaction was stirred for a further 72 h when 
it was seen to be complete by LCMS. The residue was concentrated in 
vacuo to yield the product as a yellow solid (4 mg, 16 %). LCMS (M+H)+ 
found 496.4, requires 496.3, RT 2.42 min; HRMS ESI (M+H)+  found 
496.2960, C32H38N3O2 requires 496.2959;  δH (300 MHz, CDCl3) 1.16 (6H, s, 
C11(CH3)2), 1.74 (2H, t, J = 6.6 Hz, C12H2), 2.07 (3H, s, C3CH3), 2.09 (3H, 
s, C7CH3), 2.39 (3H, s, C15CH3), 2.57 (2H, t, J = 6.6 Hz, C13H2), 6.00 (1H, 
s, C2H), 6.34 (4H, m, C4-, C6-, C8-, C9-H), 6.76 (2H, d, J = 8.8 Hz, C3’, 5’-
H), 7.07 (1H, m, C5-H), 7.12 (4H, m, C2’’-, C3’’-, C5’’-, C6’’-H), 7.39 (2H, d, J 
= 8.8 Hz, C2’-, C6’-H), 7.40 (1H, m, C4’’H), 7.78 (1H, br s, NH); δC (125 MHz; 
CDCl3) 12.85 (C15CH3), 13.94 (C3CH3), 15.61 (C7CH3), 21.89 (C13), 28.33 
(C11(CH3)2), 35.49 (C11), 37.96 (C12), 114.07 (C2’’, 6’’), 117.31 (C3’, C5’), 
120.19 (C2), 123.17 (C2’, C6’), 123.26 (C4’’), 123.48 (C5), 128.68 (C9), 
129.93 (C3’’, C5’’), 130.15 (C1’), 130.24 (C7), 130.94 (C15), 132.20 (C6), 
137.68 (C4), 139.57 (C8), 145.63 (C1’’), 145.92 (C4), 147.81 (C3), 150.43 
(C10), 155.32 (C4’), 167.65 (C1); IR (cm-1) 3316, 2922, 1510, 1306, 1162, 
831; MP 174-178 °C. 
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tert-butyl 2-(1,3-dioxoisoindolin-2-yloxy)ethylcarbamate (355) 
 
This compound was synthesised as previously described by Takeda 
Pharmaceutical company Ltd.217 N-Boc-ethanol amine (354) (1.4 g, 1 eq), N-
hydroxypthalimide (1.6 g, 1.1 eq) and PPh3 (2.5 g, 1.1 eq) were dissolved in 
dry THF (50 ml) under N2 and cooled to −5 °C. DIAD (2.35 ml, 1.3 eq) was 
dissolved in dry THF (15 ml) and slowly added to the reaction. The reaction 
was stirred at −5 °C for 10 minutes and subsequently allowed to warm to 
room temperature to stir overnight. The residue was concentrated in vacuo 
and purified using Biotage silica column chromatography eluted with a 
hexane / EtOAc gradient (1:0 to 0:1) and recrystalised in Et2O to yield the 
product as colourless crystals (902 mg, 36 %). LCMS (M+H)+ found 207.0, 
requires 207.1, RT 1.87 min; δH (300 MHz, CDCl3) 1.36 (9H, s, CCH3)3), 3.35 
(2H, t, J = 4.2 Hz, NHCH2), 4.15 (2H, t, J = 4.2 Hz, OCH2), 5.62 (1H, s, NH), 
7.71 (4H, m, ArCH); δC (125 MHz; CDCl3) 28.78 (C(CH3), 39.89 (NHCH2), 
76.10 (OCH2), 80.32 (C(CH3)3), 124.46 (C2’, C5’), 129.56 (C1, C6), 131.34 
(C3, C4), 131.54 (C1/C6-CO), 133.47 (CO). 
tert-butyl 2-(aminooxy)ethylcarbamate (356) 
 
Synthesis of this compound was adapted from that previously described by 
Takeda Pharmaceutical company Ltd.217 Compound (355) (450 mg, 1 eq) 
was dissolved in MeOH (10 ml) and hydrazine monohydrate (1 ml, 2 eq) was 
added. The reaction was allowed to stir at room temperature overnight and 
once seen to be complete, the product was isolated by removal of solvents 
and excess hydrazine under reduced pressure (246 mg, 90 %). The product 
did not ionise by LCMS. δH (300 MHz, CDCl3) 1.26 (C(CH3)3), 3.15 (2H, q, J 
= 5.1 Hz, NHCH2), 3.51 (2H, t, J = 5.1 Hz, OCH2), 5.33 (1H, br s, NH). 
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tert-butyl 2-((Z)-3-((1E,3E,5E,7E)-9-(4-hydroxyphenylamino)-3,7-
dimethyl-9-oxonona-1,3,5,7-tetraenyl)-2,4,4-trimethylcyclohex-2-
enylideneaminooxy)ethylcarbamate (357) 
 
4-oxo-fenretinide (3) (51 mg, 1 eq) and compound 356 (25 mg, 1.1 eq) were 
dissolved in EtOH (5 ml). Acetic acid (2 drops) was added and the reaction 
was stirred at room temperature for a 72 h when it was seen to be complete 
by LCMS. The reaction was diluted with EtOAc (20 ml) and washed with 
saturated sodium bicarbonate solution (3 × 20 ml) and brine (3 × 20 ml). The 
organic layer was dried over sodium sulphate and concentrated in vacuo. 
The residue was purified by Biotage silica column chromatography, eluted 
with a 0-100 % EtOAc in hexane, to yield the product as a yellow solid (30 
mg, 42 %).  
OR 
4-Oxo-fenretinide (3) (70 mg, 1 eq) and compound 356 (11 mg, 1.1 eq) were 
dissolved in EtOH (3 ml) and the reaction was heated to 100 °C at 200 bar 
by microwave radiation. After 72 h the reaction was seen to be complete by 
LCMS. The product was concentrated in vacuo to yield the product as a 
yellow solid (45 mg, 45 %). LCMS (M+H)+ found 564.5, requires 564.4, RT 
2.40 min; HRMS ESI (M+H)+  found 564.3448, C33H46N3O2 requires 
564.3432; δH (500 MHz, CDCl3) 1.09 (6H, s, C11(CH3)2), 1.47 (9H, s, 
C(CH3)3), 1.60 (2H, t, J = 6.0 Hz, C12H2), 1.91 (3H, s, C3CH3), 2.02 (3H, s, 
C7CH3), 2.41 (3H, s, C15CH3), 2.62 (2H, t, J = 6.0 Hz, C13H2), 3.45 (2H, br 
m, C16-H), 4.15 (1H, m, C15-H), 5.15 (1H, br s, OH), 5.85 (1H, s, C2H), 6.26 
(4H, m, C4-, C6-, C8-, C9-H), 6.78 (2H, d, J = 8.7 Hz, C3’-, C5’-H),  6.94 (1H, 
m, C5-H), 7.34 (2H, d, J = 8.7 Hz, C2’-, C6’-H), 7.53 (1H, s, C17NH) 7.93 
(1H, app d, J = 15 Hz, C1NH); δC (125 MHz; CDCl3) 12.82 (C15CH3), 13.72 
(C3), 14.90 (C7), 20.06 (C13), 27.66 (C11(CH3)2), 28.44 (C(CH3)3), 34.84 
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(C11), 36.12 (NHCH2), 40.98 (C12), 72.62 (OCH2), 79.39 (C(CH3)3), 115.80 
(C3’, C5’), 122.15 (C2), 122.38 (C2’, C6’), 125.21 (C15), 126.75 (C9), 129.77 
(C5), 130.43 (C1’), 131.43 (C6), 136.61 (C4), 138.14 (C7), 139.10 (C8), 
149.25 (C4), 149.79 (C4’), 153.41 (OCO), 156.17 (C14), 157.46 (C15), 
165.48 (C1); IR (cm-1) 3306, 2925, 1724, 1673, 1510, 1267, 1122; MP 122-
125 °C. 
(2E,4E,6E,8E)-9-((E)-3-(2-aminoethoxyimino)-2,6,6-trimethylcyclohex-1-
enyl)-N-(4-hydroxyphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide (358) 
 
Compound 357 (56 mg) was dissolved in DCM (3 ml) and TFA (1 ml) was 
added. The reaction was allowed to stir at room temperature for 1 h, when it 
was seen to be complete by LCMS. The reaction was diluted with EtOAc (50 
ml) and washed with saturated sodium bicarbonate solution (3 × 50 ml). The 
organic layer was dried over sodium sulphate and concentrated in vacuo. 
Trituration with EtOAc yielded the clean product as a yellow solid (35 mg, 76 
%). LCMS (M+H)+ found 464.3, requires 464.3, RT 1.71 min; HRMS ESI 
(M+H)+  found 464.2917, C28H38N3O3 requires 464.2908; δH (500 MHz, 
CDCl3) 0.98 (6H, s, C11(CH3)2), 1.47 (2H, m, C12H2), 1.81 (3H, s, C3CH3), 
1.92 (3H, s, C7CH3), 2.23 (3H, s, C15CH3), 2.53 (2H, m, C13H2), 3.20 (2H, 
m, C16-H), 4.02 (1H, m, C15-H), 4.21 (2H, m NH2), 5.90 (1H, s, C2H), 6.21 
(4H, m, C4-, C6-, C8-, C9-H), 6.64 (2H, d, J = 8.1 Hz, C3’-, C5’-H),  6.81 (1H, 
m, C5-H), 7.28 (2H, d, J = 8.1 Hz, C2’-, C6’-H); δC (125 MHz; CDCl3) 12.93 
(C15CH3), 14.03 (C3CH3), 15.57 (C7CH3), 21.21 (C13), 28.28 (C11(CH3)2), 
36.02 (C11), 37.51 (NH2CH2), 40.74 (C12), 74.25 (OCH2), 116.38 (C3’, C5’), 
123.22 (C2’, C6’), 123.91 (C2), 123.96 (C15), 127.85 (C9), 130.77 (C5), 
132.16 (C1’), 132.96 (C6), 138.38 (C4), 139.09 (C7), 140.68 (C8), 150.35 
(C3), 155.40 (C4’), 158.37 (C14), 159.81 (C15), 167.59 (C1) ; IR (cm-1) 
3650, 3305, 2923, 1509, 1447, 1363, 1167, 1065, 969, 833; MP 119-122 °C. 
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tert-butyl 2-hydrazinyl-2-oxoethylcarbamate (361) 
 
N-Boc-glycine methylester (360) (500 mg, 1 eq) was dissolved in MeOH (10 
ml) and hydrazine monohydrate (1 ml, 12 eq) was added. The reaction was 
allowed to stir at room temperature overnight and once seen to be complete, 
the product was isolated by removal of solvents and excess hydrazine under 
reduced pressure (503 mg, 100 %). LCMS (M+Na)+ found 212.0, requires 
212.1, RT 0.62 min; δH (500 MHz, CDCl3) 1.37 (9H, s, C(CH3)3), 3.74 (2H, d, 
J = 6.3 Hz, CH2), 4.02 (2H, br s, NH2), 5.94 (1H, br s, NHNH2), 7.28 (1H, br 
s, CH2NH); δC (75 MHz; CDCl3) 28.71 (C(CH3)3, 43.39 (CH2), 80.74 
(C(CH3)3), 158.39 (OCO), 171.81 (CH2CO); MP 94-98 °C. 
tert-butyl 2-((E)-2-(3-((1E,3E,5E,7E)-9-(4-hydroxyphenylamino)-3,7-
dimethyl-9-oxonona-1,3,5,7-tetraenyl)-2,4,4-trimethylcyclohex-2-
enylidene)hydrazinyl)-2-oxoethylcarbamate (362) 
 
4-Oxo-fenretinide (3) (70 mg, 1 eq) and compound 361 (33 mg, 1 eq) were 
dissolved in EtOH (3 ml) the reaction was heated by microwave radiation 
(100 °C, 200 bar) for 24 h. A further quantity of compound 361 (60 mg, 1.8 
eq) was added and the reaction was heated for a further 48 h until seen to be 
complete by LCMS. The residue was purified by Biotage, eluted with a 0-100 
% EtOAc in hexane, to yield the product as a yellow solid (45 mg, 45 %). 
LCMS (M+H)+ found 577.4, requires 577.3, RT 2.43 min;  HRMS ESI (M+H)+ 
found 577.3402, C33H44N4O5 requires 577.3384; δH (500 MHz, CDCl3) 1.10 
(6H, s, C11(CH3)2), 1.48 (9H, s, C(CH3)3)), 1.69 (2H, m, C12H2), 1.91 (3H, s, 
C3CH3), 2.02 (3H, s, C7CH3), 2.35 (2H, m, C13H2), 2.40 (3H, s, C15CH3), 
3.91 (1H, br s, OH), 4.35 (2H, d, J = 4.2 Hz, NHCH2), 5.44 (1H, s, NNH), 
5.86 (1H, s, C2H), 6.26 (4H, m, C4-, C6-, C8-, C9-H), 6.78 (2H, d, J = 8.7 Hz, 
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C3’-, C5’-H),  6.94 (1H, m, C5-H), 7.37 (2H, d, J = 8.7 Hz, C2’-, C6’-H), 7.68 
(1H, s C17NH), 8.74 (1H, s, C1NH); δC (125 MHz; CDCl3) 12.81 (C15), 13.69 
(C3), 15.04 (C7), 20.58 (C13), 27.58 (C11(CH3)2), 28.31 (C(CH3)3), 34.68 
(C11), 35.85 (C12), 42.50 (C17), 79.86 (C(CH3)3), 115.77 (C3’, C5’), 122.21 
(C2’, C6’), 126.50 (C2), 126.75 (C9), 127.59 (C15), 129.70 (C5), 130.67 
(C1’), 131.81 (C6), 136.84 (C4), 138.02 (C7), 139.42 (C8), 149.72 (C14), 
150.45 (C3), 150.98 (C10), 153.20 (C4’), 156.18 (OCO), 165.30 (C1), 171.38 
(NHCO) ; IR (cm-1) 3306, 2958, 2925, 2857, 1724, 1510, 1267, 1122; MP 
122-125 °C. 
(2E,4E,6E,8E)-9-((E)-3-(2-(2-aminoacetyl)hydrazono)-2,6,6-
trimethylcyclohex-1-enyl)-N-(4-hydroxyphenyl)-3,7-dimethylnona-
2,4,6,8-tetraenamide (363) 
 
Compound 362 (34 mg) was dissolved in DCM (10 ml) and TFA (5 ml) was 
added. The reaction was allowed to stir for 1 h at room temperature. The 
solvents were removed under reduced pressure, the residue was dissolved 
in EtOAc (20 ml) and washed with saturated sodium bicarbonate solution (3 
× 20 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified by HPLC to yield the 
product as a yellow solid consisting of 4 isomers (10 mg, 37 %); LCMS 
(M+H)+ found 477.3, requires 477.3; δH (500 MHz, MeOD) (Major isomer) 
1.03 (6H, s, C11(CH3)2), 1.61 (2H, m, C12H2), 1.86 (3H, s, C3CH3), 1.95 
(3H, s, C7CH3), 2.28 (3H, s, C15CH3), 2.40 (2H, m, C13H2), 4.04 (2H, d, J = 
4.2 Hz, NHCH2), 5.90 (1H, s, C2H), 6.30 (4H, m, C4-, C6-, C8-, C9-H), 6.64 
(2H, d, J = 8.7 Hz, C3’-, C5’-H),  6.95 (1H, m, C5-H), 7.27 (2H, d, J = 8.7 Hz, 
C2’-, C6’-H); δC (125 MHz; MeOD) (Major isomer) 13.13 (C15CH3), 14.26 
(C3CH3), 15.87 (C7CH3), 22.96 (C13), 28.33 C11(CH3)2, 36.16 (C11), 37.66 
(C12), 41.89 (C17), 116.64 (C3’, C5’), 123.50 (C2’, C6’), 124.21 (C15), 
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128.00 (C2), 131.00 (C9), 132.39 (C5), 133.47 (C6), 138.66 (C1’), 139.35 
(C7), 141.15 (C8), 150.50 (C14), 152.84 (C3), 154.50 (C14), 155.70 (C1’), 
167.87 (C1O), 169.84 (CO).
 
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohex-1-
enyl)nona-2,4,6,8-tetraenoic pivalic anhydride (367) 
 
Compound (7) (240 mg, 1 eq) and triethylamine (150 µl) were dissolved in 
EtOAc (5 ml). Trimethyl acetyl chloride (147) (150 µl, 1.7 eq) was added and 
the mixture was allowed stir for 2 h. The reaction was seen to be complete 
by TLC after 30 minutes. The reaction was diluted with EtOAc (50 ml) and 
was washed with 20 % HCl (2 × 50 ml) and saturated sodium bicarbonate 
solution (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo to yield the pure compound as a yellow oil (93 mg, 31 
%). The compound was not ionised by LCMS; δH (300 MHz, CDCl3) 1.05 
(6H, s, C11(CH3)2), 1.26 (9H, s, C(CH3)3), 1.85 (3H, s, C3CH3), 1.85 (2H, m, 
C12H2), 2.05 (3H, s, C7CH3), 2.40 (3H, s, C15CH3), 2.51 (2H, m, C13H2), 
5.78 (1H, s, C2H), 6.34 (4H, m, C4-, C6-, C8-, C9-H), 7.01 (1H, m, C5-H). 
(2E,4E,6E,8E)-N-(4-methoxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-3-
oxocyclohex-1-enyl)nona-2,4,6,8-tetraenamide (368) 
 
Compound (367) (194 mg, 1 eq) and para-methoxyaniline (150) (137 mg, 1.2 
eq) were dissolved in DCM (10 ml) and pyridine (1 µl) was added. The 
reaction was allowed to stir overnight at room temperature. Once complete, 
the reaction was diluted with EtOAc (50 ml) and washed with saturated 
sodium bicarbonate solution (2 × 50 ml) and brine (2 × 50 ml). The organic 
layer was dried over sodium sulphate and concentrated in vacuo. The 
residue was purified using Biotage silica column chromatography, eluted with 
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a 0-30 % EtOAc in hexane, as a yellow solid (59 mg, 23 %). LCMS (M+H)+ 
found 420.5, requires 420.3, RT 2.28 min; HRMS ESI (M+H)+  found 
420.2545, C27H34NO3 requires 420.2533;  δH (300 MHz, CDCl3) 1.20 (6H, s, 
C11(CH3)2), 1.26 (2H, m, C12H2), 1.88 (3H, s, C3CH3), 2.03 (3H, s, C7CH3), 
2.41 (3H, s, C15CH3), 2.52 (2H, d, J = 6.3 Hz, C13H2), 3.77 (3H, s, OCH3), 
5.91 (1H, s, C2H), 6.29 (4H, m, C4-, C6-, C8-, C9-H), 6.84 (2H, d, J = 8.7 Hz, 
C3’-, C5’-H), 6.93 (1H, m, C5-H), 7.50 (2H, d, J = 4.8 Hz, C2’-, C6’-H), 7.98 
(1H, s, NH); δC (75 MHz; CDCl3) 12.72 (C3CH3), 13.59 (C7CH3), 13.85 
(C15CH3), 27.61 (C11(CH3)2), 34.28 (C13), 35.75 (C11), 37.30 (C12), 55.44 
(OCH3), 114.08 (C3’, C5’), 121.54 (C2’, C6’), 123.07 (C2), 125.50 (C9), 
129.19 (C5), 129.92 (C5), 131.61 (C15), 133.10 (C6), 137.31 (C7), 137.78 
(C4), 140.77 (C8), 149.20 (C3), 156.20 (C4’), 161.32 (C10), 165.00 (C1), 
195.50 (C14); IR (cm-1) 3331, 2923, 1641, 1438, 1110, 965, 832; MP 153-
156 °C. 
tert-butyl 2-((Z)-3-((1E,3E,5E,7E)-9-(4-methoxyphenylamino)-3,7-
dimethyl-9-oxonona-1,3,5,7-tetraenyl)-2,4,4-trimethylcyclohex-2-
enylideneaminooxy)ethylcarbamate (369) 
 
Compound 368 (25 mg, 1 eq) and compound 356 (13 mg, 1.1 eq) were 
dissolved in EtOH (2 ml). Acetic acid (2 drops) was added and the reaction 
was stirred at room temperature for a 72 h when it was seen to be complete 
by LCMS. The reaction was diluted with EtOAc (20 ml) and washed with 
saturated sodium bicarbonate solution (3 × 20 ml) and brine (3 × 20 ml). The 
organic layer was dried over sodium sulphate and the residue was 
concentrated in vacuo to yield the product as a yellow solid (17 mg, 49 %). 
LCMS (M+H)+ found 578.6, requires 578.4, RT 2.58 min; HRMS ESI (M+H)+  
found 578.3602, C34H48N3O5 requires 578.3588; δH (500 MHz, CDCl3) 0.98 
(6H, s, C11(CH3)2), 1.47 (9H, s, C(CH3)3), 1.60 (2H, t, J = 6.6 Hz, C12H2), 
1.92 (3H, s, C3CH3), 2.04 (3H, s, C7CH3), 2.43 (3H, s, C15CH3), 2.63 (2H, t, 
- 217 - 
 
J = 6.6 Hz, C13H2), 3.46 (2H, br m, C17-H2), 3.80 (3H, s, OCH3), 4.18 (1H, t, 
J = 4.8 Hz, C16-H2), 5.1 (1H, br s, C1NH), 5.84 (1H, s, C2H), 6.26 (4H, m, 
C4-, C6-, C8-, C9-H), 6.87 (2H, d, J = 8.7 Hz, C3’-, C5’-H),  6.97 (1H, m, C5-
H), 7.36 (1H, s, C17NH), 7.49 (2H, d, J = 8.7 Hz, C2’-, C6’-H); δC (125 MHz; 
CDCl3) 12.83 (C15CH3), 13.65 (C3CH3), 14.87 (C7CH3), 20.05 (C13), 27.67 
(C11(CH3)2), 28.44 (C(CH3)3), 34.85 (C11), 36.15 (NHCH2), 40.98 (C12), 
55.49 (OCH3), 72.72 (OCH2), 79.17 (C(CH3)3), 114.16 (C3’, C5’), 121.54 
(C2’, C6’), 122.13 (C2), 125.26 (C15), 126.81 (C9), 129.74 (C5), 131.36 
(C6), 131.46 (C11), 136.56 (C4), 138.16 (C7), 139.05 (C8), 149.14 (C3), 
149.79 (C10), 155.99 (OCO), 156.30 (C14), 157.35 (C4’), 164.92 (C1); IR 
(cm-1) 3309, 2930, 1710, 1642, 1510, 1242, 1167, 953, 798; MP 168-170 °C. 
7.3.5 Non-retinoid analogues 
N-(4-(4-hydroxyphenylcarbamoyl)phenyl)-3-methylbenzamide (251) 
N
H
N
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O
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Compound 339 (33 mg) was dissolved in THF (3 ml) and TBAF (1 ml) was 
added. The reaction was allowed to stir for 30 min at room temperature and, 
once complete by TLC, reaction was diluted with EtOAc (50 ml) and washed 
with saturated sodium bicarbonate solution (3 × 50 ml).  The organic layer 
was dried over sodium sulphate and the residue was concentrated in vacuo 
to yield the product as a white solid (22 mg, 89 %). The product did not 
ionise by LCMS; HRMS ESI (M+H)+ found 347.1397, C21H19N2O3 requires 
347.1390; δH (300 MHz, (CD3)2SO) 2.23 (3H, s, CH3), 6.58 (2H, d, J = 9 Hz, 
C3-, C5-H), 7.21 (2H, m, C5’’-, C4’’-H), 7.24 (2H, d, J = 9 Hz, C2-, C6-H), 
7.52 (2H, m, C2’’-, C6’’-H),  7.66 (2H, d, J = 9 Hz, C2’-, C6’-H) 7.73 (2H, d, J 
= 9 Hz, C3’-, C5’-H); δC (75 MHz; CDCl3) 20.94 (CH3), 114.93 (C3, C5), 
119.36 (C3’, C5’), 122.23 (C2, C6), 124.90 (C6’’), 129.18 (C5’’), 128.21 (C2’, 
C6’), 128.32 (C2’’), 129.80 (C1’), 130.77 (C1), 132.33 (C4’’), 134.68 (C1’’), 
137.74 (C3’’), 141.94 (C4’), 153.60 (C4), 164.31 (C1’’CO), 165.90 (C1’CO); 
IR (cm-1) 3310, 2919, 1638, 1433, 1272, 1251, 807, 656; MP 260-262 °C. 
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N-(4-hydroxyphenyl)-4-(3-methylbutanamido)benzamide (263) 
 
Compound 340 (114 mg) was dissolved in THF (3 ml) and TBAF (1 ml) was 
added. The reaction was allowed to stir for 30 min at room temperature and, 
once complete by TLC, reaction was diluted with EtOAc (50 ml) and washed 
with saturated sodium bicarbonate solution (3 × 50 ml).  The organic layer 
was dried over sodium sulphate and the residue was concentrated in vacuo 
to yield the product as a white solid (83 mg, 100 %). LCMS (M+H)+ found 
313.2, requires 313.2, RT 1.67 min; HRMS ESI (M+H)+  found 313.1555, 
C18H21N2O3 requires 313.1547; δH (300 MHz, (CD3)2SO) 1.03 (6H, d, J = 6.3 
Hz, C(CH3)2), 2.19 (1H, m, CH), 2.29 (2H, d, J = 6.9 Hz, CH2), 6.80 (2H, d, J 
= 9 Hz, C3-, C5-H), 7.45 (2H, m, C2-, C6-H), 7.24 (2H, d, J = 9 Hz, C2-, C6-
H), 7.73 (2H, d, J = 8.7 Hz, C2’-, C6’-H),  7.91 (2H, d, J = 8.7 Hz, C3’-, C5’-
H); δC (75 MHz; CDCl3) 22.79 (CH(CH3)2), 27.57 (CH), 116.31 (C3, C5), 
120.46 (C3’, C5’), 124.54 (C2, C6), 129.50 (C2’, C6’), 131.32 (C1’), 131.69 
(C1), 143.26 (C4’), 155.81 (C4), 168.12 (C1’CO), 174.37 (CHCO); IR (cm-1) 
3303, 2955, 1637, 1512, 1248, 1103, 826; MP 277-279 °C. 
2-(2,5-dimethylphenoxy)-N-(4-hydroxyphenyl)acetamide (275) 
 
2,5-dimethylphenoxyacetic acid (341) (500 mg, 1 eq) was dissolved in DMF 
(10 ml), HOBt (450 mg, 1.2 eq) was added and the reaction was allowed to 
stir for 5 min. EDC·HCl (638 mg, 1.2 eq) was added and the reaction was 
allowed to stir for 20 min. Triethylamine (386 µl, 1.1 eq) and 4-aminophenol 
(226) (333 mg, 1.1 eq) were added and the reaction was allowed to stir 
overnight at room temperature. The reaction was seen to be complete by 
LCMS. Water was added until the product precipitated out of solution and 
was subsequently filtered. The residue was purified by recrystallisation in 
MeOH to afford the product as a white solid (132 mg, 18 %). LCMS (M+H)+ 
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found 272.0, requires 272.1; HRMS ESI (M+H)+ found, 272.1283 C16H18NO3 
requires 272.1281; δH (300 MHz, (CD3)2SO) 2.20 (3H, s, C2’CH3), 2.25 (3H, 
s, C5’CH3), 4.62 (2H, s, CH2), 6.70 (4H, m, C3-, C5-, C4’-, C6’-H), 7.03 (1H, 
d, J = 7.5 Hz, C3’H), 7.40 (2H, d, J = 8.4 Hz, C2-, C6-H), 9.23 (1H, s, 
NH/OH), 9.70 (1H, s, NH/OH); δC (75 MHz; CDCl3) 15.72 (C2’CH3), 20.99 
(C5’CH3), 67.48 (CH2), 112.40 (C6’), 115.04 (C3, C5), 121.35 (C4’), 121.49 
(C2, C6), 122.96 (C2’), 129.91 (C3’), 130.28 (C1), 136.01 (C5’), 153.65 (C4), 
155.91 (C1’), 165.98 (CO); IR (cm-1) 3360, 2909, 1670, 1555, 1510, 832, 
807; MP 196-198 °C. 
N-(4-(tert-butyldimethylsilyloxy)phenyl)-4-nitrobenzamide (337) 
 
Compound 231 (1 g, 1.2 eq) was dissolved in DCM (5 ml) and NEt3 (400 µl) 
and para-nitrobenzoyl chloride (336) (1 g, 1 eq) was added. The reaction 
was allowed to stir at room temperature overnight. Once seen to be complete 
by LCMS, the reaction was diluted with DCM (50 ml) and washed with 10 % 
HCl solution (2 × 50 ml), saturated sodium bicarbonate solution (2 × 50 ml) 
and brine (2 × 50 ml). The organic layer was dried over sodium sulphate and 
concentrated in vacuo. The residue was purified by Biotage silica column 
chromatography, eluted with a 0-100 % EtOAc in hexane, to yield the 
product as a white solid (676 mg, 40 %). The product was not ionised by 
LCMS. δH (300 MHz, CDCl3) 0.00 (6H, s, Si(CH3)2), 0.80 (9H, s, C(CH3)),  
6.59 (2H, d, J = 8.7 Hz, C3-, C5-H), 7.27 (2H, d, J = 8.7 Hz, C2-, C6-H), 7.74 
(2H, d, J = 8.7 Hz, C2’-, C6’-H), 7.94 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 8.57 
(1H, br s, NH). 
4-amino-N-(4-(tert-butyldimethylsilyloxy)phenyl)benzamide (338) 
 
Compound (337) (676 mg) was dissolved in MeOH (20 ml). Pd/C (50mg) 
was added as a suspension in MeOH. The reaction was stirred under H2 
overnight at room temperature. The Pd/C was filtered through celite and the 
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residue was concentrated in vacuo to yield the product as a white solid (574 
mg, 92 %). The product was not ionised by LCMS. δH (300 MHz, CDCl3) 0.00 
(6H, s, Si(CH3)2), 0.81 (9H, s, C(CH3)),  4.28 (2H, br s, NH2), 6.36 (2H, d, J = 
8.4 Hz, C3’-, C5’-H), 6.58 (2H, d, J = 8.7 Hz, C3-, C5-H), 7.30 (2H, d, J = 8.7 
Hz, C2-, C6-H), 7.41 (2H, d, J = 8.4 Hz, C2’-, C6’-H), 8.43 (1H, br s, NH); δC 
(125 MHz; DMSO) -4.55 (Si(CH3)2), 17.92 (Si(C(CH3)3), 25.58 (Si(C(CH3)3), 
113.15 (C3’, C5’), 119.52 (C3, C5), 121.71 (C2, C6), 122.05 (C1’), 129.16 
(C2’, C6’), 133.53 (C1), 150.61 (C4’), 150.91 (C4), 164.89 (CO);  IR (cm-1) 
3336, 2929, 2856, 1601, 1569, 1471, 1254, 909, 833, 778; MP 64-66 °C. 
N-(4-(4-hydroxyphenylcarbamoyl)phenyl)-3-methylbenzamide (339) 
 
Compound (338) (100 mg, 1 eq) was dissolved in DCM (5 ml) and NEt3 (100 
µl) and meta-toluoyl chloride (42 µl, 1 eq) was slowly added. The reaction 
was allowed to stir overnight at room temperature. The residue was 
concentrated in vacuo and triturated with MeOH to yield the product as a 
white solid (33 mg, 25 %). LCMS (M+H)+ found 461.2, requires 461.2, RT 
2.47 min; δH (300 MHz, (CD3)2SO) 0.00 (6H, s, Si(CH3)2), 0.79 (9H, s, 
C(CH3)3), 2.20 (3H, s, CH3), 6.62 (2H, d, J = 8.7 Hz, C3-, C5-H), 7.14 (2H, m, 
C5’’-, C4’’-H), 7.30 (2H, d, J = 8.7 Hz, C2-, C6-H), 7.50 (2H, m, C2’’-, C6’’-H), 
7.51 (2H, d, J = 8.7 Hz, C3’-, C5’-H),  7.62 (2H, d, J = 8.7 Hz, C2’-, C6’-H) 
7.86 (NH), 8.11 (1H, s, NH). 
N-(4-(tert-butyldimethylsilyloxy)phenyl)-4-(3-
methylbutanamido)benzamide (340) 
 
Compound (338) (100 mg, 1 eq) was dissolved in DCM (5 ml) and NEt3 (100 
µl) and isovaleryl chloride (347) (36 µl, 1 eq) was slowly added. The reaction 
was allowed to stir overnight at room temperature. The residue was 
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concentrated in vacuo and triturated with MeOH to yield the product as a 
white solid (114 mg, 91 %). LCMS (M+H)+ found 427.3, requires 427.2, RT 
2.39 min; δH (300 MHz, (CD3)2SO) 0.00 (6H, s, Si(CH3)2), 0.77 (6H, app s, 
(CH3)2), 0.80 (9H, s, C(CH3)3), 1.99 (1H, m, CH), 2.03 (2H, app s, CH2), 6.62 
(2H, d, J = 8.7 Hz, C3-, C5-H), 7.32 (2H, d, J = 8.7 Hz, C2-, C6-H), 7.36 (2H, 
m, C2’-, C6’-H), 7.56 (2H, d, J = 8.7 Hz, C3’-, C5’-H),  7.92 (1H, s, NH), 8.03 
(1H, s, NH). 
N-(4-(tert-butyldimethylsilyloxy)phenyl)-4-(2-
chloroacetamido)benzamide (342) 
 
Compound (338) (315 mg, 1 eq) was dissolved in DCM (5 ml) and NEt3 (100 
µl) and chloroacetyl chloride (75 µl, 1 eq) was slowly added. The reaction 
was allowed to stir overnight at room temperature. The residue was 
concentrated in vacuo and triturated with MeOH to yield the product as a 
white solid (137 mg, 36 %). The product did not ionise by LCMS; δH (300 
MHz, CDCl3) 0.00 (6H, s, Si(CH3)2), 0.79 (9H, s, C(CH3)3), 4.03 (2H, s, CH2), 
6.65 (2H, d, J = 8.7 Hz, C3-, C5-H), 7.28 (2H, d, J = 8.7 Hz, C2-, C6-H), 7.50 
(2H, m, C2’-, C6’-H), 7.68 (2H, d, J = 8.7 Hz, C3’-, C5’-H),  8.19 (1H, s, NH). 
N-(4-methoxyphenyl)-4-(3-methylbutanamido)benzamide (345) 
 
Synthesis of this compound was adapted from that previously described by 
Martins et al.218 para-Methoxyaniline (150) (507 mg, 1.2 eq) was dissolved in 
DCM (10 ml) and NEt3 (305 µl) and para-nitrobenzoyl chloride (336) (637, 1 
eq) was added slowly. The reaction was allowed to stir overnight at room 
temperature when it was seen to be complete by TLC. The reaction was 
diluted with EtOAc (50 ml) and washed with saturated sodium bicarbonate 
solution (3 × 50 ml) and brine (3 × 50 ml). The organic layer was dried over 
sodium sulphate and concentrated in vacuo. The residue was recrystalised 
from MeOH to yield the pure product as a white solid (460 mg, 50 %). The 
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product did not ionise by LCMS. δH (300 MHz, (CD3)2SO) 3.76 (3H, s, CH3), 
6.95 (2H, d, J = 9 Hz, C3-, C5-H), 6.91 (2H, d, J = 9 Hz, C2-, C6-H), 8.17 
(2H, d, J = 9 Hz, C2’-, C6’-H), 8.36 (2H, d, J = 9 Hz, C3’-, C5’-H), 7.64 (1H, 
br s, NH). 
4-amino-N-(4-methoxyphenyl)benzamide (346) 
 
This compound has been previously synthesised by Zhichkin et al.219 
Compound (345) (460 mg) was dissolved in MeOH (20 ml) and Pd/C (50 mg) 
was added as a solution in MeOH. The reaction was stirred under H2 
overnight at room temperature. The Pd/C was filtered through celite and the 
residue was concentrated in vacuo to yield the product as a white solid (407 
mg, 100 %). LCMS (M+H)+ found 243.0, requires 243.1, RT 1.52 min; δH 
(300 MHz, CDCl3) 3.82 (3H, s, CH3), 4.04 (2H, br s, NH2), 6.71 (2H, d, J = 9 
Hz, C3’-, C5’-H), 6.91 (2H, d, J = 9 Hz, C2-, C6-H), 7.53 (2H, d, J = 9 Hz, 
C2’-, C6’-H), 7.64 (1H, br s, NH), 7.71 (2H, d, J = 9 Hz, C2’-, C6’-H); δC (75 
MHz; CDCl3) 55.10 (OCH3), 112.51 (C3’, C5’), 113.57 (C3, C5), 121.25 
(C1’), 121.69 (C2, C6), 129.13 (C2’, C6’), 132.82 (C1), 151.88 (C4’), 155.02 
(C4), 164.89 (CO). 
N-(4-methoxyphenyl)-4-(3-methylbutanamido)benzamide (348) 
 
Compound (346) (100 mg, 1 eq) was dissolved in DCM (20 ml) and NEt3 
(100 µl) and isovaleryl chloride (347) (50 µl, 1 eq) was slowly added. The 
reaction was allowed to stir overnight at room temperature.  The residue was 
concentrated in vacuo and triturated with MeOH to yield the product as a 
white solid (68 mg, 51 %). LCMS (2M+Na)+ found 675.3, requires 675.3; 
HRMS ESI (M+H)+ found 327.1714, C19H22N2O3 requires 327.1703; δH (300 
MHz, (CD3)2SO) 0.95 (6H, d, J = 6.6 Hz, C(CH3)2), 2.10 (1H, m, CH), 2.23 
(2H, d, J = 7.1 Hz, CH2), 3.74 (3H, s, OCH3), 6.92 (2H, d, J = 8.7 Hz, C3-, 
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C5-H), 7.66 (2H, d, J = 8.7 Hz, C2-, C6-H), 7.72 (2H, d, J = 8.7 Hz, C2’-, C6’-
H), 7.91 (2H, d, J = 8.7 Hz, C3’-, C5’-H), 9.97 (1H, s, NH), 10.11 (1H, s, NH); 
δC (75 MHz; CDCl3) 22.25 (CH(CH3)2), 25.51 (CH), 45.61 (CH2), 55.11 
(OCH3), 113.64 (C3, C5), 118.13 (C3’, C5’), 121.88 (C2, C6), 128.40 (C2’, 
C6’), 129.02 (C1’), 132.27 (C1), 142.03 (C4’), 155.36 (C4), 164.41 (C1), 
171.06 (CHCO); IR (cm-1) 3297, 2995, 1507, 818; MP 271-273 °C. 
2-(2,5-dimethylphenoxy)-N-(4-methoxyphenyl)acetamide (349) 
 
2,5-dimethylphenoxyacetic acid (341) (250 mg, 1 eq) was dissolved in DMF 
(5 ml), HOBt (225 mg, 1.2 eq) were added and the reaction was allowed to 
stir for 5 min. EDC·HCl (320 mg, 1.2 eq) was added and the reaction was 
allowed to stir for a further 5 min. Triethylamine (170 µl, 1.2 eq) was added 
and allowed to stir for 20 min, followed by para-methoxy aniline (150) (188 
mg, 1.1 eq) and the reaction was allowed to stir for 24 h at room 
temperature. The reaction was seen to be complete by LCMS. Water was 
added and the precipitate was washed with excess water. The residue was 
recrystallised in Et2O to afford the product as a brown crystalline solid (20 
mg, 21 %). LCMS (M+H)+ found 286.1, requires 286.1; HRMS ESI (2M+Na)+ 
found 593.2645, C34H38N2NaO6 requires 257.1285; δH (500 MHz, CDCl3) 
2.24 (3H, s, C2’CH3), 2.26 (3H, s, C5’CH3), 3.74 (3H, s, OCH3), 4.52 (2H, s, 
CH2), 6.59 (1H, s, C6’H), 6.71 (2H, d, J = 7.5 Hz, C4’H), 6.83 (2H, d, J = 9 
Hz, C3-, C5-H), 7.01 (1H, d, J = 7.5 Hz, C3’H), 7.42 (2H, d, J = 9 Hz, C2-, 
C6-H), 8.17 (1H, s, NH); δC (75 MHz; CDCl3) 15.97 (C2’CH3), 21.33 
(C5’CH3), 55.52 (OCH3), 67.82 (CH2), 112.94 (C6’), 114.30 (C3, C5), 121.78 
(C2, C6), 122.74 (C4’), 123.31 (C2’), 130.03 (C1), 130.92 (C3’), 137.33 (C5’), 
155.21 (C1’), 157.82 (C4), 166.34 (CO). 
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N-(4-aminophenyl)-2-(2,5-dimethylphenoxy)acetamide (350) 
 
2,5-dimethylphenoxyacetic acid (341) (250 mg, 1 eq) was dissolved in DCM 
(10 ml), DMAP (203 mg, 1.2 eq) and DCC (343, 1.2 eq) were added and the 
reaction was allowed to stir for 10 min. para-phenylenediamine (153) (150 
mg, 1 eq) was added and the reaction was allowed to stir for 2 h at room 
temperature. The reaction was seen to be complete by LCMS. The reaction 
was diluted with EtOAc (20 ml) and washed with saturated sodium 
bicarbonate solution (3 × 20 ml) and brine (3 × 20 ml). The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified by Biotage silica column chromatography, eluted with a 0-100 % 
EtOAc in hexane, and recrystallised in acetonitrile to afford the product as a 
pale brown solid (46 mg, 12 %). LCMS (M+H)+ found 271.1, requires 271.1; 
HRMS ESI (M+H)+ found 271.1452, C16H19N2O2 requires 271.1441; δH (500 
MHz, CDCl3) 2.23 (3H, s, C2’CH3), 2.25 (3H, s, C5’CH3), 3.56 (2H, s, NH2), 
4.50 (2H, s, CH2), 6.61 (3H, m, C3-, C5-, C6’-H), 6.70 (1H, d, J = 7.5 Hz, 
C4’H), 7.01 (1H, d, J = 7.5 Hz, C3’H), 7.27 (2H, m, C2’-, C6’-H), 8.09 (1H, s, 
NH); δC (75 MHz; CDCl3) 15.97 (C2’CH3), 21.33 (C5’CH3), 67.81 (CH2), 
112.91 (C6’), 115.46 (C3, C5), 121.96 (C2, C6), 122.66 (C4’), 123.31 (C2’), 
128.28 (C1), 130.89 (C3’), 137.30 (C5’), 143.74 (C4), 155.25 (C1’), 165.20 
(CO). 
2-(2,5-dimethylphenoxy)-N-(pyridin-4-yl)acetamide (351) 
 
2,5-dimethylphenoxyacetic acid (341) (350 mg, 1 eq) was dissolved in DMF 
(10 ml), HOBt (446 mg, 1.2 eq) was added and the reaction was allowed to 
stir for 5 min. EDC·HCl (446 mg, 1.2 eq) was added and the reaction was 
allowed to stir for 20 min. Triethylamine (236 µl, 1.2 eq) and 4-aminopyridine 
(201 mg, 1.1 eq) were added and the reaction was allowed to stir for 3 h at 
room temperature. The reaction was seen to be complete by LCMS. Water 
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was added and the product extracted with EtOAc. The organic layer was 
dried over sodium sulphate and concentrated in vacuo. The residue was 
purified by Biotage silica column chromatography, eluted with a 0-100 % 
EtOAc in hexane, to afford the product as a white solid (72 mg, 14 %). LCMS 
(M+H)+ found 257.1, requires 257.1; HRMS ESI (M+H)+ found 257.1308, 
C15H17N2O2 requires 257.1285; δH (300 MHz, CDCl3) 2.21 (3H, s, C2’CH3), 
2.23 (3H, s, C5’CH3), 4.49 (2H, s, CH2), 6.54 (1H, s, C6’H), 6.70 (1H, d, J = 
7.5 Hz, C4’H), 6.99 (1H, d, J = 7.5 Hz, C3’H), 7.45 (2H, m, C2-, C6-H), 8.44 
(2H, m, C3-, C5-H) 8.53 (1H, s, NH); δC (75 MHz; CDCl3) 15.94 (C2’CH3), 
21.30 (C5’CH3), 67.84 (CH2), 112.99 (C6’), 113.71 (C2, C6), 123.07 (C4’), 
123.28 (C2’), 131.03 (C3’), 137.38 (C5’), 143.90 (C1), 150.87 (C3, C5), 
154.94 (C1’), 167.42 (CO). 
7.4 ROCS ligand-based database search 
The structure of fenretinide was drawn using Maestro (Schrödinger)220 and 
energy minimised in an aqueous environment using Maestro Macromodel. 
The ChemBridge database search was carried out by comparison of the 
database structures with the fenretinide structure (based on structural and 
pharmacophoric patterns), using ROCS (Rapid Overlay of Chemical 
Structures, OpenEye Scientific Software) software script. The overlay of the 
structures and the calculated scores could be viewed using the 3D modelling 
software, VIDA (Visualization and Communication of Modelling Results, 
OpenEye Scientific Software). The results were ranked in order of their 
likeness of shape and chemical features to fenretinide. 
7.5 Biological evaluation 
7.5.1 Cell lines and tissue culture 
The human TC32, SK-N-MC and TTC466 ESFT, SHEP-1 and SK-N-SH 
neuroblastoma and MSC (immortalised with hTERT) cell lines were used to 
test the effect of compounds on viable cell number. All cell lines were 
substrate adherent, growing as a single monolayer, and were mycoplasma 
free. Cells were used at 70 % confluency for experimental procedures, 
seeded and treated in a sterile environment using aseptic techniques in a 
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Envair class II microbiological safety cabinet. After washing with 5 ml of 1 × 
Phosphate Buffered Saline (PBS; w/v; Oxoid Ltd, Hampshire, UK), cells were 
harvested by treating for 2 minutes with ethylenediaminetetracetate (EDTA; 
0.1 % in PBS, w/v; Invitrogen Life Technologies, Paisley, Scotland), followed 
by a 2 minute incubation with 5 ml of 1x trypsin (0.25 % in PBS, w/v; Sigma 
Aldrich Company Ltd, Dorset, UK). Cells were maintained at 37 °C in a 
saturated humid atmosphere of 5 % CO2 in air (v/v) in a Sanyo Gallenkemp 
CO2 incubator (MCO-2OAIC, Sanyo Gallenkamp PLC, Leicestershire, UK). 
Cells were maintained in cell line specific tissue culture media supplemented 
with 10 % fetal calf serum (FCS) (v/v) and 2 mM glutamine (w/v). ESFT cell 
lines, TC32 and TTC466 were maintained in RPMI 1640 (TTC466 media was 
supplemented with 10 % conditioned media (v/v)) and SK-N-MC cells were 
maintained in DMEM F12. Neuroblasoma cell lines SK-N-SH and SHEP-1 
were maintained in 1:1 mixture of Dulbecco’s Minimum Essential Medium 
(DMEM) and Eagle's Minimum Essential Medium (EMEM). MSC cells were 
maintained in NH expansion media. 
7.5.2 Preparation of stock solutions   
All synthetic retinoids and ChemBridge compounds plus fenretinide were 
dissolved in DMSO to give 10 mM stock solutions. Samples were aliquoted 
into 20 µl single use aliquots and stored at −20 °C until required.  
7.5.3 Seeding of cells 
Cells were harvested for experiments at ca.70 % confluency. The media and 
PBS were warmed to 37 °C in a water bath prior to use. The cells were 
washed with PBS (5 ml) to remove any floating cells and debris. For cancer 
cell lines, EDTA (0.1 %, 5 ml) was added and left on the cells for 2 minutes 
before removing by aspiration. Trypsin (0.1 %, 5ml) was added and the flask 
was tapped gently to remove the cells from the surface of the flask. For the 
MSC cell line, cells were removed from the flask by incubation (5 min) with 
trypsin-EDTA (0.25 % trypsin, 1 mM EDTA, 5 ml) solution. Trypsin was 
neutralised by adding media containing serum (5ml) and the contents of the 
flask were transferred to a sterile Falcon centrifuge tube and centrifuged at 
500g for 5 minutes. The supernatant was removed by aspiration and 
discarded; the cell pellet was resuspended in 30 ml of fresh media using a 
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pastette to ensure a single cell suspension. The number of viable cells was 
counted using the trypan blue exclusion assay and a Neubauer 
haemocytometer, visualised by light microscopy on a Nikon ECLIPSE 
TS100. Cells were seeded in Primeria™ 6-well (2 × 105) or 24-well (2.5 × 
104) plates. 
7.5.4 Effect of compounds on viable cell number 
Cells were treated with 10µM of a compound in an initial TC32 and MSC 
screen for activity, or with a concentration range (3, 6, 10, 20 and 40 µM) in 
dose response studies. Cells were also treated with DMSO (vehicle control) 
and fenretinide (positive control) at the maximum volume/concentration used 
in the assay. After 24 hours the media was collected and the wells were each 
washed with PBS (1 ml). For cancer cell lines, this was followed by EDTA 
(0.1 %, 1 ml). The media, PBS and EDTA from each well were collected and 
pooled into a centrifuge tube. Trypsin (0.1 %, 1 ml) was added to the well 
and the plate tapped gently to remove the cells from the surface. For MSC 
cells, the cells were incubated with trypsin-EDTA (0.25 % trypsin, 1 
mM EDTA, 1 ml) solution for 5 minutes and the plate tapped gently to 
remove the cells from the surface. Media (1 ml) was added to neutralise the 
trypsin and the cells and media then collected and also pooled in the 
centrifuge tube. The tubes were centrifuged at 500g for 5 minutes, the 
supernatant aspirated from the cell pellet, and the cell pellet resuspended in 
0.5 ml of fresh media. A cell viability analyser (Vi-Cell XR 2.03) was used to 
count the number of viable cells using the trypan blue exclusion assay. Each 
compound was analysed by in 3 technical repeats in each experiment and 
each independent experiment was repeated a minimum of three times. The 
mean viable cell number ± standard error is presented as a percentage of 
the vehicle (DMSO) treated control.  
7.5.5 Statistical analysis of data 
Statistical analysis was carried out using GraphPad InStat 3. The effects of 
compounds on viable TC32 cell number were compared using a 1-way 
ANOVA with Dunnett’s post hoc test to identify any significant effects on 
viable cell number, where p < 0.05 was considered significant. Compounds 
were deemed significantly active when they displayed a significant decrease 
- 228 - 
 
in viable cell number compared to the DMSO control and comparable to 
fenretinide when activity was statistically comparable to fenretinide, 
evaluated by ANOVA with Dunnetts post hoc tests. 
7.6 ROS studies 
TC32 cells were seeded into 6 well plates and allowed to adhere to the plate 
surface overnight. Cells were treated with the compounds at 10 µM of the 
solution and incubated for 30 min. Cells were harvested by trypsination (as 
described in Section 7.5.4) and centrifuged at 500g for 5 min. DCFDA 
(Molecular Probes, 50 µg) was dissolved in DMSO (87 µl). The 
DCFDA/DMSO solution was diluted to (2.5 µl/ml) in PBS and was made up in 
sufficient volume to resuspend each cell pellet in 1 ml of solution. The cell 
pellet was resuspended in 1 ml of PBS containing DCFDA solution and the 
suspension was incubated in the dark at 37 °C for 15 min. The cells were 
centrifuged at 500g for 5 min, the supernatant removed and the cell pellet 
resuspended in PBS (500 µl). An aliquot of untreated cells were treated with 
H2O2 (50 µl) 10 minutes prior to analysis to use as a positive control. 
Fluorescence was detected immediately by FACS (Attune Acoustic Focusing 
Cytometer with Attune Cytometric Software), where 10,000 events were 
recorded per sample. Each compound was analysed in 3 technical repeats in 
each experiment and a minimum of three independent experiments were 
carried out. 
7.7 Caspase-3 activation 
7.7.1 Protein extraction 
TC-32 cells were seeded into 10 cm plates (as described in Section 7.5.3) 
and allowed to adhere to the plate surface overnight. Cells were treated with 
the compounds at 10 µM for 24 h. Cells were washed with PBS (5 ml) and 
scraped from the plate surface into PBS (3 ml) using a silicone rubber cell 
scraper. Jurkat control cells were treated with etoposide (25 µM, 4 h). The 
cell suspensions were centrifuged (500 g, 5 min), the supernatant was 
discarded following aspiration and the cell pellet resuspended in RIPA lysis 
buffer (PBS containing 1 % nonidet P-40, 0.5 % sodium deoxycholate,  0.1 % 
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w/v SDS and the protease inhibitors phenylmethylsulfonyl fluoride (PMSF, 1 
mM), sodium orthovanadate (1 mM), leupeptin (10 µg/ml) and aprotinin (2 
µg/ml). The cell lysate was incubated on ice for 30 min and vortexed twice 
within this time. The cell suspension was centrifuged at 12,500g for 10 
minutes at 4 °C and the supernatant was collected and incubated on ice. 5 µl 
of the supernatant was added to deionised H2O (45 µl) for protein analysis. 
The remaining supernatant was mixed with an equal volume of 2 × SDS-
loading buffer (100 mM Tris-HCl (pH 6.8), 20 % w/v glycerol, 4 % w/v SDS, 
200 mM dithothreitol (DTT) and 0.2 % w/v bromophenol blue) and stored at 
−20 °C. Extracts were heated to 95 °C for 5 min immediately prior to use. 
7.7.2 Protein assay 
An estimation of the protein content of the supernatant was made using the 
Bio-rad DC Protein Assay. The chemical composition of buffer solutions used 
in the assay is company proprietary. A standard curve using bovine serum 
albumin (BSA) diluted in lysis buffer at six concentrations ranging from 0.1 
µg/µL – 1.5 µg/µL was prepared. Protein samples and standards (5 µl) were 
pipette in triplicate into a 96-well standard microplate. Reagent SA (20 µl, 
1:50 dilution of reagent S:A) was added to each well, followed by Reagent B 
(200 µl) and the plate was shaken for 10 sec. The plate was incubated at 
room temperature for 15 min. The absorbance was measured at 690 nm 
using a plate reader (Titertek Multiscan Plus MK II) and the protein 
concentration of test samples was calculated from the BSA standard curve. 
7.7.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples (100 µg) were loaded onto precast Mini-PROTEAN TGX 
Gels (4-15 %, 15 well comb, 15 µl, Bio-Rad) alongside LI-COR molecular 
weight markers (5 µl). The gel was run at 150 volts in SDS electrophoresis 
buffer (250mM glycine, 25 mM Tris-HCl (pH 8.3), 0.1 % w/v SDS) in a Mini-
PROTEAN Tetra Cell (Bio-Rad) until adequate protein separation was 
observed, as determined by movement of the bromophenol blue dye front 
and molecular weight marker separation. 
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7.7.4 Western blot 
The SDS-PAGE gel was washed by shaking on a rotating platform for 5 min 
in transfer buffer (192 mM glycine, 25 mM Tris base, 20 % v/v methanol).The 
gel was then placed on a Hybond-C nitrocellulose membrane and 
sandwiched between two pieces of 3 mm filter paper and two foam pads. 
The gel was locked into the blotting apparatus and proteins were transferred 
on to the nitrocellulose membrane at 300 mA for 90 min with constant stirring 
in a Mini-PROTEAN Tetra Cell (Bio-Rad) cooled with an ice block. 
After transfer the membrane was removed from the blotting apparatus and 
placed in LI-COR blocking buffer (5 ml) on a rotating platform for 30 min at 
room temperature; this blocking step was important to minimise non-specific 
binding of antibodies. The membrane was then incubated in the dark 
overnight at 4 °C with caspase-3 rabbit Ab (1:1000 dilution, Cell Signalling) 
and α-tubulin B-7 mouse monoclonal IgG2a (1:5000, Santa Cruz 
Biotechnology) primary antibodies diluted in a 1:1 solution of PBS and 
blocking buffer with 0.1 % Tween-20. The membrane was then washed three 
times by shaking in PBS containing 0.1 % Tween (5 ml) for 5 min. The 
membrane was shaken for 1 h in the dark at room temperature in goat Alexa 
Fluor 680 goat anti-rabbit IgG (H+L) and Alexa Flour 680 rabbit anti-mouse 
IgG (H+L) secondary antibodies (1:5000, Molecular Probes) diluted in a 1:1 
solution of PBS and blocking buffer with 0.1 % Tween-20. The membrane 
was washed three times by shaking in PBS containing 0.1 % Tween (5 ml) 
for 5 min followed by two washes for 5 min each in PBS. Membranes were 
visualised using a LI-COR Odyssey CLx Infrared Imaging System. 
7.8 Affinity chromatography 
7.8.1 Preparation of Sepharose affinity chromatography resin 
Epoxy activated Sepharose 6B was purchased from GE Healthcare as a 
freeze-dried solid in the presence of additives. In order to wash away the 
additives, the Sepharose (300 mg) was suspended in distilled water (5 ml) 
and washed with distilled water (100 ml) on a sintered filter. The ligand 
(ca.30 mg) was dissolved in a 1:1 solution of 100 mM sodium carbonate 
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(coupling buffer) at pH10 and DMF (5 ml) and added to the Sepharose 6B 
slurry. The mixture was shaken in an incubator at 40 °C overnight. The 
suspension was filtered on a sintered disc and excess ligand was washed off 
using coupling buffer. To block any remaining active groups, the medium 
was suspended in 1 M ethanolamine at pH8 and shaken overnight at 40 °C. 
The suspension was filtered on a sintered disc and washed with four cycles 
of alternating pH to remove any unbound fragments, consisting of a wash 
with 0.1 M acetate buffer pH4 containing 0.5 M NaCl followed by a wash with 
0.1 M Tris-HCL buffer pH 8 containing 0.5 M NaCl. 
The resin was stored in a 20 % EtOH/ 0.1M Tris-HCL buffer pH 8 at 4 °C.  
7.8.2 Enrichment of cellular protein extracts for membrane 
proteins  
ESFT SKES1 (5 x106) cells were suspended in 2.5 ml of PBS to which was 
added EZ link Sulfo-NHS-SS-Biotin (0.5 mg/ml). Cells were incubated with 
rotation for 30 minutes at room temperature.  After biotinylation the reaction 
was stopped by adding an equal volume of 50 mM Tris-HCl (pH 7.4). Cells 
were collected by centrifugation (1500 g, 5 minutes), washed twice with ice-
cold PBS and then homogenised in 500 µl of RIPA buffer using a glass-glass 
homogeniser. The protein concentration in a 5 µl aliquot of the lysate was 
analysed using the modified Bradford assay. Nuclei and unbroken cell debris 
were removed from the remaining lysate by centrifugation at 1000 g for 10 
min at 4 °C and the supernatant retained. Biotin-labelled proteins were 
extracted from the supernatant by incubation with rotation for 2 h at 4 °C with 
streptavidin-sepharose beads (20 µl beads/106 cells). The beads were 
collected by centrifugation (10,000 g, 1 min), the supernatant removed and 
the beads washed in RIPA buffer, followed by a wash in RIPA buffer 
containing 1 M KCl and then in RIPA buffer containing 0.1 M NaHCO3. 
Bound membrane proteins were solubilised in PBS + 1 % NP40 (non-ionic 
detergent). This method was optimised to obtain the greatest protein yield 
whilst maintaining the native protein state. Cellular extracts were 
subsequently precleared by incubating extracts with sepharose beads and 
removing these by centrifugating prior to application to the columns. An 
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aliquot of the solubilised membrane proteins was retained for SDS-PAGE 
(unbound proteins).  
7.8.3 Pull down assay 
The precleared membrane enriched biotinylated cell lysate was incubated 
with the covalently immobilised molecules (352, 353 and 364) bound to the 
sepharose resin or sepharose resin alone overnight at 4 °C. The resin was 
then poured into a column under gravity, and the Flow through (fraction 
containing unbound proteins) collected. The column was then washed in 
50ml of wash buffer (10 mM, HEPES (pH 7.1), 100 mM KCl, 2 mM MgCl2, 1 
mM EDTA) and bound proteins eluted in 50 mM glycine pH2.3, 10 % sucrose 
buffer.   
The purified proteins, bound and unbound, were analysed by 1D gradient 
SDS-PAGE (4-20 % acrylamide) and silver staining (Proteosilver Plus, 
Sigma). In total 12 bands were identified that were eluted from the specific 
affinity columns but were absent in the non-specific negative control column. 
The bands were excised from the gels, each one placed into a separate 
eppendorf tube and digested with trypsin for identification. 
7.8.4 Identification of proteins 
Each protein band was analysed by mass spectrometry using an Agilent 
1100 Series nano-LC System (Agilent Technologies) coupled online with a 
QSTAR XL quadrupole TOF hybrid mass spectrometer (Applied Biosystems) 
as previously described.183 Data was analysed using a local Mascot 
database search engine (Matrix Science) and the UniProt protein sequence 
database (restricted to human; 88214 sequences) with the following search 
parameters: Fixed modification: Carbamidomethyl (C), Variable modification: 
Oxidation (M), Peptide Mass Tolerance: 0.15 Da, Fragment Mass Tolerance: 
0.1 Da, Missed Cleavages: 1. Peptides with scores over the identity 
threshold (p < 0.05) were considered as identified, proteins required at least 
one significant bold red peptide (that is, the highest scoring match to a 
particular query listed under the highest scoring protein containing that 
match). 
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The expression of proteins that appeared to be specifically binding to the 
fenretinide molecule was confirmed by western and immunoprecipitation blot 
of ESFT cellular extracts (results not shown). No hits were identified for two 
bands, one at ca.100 kDa and one at ca.30 kDa. In the remaining bands 
many ribosomal proteins were identified, along with tubulin and nucleolin. 4 
proteins demonstrated specificity towards affinity chromatography ligands 
352 and 353. 
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Appendix A – compound activity in TC32 cells 
 
Chart A.1 Effect of the retinoid compounds at 10 µM on TC32 viable cell number. Viable 
cell number was counted after treatment of cells for 24 hours. Results are shown as 
mean ± SEM, n ≥ 9. 
 
Chart A.2 Effect of the affinity chromatography ligand compounds at 10 µM on TC32 viable 
cell number. Viable cell number was counted after treatment of cells for 24 hours. 
Results are shown as mean ± SEM, n ≥ 9. 
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 Chart A.3 Effect of the non-retinod compounds at 10 µM on TC32 viable cell number. Viable cell number was counted after treatment of cells for 24 hours. 
Results are shown as mean ± SEM, n ≥ 9. 
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Appendix B – concentration response by cell line 
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Chart B.2 Cell viability of TTC-466 ESFT cells treated with 3-10 µM of compounds 1, 58, 
198, 199, 275 and 298 for 24 h (n = 9). 
Chart B.1 Cell viability of TC32 ESFT cells treated with 3-10 µM of compounds 1, 58, 
198, 199, 275 and 298 for 24 h (n = 9). 
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Chart B.4 Cell viability of SK-N-SH neuroblastoma cells treated with 3-10 µM of compounds 
compounds 1, 58, 198, 199, 275 and 298 for 24 h (n = 9). 
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Chart B.3 Cell viability of SK-N-MC neuroblastoma cells treated with 3-10 µM of 
compounds compounds 1, 58, 198, 199, 275 and 298 for 24 h (n = 9). 
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Chart B.5 Cell viability of SHEP-1 neuroblastoma cells treated with 3-10 µM of compounds 
1, 58, 198, 199, 275 and 298 for 24 h (n = 9). 
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Appendix C – mass spectroscopy analysis of binding 
proteins 
Protein Name 
 
Accession* 
 
Number of 
significant 
peptides† 
Score† MW kDa‡ 
Heterogeneous nuclear ribonucleoprotein U (hnRNP U) HNRPU_HUMAN 3 74 90 
Nucleolin NUCL_HUMAN 6 153 76 
Insulin-like growth factor 2 mRNA binding protein1  IF2B1_HUMAN 1 40 63 
Tubulin β-chain TBB5_HUMAN 2 182 50 
Ribosomal protein S3 
Acidic leucine rich nuclear phosphoprotein 32 family 
member A (ANP32A) 
Ribosomal protein S3A 
Acidic leucine rich nuclear phosphoprotein 32 family 
member B (ANP32B) 
RS3_HUMAN 
AN32A_HUMAN 
RS3A_HUMAN 
AN32B_HUMAN 
4 
1 
2 
1 
147 
76 
56 
53 
27 
29 
30 
29 
Phosphatase 2A inhibitor (I2PP2A) 
Ribosomal protein S5 
Ribosomal protein S9 
SET_HUMAN 
RS5_HUMAN 
RS9_HUMAN 
2 
1 
1 
107 
50 
39 
33 
23 
22 
Ribosomal protein S14 
Ribosomal protein S25 
Ribosomal protein S16 
Ribosomal protein S10 
Ribosomal protein S19 
Ribosomal protein S18 
Ribosomal protein S20 
Ribosomal protein L22 
Ribosomal protein S13 
Ribosomal protein L12 
Ribosomal protein S23 
Ribosomal protein S17 
RS14_HUMAN 
RS25_HUMAN 
RS16_HUMAN 
RS10_HUMAN 
RS19_HUMAN 
RS18_HUMAN 
RS20_HUMAN 
RL22_HUMAN 
RS13_HUMAN 
RL12_HUMAN 
RS23_HUMAN 
RS17_HUMAN 
2 
2 
3 
2 
2 
2 
1 
1 
1 
1 
1 
1 
104 
96 
83 
78 
71 
63 
57 
52 
51 
49 
41 
40 
16 
14 
16 
19 
16 
18 
13 
15 
17 
18 
16 
15 
Elongation factor 1-α EF1A1_HUMAN 2 78 50 
Ribosomal protein SA RSSA_HUMAN 3 109 33 
Phosphatase 2A inhibitor (I2PP2A) SET_HUMAN 1 67 33 
     *The accession is for the UniProt database; 
†
the number of significant peptides and score are from Mascot; 
‡
the molecular weight (MW) 
     is that of the unmodified mature protein product.  
Table C.1 Summary of the 26 proteins isolated (within 10 bands) using affinity 
chromatography confirmed by mass spectrometry. 
